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CHAPTER I 
INTRODUCTION 
When, in 1973, I embarked upon this study, the hormone gastrin 
seemed a suitable hormone to study with regard to investigation of 
structure-activity relationships and physiology of a peptide hormone. 
Gastrin was best known at that stage as a linear peptide comprising 
17 amino acids, which was stable at room temperature and was resistant 
to degradation by vigorous treatments such as boiling {Gregory and Tracy, 
1964; Berson and Yalow, 1971; Yalow and Berson, 1972) and pH 
extremes (Piszkiewicz, 1974). Such a molecule could thus be studied 
at room temperature, using conventional biochemical techniques, without 
the need for any special precautions to preserve its integrityo 
Heptadecapeptide gastrin had been isolated and purified from porcine 
(Gregory and Tracy, 1964) and human antral mucosa (Gregory, Tracy and 
Grossman, 1966) twelve to fourteen years previously, and its primary 
structure in each case had been determined (Gregory, Hardy, Jones, Kenner 
and Sheppard, 1964; Bentley, Kenner and Sheppard, 1966), so that at the 
time of commencement of this study pure preparations of synthetic human 
heptadecapeptide gastrin were freely available commercially. This meant 
that a radioimmunoassay for the measurement of gastrin levels in the circu-
lation could be developed, which entails: 
(i) immunizing rabbits with purified gastrin preparations to raise antisera, 
(ii) labelling the peptide with a radioactive tracer such as 125!odine, and 
(iii) preparing a series of standard concentrations of the hormone with which 
samples containing unknown levels of gastrin could be compared. 
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In addition, the availability of pure preparations of gastrin allowed 
estimations of gastrin activity by the technique of bioassay, studies of the 
effect of administration of this peptide hormone to human subjects and 
experimental animals, and investigation of its behaviour in vitro under 
various conditions. 
Studies aimed at elucidating the physiological role of a hormone are 
designed to answer such questions as: 
(i) where in the body is the hormone synthesised and secreted, or more 
specifically, in which cell of which organ, and which sub-cellular 
organelle is responsible for the manufacture of the hormone? 
(ii) what is the stimulus for secretion of the hormone, how is its effect 
on the hormone-secreting cell mediated, and how is the secretion 
of the hormone regulated? 
(iii) in what molecular form is the hormone secreted; is it pre-formed 
and stored in the cell or is it synthesised in the cell on demand? 
(iv) does the hormone exist in the circulation in an inactive precursor 
form which is cleaved to a smaller biologically active form, and if 
so, where is the site of this conversion? 
(v) what is the target organ of the hormone and how does the hormone 
produce its effect on the target cell? 
(vi) in the case of the gastrointestinal hormones, one must ask whether 
they are secreted into the lumen of the gut or into the bloodstream 
and by which route they reach the target cell, whether it be via 
the I umen of the gut or via the bloodstream; 
(vii) after the hormone has produced its effect it is degraded and removed 
from the circulation; the organ or organs responsible for metabolism 
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of the hormoner and the half-time of disappearance of the hormone 
from the circulation must be defined. 
Some of the answers to these questions were known in the case of 
gastrin in 1973. It was known that gastrin is secreted by the G-cell in 
the antral mucosa, and to a lesser extent by the duodenal mucosa, in the 
human. Physiological stimuli known to cause release of gastrin in the 
stomach included gastric distension (shown in the dog), ingestion of food, 
especially protein, the presence of certain amino acids in the lumen of 
the stomach, blood-borne calcium and catecholamines, and vagol cholin-
ergic stimuli. The primary action of gastrin is stimulation of the parietal 
cell in the gastric fundus to secrete hydrochloric acid for digestion and 
c negative feedback system appeared to regulate the secretion of gastrin, 
in that the presence of acid in the stomach inhibited further release of 
gastrin. It was not known how gastrin elicited this response in the parietal 
cell, but on the basis of findings relating to other peptide hormones, it 
seemed likely that the first stage involved binding of gastrin to a receptor 
in or on the target cell • 
Preliminary studies had revealed that serum gastrin was heterogeneous, 
in that several molecular forms of immunoreactive gastrin of different mole-
cular sizes had been observed following Sephadex gel filtrc1tion of hyper-
gas-rrinaemic serum (Yalow and Berson, 1970b; 1971a; 1972; Rehfeld, 
1972). The predse number of serum gastrin components, their interrelation-
ships and whether or not they al! possessed biological activity had not been 
conclusively established Q Which form of gastrin was secreted by the antral 
G-cel I, whether the same form was secreted by the duodenal mucosa, and 
whether the secreted form was an inacrive large precursor form, were all 
unonsvvered questions. Although the antrai G-cell had been shown to 
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communicate both with the lumen of the stomach and with the capillaries 
bathing the basement membrane of the mucosa (Creutzfeldt, Arnold, Creutz-
feldt, Feurle and Ketterer, 1971; Greider, Steinberg and McGuigan, 1972), 
the proportions of lumenal and humeral secretion of gastrin were not known, 
nor the route to the fundic parietal cell. 
Regarding the removal of gastrin from the circulation, reports had 
suggested the importance of the kidneys in this connection (Jaffe and Newton, 
1969; Dent, Hirsch, James and Fischer, 1972; Korman, Laver and Hansky, 
1972; Hjelmquist, Reeder, Brandt and Thompson, 1972) and one study had 
implicated the liver in this role (Thompson, Reeder, Davidson, Charters, 
BrlJckner, Lemmi and Miller, 1969). Early studies of the disappearance of 
heptadecapeptide gastrin from the circulation had shown a half-life of between 
2 and 10 minutes, depending on the design of the experiment (Blair, Harper 
and Reed, 1962; Jaffe and Newton, 1969; Yalow and Berson, 1970a; 
Ganguli, Eider, Smith and Hunter, 1970; McGuigan, Isaza and Landor, 
1971; Reeder, Jackson, Brandt and Thompson, 1972). 
Turning to the structure-function relationships of gastrin and the related 
peptides, cholecystokinin-pancreozymin (CCK-PZ), caerulein and the C-
terminal pentapeptide of gastrin, one is struck by the close similarities in 
the amino acid sequences displayed by these peptides. Ali four peptides 
contain within their primary structure the C-terminal pentapeptide amide 
sequence: Gly-Trp-Met-Asp-Phe-NH2 , which includes the C-terminal tetra-
peptide amide sequence shown to be responsible for the biological action 
of stimulation of gastric acid secretion by Tracy and Gregor;· in 1964. 
The structure I similarities between the peptides CCK-PZ and caerulein 
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extend as far as eight residues from the (-terminus, with identity in all 
positions except one. Gastrin, CCK-PZ and caerulein all bear a tyrosine 
residue, which is situated six positions from the C-termi nus in the case of 
gastrin and seven positions from the (-terminus in the latter two cases. 
Both caerulein and CCK-PZ require the presence of a sulphate group 
attached to the tyrosine ring for biological activity, whereas gastrin occurs 
naturally in both the sulphated and non-sulphated forms and both are 
biologically active. 
The structural similarities in these peptides are accompanied by overlap 
in the pharmacological effects produced by their administration in man 
and experimental animals. All four peptides can elicit responses such as 
increased output of gastric juice, hydrochloric acid and pepsin secretion, 
contraction of the gall bladder and other smooth intestinal muscle, alterations 
in blood pressure by their action on the vessel musculature, increased 
production of pancreatic juice, pancreatic enzymes and bicarbonate secretion, 
as well as affecting the endocrine pancreas and causing release of insulin 
and gl ucagon. The differences between the actions of gastrin and these 
related peptides lie in the dose required to elicit a particular response; 
thus at physiological levels each peptide is more poteni" in producing its 
individual response, although at pharmacological ievels the overlap in actions 
is observed. 
Similar overlaps in primary structure end pharmacologic effects are found 
in the case of the gut peptides, secretin and glucagon; it is becoming 
increasingly apparent that structural resemblances occur among many other 
gut peptide-hormones as well e 
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This overlap i·n primary structure of gastrin and the related peptides 
strongly suggests a common molecular ancestry. It was considered of 
interest to trace the origin of the gastrin molecule down the evolutionary 
tree by investigating the occurrence of this peptide in various mammalian, 
vertebrate and invertebrate species, in the hope of providing answers to 
such questions as: 
(i) is the tissue distribution of this peptide in mammals the same as in the 
human, and 
(ii) how far back in evolutionary development did the gastrin molecule 
arise? 
Although a sprinkling of reports on the occurrence of the gut peptide 
hormones insulin, glucagon, CCK-PZ and secretin in lower specias had 
appeared, there was a dearth of information regarding this aspect of gastrin 
in the literature in 1973. Lai (1964b) had reported finding a gradient of 
gastrin activity on descending the human gut, as determined by bioassay of 
tissue extracts. Elwin and Uvrxis (1966) and Em8s, Borg and Fyr8 (1971) 
had studied the relative gastrin bioactivity found in the antrum and duo-
denum of the cat and the human. In 1973 two reports of measurements of 
immunoreactive gastrin in mammals appeared (Nilsson, Yalow and Berson, 
1973; Thompson, Reeder, Davidson, Jackson and Clendinnen, 1973), and 
Kenner and Sheppard (1973) determined the primary structures of heptadeca-
peptide gastrin isolated from pig, cow, sheep, dog and cat. No information 
pertaining to investigation of gastrin distribution in lower species was found. 
The aims of this study, accompanied by an outline of the way in which 
the investigations were undertaken, wii I now be described. 
(i) A sensitive radioimmunoassay, capable of measuring basal circulating 
levels of gastrin, was established in our laboratory. The reliability 
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and validity criteria of the assay, and the specificity of three 
antisera used in the assay were determined; 
(ii) The assay was used to establish a normal range of serum gastrin 
levels and a survey of serum gastrin concentrations in patients 
belonging to different categories was carried out; 
(iii) The molecular heterogeneity of gastrin in human serum was investi-
gated using Sephadex column chromatography; 
(iv) The distribution of tissue gastrin in the gastrointestinal tract of the 
human and five mammalian species was studied, and characterisation 
of human antral and duodenal gastrins was attempted by gel filtration 
and investigation of their immunochemical behaviour; 
(v) The occurrence of immunoreactive gastrin among nineteen invertebrate 
species was investigated by radioimmuncassay measurements of serum, 
and, in some instances, tissue gastrin content; 
(vi) More detailed studies aimed at characterisation of a gastrin-like 
material found in the serum and skin extracts of the frog, Xencpus 
laevis, were performed; 
(vii) Tissue extracts prepared from nine different invertebrate species were 
tested for the presence of immunoreactive gastrin. It was hoped that 
these investigations would throw some light on the evolutionary origin 
of the gastrin molecule; 
(viii) Transhepatic measurements of basal endogenous gastrin levels in the 
pig were carried out to assess the importance of the liver in relation 
to possible removal of gastrin from the circulation; 
(ix) The kinetic parameters of half-life, metabolic clearance rate, and 
space of distribution of infused exogenous heptadecapeptide gastrin 
in the pig were determined, since no information of this kind 
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regarding the pig was found in the literature; 
{x) Serum samples following infusion of synthetic human heptadecapeptide 
gastrin into the pig were chromatographed to assess whether the mole-
cular species of gastrin was altered by prolonged circulation in vivo; 
(xi} The effect of the isolated rat liver on physiological and supraphysio-
logical levels of gastrin perfused cyclically through this organ in a 
plasma-free medium was studied. Column chromatography of perfusate 
samples was performed to assess whether the rat liver had any effect 
on circulating gastrin; 
(xii) Finally, the in vitro binding of heptadecapeptide gastrin to the basic 
liver cytosol protein, ligandin, was studied to assess the importance 
of this protein in relation to gastrin transport and/or inactivation. 
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In setting out this thesis I have reviewed the relevant literature (including 
that which has postdated many of my studies) pertaining to the aspects of 
gastrin which I investigated, and grouped this into ten different sections in 
Chapter 2. Chapter 3 contains an account of al I the methods and materials 
used in these studies, and is divided into five sections, which in turn com-
prise several sub-sections. The results of these studies are contained in 
Chapter 4, in which case the same sequence of the various sub-sections is 
maintained. The findings in this study are discussed in the light of the 
findings of other groups working in the same field in Chapter 5, and as 
far as possible the sequence set out in the two preceding chapters is ad-
hered to. Chapter 6 contains a summary of the results of this investigation 
and suggestions for future research arising from the findings of this study. 
In Chapter 7, the appendix, severe I methods relevant to the thesis, al-
though not carried out by myself, are described. 
CHAPTER 2 
LITERATURE REVIEW 
Section I Historical Aspects 
The birth of endocrinology occurred with the discovery by Bayliss and 
Starling in 1902 of an active principle in the upper intestinal mucosa which 
on extraction and intravenous injection into anaesthetised dogs, caused the 
flow of pancreatic juice. They called this active principle 11 secretin 11 and 
on the basis of their experiments they concluded that contact of the acid 
chyme with the epithelial eel Is of the duodenum causes the production of a 
body (secretin) which is "absorbed from the cells by the blood current and 
is carried to the pancreas, where it acts as a specific stimulus to the pan-
creatic cells, exciting a secretion of pancreatic juice proportional to the 
amount of secretin present " (Bayliss and Starling, 1902). This was the 
first demonstration of the existence of a humeral mechanism in the body, 
by which is meant a process demonstrated to be independent of nervous 
connections between the site of stimulation and the effector site (Grossman, 
1950). Three years later, in 1905, Starling introduced the word 11hormone" 
to designate this class of chemical coordinators (Walsh and Grossman, 1975a). 
In the same year Ed kins suggested that a "gastric secret in" mechanism 
operated by means of a substance produced by the presence of partially 
digested food in the stomach, which passes into the blood or lymph and 
later stimulates the secretory cells of the stomach to functi ona I activity. 
He showed that extracts of pyloiic mucous membrane made in boiiing water 
or 0,4% HCI, prepared from the cat or the pig, contained an active sub-
stance which on intravenous injection into anaesthetised cats led to the 
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secretion of acidic gastric juice. This effect was not observed with an 
extract prepared from the mucous membrane of the fund us ( Edkins, 1905a). 
He suggested that this active principle, which was not destroyed by boiling, 
be named "gastrin 11 (Edkins, 1905b). 
Edkins' findings regarding pyloric extracts and their effect in causing 
gastric secretion were confirmed by Lim (1923), who reproduced his ex-
periments essentially as Edkins had done them. Sacks, Ivy, Burgess and 
Vandolah (1932) isolated histamine from hog pyloric mucosa and showed 
that this gastric secretory excitant was active when injected subcutaneously, 
leading them to conclude that "histamine is the gastric hormone, or if not, 
there is no gastric hormone, or the gastric hormone has never been ex-
tracted from pyloric mucosa". Boller and Pilgerstorfer (1937, cited by 
Grossman, 1950, p. 42) modified Edkins 1 procedure either by using different 
methods of extmction, or by injecting their extracts subcutaneously as 
opposed to intravenously, and found that subcutaneously effective extracts 
could be prepared from both pyloric and fundic mucosa as well as from 
many other tissues. We now know that these observations were due to 
the presence of that ubiquitous substance, histamine, in these extracts. 
This controversy as to whether the extracts contained a stimulant 
other than histamine raged for many years, until the work of Komarov 
in 1938, which radically changed the general belief that the activity 
of Edkins' extracts was probably attributable to the presence of histamine. 
Komarov, recognising that the antral hormone might be of a protein nl1ture, 
succeeded in precipitating a protein fraction from an acid aqueous extract 
of canine pyloric mucosa with 10% trichloroacetic acid. On injection 
into anaesthetised cats this protein fraction stimulated the copious secretion 
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of gastric juice with high acidity and low peptic pO'Ner (Komarov, 1938). 
He found this active principle only in the pyloric region of the stomach, 
and he also detected a small amount in duodenal extracts prepared in the 
same manner. Komarov's preparations were of low potency and non-toxic 
when injected intravenously. Subcutaneous injection of his extracts did 
not stimulate secretion, providing further evidence that the active principle 
was of protein nature and thus not readily absorbed when administered sub-
cutaneously (Komarov, 1942 (a) and (b), cited by Gregory and Tracy, 1961, 
p. 523). 
Uvnas was able to confirm Komarov's results using the same method of 
preparing gastrin with some modifications (Uvncls, 1942). In the same year 
Uvnas demonstrated that vagal impulses caused the release of gastrin (Uvnas, 
1942). Further studies by Uvnas (1945), Harper (1946) and Jorpes, Jailing 
and Mutt (1952) established that a potent gastric acid secretory stimulant 
could be extracted from the pyloric mucosa of dogs, cats, pigs and humans. 
The histamine content of these active extracts was usually too small to be 
detected (Uvncls, 1943) and incubation with histaminase failed to reduce the 
effectiveness of potent extracts (Bauer and Uvnas, 1944). _ 
Although these investigations established beyond doubt that these gastrin 
extracts stimulated gastric secretion in anaesthetised cats, there was little 
evidence that such preparations were active when injected into conscious 
animals (Gregory and Tracy, 1961). P;ompted by the need to find a 
suitable gastrin preparation for such studies, Grngory and Tracy (1961) 
deveioped a method of extraction of gastrin from hog antra I mucosa which 
strongly stimulated gastric acid secretion when injected subcutaneously as 
well as intravenously or intramuscularly into conscious dogs with gastric 
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fistulae or gastric pouches. The preparation was pure enough to be suitable 
for experiments in humans (Gregory and Tracy, 1961). However, the ex-
traction procedure was tedious, expensive and inefficient, making it un-
suitable for the isolation of the hormone in amounts large enough for 
structural studies (Gregory and Tracy, 1964). 
In 1964 Gregory and Tracy evolved a new method of preparation of 
gastrin from hog antral mucosa which could be worked easily and cheaply 
on a very large scale (Gregory and Tracy, 1964). They identified the 
final product as consisting of two almost identical peptides which they 
called gastrin I and gastrin II. The extraction procedure was commenced 
by boiling batches of 300 hog antra in tap water for 30 minutes. The 
final yield from 600 antra after the extraction procedure, which culminated 
in fractionation on a Sephadex G-50 column and two fractionations on 
aminoethylcellulose columns, produced two well defined peaks containing 
gastrin activity, comprising 17 mg gastrin I and 22 mg gastrin II (Gregory 
and Tracy, 1964). High voltage electrophoresis did not alter either the 
amino acid constitution or the physiological activities of either gastrin, 
and both gastrins ran as single compact spots on the paper (Gregory and 
Tracy, 1964), indicating biochemical purity. The absence of a terminal 
amino group in the molecule was confirmed by negative fluorodinitrobenzene 
and ninhydrin tests (Gregory and Tracy, 1964). Amino acid analyses of 
gastrins I and 11 after acid hydrolysis showed that both molecules had the 
same amino acid constitution, and the minimal molecular weight for each 
gostrin, calculated on amino acid composition, was found to be 2114 
(Gregory and Tracy, 1964). Both gastrins were shown to be many times 
more potent than histamine when injected as single subcutaneous doses in 
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conscious dogs with denervated fundic pouches (Gregory and Tracy, 1964). 
On a molar basis gastrin II was shown to be 500 times more effective than 
histamine in stimulating gastric secretion in human subjects (Makhlouf, 
McManus and Card, 1964). 
Working in collaboration with Gregory and Tracy on the hormones they 
had isolated, Gregory, Hardy, Jones, Kenner and Sheppard (1964) determined 
that porcine gastrin 11 was a heptadecapeptide amide with the structure: 
t1Glu - Gly - Pro - Try - Met - Glu - Glu - Glu - Glu - Glu - Ala -
Tyr - Gly - Try - Met - Asp - Phe - NH2 I 
S03H 
and they showed that gastrin I differs from gastrin II only in that it lacks 
the sulphate group esterified to the tyrosine in position 12. This group of 
workers succeeded in synthesising gastrin in the same year, thus confirming 
the sequence deduced from the degradative investigations (Anderson, Barton, 
Gregory, Hardy, Kenner, Macleod, Preston, Sheppard and Morley, 1964), 
and they were able to show that their purified product of synthetic gastrin I 
was indistinguishable from natural gastrin I on column chromatography, high-
voltage electrophoresis and thin-layer chromatography. The same was true 
of their preparation of gastrin II. In addition their synthetic gastrin I pre-
paration gave full biological responses when iniected subcutaneously into a 
conscious dog (Anderson, Barton et ai., 1964). 
The actions of the pure natural gastrins were summarised by Tracy and 
Gregory in 1964. By using the peptides produced during the programme of 
synthesis of gastrin and testing their activity, Tracy and Gregory (1964) 
were able to show that all the physiological actions displayed by the 
gastrins were possessed by the (-terminal tetrapeptide amide, and that 
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these activities were largely abolished by rnmoval from this structure of the 
amide group masking the C-termi na I phenylalanine residue. 
Extending this work, Gregory, Tracy and Grossman (1966) applied the 
same extraction procedure as used for hog antra to isolate gastrin from 
human antra I mucosa. Antral mucosa was collected from human subjects 
undergoing partial gastrectomy, boiled in tap water for 5 minutes, and 
gastrin isolated ,n the same manner as for porcine gastrin (Gregory and 
Tracy, 1964). Gradient elution of the final product on an aminoethyl-
cellulose column produced separate peaks of human gastrin I and II, but 
in this case the yield from 23 antra gave 1,35 mg gastrin I and 0,79 mg 
gastrin II (Gregory, Tracy and Grossman, 1966), in contrast with the ratio 
of approximately 3 :4 found for porcine gastrins I and 11 (Gregory and 
Tracy, 1964). 
Bentley, Kenner and Sheppard ( 1966) found the amino acid sequence of 
human gastrin to differ from that of porcine gastrin only in the substitution 
of methionine in position 5 by leucine, while the presence or absence of 
a sulphate group esterified to the tyrosine residue in position 12 was the 
same as for porcine gastrins II and I respectively. Human gastrins I and 11 
displayed the same physiological activity as did porcine gastrins (Gregory and 
Tracy, 1964; Gregory, Tracy and Grossman, 1966), which was not surprising 
since the differences in primary structure between the two molecules occurred 
in the region of the molecule which is not essential for biological activity 
(Tracy and Gregory, 1964). Synthetic human gostrin prepared according to 
the structure determined by sequential analysis was shown to be biologically 
active and its identity with the natural human gastrin I was confirmed by 
degrading both peptides in parallel with papain and comparing the peptides 
thus obtained using thin-layer chromatography (Beacham, Bentley, Gregory, 
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Kenner, Macleod and Sheppard, 1966). 
With the advent of purification of gastrin from hog and human antral 
mucosae and the demonstration of their biological activity by injection into 
test animals came the need to quantitate the biological activity of these 
preparations. Early measurements of gastrin activity were performed using 
bioassay techniques, as described in the next section. 
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Section II Measurement of Gastrin Activity by Bioassay 
The technique of bioassay of gastrin involves comparing the response in 
gastric acid secretion evoked by administration of a test substance to an 
experimental animal with that produced by a standard reference preparation 
of known biological activity. Animals used in bioassay techniques which 
have been described include the cat, rat and dog, either in the anaesthetised 
or conscious state, although dogs have the disadvantage that a larger total 
dose of the test material is required to stimulate acid secretion (Em8s and 
Uvn8s, 1973). Histamine was used as the reference standard before pre-
parations of gastrin were avai fable, but the disadvantage of using a reference 
standard which differs from gastrin is obvious. A crude gastrin extract pre-
pared by the method of Blair, Harper, Lake, Reed and Scratcherd (1961) was 
used as the standard reference preparation in some earlier bioassays, whereas 
pure gastrin or synthetic human gastrin were used in more recent methods. 
For a reliable bioassay certain basic requirements must be met: the 
animal used must be sensitive to gastrin, it must respond predictably to 
different doses of the test material, the reference standard must be of a 
constant potency, and it must behave as gastrin (Em8s and Uvnc!s, 1973). 
The first method of gastrin bioassay that fulfilled these requirements was 
described by Uvntls and Em8s (1961). They used conscious cats with gastric 
fistulae, since it had been shO'Wn by Em8s ( 1960) that smaller doses of 
stimulant were required to stimulate Clcid secretion than in anaesthetised 
cats, and conscious cats responded more uniformly to stimulation than did 
anaesthetised cats. Histamine was used as the reference standard; it was 
shown that the slopes of the dose-response curves for gastri n and histamine 
did not differ (Uvnc!s and Em8s, 1961). Two identical doses of a gastrin 
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extract were infused for 15 minutes per hour, interposed between a small 
and a large dose of histamine, so that as long as the gastrin doses fell within 
the range of the two histamine doses, the mean secretory activity of a gastrin 
extract could be expressed in histamine units per milligram preparation. Only 
one gastrin extract could be assayed in each experiment, the duration of 
which was 4, 5 hours, but the cats could be used repeatedly. Once pure 
synthetic human gastrin was available this was used instead of histamine as 
reference standard, and the smallest effective dose, or sensitivity of the 
assay, was found to be 0,08 - 0,2 micrograms (µg) synthetic human gastrin 
infus~ for 15 minutes (Em8s and Uvnas, 1973). 
Blair, Harper and Reed (1962) described a gastrin bioassay method using 
anaesthetised cats in which they overcame the great variation in acid response 
to 15-minute infusions of gastrin extracts or histamine, described by Em8s 
(1960}, by injecting a standard gastrin extract every 15 minutes, to maintain 
a continuous secretion of acid. The activity of a test extract was measured 
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by replacing one injection of the gastrin standard with the test extract and 
comparing the response with that expected to the standard extract. A reliable 
assay required that the response fell within: 25% of the anticipated response 
to the standard. This technique was further refined by Blair, Keenlyside, 
Newell, Reed and Richardson (1968). As many as ten extracts could be 
assayed with good precision in a single experiment. Using this technique, 
B!air and Wood (1968) estimated the half-life of gastrin activity in plasma 
to be less than 4 minutes between the second and tenth minutes after an 
intravenous injection of a gastrin extract. This value is remarkably close 
to the half-life value for gastrin in the circulation found by later investigators, 
as discussed in section IX(iii) of this chapter. 
Ghosh and Schild (1958) developed a method for the continuous 
recording of gastric acid secretion in the anaesthetised rat by perfusing 
the stomach with a dilute sodium hydroxide solution ( 1/4000 N) via the 
oesophagus, and monitoring the pH of the fluid emerging from a cannula 
in the pylorus which passed over a glass electrode connected to a recording 
pH meter. Test substances were given as a rapid intravenous injection, and 
the response was measured as a pH change in the perfusate passing through 
the stomach. This system was suitable for the bioassay of secretory stimulants, 
and 10 or more drug doses could be administered in succession in the same 
preparation, provided that successive doses of drugs were only administered 
once the effect of a previous dose had subsided (Ghosh and Schild, 1958). 
The advantage of this method was that each animal served as a self-contained 
assay unit. Although this method measured total acid secretion it did not 
allow quantitation of the volume or acidity of the gastric juice secreted in 
response to various stimulants. In addition, the gastric secretion may have 
been affected by the artifi cia I conditions prevailing during the study, such 
as the body temperature which was kept at 30°(, the alkaline perfusate in 
the stomach, and tha effect of anaesthesia on acid and mucous secretion 
(Ghosh and Schild, 1958). 
Two modifications of the method of Ghosh and Schild (1958) have since 
been used for the bioassay of gastrin in rats. Amure and Ginsburg (1964) 
described an assay based on the observation that a linear relationship existed 
between the maximal pH change of the gastric effluent and the dose of 
gastrin extract given in the anaesthetised rat, prepared according to the 
method of Ghosh and Schild (1958). They used a crude gastrin extract 
as standard, and the assay involved injection of a high and a low dose 
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of both standard and test extract. However, the method on!y applied to 
a narrow range of doses where this relationship held true, which meant 
that preliminary tests were necessary before the final assay. Only one 
test extra ct could be assayed per experiment. 
Lai (1964a) modified the method of Ghosh and Schild (1958) by washing 
the stomach of an anaesthetised rat clean in a slow stream of tap water and 
then perfusing it in situ with 0,9% saline, warmed to 37°(, and collecting 
10-minute samples of gastric effluent. These samples were titrated against 
1/100 N- Na OH so that the acid secretion could be expressed as µ Eq/10 
minutes. Test substances were injected intravenously over a period of 15 
minutes and the mean rate of acid secretion, corrected for the continuous 
basal acid secretion, was determined as the mean acid output per 10 minutes, 
calculated over several 10-minute periods. The response to the first dose was 
excluded as it was unreliable. The effects of test preparations were deter-
mined by comparison of the mean rates of acid secretion which they elicited 
with the response to graded intravenous doses of gastrin extracts (Lai, 1964a). 
However, the assay of one extract required 6 infusions of both test and 
control extract and 4 rats had to be used (Em8s and Uvntis, 1973). According 
to Em8s and Uvntls ( 1973), the sensitivity of the assay methods of Amure and 
Ginsburg (1964) and Lai (1964a) cannot be evaluated from available data. 
An improved bioassay for gastrin, using the perfused rat stomach, was 
described by Smith, Lawrence, Colin-Jones and Schild (1970), who developed 
a method based on reperfusion of the rat stomach, in which the acid output 
could be accurately quantitated. The anaesthetised rat stomach was reper-
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fused continuously, stimulants were injected intravenous! y, and the accumulation 
of hydrogen ions in the recirculating buffer was integrated as it occurred, so 
that the amount of acid secreted in a given time, and the time course of 
secretion could be continuously followedo Correction for baseline acid 
secretion was made, and the results of the first test dose were disregarded 
as they were inconsistent. The reperfusion solution was changed before each 
dose of secretagogue was administered. The assay had a sensitivity of 10-20 
nanograms {ng} of synthetic human gastrin, and the steepest part of the dose-
response curve lay between 40 and 200 ng synthetic human gastrin. This 
assay was used to measure gastrin activity in the plasma and tumour extract 
of a patient with Zollinger-Ellison syndrome (Z.E.S.) 
From this discussion it is apparent that the technique of bioassay poses 
certain limitations. Only a very small number of unknown or test specimens, 
and in some cases only one, could be assayed at a time, and most of the 
methods were tedious and time consuming to execute. Variations in the 
methods and the animals used, which included rats, dogs and cats, made 
comparison between different assays difficult. This problem was compounded 
by the fact that pure gastrin preparations were not available in the early 
days of bioassay, and in some cases histamine was substituted for gastri n as 
the standard reference preparation. In addition, these methods were very 
insensitive, with the lowest detectable level in the range of 1 ng (Walsh 
and Grossman, 1975a)i this is not sensitive enough to measure normal 
circulating gastrin levels, which are usually less than 100 picograms per 
millilitre (pg/ml) serum. Bioassay techniques are only useful in measurement 
of serum gastrin levels in hypergastrinaemic patients with gastrinoma (Walsh 
and Grossman, 1975a). However, bioassays can be performed with good 
precision, so that repeated measurements of the same sample agree to within 
10% of each other {Walsh and Grossman, 1975a; Loraine and Bell, 1971). 
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Once pure gastrin preparations became available, the technique of 
radioimmunoassay of gastrin could be developed. This technique is about 
a thousand times more sensitive than bioossay, allowing detection of gastrin 
levels as low as 1 picogram (Walsh and Grossman, 1975a),and large numbers 
of serum gastri n estimations can be performed simultaneous! y, with high 
sensitivity and specificity {Loraine and Bell, 1971; Walsh and Grossman, 
1975a). 
Bioassay is still very useful currently for the measurement of the physio-
logical activity of secretory stimulants, compared to their immunological 
reactivity, which is detected by radioimmunoassay, and for comparison of 
the biological and immunochemical activity of natural and synthetic gastrin 
preparations. Ideally the two techniques should be used together, although 
this is impractical in most instances. 
Since the development of radioimmunoossay a further technique for the 
bioassay of gastrin has been described, which allows exquisitely sensitive 
measurements of gastrin activity as low as 5 femtograms per millilitre (fg/ml). 
Loveridge, Bloom, Welbourn and Chayen (1974) described the cytochemical 
bioassay of gastrin, which entails measuring the hydrochloric acid secretion 
by the parietal cells of the gastric fundus of the guinea pig in response to 
stimulation by graded concentrations of gasrrin in the range 5 pg/ml to 
5 fg/ml. The response is quantitated by recording the intensity of staining 
in the parietal cells, since the optical density is directly proportional to 
the gastrin activity. This technique has not yet been widely used, and is 
rather time consuming and labodous to execute,so at present radioimmuno-
assay remains the most practical method for gastrin determinations on large 
numbers of samples. 
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Section 111 Radioimmunoassay of Gastrin 
The observation that serum of human diabetic subjects who had been 
treated with mixtures of beef and pork insulin contained insulin-binding 
antibodies, and that increasing concentrations of unlabelled beef insulin 
produced a progressive decrease in the binding of 131 Iodine-labelled beef 
insulin by these antibodies (Berson, Yalow, Bauman, Rothschild and Newerly, 
1956) was fundamental in the development of the technique of radioimmuno-
assay. Radioimmunoassay was first developed for the assay of insulin in 
plasma by Yalow and Berson in 1960, using antisera raised in guinea pigs 
immunised with beef insulin, and 131 1-beef insulin as tracer (Yalow and 
Berson, 1960; Berson and Ya low, 1972). 
The first radioimmunoassay for gastrin was described by McGuigan in 
1968 (McGuigan, 1968a). He produced antisera by immunizing rabbits via 
foot pad injections with synthetic human gastrin (SHG) (2-17) coupled to 
bovine serum albumen (BSA) with carbodiimide (1-Ethyl-3-(3-dimethylamino-
propyl carbodiimide)) (CD i) according to the method of Goodfriend, Levine 
and Fasman (1964), and purified the gamma globulin fraction by ammonium 
sulphate precipitation before use in the assay. He used SHG (2-17) as 
standard, and his tracer was prepared by iodinating SHG (2-17) with 
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131 Iodine to a specific activity of 32-136 microcuries per microgram (.uCi/.ug), 
according to a modification of the method described by Hunter and Greenwood 
for i·he iodination of human growth hormone (Hunter and Greenwood, 1962). 
The assay diluent was 0,15M-NaCI-O,OlM-potassium phosphate pH 7,4 
containing 2,5 mg/ml ovalbumen. The total incubation volume was 0,5 ml 
and the assay was incubated for 24 hours at 4°(. Separation of antibody-
bound and free label led hormone was effected using anti-rabbit gamma globulin 
raised in goat. McGuigan (1968a) reported that it was possible to detect 
as little as 5 picograms (pg) gastrin I with this assay system. 
In the years that fol lowed a flurry of techniques for the radi oimmuno-
assay of gastrin were published. Rather than attempt to describe these 
different assays in detail they are presented in table (2.111.1) with respect 
to the standard, tracer, antiserum, assay diluent and separation methods 
employed, as wel I as the sensitivity of the assay and norma I fasting serum 
gastrin levels where available. Where detai Is such as the molarity of the 
buffer used and whether the gastrin standard used was the (l-17) or the 
(2-17) sequence are missing in the table, the relevant information was not 
given in the references quoted. 
Antisera 
Antisera were raised chiefly by immunising rabbits (McGuigan, 1968a; 
Hansky and Cain, 1969; Stadil and Rehfeld, 1971; Ganguli and Hunter, 
1972) and guinea pigs (Yaiow and Berson, 1970a; Stadil and Rehfeld, 1971; 
Ganguli and Hunter, 1972), although in one case chickens were used for 
immunisation (Young, Byrnes, et al., 1969). Due to its smcil molecular 
size gastrin is not a good antigen (Walsh, 1974) so generally it is conjug~ted 
to a large carrier protein such as BSA by a coupling reagent such as carbo-
diimide before injection. The injection may be administered via the foot 
23 
pad, subcutaneously, intraperitoneal ly, or intramuscular! y. Synthetic human 
gastrin I (l-17) and (2-17) have been used for conju£ation and immunisation; 
the rationale behind using SHG (2-17) being that removal of the N-terminal 
pyroglutamyl group reveals a free amino group to react with the carbodiimide. 
However, since COi cross-links equally well through acidic side chains, of 
which gastrin has six, it is unlikeiy that a high proportion of conjugation 
TABLE (2.111.1) 
Details of Rodi oimmunoassays for Gastrin Previously Published 
Abbreviations 
SHG I 
gastri n 
gastrin 11 
synthetic human heptadecapeptide gastrin I 
non-sulphated gastrin 
sulphated gastri n 
numbers following a peptide in brackets indicate the amino 
acid sequence employed 
,.,Cijµg 
BSA 
HSA 
CDI 
pg/ml 
131 lod" 1 ne 
1251od" , ne 
mi crocuri es per microgram 
bovine serum a I bum en 
human serum a I bum en 
1-Ethyl-3(3-Dimethyl-amino-propy!)-carbodi imide 
picograms per millilitre 
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occurs through the single amino group of gastrin (2-17) (Walsh, 1974). 
Young, Byrnes et al. (1969) immunised chickens with pentagastrin conjugated 
to rabbit serum albumen. Yalow and Berson (1970a) obtained antisera upon 
immunising guinea pigs with unconjugated crude porcine gastrin, as did 
Ganguli and Hunter (1972). Chan Yip and Jordan (l 970) used a mixture 
of partially purified porcine gastrins I and II conjugated to BSA with CDI 
to obtain their antiserum in rabbits, and in 1976 Dockray and Taylor 
described measurement of heptadecapeptide gastrin with a specific antiserum 
raised by immunising rabbit with natural porcine gastrin conjugated to BSA 
(Dockray and Taylor, 1976). 
Although McGuigan (1968a) isolated the gamma globulin fraction from 
his antiserum by ammonium sulphate precipitation, the general practice is 
to use the straight serum as collected afte; centrifugation of the blood, 
without further purification (Rehfeld, Stadil and Rubin, 1972). Dilutions 
quoted refer to the dilution of such antisera with assay diluent. 
Gastrin Standard 
Synthetic human heptadecapeptide gastri n I (SHG-17 l} prepared by 
Imperial Chemical Industries (I. C. I.) was the preparation used most often 
as the assay standard (Stadil and Rehfeld, 1971; Schrumpf and Sand, 1972; 
Ganguli and Hunter, 1972; Hansky and Cain, 1969), McGuigan (1968a) 
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used the hexadecapeptide molecule (2-17) as standard, while Feurle, Ketterer, 
Becker and Creutzfeldt (1972) used synthetic human 15-ieuci ne gastiin as 
standard and for iodination. Yalow and Berson (1970a) found a discrepancy 
in immunochemical potency between two different batches of synthetic human 
gastrin obtained from I.C.I. and they chose to use porcine gastrin I as 
standard, since it showed the greatest immunochemi ca I potency, and porcine 
gastrins I and II were equipotent immunologically in their assay system. 
Stadil and Rehfeld (1972) also reported that different ampoules of SHG 
obtained from I .C. I. contained impurities and differed in immunoreactivity. 
Porcine gastri:1 I was used as standard by Ganguli and Hunter (1972); Walsh 
(1974) reported using both porcine gastrin 17 II and human gastrin 17 I as 
standards. According to Walsh (1974), newly synthesised batches of SHG 
are available from I.C.I., and differences in potency among various vials 
have not been reported with this material. 
Iodination of Gastdn 
Earlier assays were carried out using synthetic human gastrin labelled 
with 131 iodine (McGuigan, 1968a; Young, Byrnes et al., 1969; Chan 
Yip and Jordan, 1970), whereas more recently 125 1odine has been the 
isotope of choice (Schrumpf and Sand, 1972; Ganguli and Hunter, 1972; 
Walsh, 1974). To obtain maximal sensitivity in a radioimmunoassay it is 
necessary to have a satisfactory counting rate with a very small concentration 
of labelled hormone. The ratio of counting rate to tracer concentration is 
influenced by the specific activity of the tracer and the efficiency of 
counting (Yalow and Berson, 1968). 
The specific activity attainable depends on the individual hormone and 
on the isotopic abundance of the iodine itself (Yalow and Berson, 1968). 
131 
Iodine has a half-iife of 8 days and 1251odine has a half-life of 57 days, 
sc it would appear that 131 Iodine would be better for obtaining a high count 
t b f • 1 f Ir I" f '-I f• • od d 131 J od • ra e ecause o its snorter 10 i- 1 e. 1 owever, 1ss1on-pr uce me 
I h b d ~ . I 30°· I 125 1od· • ·1 bl on y as an a un ance ot approximate y 1o, wnereas 1ne 1s avm a e 
virtually in a carrier-free state. In addition, the efficiency of detection of 
125 1odine may be two to three times that of 131 Iodine (Yalow and Berson, 
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1968). Thus 1251odine is the more suitable isotope for use in a radioimmuno-
assay sensitive enough to detect hormone concentrations in the pi cogram range 
(Yalow and Berson, 1968). 
The specific activity of carrier-free 131 Iodine is approximately 125 milli-
curies per microgram (mCi/,,ug) and of 125 1odine is approximately 18 mCi/,,ug 
(Yalow and Berson, 1968). This value refers to the ratio of radioactive 
iodine atoms to cold iodine atoms and should not be confused with the 
specific activity of the labelled hormone, which refers to the ratio of radio-
active iodine atoms incorporated per unit weight of hormone. Increasing 
the number of radio iodine substitutions in the tyrosine ring increases the 
specific activity of the labelled hormone, but over-iodination may decrease 
the immunoreactivity of the label led preparcti on (Yalow and Berson, 1968). 
In the case of monoiodinated gastrin, with a substitution of l atom of icdine 
per molecule of gastrin, the specific activity of the label led product is 
approximately 900 ,,u(i/.ug according to Walsh (1974) and approximately 
1 000 NCi/.ug according to Ganguli and Hunter (1971), assuming an isotopic 
abundance of 100% for 125 1odine. 
lodinations have been performed as modification of the chloramine- T 
technique described by Hunter and Greenwood (1962) for the iodination of 
human growth hormone with 131 Iodine (Ganguli and Hunter, 1972; Yalow 
and Berson, 1970a; Stadil and Rehfeld, 1971), or according to the method 
described by Ganguli and Hunter (1971) for the iodination of gastrin with 
1251od" 1ne. Specific activities obtained in assays described ranged from 
200 - 500 JJCi/J.Jg for 131 1-gastrin labelled by Young, Byrnes et al. (1969) 
to 900.uCi/..ug for 125 1-gastrin described by Walsh (1974). 
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Standard gastrin preparations that have been used for iodination include 
SHG-17 I (Stadil and Rehfeld, 1971), synthetic human 15-leucine gastrin 
(Feurle, Ketterer et al., 1972) and highly purified porcine gastrin (Yalow 
and Berson, 1970a; Ganguli and Hunter, 1972). 
Assay Procedure 
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Assay diluent buffers that have been used include 0,15M-NaCI-0,01M-
potassium phosphate pH 7,4 (McGuigan, 1968a; Chan Yip and Jordan, 1970), 
phosphate buffer pH 7,5, 0,15M (Young, Byrnes et al., 1969) or 0,05M 
(Ganguli and Hunter, 1972), 0,02M-veronal pH 8,4 (Stadil and Rehfeld, 
1971; Yalow and Berson, 1970a), or straight charcoal-adsorbed serum (Hansky 
and Cain, 1969). All buffers contained low concentrations {usually 0,25%) 
of ovalbumen, bovine serum albumen {BSA), or human serum albumen (HSA), 
presumably to minimise adsorption of hormone to the assay vessel. Schrumpf 
and Sand (1972) obtained a steeper standard curve with 0, 1 M-sodium phosphate 
buffer pH 7,5 compared to O,lM-veronal buffer pH 8,4, and O,lM-Tris-HCI 
buffer pH 7,5, both of which gave similar results. 
Total volumes incubated ranged from 0,5 ml (McGuigan, 1968a) to 
2,5 m! (Yalow and Berson, 1970a) and incubation times varied from 24 hours 
at 4°C (McGuigan, 1968a) to 4-6 days at 4°C (Stadil and Rehfeld, 1971). 
The length of time of incubation depends on the nature of the antibody and 
the range of gastrin concentrations in unknown samples (Walsh, 1974), so that 
longer incubation periods are used when low concentrations of antibody and 
tracer are used to measure very low concentrations of gastrin (Walsh, 1974). 
In some cases J-he use of preservatives in the assay diluent has been 
described. Young, Byrnes et al. (1969) used 0,005% mercuric chloride in 
their buffer, while Schrumpf and Sand (1972) added O ,02% sodium azide to 
their phosphate buffer. 
Stadil and Rehfeld (1973a) found that sodium chloride and heparin in 
the incubation mixture interfered with the binding of antigen, and when 
separation of antibody-bound and free labelled hormone was carried out 
using Amberlite anion exchange resin, heparin had to be excluded altogether. 
Separation Techniques 
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Early methods for separation of antibody-bound and free label led hormone 
involved the technique of high voltage paper electrophoresis using Whatman 
no. 3 or 3MM paper, or chromatoelectrophoresis using Whatrnan WB-2 resin 
paper (Yalow and Berson, 1970a). Yalow and Berson (1970a) reported that 
free labelled gastrin added to plasma does not adsorb to Whatman no. 3 or 
3MM paper but migrates immediately in front of serum albumen, whereas 
antibody-bound gastrin migrates only very slightly from the site of application. 
This paradoxical behaviour of gastrin on paper strips rules out the technique 
of chromatoelectrophoresis for separation of antibody-bound and free labelled 
gastrin. Yalow and Berson (1960) developed the technique of immunoassay of 
insulin in plasma using Whatman 3MM paper to separate antibody-bound and 
free label led insulin in the presence of increasing concentrations of insulin. 
However, the use of separate paper strips for each standard and unknown is 
laborious and this separation technique has been superceded by more suitable 
techniques described below. 
Separation of antibody-bound and free label led hormone has been described 
using Amberlite anion exchange resin (Young! Byrnes et al., 1969; Yalow 
and Berson, 1970a; Stadil and Rehfeld, 1971; Feurle, Ketterer et al., 1972; 
Walsh, 1974) and dextran-coated charcoal (Hansky and Cain, 1969; Schrumpf 
and Sand, 1972; Haye!:, Ardill, Kennedy, Shanks and Buchanan, 1972) to 
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adsorb and precipitate the free labelled hormone. Precipitation of antibody-
bound labelled hormone has been effected using a double antibody precipi-
tating technique such as goat anti-rabbit gamma globulin (McGuigan, 1968a; 
Chan Yip and Jordan, 1970; Ganguli and Hunter, 1972) or 50% polyethylene 
glycol (Carbowax 6000) in water (Stadil and Rehfeld, 1973a). 
Stadil and Rehfeld (1973a) obtained identical curves of displacement of 
antibody-bound iabelled gastrin with increasing concentrations of unlabelled 
gastrin when separation was effected using charcoal, polyethylene glycol, 
and two types of Amberlite resin, CG 48 and IRP 58. They showed no 
advantage in using dextran-coated charcoal over untreated charcoal and they 
found that it was essential to have a uniform protein concentration in all 
samples when separation was carried out using polyethylene glycol and un-
coated charcoal, whereas this was not critical when Amberl ite was used 
(Stadil and Rehfeld, 1973a). The presence of heparin influenced separation 
using Amberlite resin CG 48, making it necessary to avoid using this com-
bination (Stadil and Rehfeld, 1973a). 
Rehfeld and Stadil (1973b) described a solid phase gastrin radioimmuno-
assay employing the immunosorbent bromoacetylcellulose (8AC) to which they 
covalently coupled their antiserum 2604-7. This technlque allows a very 
simple preparation procedure whereby the antibody-bound free labelled 
hormone is precipitated by centrifugation of the BAC-cntibody conjugate. 
Apart from a small decrease in sansitivity and the fact that more antiserum 
is used than with conventional methods, the assay parameters using this method 
compare favoumbly with those obtained when separation of free and bound 
hormor.e is carried out using charcoal, polyethylene glycol, and anion ex-
change resin (Rehfeld and Stadil, 1973b). 
Detection Limits of the Assay 
The lowest concentration of hormone measurable that differs significantly 
from zero is known as the detection limit or sensitivity of the assay. The 
most sensitive assays for gastrin reported sensitivities of 5 picograms per milli-
litre (pg/ml) or less (Hansky and Cain, 1969; Yalow and Berson, 1970a; 
Stadil and Rehfeld, 1971). Ganguli and Hunter (i972) reported an assay 
sensitivity of 25 pg/ml, while Young, Byrnes et al. (1969) and Hayes, Ardill 
et al. (1972) reported a sensitivity of 50 pg/ml. 
Serum Gastrin Levels in Control Subjects 
McGuigan and Trudeau (1968) reported a mean fasting serum gastrin level 
of 425 pg/ml in 24 normal adult subjects. In 1970 the same workers found 
a mean fasting sarum gastrin concentration of 165 pg/ml in 102 subjects 
(McGuigan and Trudeau, 1970a), while in 1971 they reported an even lower 
normal fasting serum gastrin level in 35 controls of 85 pg/ml (Trudeau and 
McGuigan, 1971). A similar finding was described by Stadil and Rehfeld 
(1971), who reported a mean normal serum gastrin level of 93 pg/ml, whereas 
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in 1973(a) they found a mean fasting level of 52 pg/ml,: 4,6 pg/ml (,: S.E.M.) 
in 120 control subjects. This decrease in gastrin levels is attributable to an 
improvement in the quality of the labelled preparation in more recent years 
(Stadil and Rehfeld, 1973a) or to improvements in the radioimmunoassay 
technique (McGuigan and Trudeau, 1970a; Berson and Yalow, 1972). 
Most other groups reported mean fasting serum gasrrin levels in normal 
subjects of below 125 pg/ml, which was the highest value found by Feurle, 
Ketterer et al. (1972), with the lowest values reported being 20 pg/ml 
(Walsh, 1974). In general, normal levels appear to be below 100 pg/ml, 
as shown in table (2.lil.1). Two exceptions to this are the assays reported 
by Young, Byrnes et al. (1969), who reported a mean fasting level of 
400 pg/ml and Chan Yip and Jordan (1970) who found a normal level of 
391 pg/ml. Since Young, Byrnes et al. (1969) could only obtain an assay 
sensitivity of 50 pg/ml it is hardly surprising that their normal levels were 
so high. 
McGuigan and Trudeau (1970a) showed a direct relation between in-
creasing age and increasing fasting serum gastrin concentrations. They 
found mean fasting serum gastrin levels of below 100 pg/ml in subjects 
from the age group 20-39 years, with an increase up to between 500 and 
600 pg/ml in subjects over the age of 80 years. They suggested that the 
higher serum gastrin concentrations in older patients were due to gastric 
mucosa! atrophy or reduced rates of acid secretion (or both) (McGuigan 
and Trudeau, 1970a). In contrast to these findings no increase in serum 
gastrin concentrations with age was found by Ganguli and Hunter (1972) 
or Stadil and Rehfeld (1973a). These two groups of workers did not find 
any differences in serum gastrin levels between normal males and females 
(Ganguli and Hunter, 1972; Stadil and Rehfeld, 1973a). 
An increase in serum gastrin levels in response to feeding was first 
reported by Hansky and Cain (1969). This has been confirmed by several 
workers and in every case ingestion of proteins has been shown to elicit 
the greatest response. McGuigan and Trudeau (1970a) showed an increase 
in serum gastrin levels from 165 pg/ml in fasting subjects to 209 pg/ml 
postprandia!ly. Young, Byrnes et al. (1969) reported an increase from a 
basal level of 400 pg/ml to 2 700 pg/ml following ingestion of protein. 
Ganguli (1970) examined the effect of ingestion of protein, carbohydrate 
and fat on serum gastrin levels and found the greatest response was to a 
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55% protein meal. Serum gastrin levels rose 4 to 5 times the fasting level, 
with the peak response occurring 30 to 60 minutes after eating. Korman, 
Soveny and Hansky (1971) also reported an increase in gastrin levels of up 
to 5 times basal 45 minutes after eating protein, with levels increasing from 
15 ! 2,3 pg/ml (! S.E.M.) to 78 ! 16 pg/ml. These authors showed a 
lower gastrin releasing potency with alcohol, fat and glucose, decreasing in 
that order, whereas Ganguli ( 1970) found that no significant effect on serum 
gastrin levels was produced by a 93% carbohydrate or a 93% fat meal. 
Normal fasting serum gastrin levels and postprandial levels in controls are 
shown in table (2.111.2). 
A circadian pattern of gastrin release has been described by Feurle, 
Ketterer et al. (1972) and by Moore and Wolfe (1974). Both groups found 
higher gastrin levels during the day and the lowest levels during the hours 
following midnight. Moore and Wolfe (1974) found the highest mean 2-
hourly secretion rate of gastri n at 8 p .m. (75 pg/ml) and the lowest at 
4 a.m. (33 pg/ml). Feurle, Ketterer et al. (1972) reported that the major 
gastrin peaks during the day seemed to be in response to food intake. 
In addition to ingested protein producing elevated gastrin levels, gastrin 
release is stimulated by a number of other factors. The mechanical effect 
of food in the stomach causing distension has been shown to stimulate release 
of gastrin in the dog (Grossman, Robertson and Ivy, 1948) and Feurle, 
Ketterer et al. (1972) ;eported very high gcstrin levels in patients with 
prepyloric ulcer and pyloric stenosis, which leads to gastric distension. 
Insulin hypoglycaemia stimulates gastrin release in man (Stadil, 1972) and 
this may operate via vagal excitation, which is known to cause release of 
gastrin as determined by bioassay (Fyr8, 1967). Catecholamines stimulate 
release of gostrin in man (Stadil and Rehfeld, 1973b) and infusion of epi-
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nephrine into dogs produced elevated gastrin levels (Hayes, Ardill et al., 
1972), 
Serum Gastrin Levels in Disease States 
In keeping with the numerous radioimmunoassays published for gastrin 
which are out Ii ned in tab I e (2. II I .1) there have been many reports on serum 
gastrin levels measured in various disease conditions. Some of this information 
has been extracted from the literature and is presented in table (2.111.2). 
From the table it appears that serum gastrin levels in duodenal ulcer (D .U .) 
patients in the fasting state do not differ notably from those in fasting controls 
(Stadil and Rehfeld, 1971, 1973a; Schrumpf and Sand, 1972; Feurle, 
Ketterer et al., 1972) or may even tend to be lower than controls {Trudeau 
and McGuigan, 1970; Hansky and Cain, 1969; Ganguli and Hunter, 1972). 
Higher levels in D.U. patients as opposed to normals were found by Byrnes, 
Young et al. (1970) and Reeder, Jackson et al. (1970), but the serum gastrin 
levels reported by Byrnes, Young et al. (1970) were particularly high, even 
in fasting controls. Generally gastrin levels in patients with gastric ulcer 
(G.U.) were higher than in controls and levels in D.U. patients (Hansky 
and Cain, 1969; Schrnmpf and Sand, 1972; Ganguli and Hunter, 1972). 
Young, Byrnes et al. (1969) reported levels of 400 pg/ml in G .U. and normal 
fasting subjects, whereas in D.U. patients they detected levels as high as 
1 300 pg/ml {Byrnes, Young et al., 1970). Stadil and Rehfeld (1973a) 
found no difference between gastrin levels in patients with pre-pyloric or 
duodenal ulcers and no;mals. 
On the basis of their findings Trudeau and McGuigan (1970) suggested 
that a I though the mean fasting gastiin levels were not elevated in patients 
with peptic ulcer disease, these patients may be more sensitive than normal 
TABLE (2.111.2) 
Gastrin Levels in Various Clinical Conditions 
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p .A. 
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subjects to gastrin-provoking stimuli, resulting , n responses of greater 
magnitude and longer duration. 
Postprandial serum gastrin levels rn D .U. patients are higher than those 
in normals (Byrnes, Young et al., 1970; Reeder, Jackson et al., 1970); 
the first group showed a greater integrated gastrin response from O to 20 
minutes after ingestion of protein in D. U. patients as compared with normal 
subjects. 
In their study on circadian gastrin concentrations Feurle, Ketterer et al. 
(1972) observed gastrin levels somewhat but not significantly higher in D.U. 
patients compared with controls during the day, whereas during the night 
gastrin levels in D .U. patients were consistent! y higher than in controls. 
Gastrin levels in patients with pyloric ulcer were higher than both controls 
and D. U. patients throughout the 24 hours. 
Grossly elevated levels of circulating gastrin have been well documented 
rn patients with Zollinger-Ellison syndrome (Z.E.S .) (McGuigan and Trudeau, 
1968; Young, Byrnes et al., 1969; Hansky and Cain, 1969; Yalow and 
Berson, 1970a; Schrumpf and Sand, 1972; Ganguli and Hunter, 1972; 
Stadil and Rehfeld, 1973a). This condition, also known as gastrinoma, was 
first described by Zollinger and Ellison in 1955 (Zollinger and Ellison, 1955) 
and invoives massive gastric acid hypersecretlon caused by a non-beta islet 
cell tumour arising usually in the pancreas, which releases massive amounts 
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of gastrin, producing severe and intractable peptic ulceration (Gregory, 1970). 
Primary tumours of this type have also been found in the submucosa of the 
duodenum (Creutzfeldt, Arnold, Creutzfeldt and Track, 1975), al though they 
are uncommon (Isenberg, Walsh and Grossman, 1973). Gastrinoma was the 
first clinical condition described involving a tumour of gastrointestinal endo-
crine cells (Gregory, 1970). Sernm gastrin levels reported in this condition 
range from approximately l nanogram par millilitre (ng/ml) up to as high 
as 94 ng/ml (Ganguli and Hunter, 1972; Schrumpf and Sand, 1972; 
Yalow and Berson, 1970a) as can be seen in table 2.111.2). The importance 
of serum gastrin measurements in the pre-operative diagnosis of this con-
dition is obvious. 
Pernicious anaemia (P.A.) is also associated with very high gastrin 
levels (Hansky and Cain, 1969; Yalow and Berson, 1970a; McGuigan 
and Trudeau, 1970a; Ganguli and Hunter, 1972; Stadil and Rehfeld, 
1973a). Reported serum gastrin levels appear in table (2.111.2). This 
condition is characterised by gastric mucosa! atrophy with extensive 
destruction of oxyntic (parietal) cells and zymogen (chief) cells, resulting 
in the absence of gastric secretion of both hydrochloric acid and intrinsic 
factor, which in man are both produced by the parietal cells (McGuigan 
and Trudeau, 1970a). It is thought that the resultant achlorhydria in this 
condition causes withdrawal of the effect of inhibition of gastrin release 
exerted by antral acidification, permitting uninhibited release of gastrin in 
response to stimuli acting on the gastrin-containing cells, thus producing 
elevated serum gastrin levels (McGuigan and Trudeau, 1970a}. Yalow and 
Berson (1970a} produced an acute fa 11 in plasma gastrin concentration in 
five patients with pernicious anaemia by oral administration of hydrochloric 
acid, an observation lending support to the proposal of tvkGuigan and 
Trudeau ( 1970a). 
The two conditions involving hypergastrinaemia are thus very different. 
Zollinger-Eliison syndrome invoives hypergastrinaemia associated with acid 
hypersecretion, whereas pernicious anaemia presen~s as hypergcstrinaemia 
occurring with achlorhydria. In P.A. patients an increase in serum gastrin 
levels in response to feeding has been reported (McGuigan and Trudeau, 
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1970a; Yalow and Berson, 1972) whereos in Z.E.S. Berson and Yalow 
(1972) reported no detectable increase in serum gastrin in response to a 
protein meal in 5 patients. Patients with Z.E.S. respond to infusions of 
calcium with secretion of acid and release of gas tr in from tumour tissue 
(Creutzfeidt, Arnold et al., 1975; Passaro, Basso and Walsh, 1972). 
Intravenous secretin infused into Z.E.S. patients produces a paradoxical 
rise in gastrin secretion in about 75% of patients {Dockray, 1975; Creutz-
feldt, Arnold et al., 1975), whereas in normal subjects secretin infusion 
produces a decrease in gastrin levels (Hansky, Soveny and Korman, 1971) 
or has no effect (Creutzfeldt, Arnold et al., 1975). 
Hypergastrinaemia has been described in two cases of phaeochromocytoma, 
where the serum gastrin levels were 400 pg/ml and 450 pg/ml (Hayes, Ardill 
et al., 1972). These workers reported a normal serum gastrin level of 
96 pg/ml. After successful removal of the tumour basal gastrin levels 
returned to normal in both patients. This situation, as wel I as the elevated 
gastrin levels obtained on infusion of epinephrine into dogs by the same 
workers, supports the notion that catecholamines stimulate gastrin release. 
The fact that serum gastrin measurements obtained with various gastrin 
,mmunoassays vary considerably among different groups emphasises the need 
to characterise the antiserum used in the assay with regard to its specificity 
for the different gastrin types. Antisera raised to gastrin may recogrnse 
sulphated, non-sulphated or both types of gastrin 1 of smali or large molecular 
forms, and only when the specificity of the an~iserum is defined are the 
gastrin levels quoted really' meaningful. Some of the better known antisera 
have been well characterised and are discussed in the next section. 
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Section IV Specificity of Gastrin Antisera 
Since gastrin does not circulate only in the heptadecapeptide form 
described in the previous sections, but exists in several different forms 
of various molecular size, it is important to characterise the specificity 
of the antiserum used in the assay so that one knows what type of gastrin 
is being measured. 
The various gastrin forms are described in detail in the following two 
sections and will be outlined here for the purposes of this discussion. YalON 
and Berson (1970b, 1971a, 1972) and Yalow and Wu (1973) have described 
the existence of three types of gastrin, namely "big big" gastrin which elutes 
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in the void volume on Sephadex G-50 gel filtration, big gastrin which elutes 
between molecular weight markers proinsulin and insulin, and heptadecapeptide 
gastrin. Four gastrin types have been found by Rehfeld, Stadi I and Vikelspe 
(1974). They did not find the "big big" gastrin of Yalow and Berson in 
serum, although they did find a very large molecular weight heterogeneous 
component in gastrinoma and antral mucosa tissue extracts. They have 
identified component I which elutes immediately before proinsulin, component 
II which corresponds to big gastrin, component II! or heptadecapeptide gastrin, 
and component IV, which they cal led minigostri n. Both groups of workers 
showed that the major form of gastrin occurring in serum is big gastrin and 
not the heptadecapeptide form as was previously thought. 
Big gastrin has been purified from human gastrinoma extracts (Gregory and 
Tracy, 1972) and from hog antral mucosa {Gregory and Tracy, 1973, 1975) 1n 
two forms corresponding to the sulphated and non-sulphated species. Their 
amino acid sequences were determined by Gregory and Tracy (1972, 1973, 
1975), who showed that each consisted of 34 amino acids of which the 
(-terminal 17 amino acids were identical with the sequence of heptadeca-
peptide gastrin, and the presence or absence of a sulphate group on the 
tyrosine residue in position 12 of the heptadecapeptide determined whether 
they were big gastrins type II or I respectively. The N-terminal (1-17) 
sequence of big gastrin is I inked to the glutamyl group of heptadecapeptide 
gastrin via a lysine residue, this being the peptide bond which is cleaved 
on incubation of big gastrin with trypsin to release heptadecapeptide gastrin 
(Yalow and Berson, 1971; Rehfeld and Stadil, 1973). Component I of 
Rehfeld and Stadil and 11 big big 11 gastrin of Yalow and Berson have not yet 
been chemically or biologically characterised (Dockray, 1975; Gregory, 
1976). 
Minigastrins type I and i I have been isolated from gastrinoma tissue 
extract and have been shown to correspond to the (5- 17) tridecapeptide 
sequence of heptadecapeptide gastrin (Gregory and Tracy, 1974) in the non-
sulphated and sulphated forms respectively. The amino acid sequences of 
human big, heptadecapeptide and minigastrin are shown in figure (3.1.2.) in 
the next chapter. 
Walsh, Trout, Debas and Grossman (1974) formulated a convenient nomen-
cloture for each gostrin type referring to its source, amino acid content and 
presence or absence of sulphated tyrosine in position 12 of the heptadeca-
peptide. The source of gastrin is designated 11 P 11 for porcine, 11 H" for human, 
and other species are spelled out. The designation 11 G 11 refers to gastrin, 
fol!owed by a number indicating the number of amino acid resi.dues. There is 
uncertainty as to whether big gastrin consists of 33 or 34 amino acids, so it 
could be abbreviated as G-33 or G-34. By the same token, mi nigastrin is 
thought to comprise either 13 or 14 amino acids and is abbreviated as G-13 
or G-14. Thus the abbreviation for human heptadecapepride gastrin 11 is 
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HG-17 II. This convention has been adopted for the purposes of this thesis. 
If an abbreviation appears in which there is no letter before the "G 11 to 
indicate the source, it should be assumed that the peptide is human in origin. 
Peptides bearing a structural resemblance to heptadecapeptide gastrin 
include caerulein and cholecystokinin-pancreozymin (CCK-PZ) both of which 
bear the identical C-terminal pentapeptide sequence as does heptadecapeptide 
gastrin and both of which contain a sulphated tyrosine residue one position 
removed from the pentagastrin sequence. Caerulein is a decapeptide which 
has been isolated from the skin of the Australian bullfrog, Hyla caerulia 
(Anastasi, Erspamer and Endean, 1967). CCK-PZ is a peptide hormone 
consisting of 33 amino acids which is secreted by the duodenal mucosa in 
response to stimulation by the products of fat and protein digestion and 
causes the secretion of pancreatic juice rich in enzymes, as well as stimu-
lating contraction of the gal I bladder (Ganong, 1977). The primary structures 
of caerulein and the (-terminal octapeptide of CCK-PZ (Ondetti, Squibb) 
are shown in figure (3.1. l .) • Commercially prepared pentagastrin (Peptavlon, 
I .C.I .) as used for acid-stimulatory tests has the glycine residue in position 
13 of the heptadecapeptide replaced by alanine, which is blocked by a butyl-
oxycarbonyl group (BOC), a remnant of the synthesis of this molecule. 
From the structural homology displayed by these gut and gastrin-related 
peptides it is apparent that an antiserum produced by immunizing an animal 
with one of these peptides will not necessarily be specific for that peptide 
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on! y, but may show a degree of recognition for one or more of the related 
peptides as well. Thus it ls essential to determine the degree of cross-
reaction rn the assay of all the gastrin types, of CCK-PZ, of caerulein and of 
pentagastrin with each antiserum used. Only then can one be sure of what is 
being measured by the particular antiserum. If the specificity of an antiserum 
is not stated then the gastrin levels reported should be viewed with caution. 
A further consideration is whether the antiserum is specific for sulphated 
or non-sulphated types of gastrin or whether it recognises both types equally 
wel I. It may happen that an antiserum raised using synthetic human hepta-
decapeptide gastrin I measures only the non-sulphated form of g:istrin. Hansky, 
Soveny and Korman (1973) described two antisera raised in rabbits to synthetic 
human gastrin I. One antiserum (4) only recognised g:istrin I and showed 
minimal reactivity with gastrin II, whereas the other one (35) cross-reacted 
equally with both gastrins I and II. Using these antisera to measure serum 
gastrin levels in normal subjects and ulcer patients they found significantly 
higher levels measured with antiserum 35 than measured with antiserum 4, 
emphasising the importance of the specificity of the antiserum. 
Rehfeld, Stadil and Rubin (1972) immunized 41 guinea pigs and 72 
rabbits according to 15 different immunisation schemes. They obtained anti-
bodies to gastrin in 23 animals, of which only one was a guinea pig. Only 
three antisera had antibodies of sufficient affinity for measurement of low 
physiological concentrations, with a value of K0 , the equilibrium constant, 
greater than or equal to l 011 litres/mole (1/mol). This gives one an idea 
of how difficult it is to obtain a good antiserum to gastrin. Antiserum 2484, 
raised in guinea pig to unconjugated crude porcine gastrin showed only a 
minimal degree (l :0,001) of cross-reactivity with porcine CCK-PZ prepared 
by Jorpes and Mutt. The specificity of the antisera is expressed by the molar 
ratio between the inhibition dose 50 {ID50) for synthetic human gastrin I 
and the tD50 of the peptide with which it is being compared (Stadil and 
Rehfeld, 1973a). The inhibition dose 50 refers to the molar concentration 
of peptide that reduces the binding of labelled gastrin by antibody to 500/o 
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of its initial value. Antiserum 2604 raised to SHG(2-17) conjugated to 
bovine serum albumen reacted poorly with porcine CCK-PZ (1 :0,006) and 
with the synthetic octapeptide of CCK-PZ prepared by Ondetti of Squibb 
(1:0,001) (Rehfeld, Stadil et al., 1972). An aliquot of the seventh bleed 
obtained from this animal, designated 2604-7, was kindly donated by Dr. J. 
Rehfeld and was used in studies in this thesis. The third antiserum, 2720, 
which was raised to SHG(l-17) coupled to bovine serum albumen, showed 
a high degree of cross-reactivity with porcine cholecystokinin (1 :0,2) making 
it unsuitable for gastrin determinations in biological fluids (Rehfeld, Stadil 
et al., 1972). These three antisera did not cross-react with human growth 
hormone, human insulin, porcine glucagon or synthetic secretin, nor with 
pentagastrin (I.C.I .} or tetragastrin (Leo Pharmaceutical Products, Copen-
hagen) except in the case of antiserum 2720, which cross-reacted negligibly 
with the latter two peptides (Rehfeld, Stadil et al., 1972). Antisera 2604 
and 2484 were used in studies which showed the presence of three components 
of immunoreactive gastrin in serum (Rehfeld and Stadil, 1973a). 
Dockray (1975) and Walsh, Trout et al. (1974) have described two antisera, 
1296 and 1295, with different specificities for different regions of the hepta-
decapeptide gastrin molecule. These antisera were raised in rabbits immunized 
with G-17 conjugated to bovine serum albumen (Dockray, 1975). Antibody 
1296 gave parallel inhibit;on curves with G-17 I and G-34 I; other peptides 
with the same carboxy-termina i portion as G-17, such as the (2-17) sequence 
of G-17, and G-13, also cress-reacted with this antibody. Amino-terminal 
fragments of G-17, the (1-13) sequence of G-17 and desamido G-17 did not 
cross-react, indicating that antibody 1296 was specific for the (-terminal 
region of G-17 (Dockray, 1975). On the other hand, antibody 1295 was 
found to be specific for the N-terminal region of G-17, since it cross-reacted 
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with G-17, the (l-13) sequence of G-17 and desamido G-17, but not with 
G-34, the (2-17) sequence of G-17, or G-13 (Dockray, 1975). With both 
antibodies serum from a patient with gastrinoma gave para I I el displacement 
curves, indicating that they were both suitable for estimating serum gastrin 
components (Dockray, 1975). 
Confirmation of the specificity of these antisera was obtained by measure-
ment of column eluates obtained on fractionation of serum from a gastrinoma 
patient on Sep had ex G-50. Antibody 1296 revealed peaks of immuno-
reactivity which emerged in the same regions as standard G-34 and G-17, 
whereas antibody 1295 detected the G-17 peak but not the G-34 peak. 
However, this antibody also detected a peak which had the pattern of 
immunoreactivity of an N-terminal fragment of G-17 and the same elution 
volume as the (l-13) fragment of G-17 (Dockray, 1975). Since this frag-
ment is not biologically active (Dockray and Walsh, 1975), Dockray (1975) 
continued to use antibody 1296 for measurement of biologically active 
gastrin in blood and tissues. 
Dockray and Taylor (1976) described another antibody, L 6, which is 
virtually absolutely specific for heptadecapeptide gastrin. It was obtained 
by immunizing a New Zealand white rabbit with approximately equal amounts 
of natural porcine G-17 I and G-17 II conjugated to bovina serum albumen. 
Parallel curves showing inhibition of binding of 1251-G-17 to antiserum L 6 
were obtained with human G-17 and serum from a patient with Zollinger-
Ellison syndrome, while no inhibition of binding was shown by G-34, the 
(2-17) sequence of G-17 or the (l-13) sequence of G-17 (Dockray and 
Tayior, 1976). The antiserum cross-reacted with both sulphated and non-
sulphated human and porcine G-17 as we!I as with feline G-171 and 15-
leucine G-17 I (Dockray and Taylor, 1976). No significant inhibition of 
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binding of 125 t-G-17 was obtained with a combination of equimolar amounts 
of the sequences (1-13) and (14-17) of G-17, confirming that the intact 
peptide backbone was required for recognition by the antibody (Dockray and 
Taylor, 1976). 
Walsh, Trout et al. (1974) compared the specificity of five different 
antisera raised in rabbits. Antibody 1296 recognises all forms of gastrin as 
already described, and shows little cross-reactivity with CCK-PZ and its 
octapeptideo Antibodies 1295 and 1294 are highly specific for G-17 but do 
not distinguish between G-17 I and G-1711. Antibody 1292 distinguishes 
between sulphated and non-sulphated G-17 (Walsh, Trout et al., 1974). 
Antibody SF-10, raised by immunizing a rabbit with the conjugated C-
terminal tetrapeptide amide of gastrin, was inhibited similarly by G-33, 
G-17, G-13, CCK-PZ octapeptide and to a lesser extent by equimolar 
amounts of whole CCK-PZ (Walsh, Trout et al., 1974). 
McGuigan and Herbst (1974) obtained region-specific antibodies by 
immunizing rabbits with either SHG I (2-17) or SHG I (l-13) covalently 
conjugated to bovine serum albumen. Their antibodies raised using the 
(2-17) sequence of heptadecapeptide gastrin exhibited nearly equivalent 
immunological reactivity with big gastrin as with equimolar amounts of 
heptadecapeptide gastrin, whereas the antibodies raised to SHG (l-13) did 
not react ·with big gastrin or "big big" gastrin, but did recognise heptadeca-
peptide gastrin. Using these two antibody types McGuigan and Herbst (1974) 
demonstrated that fasting immunoreactive gastrin in serum comprised more than 
80% big gastrins, and that gastiin released into the circulation in response to 
feeding was the heptadecapeptide form. 
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Antisera may also vary in their specificity for g::istrins of different species. 
Generally antibodies raised rn mbbits with conjugcted gastrin do not 
distinguish among gastrins from different species but may react differently 
with different sizes of gastrin and may distinguish sulphated and non-
sulphated gastrins (Walsh, Trout et al., 1974). As a rule gastrin anti-
bodies prepared in guinea pigs against crude porcine gastrin are often 
specific for substitutions in the 8 and 10 positions of G-17 but do not 
differ in reactivity with G-17 and G-13 and do not discriminate between 
sulphated and non-sulphated gastrins. Thus sheep gastrin, which bears a 
substitution of alanine for glutamic acid in position 10 of the heptadeca-
peptide, as well as valine in place of leucine in position 5, reacted 
with a potency of less than 10% of that of porcine gastrin with a 
guinea pig antibody, while with a rabbit antibody the potency was 
more than 50% (Walsh, Trout et al., 1974). Porcine gastrins I and II 
were more reactive than synthetic human gastrin I with Rehfeld 1s anti-
serum 2484 which was raised in guinea pig to crude porcine gastrin, 
while in the case of antiserum 2604, raised in rabbit to SHG (2-17), 
the reaction with porcine gastrin was less than that with human gastrin 
(Rehfeld, Stadi I et a I., 1972). 
Antibodies can be regarded as the "tools" for measurement of hormone 
levels by radioimmunoassay. Once they have been characterised with 
regard to their specificity, they can be used to investigate hormona I 
heterogeneity in serum and tissue extracts. 
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Section V Heterogeneity of Gastrin in Human Serum 
By combining the techniques of radioimmunoassay and Sephadex column 
chromatography it was shown that gastrin occurs in several forms of different 
molecular size. Gastrin heterogeneity in serum and tissues should be con-
sidered together, since the findings of various types of gastrin in antral 
mucosa and gastrinoma tissues were confirmed by the discovery of similar 
gastrin forms in the circulation. For simplicity, gastrin heterogeneity in 
serum and tissues will be dealt with separately. 
Yalow and Berson (1970b) were first to show that the major fraction of 
immunoreactive plasma gastrin was not identical with the heptadecapeptide 
gastrin isolated by Gregory and Tracy from antral mucosa in 1964. Using 
plasma samples obtained from hypergastrinaemic patients with pernicious 
anaemia and Zollinger-Ellison syndrome, and one normal subject whose 
gastrin secretion was stimulated by feeding, they compared these with plasma 
containing negligible amounts of endogenous gastrin to which was added 
purified antral porcine gastrin I or synthetic human gastrin I. Endogenous 
plasma gastrin exhibited less acidic behaviour on starch gel and paper 
electrophoresis than did the heptadecapeptide. On Sephadex chromatography 
using a mixture of G-25 and G-50, or G-50 alone, most of the endogenous 
plasma gastrin emerged between the proinsulin (molecular weight 9 000) and 
insulin (molecular weight 5 700) markers, whereas the heptadecapeptide 
gastrin standards eluted after the insulin marker. A small fraction of plasma 
gastrin was found in the same region as heptadecapeptide gastrin. The 
behaviour of endogenous pfa:5ma gastrin on Sephadex chromatography led 
Yalow and Berson (1970b) to conclude that it had an approximate molecular 
weight of 7 000. 
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The electrophoretic and filtration characteristics of endogenous plasma 
gostrin were not altered by boiling, and incubation of plasma with gastrin-
free aqueous extracts of porcine antrum did not convert endogenous gastrin 
to the heptadecapeptide form, confirming that heptadecapeptide gastrin is 
not released by enzymic cleavage of the larger gastrin form in the antrum. 
From these findings and the fact that endogenous plasma gostrin showed the 
same immunorooctivity as the heptadecapeptide, Yalow and Berson {1970b) 
proposed that plasma gastrin was composed of the heptadecapeptide sequence 
firmly bound or possibly covalently linked to a larger basic peptide of 
molecular weight about 5 000. 
Further studies on gastrin in plasma from hypergastrinaemic patients 
again showed the presence of the larger basic big gastrin and a heptadeca-
peptide-like component, and that the ratio between the two gastrins varied 
in different subjects (Yalow and Berson, 1971a), with the heptadecapeptide-
like component comprising up to 50% of the total irnmunoreactive gastrin in 
some instances, especially after feeding. The secretion of both types of 
gastrin was stimulated by feeding (Yalow and Berson, 1971a). Incubation 
of plasma from a patient with Zollinger-Ellison syndrome in SM-urea and 
fractionation of this plasma in SM-urea buffer did not alter the distribution 
of the two gastrin components (Yalow and Beison, 1971a). However, incu-
bation of the same plasma with trypsin converted all the big gastrin compo-
nent into heptadecapeptide-like gastrin and the total concentration of 
immunoreactive gastrin did not change, suggesting thl1t big gastrin consists 
of a basic peptide linked via a C-terminal lysine or arginine residue to 
the N-terminal glutamyl residue of heptadecapeptide gastrin (Yalow and 
Berson, 197i a). 
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A further gastrin component was described by Yalow and Berson (1972) 
when they found a large molecular weight gastrin component in plasma 
from Zollinger-Ellison patients and extracts of human jejunum. This compo-
nent, which they called "big big 11 gastrin {BBG), eluted in the albumen 
region on Sephadex G-50 chromatography and maintained its integrity on 
refractionation. Following incubation with trypsin most of this fraction 
was converted to the heptadecapeptide-like component as shown by chromato-
graphy, while none appeared to be converted to the big gastrin form 
(Yalow and Berson, 1972). This component comprised less that 2% of the 
total immunoreactive gastrin in plasma of patients who were gastrin hyper-
secretors. It forms a major fraction of circulating gastrin in the basal state 
and was not stimulated by feeding (Yalow and Wu, 1973). "Big big" 
gastrin in eluates from the void volume of a Sephadex G-50 superfine 
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column behaved immunologically identically with porcine gastrin I, 
suggesting that BBG contains the heptadecapeptide sequence within its 
structure {Yalow and Wu, 1973). The molecular weight of BBG as de-
termined by ultracentrifugation was similar to that of human growth hormone, 
which has a molecular weight of 20 000 (Yalow and Wu, 1973). This 
suggests that BBG is not globular in conformation, since if it were, its 
elution in the albumen region wouid suggest a molecular weight closer to 
65 000. 
No!" long after the discovery of gastrin heterogeneity by Yalow and 
Berson, simiiar reports of more than one type of gastrin appeared from another 
group of workers. Rehfeld ( 1972) found three components of immunorea ctive 
gastrin in human serum from normal subjects and patients with pernicious 
anaemia on Sephadex G-50 fine gei filtration. He described a component 
which eluted immediately before proinsulin and comprised 18,4% of the 
total immunoreactive gastrin, which he named component I. The bulk of 
the immunoreactive gastrin (72,6% of the total) in his subjects eluted 
between proinsulin and insulin, in the region corresponding to the big or 
basic gastrin described by YalO'N and Berson (1970b). He named this 
component II. A third component which consisted of 9, 1% of the total 
immunoreactivity eluted after insulin (Rehfeld, 1972). It was shown that 
these components were not artefacts due to in vitro conformational changes 
due to fractionation using veronal buffer, since the same elution profile 
was obtained using human plasma as the mobile phase. This was also 
shown by the fact that incubation of sera with the protein denaturing 
agents, urea or dithiothreitol, produced no change in the elution pattern. 
However, after incubation of serum with trypsin the first two components 
disappeared and all the gastrin immunoreactivity was eluted in a single 
peak corresponding to a smaller molecular size (Rehfeld, 1972). 
The following year four immunoreactive gastrin components were 
described by this group. Using serum from patients with Zollinger-Ellison 
syndrome and Sephadex G-50 superfine columns of dimensions l cm x 
2 metres, Rehfeld and Stadil (1973a) showed the existence of components 
I and II as previously described and confirmed that component Ill, which 
eluted as a biphosic peak, corresponded to heptadecapeptide gastrins 11 and 
I respectively. In addition thay found a smaller component which they 
cal led component IV (minigastrin) which eluted immediately before the salt 
peak. In this study the percentages of total gastrin immunoreactivity 
contributed by components I to !V were 9, 7%, 57 ,8%, 26, 9% and 9 ,5% 
respectively. Incubation of components I and II with trypsin converted all 
the immunoreactive gastrin to a form which eluted in the region of hepta-
decapeptide-like gastrins (Rehfeld and Stadil, 1973a). This confirmed the 
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findings of Yalow and Berson that incubation of serum with trypsin converted 
big g:Jstrin into heptadecapeptide-like gastrin (Yalow and Berson, 1971a). 
However, Rehfeld and Stadil (1973a) did not find the "big big" gastrin 
described by Yalow and Berson (1972) in any of the 15 serum samples they 
studied. 
Extending these studies, Rehfeld, Stadil and Vikelspe (1974) examined 
immunoreactive gastrin components in serum from patients with pernicious 
anaemia and Zollinger-Ellison syndrome by Sephadex gel filtration and amino-
ethylcellulose chromatography. They showed that component I was mono-
phasic whereas components 11, 11 I and IV each consisted of two peaks, 
corresponding to big gastrins I and II, heptadecapeptide gastrins I and II 
and minigastrins I and II respectively. Fractionation of serum collected 
from porcine antral vein revealed a similar distribution of gastrin components 
with more of the total immunoreactivity in the smaller components (Rehfeld, 
Stadil and Vikelspe, 1974). No component in serum corresponding to 11 big 
big" gastrin (Yalow and Berson, 1972) could be found, although a component 
in gastrinoma and antral mucosa extracts corresponding in size to 11 big big" 
gastrin was detected. It was heterogeneous, with components of apparent 
molecular weight between 30 000 and 100 000 (Rehfeld, Stadil and Vikels,ie, 
197 4). 
Further gel filtration studies fol lowed by ion exchange chromatography 
and disc gel electrophoresis of serum resolved both components I and II into 
six different gastrins (Rehfeld, Stadil, Malmstrpm and Miyata, 1975); at the 
time of publication of this study components Iii and IV were under similar 
investigation. These studies subsequently revealed 4 heptadecapeptide gastrins 
and 4 minigastrins, giving a total of 20 different gastrin components in al/ 
(Rehfeld, cited by Gregory, 1976, p. 260). By reproducing the technique 
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whereby Yalow and Wu (1973) showed the existence of 11big big 11 gastrin 
in the circulation, Rehfeld, Stadil et al. (1975) found a large proportion 
of immunoreactive gastrin eluting in the void volume. However, by in-
creasing the ionic strength of the elution buffer the amount of gastrin 
eluted in this region was significantly reduced and subsequent treatment 
with urea caused all the gastrin in the void volume to disappear. This 
led them to conclude that at least a significant part of the 11 big big" 
gastrin described in circulation is due to non-specific binding of smaller 
gastrins to plasma proteins. This finding is supported by Dockray (1975) 
who showed that purified bovine and human serum albumen, in concen-
trations comparable to those of proteins in serum, inhibited binding of 
labelled gastrin to antiserum 1296. They too ascribed at I east some of 
the 11 big big 11 gastrin peak found with this antiserum on chromatography 
of dog serum to the action of serum proteins which elute in the void 
volume of Sephadex G-50 columns and cause non-specific inhibition of 
antibody binding of labelled gastrin. 
Since basal plasma gastrin concentrations are usually below 100 pg/ml, 
the iecovery of gastrin in serum from normal subjects is very low, making 
it impractical to use basal serum for fractionation studies in most ccses. 
Thus chromatographic separation is usually performed using serum from 
hypergastrinaemic patients, which may or may not be a true reflection of 
the normal situation. The demonstration by Rehfeld, Sl'adil, Malmstrprn 
and Miyata (1975) that sera from normal subjects and patients with pernicious 
anaemia showed a similar heterogeneity to that observed in Zollinger-Ellison 
sera would seem to indicate that this is an acceptable extrapolation. How-
ever, it should be borne in mind that cases of the Zollinger-Ellison syndrome 
have circulating tumour gastrin, wheieas in normal subjects and patients 
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with pernicious anaemia the circulating gastrin originates from the antral 
mucosa. 
Increased serum gastrin levels following ingestion of food, especially 
protein, has been wel I documented (Hansky and Cain, 1969; McGuigan 
and Trudeau, 1970a; Young, Byrnes et al., 1969; Ganguli, 1970). 
This increase is due chiefly to increased levels of the smaller gastrin 
components. Stadil, Rehfeld, Christiansen and Malmstrpm (1975) showed 
that the increased serum gastrin levels in response to eating were due to 
changes in components II and II I, the increase in component II I, or 
heptadecapeptide-like gastrin, being greater and of earlier onset. 
Patients with duodenal ulcer had a larger total gastrin response to eating, 
which was due mainly to component Ill. This may be a reason for the 
gastric hypersecretion characteristic of these patients, since heptadeca-
peptide gastrin is more potent than big gastrin (Walsh, Debas and 
Grossman, 1974). 
Yet another gastrin fragment was found in the circulation by Dockray 
and Walsh (1975), who described a fragment which behaved identically to 
the natural amino-terminal (1- J 3) sequence of G-17 isolated from gastrinoma 
tissue and the synthetic (l-13) sequence on chromatography and in radio-
immunoassay using antiserum 1295, which is specific for the amino-terminal 
region of heptadecapeptide gastri n. This tridecapeptide was present in 
these sera in high concentrations, and its concentration increased in response 
to intravenous injections of secretin, as is the case for G-17 gastrin. The 
same (1-13) sequence had been isolated and purified from hog antral mucosa 
in 1967 and was found to be biologicaliy inactive (Gregory, 1976). 
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Hansky, Korman, Soveny and Cain (l 973) also reported heterogeneity 
of gastrin in hypergastrinaemic patients as determined by column chromato-
graphy. They found most of the gastrin in serum of patients with pernicious 
anaemia in two fractions of estimated molecular weight 7 000 and 9 500, 
which they called gastrins type I and II respectively and an additional 
component with a molecular weight of 4 000 - 5 000. Patients with 
Zollinger-Ellison syndrome had mainly the gastrin type I component in their 
serum. These findings are confusing in the light of the findings of Yalow 
and Berson (1970b, 1971a, 1972), Rehfeld's group (1972, 1973a, 1974) 
and Vinik and co-workers (1973, 1975). The discrepancy may be partly 
due to the fact that Hansky, Korman et al. (1973) chromatographed their 
samples on a Sephadex column that was only 40 cm in length, affording 
poorer resolution than the larger columns used by other groups investigating 
this field. 
Studies on gastrin heterogeneity in tissues can be broadly divided into 
studies on extracts of porcine or human antral and duodenal mucosa, which 
reflect the normal situation, and extracts of gastrinoma tissue, in the case 
of patients with the Zollinger-Ellison syndrome. 
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Section VI Heterogeneity and Distribution of Gastrin in Tissuas 
2 Vl(i) Nonna! Tissues 
Although the phenomenon of hormonal heterogeneity may be detected 
by fractionation of serum into different immunoreoctive components, actual 
chemical characterisation of these hormonal forms is usually performed on 
extracts prepared from the tissue of origin of the hormone. Hormones may 
be extracted from serum for chemical purification, but this requires large 
volumes of serum to yield an amount of honnone equivalent to that present 
in glandular tissue. In the case of gastrin, studies of heterogeneity have 
been carried out chiefly on extracts of porcine and human antral mucosa, 
as wel I as on extracts of mucosa from the duodenum and lower gastro-
intestinal tract. 
Gregory and Tracy {1964) were first to describe isolation of two hepta-
decapeptide gastrin molecules, types I and 11, from extracts of hog antral 
mucosao These gastrin molecules were purified and their heptadecopeptide 
sequence was determined by Gregory, Hardy et al. {1964) o Heptadeca-
peptide gastrins I and II were extracted and purified from human antral 
mucosa and sequenced by Gregory, Tracy and Grossman (1966). Human 
heptadecapeptide gostrin was found to differ from the porcine heptadeca-
peptide in the substitution of the methionine residue in position 5 with 
leucine (Bentley, Kenner and Sheppard, 1966). 
The presence of a gastrin form larger than the heptadecapeptide in 
extracts cf porcine antral mucosa was noticed by Gregory and Tracy in 
1968. Encouraged by the findings of Yalow and Berson of a larger form 
of immunoreactive gastrin in serum {197Gb), Gregory and Tracy (1972) 
succeeded in isolating a pair of big gastrin peptides from porcine antrum, 
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which occurred in the sulphated and non-sulphated formso The total amount 
of big gastrin in the antral mucosa comprised less than 20% of the total 
gastrin in this tissue (Gregory and Tracy, 1972). The sequences of big 
gastrins I and 11 were determined and it was found that each comprised 34 
amino acids, of which the C-terminal 17 correspond to the sequence of 
heptadecapeptide gastrin (Gregory and Tracy, 1975). The sequence of 
human big gastrin was determined using a purified extract of gastrinoma 
tissue as detailed in the next section. As was the case for heptadecapeptide 
gastrin, the proportion of sulphated to non-sulphated big gastrin in the pig 
was 2: l, whereas in the human the same ratio was approximately l :2 
(Gregory and Tracy, 1975). 
As eady as 1967 Gregory and Tracy isolated from hog antral mucosa 
a pair of tridecapeptides which corresponded to the amino-terminal (1-13) 
sequence of heptadecapeptide gastri n. These peptides occurred in the ratio 
2: 1 in favour of the sulphated form, as was the case for the two larger forms 
of porcine gastrin that have been identified (Gregory and Tracy, 1975). At 
the time the reason for the existence of this peptide was not understood. 
It was biologically inactive, which is not surprising since it comprises the 
heptadecapeptide sequence, except for the C-terminal tetrapeptide, which 
is responsible for the biological activity of gastrin (Tracy and Gregory, 1964). 
However, this fragment was subsequently identified in the serum of patients 
with Zollinger-Ellison syndrome by Dockray and Walsh (1975). Such a com-
ponent has not yet been detected in extracts of human gastrinoma tissue 
(Gregory and Tracy., 1975). 
Material corresponding to component I found in serum has been identified 
in extracts of porcine antral mucosa and partially puiified but it has not yet 
been chemically characterised (Gregory, 1976). 
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"Big big" gastrin was extracted from human jejuna! mucosa obtained 
post mortem and was shown to comprise 6-24% of the total gastrin immuno-
reactivity in extracts of this tissue (Yalow and Berson, 1972). This form 
of gastrin was undetectable in the antrum and its proportion increased 
distally on descending the gastrointestinal tract. The chemical nature and 
physiological role of BBG have not yet been established (Gregory, 1976). 
Berson and Yalow (1971) investigated the relative proportions of big 
and heptadecapeptide gastrin in human antral, duodenal and proximal jejuna! 
mucosa. Extracts of mucosa! tissue obtained at post mortem examination 
were prepared by boiling in water followed by centrifugation and collection 
of the supernatant for fractionation on starch gel electrophoresis and 
Sephadex G-50 chromatography. The heptadecapeptide-like gastrin com-
ponent was found to predominate in antral mucosa! extracts and the relative 
abundance of big gastrin increased distally along the gastrointestinal tract. 
Although these components were not purified and sequenced in this study, 
they were shown to behave immunologically identically with plasma big 
and heptadecapeptide gastrin and porcine heptadecapeptide gastrin (Berson 
and Yalow, 1971). 
In a study on extracts of gastrointestinal tissues obtained at 4 autopsies 
and in 6 surgical cases, Yalow and Beison (1973) found that big gastrin 
comprised more than 50% of the total extracted gastrin in 2 antra obtained 
post mortem, in 5 surgicai cases big gastrin ranged up to 37% of the total 
antral gastrin and in the other 3 cases almost all of the gastrin was in the 
heptadecapeptide form. In the 4 post mortem cases 45-80% of the duodenal 
gastrin was in the big form and in 2 surgical specimens big gastrin comprised 
52-60% of the total (Yalow and Berson, 1973). Thus there seems to be 
considerable variation in the proportion of the different types of gastrin in 
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the gut of different individuals. Generally the ratio of big gastrin to 
heptadecapeptide gastrin is much higher in the plasma than in antral extracts, 
possibly due to preferential secretion of big gastrin, more rapid removal of 
heptadecapeptide gastrin from plasma, or perhaps to significant duodenal-
jejuna I contribution to plasma gastri n (Ya low and Berson, 1973). 
The yield of extracted gastrin obtained by Berson and Yalow (1971) on 
ice-water extraction (maceration of quick-frozen tissue in ice-water) was 
7 ,ug/g frozen mucosa! tissue, as opposed to 30 AJg/g on extraction in boiling 
water. However, the relative amounts of big gastrin and heptadecapeptide 
gastrin were approximately the same. A low er yield was obtained from tissues 
that had been kept on ice for 30-60 minutes prior to extraction compared 
with tissues that were qui ck-frozen on dry iceo However, material obtained 
5 to 6 hours post mortem did not contain significantly smaller amounts of 
gastrin than surgical specimens refrigerated for 30-60 minutes. This could 
be due to an initial rapid loss of gastrin in excised unfrozen tissues or to 
random variation among a small number of samples (Berson and Yalow, 1971). 
Malmstrpm and Stadil (1975) confirmed these findings by showing that the 
gastrin content of untreated tissue specimens decreased rapidly to 50% within 
50 minutes. This degradation was stopped by immediate boiling, or freezing 
followed by boiling at a later stage. They found no deer.ease in gastrin 
activity during storage of the tissue for 6 months in the frozen state 
(Malmstrpm and Stadil, 1975). 
A higher proportion of the heptadecapeptide gastrin component in antral 
as opposed to duodenai tissue extracts of biopsies fron, normal subjects was 
also found by Vinik, Grant et al. (1975). In keeping v1ith the findings of 
Bersonand Yalow (1971), the pattern of gastrin immunoreactivity obtained on 
gel filtration of duodenal extract resembled that of gastrin in the circulation 
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of a fasting normal individual, with a minor fraction in the heptadecapeptide 
formo The tissue extracts in this study were also prepared by boiling in water 
followed by centrifugation of the solid matter and collection of the supernatant 
for fractionation studies. 
Using refined chromatographic separation of tissue extracts prepared from 
normal subjects and duodenal ulcer patients with various sized columns of 
Sephadex G-50 superfine, Rehfeld, Stadil et al. (1975) showed that hepta-
decapeptide gastrin {G-17) constituted 95% of total gastrin immunoreactivity 
in antral extracts, and in duodenum and jejunum the small gastrins constituted 
approximately 50% of the total, with components I and II making up the 
other 50%. In some normal subjects, however, most of the duodenal and 
jejuna! gastrin consisted of components Ill and IV, the heptadecapeptide and 
minigastrin species (Rehfeld, Stadil et al., 1975)0 This variation is similar 
to that observed by Yalow and Berson (1973), aithough the latter group found 
a relatively larger proportion of duodenal gastrin in the big form. A marked 
gradient of gastrin concentration in the mucosa down the gastrointestinal tract 
was observed, with concentrations of 12,9 n mol/g (28,38 .ug/g) mucosa in 
the antrum, 1,8 n mol/g (3,96 t.Jg/g) in the duodenal bulb, 0, 1 n mol/g 
(0,22 µg/g) in the distal duodenum and 20 p mol/g (0,044 .ug/g) mucosa in 
the proximal jejunum (Rehfeld, Stadil et al., 1975). 
In a detailed study of the concentrations and components cf gastrin in 
gastric, duodenal and jejuna! mucosa in normal subjects and patients with 
duodenal ulcer, Malmstr,ci'm, Stadii and Rehfeld (1976) again found that the 
gastrin concentration in proximal duodenum was 10%, in distal duodenum 
1 to 2%, and in the jejunum and corpus of the stomach 0,5-1 % of the 
gastrin concentration in antral mucosa. The concentration of gastrin was 
higher in the antrum of normal subjects (12, 1 n mof/g mucosa; 26,62 µg/g) 
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than in patients with duodenal ulcer (9,0 n mol/g; 19,81..19/g). There was 
a gradient in total gastrin concentration along the duodenum, with approxi-
mately one tenth of the bulbar content at the ligament of Treitz, and the 
mean duodenal concentration of gastrin was higher in the patients with duo-
denal ulcer and prepyloric ulcer than in normal subjects (Malmstrpm, Stadil 
et al., 1976). A small amount of gastrin, 150 to 200 times less than in the 
antral mucosa, was detected in the corpus mucosa and this value was almost 
identical in normal subjects and duodenal ulcer patients. 
58 
Fractionation of the corpus mucosa! extract on Sephadex G-50 superfine 
revealed that most of the gastrin occurred in the component Ill or heptadeca-
peptide form (Malmstrpm, Stadil et al., 1976). No difference was found 
between the pattern of gastrin components in the duodenal ulcer and control 
group. Antral extracts contained more than 91% component Ill gastrin immuno-
reactivity, although components I and II were also detected when large 
amounts of gastrin from antral homogenates were fractionated. Duodenal 
extracts contained approximately equal amounts of components 11 and II I 
with a higher proportion of component II in the bu I bar area; the possibility 
that duodenal extracts were contaminated with CCK-PZ was excluded since 
the same component pattern was obtained using antisera with high and low 
degrees of cross-reaction with CCK-PZ. Surprisingly, 92% of the gastrin 
immunoreactivity in the jejuna! extract was eluted as component Ill, a 
finding which is at variance with Berson and Yalow's (1971) reports of 
larger gastrin components in this region of the gut. No immunoreactive 
gastdn was found in the void volume after gel fiitration of any of these 
extracts (Malmstrpm, Stadil et al., 1976). 
In contrast to the findings of Malmstrpm, Stadil et a!. (1976), Creutzfeldt, 
Arnold, Creutzfeldt and Track (1976) showed a significantly higher antral 
gastrin content in duodenal ulcer patients than in controls (35,9 ,ug/g as 
opposed to 15, 9 .ug/g). The proximal duodenal mucosa I gastrin content of 
15 duodenal ulcer patients was 3,2 .ug/g whereas in 10 control subjects the 
value was 1,8 ..ug/g (Creutzfeldt, Arnold et al., 1976). The discrepancy in 
findings of antral gastrin content in normal subjects and duodenal ulcer patients 
found by this group and by Malmstrpm, Stadil et al. (1976) is difficult to 
explain. The actual concentrations found in the extracts by both groups were 
of the same order of magnitude and the extraction piOcedures used by both 
groups were almost identical. In both cases mucosa I biopsies were frozen and 
weighed and stored frozen until extraction by boiling for 10 minutes in water, 
followed by homogenisation of the tissue. Creutzfeldt, Arnold et al. (1976) 
centrifuged the tissues after boiling whereas Malmstrpm, Stadil et al. (1976) 
did not find this necessary. The difference may be due to the lower number 
of normal subjects investigated by Malmstipm's group (8) as opposed to those 
studied by Creutzfeldt and co-workers (21). 
Close agreement on the distdbution of gastrin components in the tissue 
extracts was obtained in both these studies. Creutzfeldt, Arnold et al. (1976) 
found that fractionation of antral mucosa! homogenates on Sephadex G-50 
produced two major immunoreactive components corresponding to the elution 
patterns of G-17 and G-34, while cornponent I and minigasrrin were detected 
in a few cases. G-17 comprised 92% of the total !mmunoreactive gastrin in 
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the antral mucosa of controls and 93,3% in the case of duodenal ulcer patients. 
G-34 constituted 5% and 4% respectively in the antral mucosa of controls 
and duodenal ulcer patients; thus the component pattern in antra! mucosa 
was identical for normal subjects end duodenal ulcer patients. In the duo-
denal mucosa G-34 amounted to 35 ,8% and 50,.1% of the total immune-
reactive gastrin in controls and duodenai ulcer patients respectively. 
The corresponding values for G-17 were 59,0'% and 47,2%. The concentration 
of G-34 in duodenal mucosa of patients with duodenal ulcer was not 
significantly higher than that in controls (Creutzfeldt, Arnold et al., 1976). 
Early studies on the distribution of gastrin along the gut using the 
technique of bioassay were carried out by Lai (1964b), who prepared extracts 
of human tissues obtained from various sites along the gut at operation and 
measured the gastrin in the extracts using a rat preparation (Lai, 1964a). 
He found the highest concentration of gastrin-like activity in the antral 
mucosa with a gradient of concentration of gastrin activity down the gut. 
Tissue samples were collected from antrum, duodenum, jejunum, ileum, colon 
and pancreas. The unit activity of gastrin in the duodanum was less than in 
the antral mucosa although the total amount of extractable gastrin activity 
was greater in the duodenum. No activity was found in the pancreas at 
any time. 
Elwin and Uvncls (1966) found the S'(lstrin activity in duodenal mucosa of 
cats to be one tenth that of the antral activity, whereas Em8s, Borg and 
Fyr8 (1971) found that duodenal activity in humans was about one third that 
of the antral activity as determined by bioassay and expressed relative to the 
weight of mucosa extracted. Such discrepancies may in part be dua to 
differences in extraction methods, bioassay methods and species differences. 
The bioassay method of Lai (1964a) involved measurement of gastrin activity 
using a cruda gastrin extract as standard in a rat preparation, whereas Em8s, 
Borg et al. (1971) used histamine as standard, and cats with gastric fistulae 
as the test animals. Measurement of the gastrin content of duodenal exl"racts 
by radioimmunoassay has shown marked differences in duodenal gastrin between 
man and other species (Nilsson 1 Yalow and Berson, 1973). The total gastrin 
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content in the duodenum of man was found to be 97% of that of the antrum 
in man, whereas in the dog, cat and hog the corresponding values compared 
to the antral gastrin content were 1,5%, 1,9% and 0, 1%. 
Nilsson, Yalow and Berson (1973) carried out an extensive quantitative 
study on the gastrin content of tissues in the gastrointestina I tract and at 
other sites in man, dog, cat and hog. They found no detectable gastrin in 
liver, kidney, heart and lung. Minute concentrations were detected in the 
buccal mucosa, tongue and oesophagus but they emphasised that these results 
were only tentative, awaiting further characterisation of this material. The 
highest gastrin concentrations were found in the antral mucosa of all species, 
with a yield of 22 JJg gastrin/g mucosa from hog antrum and approximately 
2 JJg/g in the case of human, dog and cat antrum. Within each species !he 
antral content of gastrin varied from one individua I to another. The extra-
antral gastrin content of the stomach was between 1 and 4% of that of the 
antrum. A concentration gradient of gastrin was found along the intestines 
of all species examined, with the highest intestinal gastrin content in the 
proximal duodenum. As mentioned above, the duodenal content of gastrin 
in man was much higher than in the other species. The gastrin found in 
extracts of jejunum and ileum agrees with the findings of Lai (1964b), and 
the jejuna! gastrin in the extracts of Nilsson, Yalow et al. (1973) was 
shown to be distinct from CCK-PZ by starch gel electrophoresis. The 
gastrin content of the smal I intestine excluding the duodenum ranged between 
0, l and 1,4% of the gastrin content of the antrum in man, dog, cat and 
hog. lmmunoreactive gastrin was detected in extracts of human pancreas 
at very low concentrations {0,4 ng/g tissue) but not in the pancreas of the 
other species investigated. Starch gel electrophoresis revealed that human 
pancreatic gastrin was a!most ali in the heptadecapeptide form (f'Jilsson, 
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Yalo.v et al., 1973). 
The remarkably greater concentration of gastrin in human duodenum compared 
with the other species suggests species differences in the distribution of extra-
antral gastrin. Duodenal gastrin was found to resemble plasma gastrin more 
closely than did antral gastrin with regard to the distribution of big and hepta-
decapeptide components (Yalow and Berson, 1973; Berson and Yalow, 1971), 
since big gastri n constituted a large proportion of the total immunoreactivity. 
This suggested that duodenal gastrin may be physiologically important in 
stimulating gastric acid secretion (Nilsson, Yalow et al., 1973). Stern and 
Walsh (1973) showed that duodenal gastrin was released by food entering the 
duodenum in patients who had had a Billroth I gastrectomy {vagotomy, partial 
gastrectomy and gastroduodenal anastomosis), providing strong evidence for a 
physiological role of duodenal gastrin. The same study showed that Billroth II 
subjects who had undergone vagotomy, partia I gastrectomy and gastrojejunal 
anastomosis had basal and postprandial gastri n levels significantly lower than 
control subjects or subjects with duodenal ulcer who had not been operated on, 
again suggesting the importance of duodenal gastrin. Korman, Soveny and 
Hansky (1972b) have also presented evidence for the release of gastrin from 
extra-gastric sites, since they observed gastiin responses to a protein meal in 
patients who hod been totally gastrectomised. 
The findings of Vinik, Grant et al. (1975) that the heptadecapeptide form 
of gastrin originates chiefly in the antrum, and that antrectomy abolished the 
reiease of gastrin stimulated by intravenous arginine (Vinik, Kalk et al., 1975) 
confirm the earlier report that smaller gasrrin forms are released from the antrum 
in response to arginine stimulation (Kalk, Vinik et al., 1973). Release of the 
big gastrin species, found largely in the duodenal extracts (Vinik, Grant et al., 
1975), foiiowing arginine stimulation in antrectomised subjects was not observed~ 
This suggests that duodena! gastrin is not released by arginine, although it may 
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be released by food ingestion, but does not exclude a role for duodenal gastrin 
in hydrochloric acid secretion. 
In another study of the distribution of gastrin in gastric mucosa, Malmstrpm 
and Stadi I ( 1975) investigated mucosa I extracts prepared from pig, dog, cat 
and rabbit. They found small but measurable amounts of gastrin in the corpus 
(body) of all species, with highest gastrin levels in the antrum in each case. 
They showed that the borderline between body and antrum was narrow, with 
an abrupt change in gastrin content of the mucosa, and that the gastrin activity 
in each area was evenly distributed. Like Nilsson, Yalow et al. (1973) they 
noticed a great variation in gastrin content of tissues between different indi-
viduals of the same species. In contrast to Nilsson, Yalow et al. (1973), 
Malmstrpm and Stadil (1975) found the highest antral gastrin content in man. 
They suggested that the higher levels in pig antrum detected by Nilsson, 
Yalow et al. (1973) may be due to the fact that the human tissues in this 
study were either autopsy specimens or were not processed immediately, thus 
reducing the antral gastrin conteni". 
The gastrin producing cells or G-cells have been shown to occur pre-
dominantly in the mid-portion of the pyioric glands in the antrum of the 
stomach, interspersed between adjacent mucous epithelial cells, in the human 
and the hog U·AcGuigan, 1968b; McGuigan and Greider, 1971; McGuigan, 
Greider and Grawe, 1972; Pearse and Bussolati, 1972). G-cells have also 
been demonstrated in the duodenal mucosa (Polak, Stagg and Pearse, 1972). 
Localisation of G-cells was achieved using the immunocytochemical techniques 
;f immunofluorescence or peroxidase anti-peroxidase (P .A.P .), which involve 
reacting cryostat or paraffin sections with cnti-gastrin antiserum raised in 
rabbit for example, followed by labelling of the positive cells with anti-
rabbit immunoglobuiin to which is attached either a fluorescent dye or a 
peroxidase marker, which is developed using hydrogen peroxide (Greider, 
Steinberg and McGuigan, 1972). By coupling immunohistochemical techniques 
with electron microscopy the typical appearance of a G-cell was determined 
(Greider, Steinberg et al., 1972). The G-cell is flask-shaped with a broad 
base and a narrow neck which reaches the lumen of the mucosa! gland and 
projects microvilli into the lumen. In the apical pole of the cell are 
situated the synthesising organelles which include lamellar endoplasmic 
reticulum with numerous ribosomes and the Golgi apparatus. The base of 
the cell, which is often adjacent to a ccpil lary, contains numerous granules 
of varying electron density (Creutzfeldt, Arnold, Creutzfeldt, Feurle and 
Ketterer, 1971). Greider, Steinberg et al. (1972) confirmed that this cell 
contains gastrin by staining secretory granules with peroxidase-labelled anti-
bodies. Different functional states of G-cells observed on ultrastructural 
analysis by Creutzfeldt, Arnold et al. (1971) led them to suggest that gastrin 
was not secreted by emeiocytosis (granule extrusion after fusing with the cell 
membrane) but rather by dissolution of the granule within the membranous 
sac fol lowed by transfer of the hormone through the granule membrane to 
the cell membrane via the cytoplasm. 
According to Creutzfeldt, Creutzfeldt and Arnold (1974) the distribution 
of G-cells in the antral mucosa is patchy and uneven. Extra-antral G-cells 
were found in the upper duodenum in this study, whereas no G-cells were 
found immunohistological ly in the fundic mucosa of animals and man. The 
ultrastructure of the G-cel! is relatively constant in different species which 
have been investigated, which include the guinea pig, rat, mouse, rabbit, 
cat, dog, pig and man {Creutzfeldt, Creutzfeldt et al., 1974). 
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The question of whether gastrin is present in the pancreas has not been 
resolved. Some investigators have been able to extract small amounts of 
immunoreactive gastrin from normal pancreas or have detected gastrin-
contai ning eel Is by immunohistochemistry, while others have not. Greider 
and McGuigan (1971) demonstrated positive immunofluorescent cells stained 
with gastrin antiserum in cryostat sections of normal human pancreas obtained 
at autopsy, which was confirmed by finding immunoreactive gastrin in 
extracts of 4 human pancreatic tissue samples, with a mean content of 
75 ng/g. Lomsky, Langr et al. (1969) also demonstrated positive gastrin 
eel Is by indirect immunofluorescence in normal human pancreas obtained at 
autopsy. Like Greider and McGuigan (1971) they found these cells to be 
located at the border and in the inner portions of the islets. In contrast, 
Lotstra, van der Loo and Gepts (1974) failed to demonstrate gastrin cells 
immunohistological ly in the pancreas of man, dog, rabbit, rat and pig, and 
their pancreatic extracts did not contain any immunochemically detectable 
gastri n. 
Nilsson, Yalow et al. (1973) demonstrated small amounts of gastrin in 
human pancreatic extracts when measured by radioimmunoassay (0,4 ng/g) 
but could not detect gastrin in extracts of cat, dog or hog pancreas. 
Minimal amounts of gastrin were detected in human pancreatic extmcts b)' 
Rehfeld and Iversen (1973)r who found 1,5 ng/g and Gepts (1973), who 
measured 2-10 ng/g (both cited by Creutzfeldt et al., 1974, po 50). 
Em8s and Fyr8 (l 968) failed to demonstrate any gastrin activity in 
extracts of cat pancreas by bioassay. Gepts (1973) ( cited by Creutzfeldt 
et al., 1974, p. 50) failed to extracts gas tr in from isolated rat islets when 
measured by radioimmunoossay. Creutzfeldt, Arnold et ai. (1971) could not 
demonstra~e the presence of G-cells in human pancreatic islets using indirect 
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immunofluorescance, and they did not detect any immunoreactive gastrin in 
human pancreatic extracts. According to Creutzfeldt, Creutzfeldt et al. 
(1974), G-cells have never been found ultrastructurally in the pancreatic 
islets of adult animals or man. 
Erlandsen, Hegre, Parsons, McEvoy and Eide (1976) suggested that these 
inconsistencies in staining of gastrin in pancreatic islets reported by different 
investigators may in part be due to the use of antisera with differing speci-
ficities for different gastrin forms. In addition, different methods of tissue 
preparation or fixation may also give rise to discrepancies. To add to the 
confusion, Erlandsen, Hegre et al. (1976) very elaborately demonstrated the 
presence of gastrin and somatostatin (grcwth hormone release inhibiting 
hormone) in the same pancreatic D or delta cells (Wiesbaden nomenclature) 
of man. The pancreatic D cell has been demonstrated to contain somato-
statin independently by other workers (Polak, Pearse, Grimelius and Bloom, 
1975). 
Turning to the question of pancreatic gastrin in the foetus and the 
neonate, Larsson, Rehfeld, Sundler and H8kanson (1976) demonstrated pan-
creatic gastrin cells at the 18th day of foetal life in the rat, and observed 
an increase in the number of these eel Is until day 4 after birth; after which 
they decreased. Gastrin eel Is were never obser,1ed in the pancreas of rats 
older than 20 days when stained by the immunoperoxidase method. Gastrin 
cells in the duodenum fol lowed a similar pattern, increasing in number until 
a few days after birth and then decreasing. Anrrai mucosa! gastrin cells 
could only be detected after birth. Extracts prepared from the pancreas and 
antrum of 4-day old rats eluted in the se1me chromatographic pattern as antral 
gastrin from adult rats. Duodenal extracts prepared from 4-day old rats 
contained a greater proportion of component II (big gostrin) than did the 
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antral and pancreatic extracts, as was the case in the adult human, as 
discussed earlier in this section. This study suggested that gastrin cells 
appear first in the duodenum and pancreas and not in the antral mucosa. 
In keeping with these findings, Braaten, Greider, McGuigan and Mintz 
(1976) found pancreatic gastrin for the first time in the 16-day old rat 
foetus, but in this case the gastrin levels increased until day 5 after birth, 
and then a relatively constant level was maintained unti I day 35 of neonatal 
life, as measured by radioimmunoassay of gastrin in the cell culture medium 
and in pancreatic extracts. Antral gastrin was also detected in foetal rats 
and the concentration increased rapidly and continuously in the neonatal 
period, as determined by radioimmunoassay of antral extracts. Monolayer 
cultures of pancreatic cells studied by immunofl uorescence revealed that the 
gastrin-containing cells were located at the periphery of the endocrine cell 
clusters, which were thought to represent whole islets. This distribution of 
gastrin cells is in agreement with that reported in intact pancreatic islets by 
Greider and McGuigan (1971) and Lomsky, Langr et al. (1969). However, 
the finding of increased pancreatic gc;;trin content in the neonatal rat is at 
variance with the findings of Larsson, Rehfeld et al o (1976). 
Two studies of the development of antral gastrin activity in the newborn 
rat which suggest that gastrin levels increase at the time of weaning have 
been described. Zelenkova and Gregor (1971) studied the development of 
antral gastrin activity in newborn rats using the bioassay method involving 
continuous perfusion of the rat stomach as described by Ghosh and Schild 
(1958). No gastrin acHvity was detected at birth or during the first 21 days 
of life, during which time the animals were fed exclusively on mother's milk. 
Gastrin activity appeared durir.g the weaning period when solid food was 
eaten and was found to increase steadily in the juvenile period. During 
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sexual maturation gastrin activity declined, after which it continued to 
increase o 
Similar results were obtained by Lichtenberger and Johnson (1974) who 
measured antral gastrin concentrations in the rat by radi oimmunoassay o 
Gastrin was present in low concentrations in the antrum of newborn rats and 
remained at this level until 21 days, when the levels rose to those found in 
the adult. This increase was coincidental with the time of weaning. At 
the same time major developmental changes in the structure of rat gut were 
found to occur. By comparing gut development in weaned rats with that in 
rats which were prevented from weaning Lichtenberger and Johnson (1974) 
showed that gastrin levels remained low and gut develc,pment was suppressed 
in the group prevented from weaning, suggesting that some aspects of gut 
development are dependent on weaning and that gastrin may be the mediator 
between these two event:;. 
In the case of the human, it appears that the gastrin measured in the 
plasma of neonates is of neonatal origin, and that the newborn baby can 
secrete gastrin independently. Rogers, Davidson, Lawrence, Ardill and 
Buchanan (1974) found higher gastrin levels in cord blood than in the maternal 
circulation in mothers undergoing spontaneous labour, and on the fourth day 
after birth the gastrin levels in the neonate were higher than the cord level. 
Von Berger, Henrichs, Raptis, Heinze, Jonatha, Teller and Pfeiffer (1976) 
also found higher sastrin levels in cord plasma than in the peripheral venous 
pla~ma of the mothersr and an incrnase in gastrin levels in the neonate 'NOS 
observed after the first feeding. in keeping vvith the suggestion that the 
neonate produces gastrin independently, this group demonstrated that 1251-
label!ed gastrin injected into female rats did not cross the placenta. 
A spate of recent reports showing the occurrence of several gut peptides 
in neural tissue and brain as well as in gut tissue, as demonstrated by 
immunohistochemi cal and extraction procedures, has reinforced the theory 
that endocrine cells in gut and neural tissue may be related, in that the 
endocrine polypeptide producing eel Is of the intestine may have a common 
neuroectodermal origin. Pearse and Polak (1971) have proposed that the 
ancestors of gut endocrine eel Is originate in the neural crest, on the basis 
of their observations that a group of cells displaying APUD-FIF characteristics 
were found to migrate ventrally from the neural crest to colonize the 
developing foregut and its derivatives, including the pharynx, stomach, 
duodenum, ultimobranchial body and pancreas in the mouse embryo. The 
abbreviation APUD-FIF stands for Amine Content and/or Amine Precursor 
Uptake and Decarboxylation - Formaldehyde - Induced Fluorescence (Pearse, 
1974), staining characteristics which are peculiar to this type of cell. These 
eel Is take up injected amine precursors such as dihydroxyphenylalanine (DOPA) 
and 5-hydroxytryptophan, and contain the fluorogenic amines catecholamine 
and 5-hydroxytryptamine (Pearse and Welbourn, 1973). Exposure of such 
tissues to formaldehyde vapour at 60°( o; 80°( for four hours induces these 
eel Is to fluoresce by virtue of their amine content. 
The discovery of a gastrin-like peptide in extracts of human and animal 
brain by Vanderhaegen, Signeau and Gepts (1975), which reacted with anti-
gastrin antibodies is in keeping with the theory of a neural origin of poly-
• ' I od . II peptrae norm one pr ucing ce. s. Th0 highest ievels of this brain gastrin 
peptide (BGP) were found in the cortical grey matter of the cerebral lobes, 
with concentrations of 200 pg/mg dry weight of tissue, whereas lower con-
centrations were found in the hypothalamus, brain stem and spinal chord. 
High levels of this peptide were aiso found in the hemispheres of the brain 
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of the dog, pigeon, trout and frog. No BGP was detected in the peripheral 
nervous system, the cerebellum or 1n the molluscan or crustacean nervous 
tissue studied. Extracts of human corti ca I grey matter did not behave immuno-
logically identically with gastrin (2-17) on dilution in the assay, suggesting 
that this peptide is not identical with gastrin. Preliminary results of 
Sephadex G-25 chromatography showed that BGP eluted between gastrin 
(217) d 131 100 • · I I ·h fl h 2020 - an ine, suggesting a mo ecu ar we1g t o ess t an 
(Vanderhaegen, Signeau et al., 1975). 
Dockray (1976) showed that extracts of entire rat brain and of the 
cerebral cortex of hog and dog contained immunoreactive material that 
differed from normal gastrin and CCK-PZ. From the elution profile obtained 
on Sephadex G-25 fractionation of these extracts measured with antiserum 
1296, which is specific for the C-terminus of gastrin, it appeared that these 
brain factors resembled CCK-PZ-like peptides more closely than they did 
gastrin. 
These findings were substantiated by the demonstration of Straus, Muller, 
Choi, Paronetto and Yalow (1977) of a peptide resembling the carboxyl-
terminai octapeptide of CCK-PZ in neurons of rat cerebral cortex. The 
presence of this material was demonstrated using the immunohistochemicai 
peroxidase-antiperoxidase system and an antiserum raised in rabbit which 
cross-reacted equally with CCK-PZ octapeptide and porcine gastrin I. 
Extracts of pig cerebral cortex were found to contain two peptides on 
Sep had ex G-25 chromatogrcphy, one resembling intact CCK-PZ and the 
other resembling the C-terminal octapeptide of CCK-PZ (Muller, Straus and 
Yalow, 1977). 
Somatostatin and vasoactive intestinal polypeptide (VIP) have also been 
found to occur in neural· and intestinal tissues. Somatostatin has been 
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localised immunocytochemically in the neurons cf the nucleus periventricularis 
of the hypothalamus, in nerve fibres in the neurohypophysis, and in some 
nerve fibres in the wall of the intestine (H8kfelt, Efendic, Hellerstr&n, 
Johansson, Luft and Arimura, 1975). Somatostatin-like immunoreactivity 
has also been demonstrated in the D cells of the pancreatic islets and the 
D cells of the upper gastrointestinal tract (Wiesbaden classification) by Polak, 
Pearse, Grimelius, Bloom and Arimura (1975). VIP immunoreactivity has 
been demonstrated in brain tissue by Bryant, Bloom, Polak, Albuquerque, 
Modi in and Pearse (1976) and by Said and Rosen berg (1976). Bryant, 
Bloom et al. (1976) showed that 94% of the VIP extractable from porcine 
and human brain eluted in the same position as the pure intestinal peptide 
on gel filtration. In addition they found that VIP in the human and in 
the pig occurred not only in the endocrine VIP cells of the intestine but 
also in some fine nerve fibres in the lamina propria, in the cell bodies of 
the myenteric plexus, and in the adrenal medulla. 
The significance of these findings of gut peptides in brain and nervous 
tissue awaits further investigation. It seems likely that these peptides may 
have a role as neurotransmitter substances or releasing factors, as has been 
suggested by Dockray (1976) and Muller, Straus et al. (1977). This seems 
feasible in the light of demonstrations that somatostctin, which has been 
localised in many neural and gastrointestinal tissues, appears to play an 
important role in regu:ation of secretion of several hormones and has been 
suggested to have a neurotransmitter function {Polak, Pearse et al. 1975). 
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2 Vl(ii) Abnormal Tissues 
Studies on gastrin heterogeneity in abnormal tissues involve preparation 
of extracts of gastrinoma tissue collected from patients with Zollinger-Ellison 
syndrome at opera ti on. These tumours, which arise from the pancreas or 
gastrointestinal mucosa, usually contain concentrations of gastrin as great as 
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or greater than those found in normal antral mucosa (Walsh and Grossman, 
1975b). High concentrations of gastrin in these tumours have been demonstrated 
by extraction of the tumour by boiling (Creutzfeldt, Arnold, Creutzfeldt and 
Track, 1975) and by immunohistochemical techniques (Polak, Stagg and Pearse, 
1972; Creutzfeldt, Arnold et al., 1975). 
Extraction of a pair of gastrin heptadecapeptides from human gastrinoma 
tissue and their subsequent purification and characterisation by Gregory, 
Tracy, Agarwal and Grossman (1969) revealed that the sequence of amino 
acids was identical to that of heptadecapeptide gastrin previously isolated 
from human antral mucosa (Ben~ley, Kenner et al., 1966). In 1972 Gregory 
and Tracy isolated two big gastrin peptides from gastri noma tissue which had 
been collected from human subjects with Zollinger-Ellison syndrome over a 
period of four years. These big gastrin peptides were very similar to the 
big gastrins isolated from porcine antral mucosa by this group in amino acid 
composition, and were identical to pordne antral big gasrrin and serum big 
gastrin in chromatographic and electrcphoretic properties (Gregory and Tracy, 
1972). 
During the purification of big gastrin from gastrinoma tissue Gregory and 
Tracy (1974) identified a pair of smaller peptides in the heptadecapeptide 
fraction obtained on Sep had ex G-50 gel filtration. These peptides corresponded 
in amino acid sequence to the (5-17) sequence of the heptadecapeptide, known 
as minigastrin, and were found in both the sulphated and non-sulphated forms 
in the proportion 1 :2, as was the case for the two larger forms of human 
gastrin previously purified. Any doubts that these C-terminal tridecapeptides 
were artefacts were dispelled by the demonstration of Rehfeld and Stadil 
(1973a) of an immunoreactive form of gastrin smaller than the heptadeca-
peptide in the circulation of gastrinoma patients. Both minigastrins were 
shown to be potent stimulants of gastric acid secretion when injected intra-
venously into conscious dogs with denervated fundi c pouches (Gregory and 
Tracy, 1974). 
Preparations of natural human big gastrin I (NHG-34 I) and natural human 
heptadecapeptide gastrins type I and II (NHG-17 I and II}, extracted and 
purified from gastrinoma tissue by Gregory and Tracy, have been made 
available in small quantities and distributed by the Centre for Ulcer Research 
and Education by courtesy of Dr. M .Grossman. Such preparations have been 
used in various studies desciibed in this thesrs. 
Recent studies have shown that the heterogeneity of gastrin in tumour 
extracts is more complicated than had been thought, since still more gastrin 
subtypes have been resolved on column chromatography by Gregory and 
Tracy (1975). During their isolation of big gastrins type I and 11 from 
gasrrinoma tissue they found two additional small peaks in the region of 
the heptadecapeptide gastrins, which they calied little or heptadecapeptide 
gastrins IIA and IIB. These pE:ptides have the same amino acid composition 
and biological potency as heptadecapept:de gastrin and both contain sulphated 
tyrosine (Gregory and Tracy, 1975). Until their prnsence in serum has been 
demonstrated, the possibility thct they are mtefacts cannot be exduded. 
Likewise, a third big gastrin, intermediate in polarity between big gastrins 
I and II, has bean identified on DEAE cellulose chromatography of the big 
gastrin ii fraction from gastrinoma tissue (Gregory and Tracy, 1975). 
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Amino acid analysis revealed that its composition was the same as that of 
non-sulphated big gastrin, hence it was named big gastrin IA. Demonstration 
of the presence of this fragment in serum is awaited to rule out the possibility 
that this fragment is an artefact of the extraction procedure. 
It seems likely that the findings of these multiple hormonal forms in 
tissue extracts are related to the multiple heterogeneity of serum gastrins 
observed by Rehfeld, Stadil et al. (1975), who have so far identified 20 
different gastrin components ,n serum. However, it is possible that some 
of the multiple components of hormones found in tissue extracts are the result 
of nonspecific enzymic degradation and are thus not normally found under 
physiological conditions. 
Component I has been identified chromatographi cally in an extract of 
gastrinoma tissue (Rehfeld, Stadil et al., 1974), and immunoreactive material 
eluting in the void volume of a Sephadex G-50 column, corresponding to 
"big big" gastrin has also been found in such extracts. BBG comprised less 
than 2% of the total gastrin immunoreactivity in a Zollinger-Ellison tumour 
investigated by Yalow and Wu (1973), and this fraction was found to comprise 
a series of immunoieactive components eluting between the positions of 
albumen and big gastrin on Sephadex G-50. The heterogeneous nature of 
BBG extracted from gastrinoma tissue was also reported by Rehfeld, Stadil 
et al. (1974), who estimated that the apparent molecular weight rnnged from 
30 000 to 100 000. 
With regard to the relative proportions of the different gastrin types 
found in g:istrinoma tissue, the predominant form of tumour gastrin is of rhe 
heptadecapeptide variety. According to Dockmy (1975), big gastrin con-
stitutes a fair proportion of tumour gastrin; in a few cases "big big" gastrin, 
component I and minigastrin have together been found to comprise up to 
15% of the total tumour immunoreactive gastrin. When serum and tumour 
extract from the same patients were examined chromatographically, G-34 
usually constituted the major peak of immunoreactive gastrin in serum and 
G-17 I and II were the major peaks in tumour extract (Dockray, 1975). 
These measurements were made using antiserum 1296 which recognises the 
different gastrin components equally. Additional evidence that G-17 is 
the principal molecular form stored by gastrinoma tissue was provided by 
stimulation of gastrin release by intravenous secretin, which produced a 
marked increase in the levels of serum G-17 and G-34. The G-17 
response was proportionally greater and its levels returned to basal values 
more rapidly than G-34, due to its shorter half-life in the circulation 
(Dockray, 1975). 
Creutzfeldt, Arnold et al. (1975) also found that big gastrin was present 
in serum in larger amounts then in tumour extia cts when they examined the 
distribution of immunoreactivity of gastrin components in 9 patients with 
gastrinoma. They could find no obvious relationship between the distribution 
of gastrin components in the tumour tissue and serum of individual patients. 
However, the antiserum used in these studies had a 70% lower affinity for 
G-34 compared to G-17 on a molar basis, so the percentages reported for 
big gastrin were underestimations of the real values (Creutzfeldt, Arnold 
et al., 1975). 
A Zollinger-Ellison tumour examined by Gregory and Tracy was found 
to contain primarily big gastrin (Gregory, i976), ·which suggests that some-
thing abnormal in a tumour might block the conversion of big gastrin to 
heptadecapeptide gastrin, so that big gastrin accumulates. This would only 
apply if it could be shown that one ce!I type produces both big and hepta-
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decapeptide gastrin, and if the biosynthetic sequence BBG ~ component 
~ big gastrin ~ heptadecapeptide gastrin could be demonstrated. At 
present such information is not avai I able (Gregory, 1976) o 
The first immunohistological demonstration of gastrin-containing cells in 
a Zollinger-Ellison tumour came from Creutzfeldt, Arnold et alo (1971), 
who showed that the cells of a Zollinger-Ellison tumour were ultrastructurally 
identical with the G-cells of human antral mucosa. In a later study 
{Creutzfeldt, Arnold et al., 1975) ten gastrinomas were investigated ultra-
structurally and the appearance was found to vary from one tumour to 
another and sometimes in different areas of the same tumour. Differences 
involved the frequency of cells with or without secretory granules and the 
type of secrerory granules found. Seven of the ten tumours contained cells 
with secretory granules identical to those of antral G-cells, showing a 
broad scale of varying electron density. Most tumours also contained cells 
with atypical granules which were electron dense, round and small. Some 
tumours contained only cells with atypical secretory granules, in which 
case extraction of gastrin from the tumour was necessary to demonstrate its 
presence. Other tumours were multihormone producing, containing, for 
example, cells with typical beta granules as well as G-celis; both gastrin 
and insulin producing eel Is in these tumours were demonstrated immunohisto-
logically. No correlation was found between the relative number of cells 
with typical G-cell granules or cells with atypical granules and the gastrin 
content of the respective tumour. 
It has become apparent that iwo distinct types or perhaps stages of 
Zollinger-Eliison syndrome exist. Berson and Yalow (1972) described a 
group of 9 patients with Zollinger-Ellison syndrome who could be divided 
into two distinct groups. Four of these patients had moderate hyperchlor-
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hydria and gas~rin levels in the range of Zollinger-Ellison syndrome, but they 
did not have detectable gastrin-producing tumours. They showed significant 
plasma gastrin responses to a test meal, of a magnitude l 0-20 times greater 
than that found in normal subjects and patients with duodenal ulcer. The 
remaining five patients behaved predictably in that they showed no increase 
in serum gastrin levels in response to feeding. 
These clinical findings can be correlated with the description of two 
types of Zollinger-Ellison syndrome based on immunofluorescent, cytochemical 
and ultrastructural studies by Polak, Stagg and Pearse (1972). According 
to these workers, Zollinger-Ellison syndrome type ! is characterised by a 
short history, very high serum gastrin I eve ls, extreme hyperplasia of the 
antral G-cells, normal or slightly hyperp!astic pancreatic D-cells, and no 
tumour. This would correspond with the first group described by Berson and 
Yal0\A1 (1972), since the antral G-cell hyperplasia would account for the 
increase in gastrin levels in response to feeding. Zollinger-Ellison syndiome 
type ii described by Polak, Stagg et al. (1972) manifests itself as a long 
history of high gastrin levels and ulceration, normai antral G-cells, hyper-
plasia of the pancreatic D-cells and the presence of a tumour or gastrinoma, 
which would correspond with the second group of Berson and Yalow (1972). 
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2 Vl(iii) Significance of the Multiple Forms of Gastrin 
With the discovery and characterisation of the different molecular forms 
of gastrin arises the question of how they are all inter-related o Chemical 
characterisation of heptadecapeptide gastrins isolated from human antral and 
gastrinoma tissue has shown that they are identical in structure (Gregory, 
Tracy et ai., 1969; Bentley, Kenner et al., 1966) and this may prove to 
be true in the case of the big gastrins as well, once big gastrin from human 
antrum can be purified in sufficient quantities to allow sequencing studies 
{Gregory and Tracy, 1975). Characterisation of human duodenal big gastrin 
is difficult due to the impracticality of obtaining sufficient quantities of 
human material (Gregory, 1976). Thus gastrinoma tissue remains the most 
plentiful source of human gastrins, and extrapolations of findings relating 
to purified gastrins from this source to gastrins originating in normal human 
tissues should be made with caution until the chemical identity of gastrins 
from both these sites has been established. It seems likely that this will 
prove to be the case, since the gastrin producing cell in gastrinoma tissue 
is identical with the antral G-cell (Creutzfeldt, Arnold et al., 1971). 
The hypothetical biosyntr.etic sequence in the gastrin series is "big big" 
gastrin -. component I ~ big gastrin ~ heptadecapeptide gastrin-. 
minigastrin, if one assumes that the larger forms represent precursor forms. 
Preparations of gastrin-forming cells in slices of gastrinoma tissue cultured 
in vitro would be useful in demonstrating such a sequenceo However, this 
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is not entirely practical since gastrinoma tissue is not readily available, and 
the preferred method of treatment of this condition is removal of the target 
organ by total gastrectomy rather than removal of the tumour (Gregory, 1976). 
The conversion of big gastrin to heptadecapeptide gastrin by trypsin has 
been well documented, and the cleavage of the G-34 molecule at the 
lys-gln sequence to yield G-17 suggests that G-34 may be the precursor of 
G-17 (Gregory and Tracy, 1975). The precursor forms of hormones are 
generally biologically inactive and the conversion from larger to smaller 
molecular forms is brought about by converting enzymes in the cell of 
origin (Grossman, 1975). If big gastrin is the precursor of heptadecapeptide 
gastrin, this constitutes a situation of a biologically active prohormone, 
since G-34 has definite biological activity (Walsh, Debas et al., 1974). 
The amino acid sequence of big gastrin at its point of cleavage by 
trypsin is lys-lys-gln, and when heptadecapeptide gastrin is liberated the 
glutamine residue cyclizes spontaneously to the pyroglutamyl form, changing 
the molecule from ninhydrin-positive to ninhydrin-negative. The amino-
terminal residue in big gastrin is also pyroglutamyl, which led Gregory (1976) 
to suggest that the same sequence of events might occur on liberation of 
big gastrin from a larger precursor, such as component I. 
It may be that an even larger precursor form of gastrin, as yet undis-
covered, exists. It has been suggested that a precursor peptide may be 
attached to the carboxyl terminal end of the gastrin molecule and is removed 
by transamidation at this point, resulting in the phenylalanine-amide residue 
found in the C-terminal position of all gastrin species which are biologically 
active (Gregory, 1976). Since removal of this carboxyl-terminal amide 
abolishes the biological activity of gastrin (Tracy and Gregory, l 964), such 
a precursor would almost certainly be physiological!>, inactive. Since many 
of the gastrin antisera currently in use recognise the C-terminal region of 
the gos~rin molecule; which would be masked in a precur:;or of this nature, 
detection of such a precursor may prove difficult (Gregory, 1976). Relevant 
in this connection is the finding by Malagelada of a large gastri n component, 
eluting between tha void volume and the position of G-34 on Sephadex 
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chromatography, which was found in the serum of some patients with 
Zollinger-Ellison syndrome and was biologically inactive (Malagelada, 
1977). 
Having discussed the possible significance of the various molecular 
forms of gastrin, it may be useful to consider what is known regarding 
the nature and significance of the different forms of other peptide honnones 
which have been found to be heterogeneous. 
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Section VI I Heterogeneity of Other Peptide Hormones 
It has become apparent that many, if not a II, of the peptide hormones 
are found in more than one form, both in plasma and in glandular and other 
tissue extracts (Yalow, 1974b). The various peptide hormones can be 
separated into several groups on the basis of structure I similarities in their 
amino acid sequences. These similarities, which are very striking in some 
cases, strongly suggest a common ancestral origin for the various hormones 
of each group (Tager and Steiner, 1974)0 Hormonal heterogeneity or poly-
morphism has been demonstrated in the case of hormones belonging to almost 
every group of peptide hormones, which have been classified by lager and 
Steiner (1974) as follows:-
1. insulin, proinsulin, nerve growth factor 
2. glucagon, secretin, vasoactive intestinal polypeptide (VIP), gastric 
inhibitory polypeptide (GIP) 
3o gastrin, CCK-PZ, caerulein 
4. adrenocorticotrophic hormone (ACTH), melanotropin, lipotropin 
5. growth hormone, prolactin, placental lactogen or human chorionic 
somatomammotropin (HCS) 
6. the glycoprotein hormones, which include luteinizing hormone (LH), 
follicle stimulating hormone (FSH), human chorion1c gonadotrophin 
(HCG), thyroid stimulating hormone (TSH). 
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Hormonal polymorphism has been best characterised in the case of insulin, 
parathyroid hormone, growth hormone, g!ucagon, adrenocorticotrophic hormone, 
and melanocyte-stimulating hormone. Cho!ecystokinin-pancreozymin exists in 
at least two molecular forms (Mutt and Jorpes, 1968), whereas secretin has 
not yet been identified in heterogeneous forms (Grossman, 1975). 
Multiple hormonal forms may be detected by fractionation of tissue 
extracts or plasma using Sephadex gel filtration, starch gel electrophoresis, 
or ultracentrifugation; the presence of hormonal activity in two or more 
separate fractions suggests heterogeneity. In addition, heterogeneity may 
be suspected when measurements of the hormonal content of a sample relative 
to a given hormonal standard change when different antisera are used in the 
assay. 
According to Franchimont, Gaspard, Reuter and Heynen ( 1972) the 
causes of hormonal heterogeneity include:-
1. Precursors 
2. lsohormones 
3. Polymers 
4. Protein-bound hormones (?) 
5. Subunits 
6. Metabolites 
7 ~ Artefacts of extraction and purification 
8. Tumour or adenoma hormone analogues. 
lsohormones are forms of a hormone which can be separated on electro-
phoresis or in polyacrylamide gel by ion focusing and which have identical 
or very similar molecular weight and the same biological activity (Franchi-
mont, Gaspard et al., 1972). Three isohormones of bovine PTH, differing 
slightly in amino acid composition or sequence, have been isolated by 
Keutmann, Aurbach, Dawson, Nial I, Deftos and Potts (1971). Preparations 
of bovine pituitary extracts yielded several distinct forms of TSH which were 
all biologically active (Bates and Condliffe, 1960), and a similar hetero-
geneity in TSH obtained from monkey pituitary extracts was reported by 
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Hummel, Webster and BrONn (1970). As with the other glycoprotein hormones, 
which consist of two non-covalently bonded polypeptide subunits designated 
alpha and beta, linked to a carbohydrate moiety, the polymorphism of TSH 
could be due to mi crcheterogeneity of the carbohydrate component as a result 
of its incomplete syntesis or degradation (Franchimont, Gaspard et al., 1972). 
"Protein bound hormones" refers to the theoretical possibility of a peptide 
hormone bound to a serum carrier protein, a situation which has not yet been 
encountered (Franchimont, Gaspard et al., 1972). The possibility that the 
heterogeneity observed is due to artefacts of extraction and purification or 
due to the fa ct that metabolites a re being measured must be excluded before 
the existence of a precursor can be established. 
The use of trypsin and urea has been invaluable in elucidating the 
nature of some of the larger hormonal forms. Since urea is a protein 
denaturing agent which disrupts non-covalent bonds responsible for the native 
conformation of proteins, any alteration in the molecular weight of a large 
hormonal form fol lowing treatment with urea suggests the presence of an 
aggregate or the native hormonal form bound to a larger protein (Toger and 
Steiner, 1974). Liberc~ion of the native hormonal form together with another 
peptide following trypsin cleavage of a lmger hormonal form suggests the 
existence of a precursor or prohormone. The conversion of a large hormonal 
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form into a sma Iler form by trypsin has been demonstrated in the case of 
insulin, glucagon, parathyroid hormone and ACTH as well as gastrin1 and in 
each case, except for ACTH, the primary structure has been shown to contain 
at least two consecutive basic amino acids at the point of cleavage (Grossman, 
1975). The most convincing evidence for the existence of a ptecursor is the 
demonstration that radioactively-labelled amino acids are transferred from the 
substance with higher molecular weight to the hormone itself in vitro 
{Franchimont, Gaspard et al., 1972). 
The classic example of a precursor-hormone relationship, and probably 
one of the most well defined, is that of insulin and its precursor, proinsulin. 
Steiner, Cunningham, Spigelman and Aten (1967) demonstrated that both the 
A and B chains of insulin are initially synthesised as part of a larger single-
chain peptide, proinsulin, with the subsequent cleavage by a trypsin-like 
protease of a portion of the chain known as C-peptide, to produce the 
common form of insulin in which the A and B chains are linked by two 
disulphide bondso Roth, Gorden and Pastan (1968) demonstrated the presence 
of a proinsulin-like component in plasma on Sephadex G-50 gel filtration 
and found that it constituted up to 50% of the total immunoreactive insulin 
in plasma. Each component maintained its integrity on refractionation, 
suggesting that the two components are not readily interconvertible in plasma. 
Proinsulin was shown to have lcw biological activity by Rubenstein, Cho and 
Steiner (1968). Conversion of proinsulin to insulin is apparently initiated 
within the Golgi apparatus of the pancreatic beta cell and continues within 
the secretory granules in the cytosol (Steiner, Kemmler, Tager and Peterson, 
1974). Although only approximatel_y 4% of the total proinsulin synthesised 
escapes conversion to insulin in the beta eel l, the ratio of proinsulin to 
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insulin in the circulation is considerably higher due to the more rapid turn-
over of insulin than proinsulin in the circulation (Franchimont, Gaspard et al., 
1972). 
lmmunochemical heterogeneity was first shown for human parathyroid 
hormone (hPTH) when it was observed that a plasma dilution curve was super-
imposable on a curve of standards obtained from a normal parathyroid gland 
with two antisera but not with that obtained using a third antiserum (Berson 
and Yalow, 1968). Fractionation of glandular and plasma PTH using Sephadex 
G-100 gel filtration yielded different elution profiles when measured with 
antisera 273 and C 329, with almost twice as much immunoreactivity detected 
by the former antiserum when a parathyroid adenoma extract was fractionated 
(Silverman and Ya low, 1973; Yalow, 1974a). The first component which 
eluted in the void volume, constituted a minor fraction of the total immuno-
reoctivity. The second component corresponded to intact PTH, the third and 
predominant peak of immunoreactive hormone reacted only with antiserum 273, 
and the fourth component reacted only with antiserum C 329. Al I four com-
ponents maintained their integrity on refractionation (Silverman and Yalow, 
1973; Yalow, 1974a). 
Biosynthetic experiments involving organ culture of bovine parathyroid 
glands which could be shown to secrete PTH in response to alterations in 
calcium and magnesium ion concentrations, revealed that the hormone syn-
thesised in the glands was of a higher molecular weight than that released 
into the culture medium or that found in the bovine circulation (Sherwood, 
Rodman and Lundberg, 1970). This suggested that the parathyroid glands 
synthesise a precursor hormone, proparathyroid hormone, which is modified 
to the smaller molecule that circulates in blood. This was confirmed by 
Kemper, Habener, Potts and Rich (1972), who showed that the proparathyroid 
hormone synthesised by bovine parathyroid tissue in vitro is 15-20 amino 
acids larger than the native hormone and has a molecular weight of about 
11 500 as determined by polyacrylamide gel electrophoresis. This group 
demonstrated the incorporation of 14C-labe!led amino acids into the precursor 
initially, followed by an increase of the labelled material in the native 
hormone and a decrease in radioactivity in the precursor. Peptides obtained 
on treatment of both the precursor and the hormone with trypsin were common 
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to both molecules, and both molecules reacted identically with an antiserum 
specific for PTH, again confirming the existence of a precursor form con-
taining the PTH sequence within its structure. 
Two components of human growth hormone were detected on gel filtration 
of large volumes of plasma using Sephadex G-75 by Bala, Ferguson and Beck 
(1970). More than 50% of the total immunoreactivity in all the plasmas 
investigated eluted in a molecular size region greater than that of extracted 
pituitary human growth hormone (ep-HGH), while significant HGH immuno-
reactivity was also found in areas corresponding to a smaller molecular size 
than ep-HGH. The larger HGH form was thought to consist of aggregated 
forms of native HGH or complexes of HGH and plasma proteins. The greatest 
total amount of biological activity, as measured using a sulphation factor 
assay in vitro, was found in the large molecular size fraction although the 
smaller HGH fraction displayed the most potent sulphation factor activity 
(Ba la, Ferguson et a I., 1970). 
The studies of Goodman, Tanenbaum, Wright, Trimble and Rabinowitz 
(1974) showed that fractionation of plasma from normal subjects, acromegalic 
patients and a patient with the syndrome of dwarfism and high plasma HGH on 
Sephadex G-75 resulted in two peaks corresponding to 14 to 28% of the total 
immunoreactivity in the case of the big human growth hormone, and 67 to 
86% of the total in the case of little HGH, which migrated almost identically 
• h ' . f 125 1 H"H r h · · wit the ma1or component o - u trom t e p1tu1taryQ Both components 
retained their integrity on refractionation, confirming that conversion from one 
form to the other did not occur during gel fiitration. Freezing and thawing 
caused over half of the big HGH fraction isolated from plasma to convert to 
little HGH, a finding that was confirmed following treatment with urea. 
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Both these observations suggested that big HGH consists of little HGH bound 
non-covalently to another moiety. From its behaviour on Sephadex, Goodman, 
Tanenbaum et al. (1974) concluded that the molecular weight of big HGH was 
approximately double that of little HGH, which is about 22 000, suggesting 
the possibility of a dimer. Gel filtration of HGH extracted from the pituitary 
produced two peaks identical to those found for plasma HGH, suggesting that 
both the plasma components may be secreted by the pituitary. 
In the case of ACTH in plasma and extracts of pituitary glands and an 
ACTH-producing tumour, Sephadex G-50 fractionation again revealed two 
major components of immunoreactivity, one corresponding in molecular size 
to the 39 amino acid little ACTH and the other eluting in or near the void 
volume (Yalow and Berson, 1971 b). The relative proportions of the two com-
ponents varied greatly among plasmas, and each component ran true on re-
fractionationo The two components were immunochemically indistinguishable, 
and tiyptic digestion of big ACTH resulted in quantitative conversion to a 
little ACTH-like peptide (Yalow, 1974a). Big ACTH showed very little bio-
logical activity, and conversion of this form to the little form resulted in 
biological activity equivalent to immunological activity. These findings 
suggested that the larger form of ACTH consists of native ACTH covalently 
linked to a larger peptide with the antigenic site recognised by the specific 
antiserum fully available but with a configuration that renders it biologically 
inactive (Yalow, 1974a). Since both components were found in plasma and 
in pituitary and tumour extracts Yalow and Berson (1971 b) suggested that the 
hormone is produced at and secreted from its site of origin in at least two 
forms, in a similar manner to that suggested for growth hormone by Goodman, 
Tanenbaum et al. (1974). 
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Glucagon extracted from canine pancreas was also found to comprise 
two fractions when separated by gel filtration (Rigopoulou, Valverde, Marco, 
Faloona and Unger, 1970). Over 900/o of the immunoreactivity corresponded 
131 in molecular size to the 1-glucagon marker, while the remaining immuno-
reactive fraction appeared to be at least twice as large. The same elution 
profile was obtained with human, duck, rat and bovine pancreatic glucagon. 
Urea treatment did not alter the molecular size of the large component, 
whereas trypsin converted the LG I (large glucagon immunoreactivity) to a 
131 
molecular size close to that of 1-glucagon. Both LG I and its tryptic 
product behaved immunologically identically to crystalline glucagon but 
neither were biologically active in producing glycogenolysis in the perfused 
rat liver (Rigopoulou, Valverde et al., 1970). This emphasises the problem 
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that plasma measurements of immunoreactive glucagon do not necessarily 
represent biologically active hormone, since it was not possible to differentiate 
immunochemi cally between intact gl ucagon and these biologically inactive 
substances. 
The demonstration by Tung (1973) of a possible high molecular weight 
intermediate in the biosynthesis of avian glucagon using isolated islets of 
Langerhans from the pigeon provides additional evidence for the existence 
of a larger precursor form of gl ucagon. He isolated a component with an 
approximate molecular weight of 69 000 using Sep had ex G-100 chromato-
graphy which was shown to possess glucagon immunoreactivity. 
In addition, a minor component has been isolated from crystalline glucagon 
which consists of glucagon with eight additional residues attached at the 
carboxyl terminal end of the peptide (Steiner, Kemmler et alo, 1974). It 
was assumed that this peptide represented a portion of the proglucagon 
molecule and it was tentatively identified as a synthetic intermediate. 
From the foregoing discussion it would appear that most of the small 
peptide hormones are derived from larger precursor forms, and it seems likely 
that similar modes of cleavage are involved in each case. Since the immuno-
reactive site on the native hormone may be exposed for reaction on the pre-
cursor form of the molecule as well, measurements of total immunoreactivity 
in the circulation may include a contribution by a precursor with lower bio-
logical activity. Thus immunoreactivity and bioactivity measurements should 
ideally be coupled with fractionation data for absolute determination of 
hormone levels o 
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Section VIII Distribution of Gastrin in Vertebrates and Lower Species 
2 VI ll(i) Gastrin in Vertebrates 
A handful of reports have appeared describing the occurrence of gastrin in 
vertebrate species other than man and the mammals. Gastrin or gastrin-like 
material has been detected in species of bird, reptile, frog and ce1rtilaginous 
fish. 
The tissue distribution of gastrin in mammals such as the hog, dog, cat and 
rabbit has been studied by Nilsson, Yalow et al. (1973) and Malmstrpm and 
Stadil (1975), and was described in detail together with distribution of gastrin 
along the human gastrointestinal tract, in section 2 Vl(i). A further study on 
gastrin content of canine tissues by Thompson, Reeder, Davidson, Jackson and 
Clendinnen (1973) again showed the highest gastrin levels in extracts of antral 
mucosa. The only other tissue containing a notable amount of gastrin in this 
study was the gall bladder, which had a gastrin content of 12% of that of the 
antrum, but this may represent cross-reaction of CCK-PZ in the assay. Duo-
denal gastrin content in this study was only 2% of that in the antrum. These 
workers also investigated tissue extracts prepared from antrum, fundus, duodenum 
and pancreas as well as plasma of the frog, guinea pig, rat, rabbit, hog and 
cat. They found high concentrations of gostrin in the pancreas of the frog, rot 
and cat and in the duodenum of the guinea pig and rabbit, while the antral 
content in the frog and rat were roughly five to ten fold lower, with tissue 
concentrations of 500 ng/g and 475 ng/g respectively. 
The amino acid sequence of heptodecapeptide gastrin isolated from the pig, 
cow, sheep, dog, cat and human was determined by Kenner and Sheppard (1973). 
Basically the structures resemble that of human heptadecapeptide gastrin with one 
or two amino acid substitutions. In position 5 methionine replaces leucine in 
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porcine and canine gastrin, while this position is occupied by valine in gastrin 
from cow and sheep, and feline gastrin bears the same residue as does human 
gastrin in this position. Alanine is substituted for glutamic acid in position 10 
in gastrin of cow, sheep and cat, and in position 8 in canine gastrin. Cow and 
sheep gastrins appear to be identical in structure. 
Investigations on the occurrence of gastrin in vertebrates and lower species 
can be carried out by various techniques. Extracts of the tissue being studied 
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can be tested for gastrin content using a bioassay technique or by radioimmuno-
assay. The use of gel chromatography to separate the different gastrin components, 
combined with radioimmunoassay, is useful for determination of the nature of 
gastrin in the extract. The other line of investigation involves the immuno-
histological demonstration of gastrin-containing cells in the tissue under examination 
using the techniques of immunofl uorescent or peroxidase anti-peroxidase label ling 
of gastrin-containing cells. Various workers have described their findings of 
gastrin in different species using one of these techniques. In a few instances 
refined investigations have shown the presence of gastrin by using a combination 
of two or more of these methods, and these are the studies upon which the 
greatest emphasis can be placed. The findings of gastrin in various animal 
species will be discussed in a sequence progressing down the evolutionary scale. 
Olowo-Okorun (1975a) prepared extracts of gastrointestinal mucosa of cattle, 
goat, sheep and donkeys using the procedure described by Blair, Harper, Lake, 
Reed and Scratcherd (1961), which commenced with boiling the mucosa in water, 
followed by acetone precipitation. The extracts wern assayed for gastrin using 
a modification of the continuous rat stomach perfusion technique of Ghosh and 
Schild (1958). When the gastrin activity detected in the extracts was expressed 
as SHG I equivalent, the pyloric mucosa of all the animals was found to contain 
significantly greater amounts than the duodenal mucosa o The histamine content 
of the extracts was too low to produce an increase in acid secretion in the rat, 
confirming that the observed effects could not be attributed to histamine con-
tamination (Olowo-Okorun, 1975a). The antral gastrin content was between 
40 and 58 ng SHG I equivalent/mg crude extract for al I species investigated. 
Gastrin activity was found in the chicken proventriculus by Olowo-Okorun 
and Amure (1973). Extracts of the proventriculus and duodenum were prepared 
by the method of Blair, Harper et al. (1961) and tested for gastrin activity 
using the bioassay technique of Ghosh and Schild (1958). No increase in acid 
secretion was produced by duodenal extracts, whereas extracts of proventriculus 
were found to have gastrin activities approximately double that of pyloric antral 
extracts prepared from cattle, sheep and goat, with a content of 109,4 ng 
SHG I equivalent/mg crude extract. 
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In an excellent study on gastrin in the chicken Larsson, Sundler, H8kanson, 
Rehfeld and Stadil (1974) demonstrated gastrin-containing cells, using the 
technique of immunofluorescence, in a narrow zone joining the gizzard with the 
duodenum, where the mucosa resembled that of the mammalian pyloric antrum 
histologically. Gastrin cells were occasionally found in the duodenum and 
jejunum but were absent in the oesophagus, crop, proventri cul us and gizzard. 
Extracts of tissue collected from the oesophagus, crop, proventriculus, gizzard, 
gizzard-duodenal junction, duodenum and jejunum prepared by boiling in water 
were tested for gastrin by radioimmunoassay. The gizzard-duodenal junction 
(antrum} was the only site where immunoreactive gastrin was detected, in keeping 
with the finding of gastrin cells at this site. Chicken gastrin did not behave 
identically with human heptadecapeptide gastrin on dilution in the assay. 
Sephadex G-50 gel filtration produced a major peak eluting in the region of 
heptadecapeptide gastrin, with smaller amounts in the position of minigastrin. 
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A third study in the chicken by Polak, Pearse, Adams and Goraud (1974) 
revealed cells showing gastrin immunoreactivity occurring throughout the digestive 
tract distal to the proventriculus, which is in close agreement with the findings 
in the above study, except for the finding of gastrin-containing cells in the 
gizzard by Polak, Pearse et al. (1974). Neither study could confirm the findings 
of gastrin activity in the proventriculus as described by Olowo-Okorun and 
Amure (1973), although all three studies were performed using the same species 
of chicken, the White Leghorn variety. 
With regard to the reptiles, gastrin-like activity has been described in the 
pyloric antrum of the Indian python (Python molurus) by Olowo-Okorun (1975b). 
As with the previous studies by this worker, a crude extract of the antral mucosa 
was prepared by the method of Blair, Harper et al. (1961) and the gastrin activity 
was determined using a modification of the bioassay technique of Ghosh and 
Schild (1958). The gastrin-like activity was 52,l ng SHG I equivalent/mg crude 
extract, which was about the same as that found in cattle, sheep and goat by 
the same worker (Olowo-Okorun, 1975a). 
Using the same technique of extraction and the bioassay methods of Ghosh 
and Schild (1958) and Lai (1964<1), Oyebola and Elegbe (1975) demonstrated the 
presence of gastrin activity in the stomach of the common African toad, Bufo 
regularis. Histamine contamination of the extract was minimal and did not 
interfere in the bioassay estimations, which yielded a gastrin content of 194,7 
ng SHG I equivalent/mg crude stomach extract. This value is higher than the 
gastrin content found in extracts prepared from mammalian and avian species 
by the same group of workers. 
A more convincing demonstration of amphibian gastrin has been provided by 
Gibson, Mi has, Colvin and Hirschowitz (J 976} who prepared exfracts of the oeso-
phagus, fund us, antrum, duodenum, midgut, pancreas, I iver and terminal 
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intestine of three species of amphibia, Rana caf·esbeiana, Rana pipiens and 
Necturus. Extracts were prepared by boiling in water followed by centrifugation, 
and the gastrin content of the supernatants was estimated by radi oimmunoassay. 
Antibody 1296 which recognises the (-terminal portion of heptadecapeptide 
gastrin and cross-reacts equally with mini-, heptadecapeptide and big gastrin 
as discussed in section 2 IV, was used for these measurements. The highest 
tissue concentrations of gastrin in both species of Rana were found in the antrum, 
followed by the duodenum and pancreas. In the case of Necturus the highest 
tissue gastrin levels were detected in the area just distal to the pyloric sphincter, 
corresponding to the duodenum in mammals, fol lowed in decreasing order by 
the antrum and pancreas. 
Chromatography of amphibian serum and tissue extracts was performed using 
a Sephadex G-50 superfine column which had been calibrated with natural 
human G-13 I, G-171 and G-34 I gastrins. Serum of R. catesbeiana was 
resolved in two peaks, one corresponding to G-34 and one in the void volume, 
which may correspond to "big big" gastrin. A component eluting in the region 
of G-34 predominated in extracts of antral mucosa of both R. catesbeiana and 
Necturus and a small fraction was found eluting in the regions of G-17 and 
G-13 (Gibson, Mihas et al., 1976). In the duodenal extracts much immuno-
reactive gastrin eluted in the void volume. R. catesbeiana duodenal extracts 
also yielded a peak in the region of G-34, while Necturus was found to possess 
a smal I amount of immunoreactivity corresponding to the G-34 and G-17 elution 
volumes. The pattern of an increasing fraction of gastrin immunoreactivity in 
the "big big" form as one proceeds down the gastrointestinal tract observed here 
in the amphibia para I leis the findings of the distribution of "big big" gastrin in 
the human (Yalow and Berson, 1972; Yalow and Wu, 1973). 
A g:Jstrin-like substance has been extracted from the elasmobranch Rhino-
batus productus, the shovel nose guitarfish, by Hansen (1975). Extracts of three 
sections of the gut, the upper stomach, the antrum and the spiral valve {in-
cluding the duodenum and colon) were prepared according to the first stages 
of the method described by Gregory and Tracy (1964) for the extraction of 
porcine gastrin. Extracts of somatic muscle from the same fish were used as 
a negative control, and porcine antral mucosa was extracted at the same time 
to act as a positive control. Gastri n activity of the extracts was tested using 
a rat bioassay system, and any extract showing acid stimulatory activity was 
tested by paper chromatography to exclude the possibility of histamine contami-
nation. Extracts of the ray antrum were found to be about 25% as potent as 
the porcine antral extract in this system, whereas no response was obtained with 
extracts from the upper stomach, spiral valve or somatic muscle. Although it is 
not known whether this g:Jstrin factor is functional in g:Jstri c secretion, this work 
did establish that gastrin or a substance with g:Jstrin-like activity was present in 
one of the lowest forms of vertebrate. 
Proceeding to an even lower vertebrate species, the lampreys and hagfishes, 
there have been reports of immunofluorescent localisation of cells containing 
polypeptide hormones in the cyclostome or hagfish, Myxine glutinosa, and of 
secretin and CCK-PZ activity in intestine I extracts of both the river lamprey, 
II Lampetra fluviatilis, and the marine lamprey, Petromyzon marinus. Ostberg, 
Van Noorden, Pearse and Thomas (1976) identified cells in the epithelium of 
the hagfish intestine which reacted with antisera to synthetic human gastrin, 
pentagastrin, caerulein and porcine giucagon. These cells were argyrophil, 
contained spherical secretion· granules, and were 11 open type 11 endocrine cells, 
extending from the basal lamina to the lumenal surface of the gut. Although 
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they resembled mammalian gut endocrine cells cytochemi cally and ultrastructurally, 
they did not display the APUD characteristics of uptake and decarboxylation of 
biogeni c amine precursors. In this respect they differed from the insulin-producing 
beta cells of the hagfish, which had the appearance of "closed type" endocrine 
cells. These beta cells were found in the pancreatic islets and bile duct epi-
II 
thelium and displayed APUD characteristics (Ostberg, Van Noorden and Pearse, 
1975). The hagfish pancreas consists of exocrine zymogen cells scattered along 
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the intestinal epithelium with islet tissue parenchyma located completely separately, 
II 
in intimate association with the bile duct and intestine (Ostberg, Van Noorden 
et al., 1975). These beta cells were demonstrated to contain insulin by immuno-
fluorescence, whereas no cells in the bile duct mucosa or islet parenchyma showed 
II 
immunoreactivity to gastrin, secretin or caerulein (Ostberg, Van Noorden et al., 
1975). 
The demonstration of secretin and CCK-PZ activity in extracts of the 
intestine of the river and the marine lamprey by Barrington and Dockray (1970) 
was the first report on the occurrence of these hormones in lampreys. These 
extracts evoked an increased flow of pancreatic secretion and an increase in 
its protein concentration in a rat preparation, whereas no response was observed 
with extracts of control tissues, skin or liver. Although a substance or sub-
stances with secret in and CCK-PZ-1 ike activity have been identified in these 
species, it was not established whether molecules similar to the secretin and 
CCK-PZ of mammals were involved, or whether they function physiologically 
in the hormonal control of secretory activity in the intestinal epithelium of 
lampreys. It was suggested that these substances may not be released into the 
blood stream but may act locally as tissue hormones, released for example by 
secretagogues in the food (Barrington and Dockray, 1970). 
Having discussed the, studies demonstrating the presence of gastrin in the 
vertebrates, the next section will cover what is known regarding the occurrence 
of this hormone in invertebrate species 9 
2 Vlll(ii) Gastri n in Invertebrates 
There 1s scant information on the occurrence of gastrin in invertebrate 
species and, according to Bentley (1976), its distribution in non-mammals has 
not yet been systematically explored. Straus, Yalow and Gainer (1975) have 
described the presence of immunoreactive gastri n in the blood and intestinal 
tissues of two species of mollusc, the sea hare Aplysia californica and the 
land snail Ota la lactea. Moreover, this molluscan gastrin displayed molecular 
heterogeneity similar to that found in mammalian species. Gastrin concen-
trations in the blood ranged from 40-150 pg/ml, values similar to those found 
in mammals, and the intestinal tissues had immunoreactive gastrin contents of 
1,5-5 ng/g wet weight of tissues. Blood and gut extracts of Ota la contained 
two gastrin components, as determined using Sephadex G-50 chromatography, 
one eluting in the void volume and one with an elution volume greater than 
h f 1251 . h d "d • I t at o -porcine epta ecapeptr e gastrrn • In the active as opposed to 
the aestivating snail the smaller molecular form was stimulated, presumably by 
feeding. The "big big" gastrin comprised 43% of the total immunoreactivity in 
the gut in contrast to a corresponding value of 0, ]% of antral gastrin in man 
(Yalow and Berson, 1972). In the case of Aplysia three immunoreactive gastrin 
components were identified on Sephadex G-50 chromatography. A component 
corresponding to big gastrin as well as the "big big" and smaller forms found in 
Ota la was identified. Each peak maintained its integrity on refractionation and 
the big gastrin component was converted to the smali form on incubation with 
trypsin, as was the case for mammalian big gastrin (Yalow and Berson, 1971a). 
The prominence of a component resembling "big big" gastrin in chromatographic 
properties lends support to the theory that this molecule is a precursor form and 
suggests that the system for conversion to the smaller hormonal forms may not be 
as well developed in the lower phyla (Strnus, Yalow et al., 1975). 
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Although Straus, Yalow et al. (1975) mentioned that their antiserum, which 
was raised in guinea pigs to crude porcine antral extracts, reacted poorly with 
CCK-PZ, the fact that their antiserum was raised to crude porcine gastrin may 
be reason to view this study with reservationso Further reports on investigation 
of the occurrence of gastrin rn invertebrate species should either confirm or 
refute these observations. In the meantime it may be helpful to consider reports 
on the findings of two other gastrointestinal hormones, glucagon and insulin, 
in the invertebrates. 
Assan, Tchobroutsky and Rosselin (1969) described the presence of immuno-
reactive glucagon-like material in acid alcoholic pancreatic extracts of various 
mammals, birds and amphibia, in mesenteric extracts prepared from two fish, in 
hepatopancreatic extracts from two molluscs and a crab, and rn a total extract 
of one tuni cote. In the vertebrates a glucagon-1 ike immunoreactive material 
was found in gut extracts. None of this material was found in tissues other 
than those from the digestive system in any of the species studied. Curves of 
displacement of antibody-bound labelled glucagon by dilutions of these tissue 
extracts showed that the amphibian pancreatic extracts, the in vertebra re hepato-
pancreatic extracts and the fish mesenteri c extracts differed from those of 
mammalian pancreatic extractso In addition, the glucagon immunoreactivity of 
gastric origin behaved differently to that extracted from the pancreas. Thus 
there is concrete evidence for the presence of glucagon or a g!ucagon-like 
substance in the higher vertebrates, whereas in the invertebrates evidence for 
the occurrence of a gluccgon-like material resembling that of higher species is 
not as convincing. 
Several reports on the occurrence of insulin, or an insulin-like substance, 
in lower species have appeared. Davidson, Falkmer, Mehrotra and Wilson 
(1971) identified insulin activity in protostomian and deuterostomian species by 
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testing acid alcohol extracts of the digestive tract using the mouse hemi-
diaphragm insulin assay. These two main evolutionary lines are subdivided 
on the basis of embryological developmenti in the protostomes, which include 
the annelids, arthropods and molluscs, the blastopore gives rise to the mouth, 
whereas in the deuterostomes, including the echinoderms, tunicates and verte-
brates, the blastopore gives rise to the anus (Falkmer and Patent, 1972). In 
the deuterostomes insulin was extracted and purified from the pyloric caeca of 
the starfish, Pisaster ochraceous and Asterias rubens (Wilson and Falkmer, 1965) 
and extracted from the stomach and intestine of the sea squirt, Ciona intestinalis 
(Davidson, Falkmer et al., 1971). Insulin activity was also found in the 
digestive tract of three molluscs, Buccinium undatum, Pecten maximus and 
Eledone cirrosa, and in the hepatopancreas of a crustacean, Carcinus meanus, 
both representatives of the protostomes. Neutralisation of the insulin activities 
of intestinal extracts from the sea squirt, C. intestinalis, the octopus, E. cirrosa 
and the whelk, B. undatum by antiserum to ox insulin provided strong evidence 
that immunoreactive insulin is present in the intestinal tissue of these species 
(Davidson, Falkmer et al., 1971). 
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This group had difficulty in demonstrating beta cells by light microscopical 
reactions although scattered dark epithelial cells showing beta cell staining 
characteristics were seen in the intestinal submucosa of the scallop Pecten maximus 
and in the hepatopancreas of two crustacean arthropods, Homarus gammarus and 
Co meanus investigated. Difficulty in demonstrating beta cells by light microscopy 
and histochemical analysis was also reported by Chan and Fontaine (1971) .• who 
were unable to demonstrate beta cells in the starfish Pisaster ochraceous, using 
paraldehyde-fuchsin stain. However, Wilson and Falkmer (1965) identified 
granular cells that gave histochemical reactions similar to those of vertebrate 
beta cells in the starfish P. ochraceous and A. rubenso 
Davidson, Falkmer et al. (1971) failed to demonstrate cells which resembled 
mammalian beta cells in two coelenterate species, the jellyfish Aurelia aurita 
and the sea anemone Metridium senile, nor did they detect insulin activity in 
tissue extracts of these cnidarian species. 
Insulin-like producing cells have been identified by immunofluorescence in 
the intestine in the area of the hepatopancreas of the bivalve mollusc Mytilus 
edulis (Fritsch, Van Noorden and Pearse, 1976). The cells were scattered 
unevenly in the epithelium and appeared to rest on the basal lamina of the 
single-layer epithelium and extend to the lumen of the gut, a typical arrange-
ment for a primitive endocrine cell. No staining was obtained with antisera 
to glucagon, gastrin, pentagastrin or caerulein, either in the intestine or in 
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the rectum. Like Chan and Fontaine (1971) they found that paraldehyde-fuchsin 
stain, commonly used to demonstrate insulin-containing cells, is insufficient when 
used alone. However, by coupling light microscopical staining with the technique 
of immunofluorescence the presence within these cells of a substance with insulin-
like immunoreactivity was confirmed (Fritsch, Van Noorden et al., 1976). 
Thus the information available on the distribution of gastrin or gastrin-like 
material in the invertebrate phyla appears to be limited to one report of immuno-
reactive gastrin in two species of mollusca (Straus, Yalow et al., 1975). Gluca-
gon immunoreactivity has been detected in two invertebrate phyla, the mollusca 
and the crustacea (Assan, Tchobroutsky et al., 1969) but has not been well 
characterised. Insulin has been found in the echinoclermata, mollusca and 
crustacea, as well as in the tunicates and many vertebrate species. According 
to Bentley (1976) beta cells are present in all vertebrates. 
2 VII l(iii) Phylogenetic Considerations 
The striking structural resemblance between the gastrointestinal hormones 
gastrin, cholecystokinin-pancreozymin and the frog skin peptide, caerulein, on 
the one hand, and secretin and gluc.agon on the other hand, suggests common 
ancestral origins. The struct.ure of the (-terminal dodecapeptide of CCK-PZ 
was determined by Ondetti, P luscec, Sabo, Sheehan and Williams (1970) 
following on the work of Mutt and Jorpes (1968), who deduced the partial 
structure of CCK-PZ and showed the last 8 amino acids of the (-terminal 
tryptic octapeptide to be identical with those in the same part of the molecule 
of caerulein, except for the replacement of threonine by methionine in the 
sixth position from the (-terminus. Anastasi, Erspamer and Endean (1967) 
described the isolation of caerulein in pure form from methanol extracts of the 
skin of Hyla caerulia, the Australian amphibian. Like CCK-PZ this molecule 
bears the identical (-terminal pentapeptide sequence to gastrin, and like both 
CCK-PZ and gastrin II it bears a sulphated tyrosine residue, which is situated 
in the 7th position from the (-terminus in the case of CCK-PZ {Ondetti, 
Plusec et al., 1970) and caerulein {Anastasi, Erspamer et al., 1967) and in 
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the 6th position in gastrin II. Gastrin occurs naturally in both the sulphated 
and non-sulphated forms and both are biologically active (Gregory and Tracy, 
1964), whereas CCK-PZ and c.aerulein require the presence of this sulphate 
group for biological activity (Erspamer, 1973). The chemical similarity of these 
molecules is accompanied by a close resemblance in the pharmacological effects 
displayed by caerulein and the gastroduodenal hormones; in fact the (-terminal 
heptapeptides of both caerulein and CCK-PZ are morn potent than cholecysto-
kinin itself, even on a molar basis (Erspamer, 1973). The structures of these 
molecules are shown in figure (3.1.1.) in the next chapter. 
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Glucagon and secretin share initial octapeptides which are identical except 
for one amino acid, and there are resemblances at other sites in the two mole-
cul es (Ganong, 1977, p. 365). Porcine secretin has two less amino acids than 
porcine glucagon but shares 15 amino acids at identical positions in the molecule 
(Bentley, 1976)0 
Studies on the occurrence of these hormones in vertebrates and lower species 
lend support to the theory of a common molecular ancestry. According to 
Barrington and Dockray (1970) insulin-secreting beta eel Is occur in both gnatho-
stomes and agnathans, while glucagon-secreting alpha cells make their first 
appearance in the gnathostomes. Makhlouf (1974) is of the opinion that secretin 
probably antedates all the other gastrointestinal hormones, since it has been 
extracted from the intestine of the octopus, a mollusc (Ledrut and Unger, 1936, 
cited by Makhlouf, 1974, p. 172). Substances displaying secretin and CCK-PZ 
activity have been extracted from the intestine of the lowliest agnathan verte-
brates {Barrington and Dockray, 1970). Since according to Makhlouf (1974) 
glucagon and gastrin appear later, coincidentally with the development of jaws 
and a stomach in gnathostomes, it is tempting to speculate that CCK-PZ and 
secretin are the molecular ancestors of gastrin and glucagon respectively 
(Makhlouf, 1974; Barrington and Dockray, 1970). 
Track (1973) proposed an interesting theory in which he suggests that the 
ancestral protein for the gut peptide hormones was a proinsulin-like molecule. 
By determining the nucleotide sequence in the DNA molecule which codes for 
proinsulin and experimentally shifting the reading frame one nucleotide, he 
produced entirely new sequences of triplet codons in the DNA molecule. 
Frameshift mutations of the triplets coding for the distal 25 amino acids of 
proinsulin resulted in an amino acid sequence which resembled gastrin in 18% 
of its amino acids and glucagon in 25% of its sequence, and a 52% similarity 
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between glucagon and secretin was found. 
From these findings Track (1973) proposed that the starting material for this 
family of polypeptide hormones was a DNA nucleotide sequence coding for a 
proinsulin-like prntein, which underwent gene d~lication to yield two pro-
insulin-like molecules. One supposedly evolved into insulin while the other 
undeiwent a frameshift mutation followed by further gene duplication. One of 
these resultant DNA sequences gave rise to a protein which evolved into gastrin, 
while the other unde,went yet another gene duplication and evolved into secretin 
and glucagon. Track (1973) assumed that the occurrence of insulin, glucagon 
and gastrin in lower species supports his theory of molecular evolution of the 
gastrointestinal hormones, although he admits that more comprehensive information 
on the presence of these hormones in I ow er phyla is needed to confirm his theory. 
Another interesting theory on the evolutionary origin of peptide hormones 
was put forward by Adelson (1971), who considered the evolution of tissue function 
by examining the embryology of the protein-secreting glands and the biochemical 
characteristics of the proteins secreted by these tissues. His survey showed that 
many of the secreted proteins of vertebrates are related to each other biologically 
and chemically, and the proteins seem to have originated among the digestive 
enzymes of the gut of early pre-vertebrate species. Adelson (1971) suggested 
that many of the vertebrate peptide hormones arose by gene duplication and 
divergent evolution of a few primitive gene products. 
The finding of gastrointestinal hormones similar to those of mammals in lower 
vertebrates and invertebrates does not necessarily indicate that they subserve the 
same function in these species as they do in mammals. Indeed, Steiner, Kemmler 
et al. (1974) have suggested that most peptide hormones evolved from previously 
existing gene prcx:lucts that originally served another role, perhaps as enzymes 
such as secreted hydrolases. 
If gastrin is present in invertebrate species it may not have a role in 
stimulation of hydrochloric acid secretion, since the pH measured in the 
digestive organs of many invertebrates is predominantly neutral or slightly 
alkaline (Prosser and Brown, 1961). However, Straus, Yalow et al. (1975) 
emphasised that their finding of molluscan gastrin in the gastric portion of the 
gastrointestinal tract, which has the least alkaline pH, suggests that molluscan 
gastrin resembles mammalian gastrin in at least some of its functions. If gastrin 
or a gastrin-like molecule is found to be widely distributed in the invertebrates, 
it may subserve another function in connection with ionic regulation of the 
body fluids, or possibly may even act as a pheromone, or sexual attractant. 
These possibilities stem from the findings of forge amounts of the gastrin-related 
peptide, caerulein, in the skin of amphibia (Anastasi, Erspamer et al., 1967). 
Since the amphibia inhabit an aquatic environment the suggested functions seem 
feasible in the species. Erspamer (1973) has suggested that caerulein may have 
something to do with local regulations in the skin, interfering in some way in 
the external secretion of the skin and/or in the passage through the skin of 
water and electrolytes. 
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By the same token, the mammalian hormone prolactin, which has a role in 
stimulating lactation in mammals, subserves an entirely unrelated roie in different 
classes of vertebrates (Geschwind, 1967). During the course of evolution the 
functions of this hormone have included stimulation of the crop sac in pigeons, 
stimulation of melanogenesis in some teleosts, and it hos been demonstrated to 
promote growth in the hypophysectomised tadpole. In addition it has been shown 
to act as a survival factor for certain hypophysectomised euryhaline fish trans-
ferred to fresh water (Geschwind, 1967), implicating a role in ionic regulation 
in this instance. 
Another interesting feature in the gastrin story is the resemblance of 
the G-cell in the human pyloric antrum to the structure of the cells in which 
gastrin was localised by immunofluorescence in the epithelial lining of the 
II 
hagfish by Ostberg, Van Noorden et al. (1976). Both cells are of the primi-
tive endocrine variety, flask-shaped or elongated, resting on the basement 
membrane of the epithelium with microvillous processes extending towards the 
I umen. This is in contrast to the morphology of other endocrine cells which 
in many cases have become more specialised, such as the alpha and beta 
cells of the pancreas which have become incorporated into specialised islets, 
and the cells of the thyroid, parathyroid and adrenal glands which have 
become incorporated into glandular structures. Since g:istrin is released into 
the lumen of the human stomach in amounts 6-20 times greater than that 
into the blood stream (Knight, Fiddian-Green and Vinik, 1978), and a 
biological role for lumenal gastrin has not yet been found, this appears to 
be a wasteful process and suggests evolutionary immaturity. This· suggestion 
is upheld by the appearance of the G-cell, which has not evolved to the 
same extent as other endocrine cells morphologically. 
Measurements of the gastrin content of tissues discussed here represent 
static estimations; those described in the following section deal with kinetic 
measu.-emants of circulating gastrin. 
105 
Section IX Gastrin Metabolism and Kinetics 
2 IX(i) Where is gastrin inactivated? 
The half-life of heptadecapeptide gastrin in the circulation is of the 
order of 3-10 minutes as determined by the rate of disappearance of injected 
or infused gastrin (Ganguli, Elder, Smith and Hunter, 1970; Schrumpf and 
Semb, 1973; Schrumpf, Semb and Vold, 1973; Straus and Yalow, 1974; 
Walsh, Debas and Grossman, 1974), the rate of disappearance of 1251odine-
labelled gastrin (Jaffe and Newton, 1969) and inhibition of gastrin release 
by antral acidification {Yalow and Berson, 1970a). This short half-life is 
accompanied by a high metabolic clearance rate, indicating that some organs 
in the body have the capacity to remove heptadecapeptide gastrin rapidly 
from the circulation. 
In an early study of the capacity of various tissues to inactivate gastrin, 
Thompson, Reeder, Davidson, Jackson and Clendinnen (1973) incubated fresh 
tissue slices in buffer in the presence of synthetic human heptadecapeptide 
gastrin I at 37°( for fwo hours, followed by measurement of gastrin content 
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of the supernatant fluid by means of bioossay and radioimmunoassay. Their 
results suggested that the potential mechanisms for the inactivation of gastrin 
resided in many tissues, with the greatest inactivation occurring fol lowing 
incubation with liver, kidney and I ung. The nature of the gastri n inactivation 
process was not clearly defined but it was thought that deamidation of the 
(-terminal phenylalanine amide residue could be involved, since this would 
alter the biologically active (-terminal pentapeptide sequence (Tracy and 
Gregory, 1964). 
Laster and Walsh (1968) described an enzymatic activity that catalyses 
hydrolysis of the terminal amide group of the hormonally active acyl derivative 
of gastrin, t-BOC-tetrapeptide amide, to produce an inactive product. This 
amidase activity was found to be greatest in tissue homogenates of rat liver 
and small intestinal mucosa. A similar enzymatic activity which catalysed 
hydrolysis of the peptide bond between the penultimate aspartyl and the 
(-terminal phenylalanine amide residues was found in kidney homogenates 
(Laster and Walsh, 1968). It is tempting to speculate that the gastrin in-
activation by tissue slices described by Thompson, Reeder et al. (1973) 
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could be due to amidase enzyme systems such as the one described by Laster 
and Walsh (1968). Walsh and Laster (1973) further characterised this amidase 
activity found in liver homogenates and showed that the pH optimum for the 
intracellular enzyme system was approximately 6,7. They identified the same 
amidase activity in liver, small intestine mucosa and stomach mucosa in the 
rat, hamster, cat and dog. They concluded that these enzymes may be an 
important mechanism for inactivation of gastrin peptides used in pharmaco-
logic studies but that this system probably does not play an important role 
in the inactivation of endogenous gastrin. 
More recent studies on the metabolism and inactivation of gastrin involved 
monitoring the arteriovenous difference in gastrin levels entering and leaving 
an isolated perfused organ or an organ or limb in situ in response to stimulated 
levels of endogenous gastri n or to infused exogenous gastrin. · Endogenous 
gastrin levels were usually stimulated by instillation of, for example, 0,5% 
acetylcholine into the gastric antrum (Evans, Reeder, Becker and Thompson, 
1974). Studies involving raised exogenous gastrin lev,~ls produced by infusion 
of synthetic gastrin preparations are subject to the criticism that the infused 
gastrin may be of a different species to that into which it is being infusedr 
and that it may be infused to produce abnormally high or pharmacological 
levels which are not representative of the true physiological situation. 
Furthermore, since basal circulating gastrin consists chiefly of the big or 
G-34 type gastrin (Yalow and Berson, 1970b) and the circulating gastrin 
is heterogeneous, as outlined in section 2 V, it is apparent that infusion 
of one gastrin type may not produce an entirely physiological situation. 
The same argument holds with regard to infusions of preparations of natural 
as opposed to synthetic gastrins, and extrapolations from one to the other 
should be made with reservations. As Booth, Reeder, Hjelmquist, Brandt 
and Thompson (1973) point out, the definition and discovery of a catabolic 
system in the body does not necessa ri I y i ndi cote a physi ol ogi ca I role for 
that system. 
Infusion of 1251odine-labelled hormones enables convenient monitoring 
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of the organ distribution of the hormone but may produce very misleading 
information as a result of the ability of certain tissues to fix iodine. Newton 
and Jaffe (1971) observed that 125 Iodine-label I ed immunoreactive gastrin 
disappeared rapidly from peripheral venous plasma in dogs after a single 
intravenous injection, due to the capacity of the gastric antrum, gastric 
fund us and skeleta I muscle to concentrate more radioactivity in the form 
f 1~1od" h 1~, · o met an -gastnn. On the other hand the renal cortex 
d h 1251 . h 1251od" I . • h sequestere muc more -gastnn t an me a one, suggesrrng t at 
h I I I . h . • . f 1251 . t e reno cortex pays a roe 1n t e 1nact1vat1on o -gastnno 
The small intestine appears to be involved in gastrin metabolism. Becker, 
Reeder and Thompson (1973) found significantly higher gastrin concentrations 
in arterial blood than in mesenteric veins draining the lower intestine in 
dogs receiving antrol stimulation by intralumenal acetylcholine. Samples 
collected from the abdominal aorta were taken as representative of the 
superior mesenteric artery, and the superior mesenteric vein was cannulated 
directly via the splenic vein. There was no arteriovenous ga!:trin difference 
during the basal unstimulated period, whereas transit of stimulated levels of 
endogenous gastrin through the smal I bowel diminished the integrated gastrin 
response by 43%. These studies suggested that the small intestine may take 
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up gastrin above a certain threshold level, and can be reconciled with the 
observation by Straus, Gerson and Yalow (1974) that patients who had under-
gone massive resection of the small bowel displayed gastrin and gastric acid 
hypersecretion, which could be due to loss of catabolic mechanisms for gastrin 
in these patients. 
In a similar study the same group demonstrated that the gastric fundus 
extracts gastrin during periods of stimulated gastrin release from the antrum, 
whereas during basal conditions transit of the gastric fundus resulted in no 
change in gastrin levels (Evans, Reeder et al., 1974). Samples were collected 
simultaneously from the right femoral artery which was representative of the 
arterial supply to the fundus, and a fundic vein which was catheterised for 
sampling of venous outflow from the gastric fundus. In 9 out of 14 dogs 
studied there was a 30% arteriovenous difference in circulating gastrin values, 
while in the remaining 5 no difference was found. Since only the 9 dogs 
showing fundic extraction of gastrin responded by secreting gastric acid, and 
the remaining 5 did not exhibit an acid secretory response, probably attributable 
to the effect of anaesthesia on the parietal cell, Evans, Reeder et al. (1974) 
suggested that the rate of extraction of gastrin by the fundus is g;eater during 
active acid secretion. 
Th f • I d . . . d 131 I • • h . e recovery o intravenous y a m1n1srere ,-gastrrn ,n t e gasi·nc 
juice of dogs shown by Chan Yip and Jordan (1973) is in keeping with the 
proposed role of the gastric fundus in the extraction of endogenous gastrin. 
Chan Yip and Jordan measured the immunoreactive radioactivity recovered 
f 11 • • • t· ,. 131 1 • • h • • r • f h. • o owing 1n1ec JOn or -gastnn wit a continuous 1n,us1on o istamine 
throughout the experiment. Four hours after injection of the labelled 
material 12,4% of the injected dose was recovered in the urine, whereas 
50,7% was recovered in the gastric juice collected from innervated gastric 
fistulae in these dogs. In control experiments in which dogs were given 
Na 131 Iodide instead of 131 1-gastrin only 5% radioactivity was precipitated. 
This study suggested that the fundic gland area of the stomach is a signi-
ficant site for gastrin clearance which is correlated with the rate of gastric 
acid secretion. It is difficult to reconcile these findings with the demon-
stration by Newton and Jaffe ( 1971) that the gastric fund us concentrated 
I • I 125 100 • • f 125 1 • se ect1ve y me in pre erence to -gastnn. 
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Thompson, Becker, Evans, Hjelmquist, Brandt and Reeder {1974) demon-
strated that vascular transit of the hind limb, lung and hear~ are not 
associated with changes in concentration of either basal or stimulated levels 
of gastrin. They catheterised the femoral vein, femoral artery, right heart 
and superior mesenteric vein in three dogs and found the basal gastrin con-
centrations to be all clustered around 85 pg/ml. After irrigating the iso-
lated antrum with 0, 1% acetylcholine for 50 minutes, the gastrin concen-
trations in the femoral artery, femoral vein and right heart were all about 
400 pg/ml, whereas in the superior mesenteric vein the value was 230 pg/ml, 
confirming their previous demonstration of intestinal clearance of g::strin 
(Becker, Reeder et al., 1973)0 After antral acidification the differences 
in gastrin disappeared and all the levels fell towards basal. Failure to 
demonstrate any change in gastrin levels on vascular transit of the hind 
limb confirmed that the arteriovenous differences in stimulated endogenous 
gastrin observed for the small bowel and gastric fundus were not the result 
of non-specific tissue uptake of gastrin. The same was true for infusion of 
exogenous synthetic human heptadecapeptide gastri n in the dog (Thompson, 
Reeder et a I • , 1973) • 
The I ung was shown to have no effect on gastrin by Dent, Levine, 
James, Hirsch and Fischer (1973), thus confirming the findings of Thompson, 
Becker et al. (1974) on the role of this organ with respect to gastrin. Dent, 
Levine et al. (1973) infused synthetic human gastrin into isolated perfused 
canine lung preparations, since the lung is known to rapidly destroy or alter 
the polypeptide hormones bradykinin and angiotensin. Although the oedema-
free lung had no effect on immunoreactive plasma gastrin, interstitial pulmo-
nary oedema produced transudation of gastrin into the oedema fluid, but not 
catabol ism. 
Negligible amounts of gastrin are transported in the lymphatic system 
(Thompson, Reeder et al., 1973), so it is doubtful that this system plays 
an important role in gastrin sequestration or catabolism. McGuigan, Jaffe 
and Newton (1970) measured gastrin in serum and thoracic duct lymph 
before, during and after irrigation of the antrum with acetylcholine, and 
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found lower concentrations of gastrin in thoracic duct lymph than in peripheral 
venous blood, again suggesting that thoracic duct lymph is not a major route 
of transport of gastrin. The small increase in thoracic duct lymph gastrin 
levels following antral stimulation actually amounted to less than 1% of the 
gastrin transported via the portai vein, and probably reprnsented equilibration 
of gastrin molecules within the extracellular fluid compartment (McGuigan, 
Jaffe et al., 1970). 
There is an overwhelming weight of evidence implicating a role of the 
kidneys in the catabolism of gastrin, and peptic ulcer disease complicating 
acute and chronic renal failure has been described many times. Elevated 
gastrin levels have been described in patients with acute (Dent, Hirsch, 
James and Fischer, 1972) and chronic (Korman, Laver and Hansky, 1972) 
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renal failure. Dent, Hirsch et al. (1972) showed that plasma from patients 
with renal failure bound twice as much 1251-gastrin as did plasma from normal 
subjects, suggesting the possibility that the damaged kidney releases a protein 
involved in sequestration and inactivation of gastrin. Sullivan, Tustanoff, 
Slaughter, Linton, Lindsay and Watson (1976) demonstrated elevated fasting 
serum gastrin concentrations and prolonged circulation of stimulated gastrin 
levels in response to a test meal in patients with renal failure, suggesting 
that abnormalities in gastric function may be explained by fasting and stimulated 
hypergastrinaemia in these patients. 
In dogs bilateral nephrectomy increased the half-life of infused exogenous 
synthetic human gastrin from 2,54 minutes to 5, 15 minutes during infusion of 
a low dose of gastrin, and from 2,85 minutes to 7 ,88 minutes when gastrin 
was infused at a higher dose. The metabolic clearance rate was decreased 
approximately two-fold after nephrectomy, indicating the importance of the 
kidney in catabolism of exogenous gastrin (Clendinnen, Reeder, Brandt and 
Thompson, 1973). 
Thompson, Reeder et al. (1973) infused synthetic human gastrin I into dogs 
to study the uptake and excretion by the kidney. They showed that 40% of 
the infused gastrin was taken up by the kidneys and on! y O ,4% of this ex-
tracted gastrin was excreted in the udne, so presumably the gastrin was meta-
bol ized within the kidney. The effect of the kidney on stimulated levels of 
endogenous gastrin foliowing local irrigation of the exduded gastric antrum 
with 0,5% acetylcholine was studied by catheterising the aorta as represen-
tative of the renal artery, the renal vein and the ureter (Thompson, Becker 
et al., 1974). At all times after stimulation the gastrin levels were higher 
in the renal artery than 1n the renal vein. They demonstrated a 35% - 37% 
loss of stimulated levels of gastrin on renal transit, with less than 1% of the 
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total amount of extracted gastrin recoverable in the urine, confirming the 
earlier findings of this group. 
Several other studies involving the role of the kidneys in relation to 
levels of stimulated endogenous gastrin have been reported. Hjelmquist, 
Reeder, Brandt and Thompson (1972), in one of the first studies of endo-
genous as opposed to exogenous gastrin, demonstrated 30% inactivation of 
endogenous gastrin during a single passage through the human kidney following 
acetylcholine stimulation. Booth, Reeder, Hjelmquist, Brandt and Thompson 
(1973) reported the same findings in dogs and suggested that the failure of 
the kidneys to inactivate basal gastrin levels may be due to the fact that a 
threshold gastrin concentration is needed to activate the catabolic mechanism. 
Davidson, Springberg and Falkinburg (1973) again found 30% of renal artery 
gastrin was extracted from the blood by the kidney in the anaesthetised dog. 
In keeping with the above reports these workers also found that the excretion 
of gastrin in the urine was inconsequential. 
Dent, Levine et al. (1973) studied the effect of perfusion of isolated 
canine kidneys with synthetic human gastrin (1-17) and were able to demon-
strate consistent arteriovenous differences in gastrin levels, confirming a role 
of the kidney in the catabolism of heptadeccpeptide gastrin. 
I • · · f 1251 h ~ · · d f II d b ntravenous rn1ect1on o - .uman gas. rm rnto ogs was o awe y a 
biphasic disappearance of radioactivity from plasma, the initial rapid rate of 
disappearance lasting about 1 hour, with less than 2% of the immunoreactive 
labelled gastrin excreted in the urine within 2 hours (Jaffe and Newton, 
1969). Significant sequestration of labelled gasrrin in the renal cortex was 
observed 15 minutes after injection, suggesting inactivation at this site. 
The gastric antrum was found to concentrate extremely high levels of the 
125 Iodine label alone in this study, illustrating the problem of iodine fixation 
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by some tissues, as mentioned previously. 
The kidneys are well established as a major site of removal from the 
circulation and of metabolism of many peptide hormones (Walsh and Grossman, 
1975a). Rabkin and Colwell (1969) demonstrated a linear relationship between 
arterial plasma insulin and the renal arteriovenous insulin difference in the 
dog, with a urinary clearance of about 100/o of the insulin sequestered by 
the kidneys. They suggested that the remaining 900/o was presumably degraded 
by the kidneys, which appeared to play an important role in the extrahepati c 
regulation of blood insulin concentrations. 
In the light of the foregoing discussion it appears that gastrin is cleared 
from the circulation and inactivated by at least three organs in the body: 
the kidneys, small bowel and gastric fundus. However, the recent report of 
Strunz, Walsh and Grossman (1978) disagrees with these findings, in that 
they demonstrated removal of 21-30% of infused exogenous human heptadeca-
peptide gastrin by a single passage through the vascular beds of the intestine 
and kidney, as well as the head and a hind limb in the dog. These findings 
suggest that gastrin is removed at multipie sites throughout the body, and that 
gastrin removal may be a general property of most if not all capillary beds. 
This is difficult to reconcile with the demonstration by Thompson, Becker et al. 
(1974) of failure of the hind limb to extract stimulated levels of endogenous 
gastrin, which suggested to them that removal of gastrin by the intestine and 
gastric fundus was not the result of non-spedflc tissue uptake of gostrine 
The discrepancy between the findings of Strunz, Walsh et al. (1978) and 
those of other workers described earlier may be related to the fact that Strunz, 
Walsh et al. (1978) used infused exogenous gastrin, whereas most of the 
earlier studies involved stimulation of endogenous gastrin levels by antral 
irrigation with acetyl choiine (Becker, Reeder et a! Q, 1973; Evans, Reeder 
et al., 1974), or simply measurement of basal endogenous gastrin levels 
(Dent, Hirsch et al., 1972; Korman, Laver et al., 1972). 
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Using a separate group of 6 dogs, Strunz, Walsh et al. (1978) demonstrated 
removal of 40% of infused exogenous heptadecapeptide gastrin by both the 
intestine and the liver. After correction for intestinal removal alone and 
for hepatic arterial and portal contributions to hepatic blood flow, the cal-
culated hepatic removal of gastrin was 23%, which was similar to that for 
the other organs investigated. 
The question of whether gastrin is removed from the circulation and 
inactivated by the liver is the subject of the next section. 
2 IX(ii) The role of the liver in relation to gastrin 
Since all gastrin produced by the pyloric antrum and remainder of the 
gut must traverse the liver before entering the systemic circulation en route 
to its primary site of action, the gastric parietal cells, it is possible that 
the liver may play a part in the inactivation and rapid clearance of gastrin 
from the circulation. The liver has been shown to be capable, either in 
vivo or in vitro, of inactivating the gastrointestinal hormones insulin, 
glucagon and secretin. Samols and Ryder (1961) showed that the human 
liver can remove 20-50% of insulin passing through it for periods of over 
l hour, as measured by radioimmunoassay. Kaden, Harding and Field 
(1973) showed that the liver of anaesthetized dogs extracted 400/o of the 
insulin presented to it during a single transhepatic passage during a control 
period. Fol lowing glucose administration in the duodenum the absolute 
amount of insulin extracted by the liver increased, demonstrating an 
important role for the liver in reguiating peripheral insulin concentrations. 
It has been established that insulin is inactivated and degraded by an 
enzymatic process which is found in many tissues in the body, but pre-
dominantly in liver, kidney, pancreas, testes and placenta (Mirsky, 1964). 
Inactivation of glucagon by tissue slices in vitro was shown in homo-
genates of rat, rabbit and dog live; by Kenny (1956), who measured 
glucagon activity by bioassay, using rabbit liver slices. Further studies on 
rabbit liver homogenates revealed that the inactivating system was enzymic 
in nature (Kenny, 1956). 
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Skillman, Silen and Harper (1962) showed that the volume of pancreatic 
juice obtained following a constant infusion of secretin via the systemic as 
opposed to the portal route in dogs was greater, indicating partial inacti-
vation of secret in by the I iver. A secret in inactivating enzyme was isolated 
and partially purified from dog liver and was shown to be heat-labile, with 
an optimum pH range for activity of 3-5, by Bridgewater, Kuroyanagi, Chiles 
and Necheles (1962). They found the same enzyme in dog kidney. Way, 
Johnson and Grossman ( 1969) demonstrated a 25% reduction in pancreatic 
volume and bicarbonate output in dogs following portal administration of a 
I ow dose of synthetic secreti n (0, 06 1Jg/kg/hr) as opposed to systemic ad-
ministration, although no effect was observed with a higher dose of secretin 
(0,24 JJg/kg/hr). In the same study the pancreatic responses to portal 
administration of CCK-PZ and caerulein were shown to be unaltered by 
porta I administration o 
The liver appears to play a minor role in the inactivation of heptadeca-
peptide gastrin, whereas tetragastrin is almost completely inactivated by liver 
passage (Walsh, 1975). Very few reports have appeared showing inactivation 
of G-17 gastrin by the liver, and those that have are subject to a certain 
amount of criticism. Thompson, Reeder, Davidson, Charters, Brllckner, 
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Lemmi and Miller (1969) studied the effect of hepatic transit of histamine, 
pentagastrin and gastrin using two parallel experiments: firstly they observed 
the effect of alternate portal and caval injections of these substances in alert 
dogs in Pavlov stands, and secondly they injected histamine, 14C-pentagastrin, 
synthetic human gastri n and i nul in into the porta I vein and measured the 
concentmtions of these substances in hepatic vein blood. They showed a 
greater than 70% loss in acid stimulating potency fol lowing portal injection 
of histamine and pentagastrin, and a greater than 90% measured loss of each 
substance. The mean measured loss of immuno,eactive human heptadecapeptide 
gastrin across the liver was 46%. However, since the radioimmunoassay system 
used was too insensitive to measure basal levels of circuiating gastrin (Thompson, 
Reeder et al., 1969), the estimate of 46% inactivation of G-17 gastrin by the 
liver could be erroneous. In addition, this study involved infusion of supra-
physiologic doses of gastrin. lnitia lly it was thought that this observation 
of partial hepatic inactivation of gastrin could be involved in gastric hyper-
secretion following portacaval shunting (Thompson, 1969), but this theory 
had to be abandoned when Thompson, Reeder et al. (1973) demonstrated 
that serum gastrin concentrations actually decreased after portacaval shunting 
in dogs given a test meal. 
McGuigan, Jaffe and Newton (1970) measured endogenous gastrin at 
various sites in anaesthetized dogs which had received antral irrigation with 
1% acetylcholine for 10 minutes. Although this study appeared to indicate 
extraction of gastrin by the liver, the difference in gastrin levels observed 
between the hepatic vein and the portal vein was actually due to dilution 
of portal vein blood with hepatic arterial blood a McGuigan, Jaffe et al. 
(1970) emphasised that their findings do not support hepatic extraction of 
endogenous gastrin. 
Beger, Meves, Witte and Kraas (1972, cited by Walsh, 1975, p. 92) 
found significantly less acid secretion in man when porcine G-17 II was 
infused into the portal vein as compared with peripheral administration, 
suggesting hepatic inactivation of the biological effect of heptadecapeptide 
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gastrin. This again emphasises the fact that immunological measurements may 
not necessarily reflect measurements of biological activity. Gastrin activity 
may be substantially affected by relatively slight chemical modification of the 
physiologically active carboxyl-terminal portion of the molecule (Tracy and 
Gregory; 1964) such as deamidation of the carboxyl-terminal phenylalanine 
residue (Laster and Walsh, 1968). Such modificatiom in the structure of 
gastrin, if they occur at a site removed from the immunologically active 
site, may not be detected by radioimmunoassay 1 and can give rise to 
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immunochemical measurement of biologically inactive or degradation products. 
Such a situation has been reported by Lewin, Hunziker, Stagg and Wyllie 
(1971), who infused gastrin into the superior mesenteric artery of anaesthetized 
dogs and took samples simultaneously from the distal arterial tree and from the 
portal vein for analysis by bioassay and radioimmunoassay. Bioassay showed 
significantly lower venous than arterial plasma gastrin levels, whereas measure-
ments using radioimmunoassay showed no difference between the arterial and 
venous values. Thus gastrin was partially inactivated as it passed through the 
small bowel vascular bed, but no corresponding fall in immunoreactivity was 
detected. 
The findings of Gillespie and Grossman (1962) that gastrin was as effective 
in stimulating acid secretion when given to dogs via the portal or systemic 
route suggested that the liver is not a selective site for inactivation of gastrin. 
In the same system these workers were able to confirm the well documented 
observation that histamine is inactivated by the liver. Thompson, Reeder et al. 
(1969) proposed that the failure of Gillespie and Grossman (1962) to demonstrate 
hepatic inactivation of gastrin may be due to a protective action of contami-
nating protein and peptide material in preventing deamidation or other inacti-
vation, or sequestration of pure gastrin, since crude gastrin was used in this 
study. This seems a reasonable suggestion, but in the I ight of several other 
reports showing that the liver has a negiigible effect on heptadecapeptide 
gastrin metabolism, it is probably not of great importance. 
Perfusion of the isolated rat liver in situ with synthetic human G- l 7 I 
gastrin in a plasma-free medium failed to produce hepatic removal of gastrin 
from the perfusate, both at physiological and supraphysiological perfusion 
levels of gastrin (Sacks, Grant and Vi nik, 1978). Chromatography using a 
Sephadex G-25/G-50 mixture revealed the same elution patterns both before 
and after perfusion through the rat I iver, suggesting that the isolated rat 
liver has no function in removal from the circulation or metabolism of 
synthetic human heptadecapeptide gastrin I, measured by radioimmunoassay. 
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No hepatic removal of endogenous basal levels or stimulated levels of 
exogenous gastrin was observed in the pig on perfusion of the liver in vivo 
with synthetic human heptadecapeptide gastrin I {Vinik, Hickman and Grant, 
1978). These measurements were made by radioimmunoassay, suggesting that 
the liver has no effect on basal or stimulated levels of immunoreactive gastrin. 
Sephadex G-25/G-50 chromatography suggested qualitative changes in the 
molecular size of gastrin following circulation in vivo in the pig (Vinik, 
Hickman et al • , 1978). 
Although G-17 gastrin does not appear to be affected by the liver, the 
smaller gastrin peptides pentagastrin and tetrasnstrin are rapidly removed by 
passage through the liver. Temperley, Stagg and Wyllie (1971} demonstrated 
that pentagastrin was rapidly inactivated by the liver in experiments involving 
measurement of acid secretion in dogs and rats fol lowing its administration via 
the jugular vein and the portal vein. Acid secretion was measured by the 
bioassay technique of Smith, Lawrence et al. (1970). By the same token, 
Temperley, Stagg et al. (1971) showed that synthetic human gastrin G-171 
was not inactivated in the liver, but measurements after infusion of gasrrin 
into the jugular vein and superior mesenteric artery indicated inactivation of 
the heptadecapeptide molecule by the small bowel. These results were con-
firmed in vitro by incubation of gastrin and pentcgastrin with homogenates of 
liver and small bowel mucosa. 
Debas and Grossman (1974) reported that the degree of hepatic inactivation 
of the gastrointestinal hormones they studied was inversely related to the 
molecular size or chain length of the peptide. Using dogs with a complete 
portacaval transposition, they investig::ited the effect of passage through the 
liver on the biological activity of the gastrin peptides G-17, G-13, the 
(8-17) and (11-17) sequences, and pentagastrin. Pentagastrin and the (-
terminal heptapeptide were more than 90% inactivated by the liver, the 
gastrins with lO, 13 and 17 amino acid residues were progressively less 
inactivated by passage through the liver, and secretin (27 amino acids) 
and CCK-PZ (33 amino acids) were not significantly affected. It appears 
from this study that peptides with up to 7 amino acid residues ore markedly 
inactivated by the liver. 
Studies involving injection of pentagastrin into dogs by Stagg, Temperley 
and Wyllie (1971) showed that this peptide is excreted by the liver into the 
bile largely in an inactivated form. Unlabelled pentog::istrin was measured 
by bioassay in the portal and hepatic veins, and 14C-labelled pentag::istrin 
was used to trace the fate of the injected compound. One hour after the 
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end of a 30-minute infusion of label led pentagastrin, 24% of the administered 
dose remained in the dogs, 47% was found in the bile and 20% was recovered 
from the liver at the end of the experiments. This represented isotope which 
had been excreted into the bile canaliculi as was demonstrated by outoradio-
graphy of these livers. According to Stagg, Temperley et al. (1971) penta-
g::istrin appears to meet a similar fate in man. Since the biological activity 
of heptadecapeptide gastrin and pentagastrin resides in the (-terminal tetra-
peptide sequence (Tracy and Gregory, 1964) which is common to both mole-
cules, Stagg, Temperley et al. (1971) suggested that the (1-13) portion of 
heptadecapeptide gastrin may in some way protect the a dive tetrapeptide 
from excretion and metabolism by the I iver. 
The mode of inactivation of pentagastrin by the liver was clarified when 
Wyllie, Stagg and Temperley (1974) isolated high speed supernatant fractions 
of rat, dog and human liver which deamidated pentagastrin to pentagastrin 
acid. This compound contained all the amino acids of the parent substance, 
with the C-terrninal phenylalanine residue in the free acid form, and was 
biologically inactive. Parallel experiments in which 14C-pentagastrin was 
infused into anaesthetized dogs revealed that much of the radioactivity was 
recovered in the bile within one hour, and thin layer chromatography showed 
the presence of pentagastrin acid as well as unchanged pentagastrin in the 
bileo These findings in vivo confirm the presence of an amidase enzyme 
system in liver tissue preparations, as described by Laster and Walsh (1968) 
and Walsh and Laster (1973). 
Reeder, Brandt I Watson, Hjelmquist and Thompson ( 1972) studied the 
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effect of hepatic transit on physiologic levels of endogenous gastrin, by 
stimulating antral gastrin release with 0,5% acetylcholine irrigation and 
measuring gastrin concentrations entering and leaving the liver in anaesthetized 
dogs. Gastrin levels were measured in the portal vein, hepatic artery and 
hepatic vein by radioimmunoassay. Blood flow measurements using an electro-
magnetic flowmeter were made in the portal vein and hepatic artery, which 
together gave the total hepatic inflow, and it was assumed that hepatic out-
flow was the same. These measurements al!owed comparison of the total mass 
of gastrin entering and leaving the liver per minute. The ratio of portal 
venous blood flow to hepatic arterial flow was about 2,2 : l, and the flow 
did not change significantly after initiation of antral stimulation. Plasma 
gastrin levels rose from approximately 190 pg/ml in the basal state to over 
310 pg/ml during antral stimulation. The mass of gastrin entering and leaving 
the liver following acetylcholine stimulation was significantly increased above 
the same values under basal conditions, but there was no significant difference 
between the afferent and efferent hepatic gastri n mass either before or during 
antral stimulation. The average mass of g::istrin excreted in the bile was 
approximately 60 pg/min which amounted to less than 0, 1% of the mass of 
gastrin passing through the liver. The results of this study indicate that 
hepatic transit does not affect physiologic levels of endogenous gastrin in 
the dog (Reeder, Brandt et al., 1972). 
There is little direct information on the effect of hepatic transit on 
G-34 g::istrin. Dencker, H8kanson, Liedberg, Norryd, Oscarson, Rehfeld 
and Stadil (1973) measured the gastrin concentrations in portal and peripheral 
serum taken from human subjects and at the same time they chromatographed 
the serum to see if there was any difference in gastrin components in portal 
and peripheral serum. No differences in fasting immunoreactive g::istrin 
levels or postprandial stimulated gastrin levels between portal and peripheral 
blood were found, again suggesting that endogenous gastrin in man is not 
affected by passage through the liver. The distribution of immunoreactive 
gastrin components separated by gel filtration was similar in portal and peri-
pheral serum, suggesting that the liver has no effect on the relative concen-
trations of G-17 and G-34 as well as the other gastrin components. 
The kinetics of the different gastrin forms in the circulation have been 
determined chiefly on studies in the dog by infusion of exogenous gastrin 
preparations, as well as by fol lowing the fate of endogenous and exogenous 
gastrin in man. These studies are reviewed in the next section. 
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2 IX(iii) Disappearance Half Times, Space of Distribution and Metabolic 
Clearance Rates of Gastrins 
Most of the studies on gastrin metabolism and kinetics in vivo have 
been performed in dogs or man, by fol lowing the fate of endogenous gastrin 
levels or elevated levels of exogenous gastrin produced by pulse injections 
or prolonged infusions of natural or synthetic gastrin preparations. Measure-
ments have been made by bioassay, radioimmunoassay, or both. Table 
(2.IX.1) summarises various aspects of kinetic studies on gastrin which have 
been described. 
The half-life of endogenous gastrin in man was found to be 7 minutes 
following oral or intragastric administration of hydrochloric acid to patients 
with pernicious anaemia and measurement of the fall off in serum gastrin 
levels after such treatment (Yalow and Berson, 1970a). This value repre-
sents the disappearance rate of big and heptadecapeptide gastrins, since the 
predominant form of ciiculating gastrin is the big or G-34 type (Yalow and 
Berson, 1970b; 1971). This is in reasonable agreement with the half-life 
for big gastrin of 9 minutes determined by Straus and Yalow (1974) in dogs, 
as detailed further on in this section. 
A half-life of 3-4 minutes for endogenous plasma gastrin in man was 
determined following suppression of stimulated leveis using sematestatin by 
Le Reith, Vinik, Epstein, Baron, Olkenitzky and Pimstone (1975). The fact 
that these estimations were made with an antiserum which recognises only 
non-sulphated gastrins, may explain why the measurement of endogenous 
gastrin half-life in this instance was less than the value of 7 minutes found 
by Yalow and Berson (1970a) in man. According to Le Reith, Vinik et al. 
(1975), somatostatin had no effect on basal serum gastrin levels in normal 
subjects, whereas it did inhibit raised serum gastrin levels in cases of 
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TABLE (2.IX.1) 
Details of Gastrin Kinetics Studies Previously Published 
Abbreviations 
T ! half-life time 
V volume of distribution 
M .C.R. metabolic clearance rate 
RIA radi oimmunoassa y 
ECF extracellular fluid 
I. V. intravenous 
vg microgram 
kg kilogram 
p mol picomole 
min minute 
hr hour 
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pernicious anaemia, chronic renal disease, and in patients with elevated 
gastrin levels produced by insulin hypoglycaemia. 
The half-life of a crude gastrin extract prepared by the method of 
Blair, Harper et al. (1961) and injected intravenously into the anaesthetized 
cat was determined by bioassay (Blair, Harper et al., 1962) to be less than 
4 minutes. Pentagastrin was cleared from the circulation with a similar half 
time. Although basal gastrin levels in humans could not be detected with 
this technique the report merits due consideration because it is one of the 
few instances when the disappearance half time of gastrin was measured by 
bioassay and not by radioimmunoassay. 
The half-life of intravenously injected 1251-labelled human gastrin in 
dogs was 10,3 minutes as determined by measurement of immunoprecipitable 
labelled gastrin in plasma using the double antibody technique (Jaffe and 
Newton, 1969). The spaces of distribution of the 1251-gastrin were 19% 
(comparable to the extracellular fluid) and 28% (similar to the iodide space) 
respectively. However, the problems in interpreting distribution of radio-
activity caused by fixation of iodine by certain tissues have already been 
alluded to in section 2 IX(i). The half-life value found in this study was 
longer than that found by most other workers for G-17 gastrin, a finding 
which may be due to subtle changes induced in the hormone by the labelling 
process. In keeping with this suggestion is the finding by Straus and Yalow 
(1974) of a ionger half-iife of 131 1-porcine G-17 I in the circulation (4-5 
min) as opposed to unlabelled porcine G-17 I and Ii, which both had half-
lives of 3 minutes. 
The remaining studies outlined in table (2.IX.1) involved administration 
of exogenous natural or synthetic gastrin preparations of various molecular 
sizes, either by intravenous injection of a bolus, or by prolonged intravenous 
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infusion at constant or increasing dose levels. The half-life of these gastrin 
preparations in the circulation has been estimated by measurement of the 
decline in serum gastrin concentrations with time after such injection or 
infusion. The metabolic clearance rate is another index of degradation or 
elimination of the gastrin molecule, and for accurate estimation of both 
these parameters it is necessary to correct for endogenous gastrin production 
by subtracting the basal gastrin levels from the post-injection or -infusion 
concentrations (Schrumpf and Semb, 1973). 
The volume of distribution, expressed as a percentage of the total body 
weight, gives an indication of the body compartments into which the infused 
gastrin distributes itself. For instance, a volume of distribution of gastrin 
of approximately 5% of total body weight indicates that gastrin is distributed 
in a volume equivalent to plasma volume, whereas a value approximating 
20% for this parameter suggests distribution of gastrin throughout the extra-
cellular fluid. The volume of distribution of infused gastrin is determined 
using the plateau principle as described by Goldstein, Aronow and Kalman 
(1974), which embraces the mean infusion rate of gastrin, the mean plateau 
level of gastrin and the mean elimination rate (Schrumpf and Semb, 1973). 
Exogenous gastrin was administered as a bolus intravenous injection in 
the studies described by Jaffe and Newton ( 1969), Ganguli, Elder et al. 
(1970) and Straus and Yaiow (1974). According to Reeder, Jackson et al. 
(1972), this procedure produces distortion in the disappearance curve caused 
by mixing, and these effects are minimized by infusion of gastrin at a con-
stant rate over a period of two hours fo; examp!e, so that the spaces of 
distribution become saturated with gastrin. In such experiments the initial 
component of disappearance of the hormone after injection of a bolus is 
generally attributed to mixing within the plasma and the later component to 
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metabolism of the hormone. In order to compute the model half-life of a 
hormone in the circulation from a biexponential disappearance curve, the 
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first component, due to mixing, must be rapid ;elative to metabolism (Reeder, 
Jackson et al o, 1972)0 For this reason the gastrin infusion is often commenced 
with administration of a loading dose, fol lowed by a constant infusion, as 
described by Reeder, Jackson et al. (1972), Schrumpf and Semb (1973) and 
Schrumpf, Semb et al. (1973). 
Actual values for T! of G-17 gastrin in the circulation were all close 
to 3-5 minutes when natural or synthetic gastrin was injected or infused into 
dogs. The value in man was higher: 5,5-10,5 minutes, found by Ganguli, 
Elder et al o (1970) and 7,5 and 12,8 minutes in the first and second dis-
appearance phases reported by Schrumpf, Semb et al. (1973). The longer 
half-life of human G-17 gastrin preparations in the human as opposed to the 
dog almost certainly reflects the more rapid clearance of heterologous as 
opposed to homologous gastri n as suggested by Schrumpf, Semb et a I • ( 1973). 
This is borne out by the higher metabolic clearance rate of human gastrin 
infused into dogs, of 70 ml/i<g/min (Schrumpf and Semb, 1973), compared 
with the metabolic clearance rate of 9, 1 ml/kg/min following infusion of 
human gastrin into humans (Schrumpf, Semb et al., 1973). 
Apart from the very low metabolic clearance rate of G-17 gastrin reported 
by Walsh, Maxwell et al. (1975) of 16,5 ml/min in the human, and the high 
va! ue for clearance of human G-17 from the canine circulation found by 
Schrumpf and Semb ( 1973), there was reasonabi e agreement between the 
values found for this parameter by different groups. The range was from 
35,5 ml/kg/min (McGuigan, Isaza et ai ., 1971) to 83 ml/kg/min (Debas, 
Walsh et al., 1974) for human G-17 in the dog. 
Estimations of the space of distribution of human G-17 ranged from 
6,5% of body weight in the case of natural human gastrin infused into dogs 
(Strunz, Walsh et al., 1978) to 25% of body weight when natural human 
and porcine G-17 were infused into dogs (Walsh, Debas et al., 1974). 
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Straus and Yalow (1974) found a space of distribution of 11-13% of body 
weight following pulse injection of 131 1-labelled or unlabelled porcine G-17 
into dogs. It is interesting that two entirely different values for this para-
meter were reported by Walsh in the two separate publications just mentioned, 
although in each case the same preparation, natural human G-17, was 
infused in approximately the same dose into dogs. Yet a further value of 
0, 11 litres/kg was found following infusion of NHG-17 into man (Walsh, 
Maxwell et al., 1975), although in this instance the dose infused was lowero 
Turning to the kinetics of G-34 and G-13 gastrin in the circulation, 
studies have been described by only two or three groups who have had access 
to sufficient amounts of purified preparations of these peptides. The half-life 
of natural human G-34 fol lowing pulse injection in the dog was 9 minutes 
(Straus and Yalow, 1974) and following infusion into dogs it was 15,8 
minutes (Walsh, Debas et al., 1974). In man a half-life of 42 minutes 
for G-34 after intravenous infusion was found (Walsh, /\~axwe!I et al., 
1975), again suggesting that homologous gastrin is broken down more slowly 
than heterol ogous gastrin. Only one estimation of the metabolic clearance 
rate of G-34 has been reported: 2, 1 ml/min for the clearance of NHG-34 I 
from the human circulation following intravenous infusion (Walsh, Ma:x'IA/ell 
et al., 1975)" This very low value amounts to only 0,03 ml/kg/min in a 
man weighing 70 kilograms. Estimations of the soace of distribution of I 
NHG-34 ranged frcrn l 0-12% of body weight in the dog (Straus and Yalow, 
1974) and man (Walsh, Maxwell et al., 1975) to 23% of body weight in 
the dog, found by Walsh, Debas et al. (1974). 
One study on the kinetics of a 11 big big 11 gastrin fraction comprising 
pooled void volume eluates obtained on fractionation of a Zollinger-Ellison 
tumour extract has been reported. A half-life of 90 minutes for the meta-
bolic phase of the disappearance curve of BBG following pulse injection into 
one dog was found by Straus and Yalow (1974), and the BBG preparation was 
found to distribute itself in a volume equivalent to approximately 24% of 
body weight. 
The half-life of NHG-13 I following infusion into dogs was 1 ,8 minutes, 
with a metabolic clearance rate similar to that of G-17 gastrin, of 79 ml/ 
kg/min (Debes, Walsh et al., 1974). The space of distribution of G-13 in 
this study was slightly less than that for G-17 and G-34, with a value of 
0,17 litres/kg. Considering the limits of experimental error, this estimation 
suggests that G-13 was distributed throughout the extracellular fluid volume, 
as was the case for the larger gastrin peptides. 
Since the half-life of G- 17 in the circulation is approximately five times 
shorter than that of G-34 (3,2 minutes as opposed to 15,8 minutes) (Walsh, 
Debas et al., 1974), it follows that G-17 is cleared from the circulation 
five times more rapidly than G-34. Comparison of the exogenous potencies 
of G-17 and G-34, by measuring the acid secretory response to equimolar 
infusions of these peptides, gave similar values. However, measurement of 
the acid secretion in terms of circulating concenrrations of G-17 and G-34 
revealed that G-17 has an endogenous potency approximately five times 
greater than G-34 (Walsh, Debas et ed., 1974). This is because the circu-
lating concentrations of G-34 reached five to six times higher levels than 
G-17 due to the longer half-life and slower rate of elimination of G-34 
from the blood. 
129 
Comparison of G-17 and G-13 revealed that the exogenous potency of 
minigistrin is less than half that of G-17, whereas the endogenous potency 
of the two preparations was similar (Debas, Walsh et al., 1974). If one 
takes into account the slightly shorter half-life of G-13 (1,8 min) as opposed 
to G-17 (3,2 min) the calculated endogenous potency of G-13 approximates 
120% of that of G-17. However, since the metabolic clearance rates of 
G-13 and G-17 were so similar (79 ml/kg/min and 83 ml/kg/min), Debas, 
Walsh et al. (1974) felt that the differences in calculated half-times for 
G-13 and G-17 were probably not significant. 
These findings emphasise the difference between endogenous and exo-
genous potencies of the different gistrin preparations and indicate the impor-
tance of distinction between potency estimations based on measurement of 
the dose of a hormone administered and the immunoreactive levels measured 
in the circulation. 
In summary, this review of studies on gastrin kinetics has shown good 
agreement between different studies in some parameters, with considerable 
variations in others. Differences may be attributable to: (i) different modes 
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of administration of the gastrin preparations, (ii) different origins of the 
peptides, such as whether they are porcine or human and whether they are 
natural or synthetic preparations! (iii) whether they are labelled with radio-
active iodine or unlabelled, (iv) durations and doses of infusions administered, 
and (v) differences in sites of sampling, since higher gastrin levels would be 
measured in samoles drawn from the portal site as oonosed to samples drawn 
t I' 
from a peripheral vein. 
The differences in exogenous and endogenous potency may relate to 
the clearance of gastrin by tissues or the reaction of gastrins with their 
target organs or receptors. In the next section the interaction of gastrin 
with receptors will be reviewed. 
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Section X Interaction of Gastrin with Receptors 
For a hormone to activate a target tissue it must first bind to some 
constituent of the cell. Binding of labelled polypeptide hormones to 
specific receptors on their target cells has been studied in the case of 
insulin, glucagon, growth hormone, adrenocorticotrophic hormone, calci-
tonin, oxytocin, prolactin and many others (Roth, 1973). Although a 
handful of studies have recently appeared describing binding of gastrin to 
receptors, the intimate interaction of gastrin with the parietal cell is still 
totally unknown. 
132 
Binding of tritiated synthetic human gastrin I to gastric plasma membranes 
purified from rat fundic mucosa was demonstrated by Lewin, Soumarmon, Bali, 
Bonfils, Girma, Morgat and Fromageot (1976). Using 3 H-SHG I, with a 
specific activity of 60 Ci/mmole, which was "immunologically and biologi-
cally as reactive as unlabelled native SHG I", binding to gastric plasma 
membranes was shown to increase with time until reaching equilibrium within 
15 minutes, at which time l to 5% of the total radioactivity was bound per 
mg protein. Addition of unlabelled gastrin displaced the labelled gastrin 
from the binding sites. Increased adenyl cyclase activity in the gastric 
plasma membranes was noted following stimulation with tritiared gastrin, 
suggesting that cyclic 3', 5'-AMP is invoived in the reguiation of acid 
secretion following stimulation by gastrin (Lewin, Soumarmon et al., 1976). 
Having demonstrated saturable arid reversible binding of labelled gastrin 
to gastric plasma membranes, which included membranes derived from 
parietal, peptic and mucous cells, the next step was to isolate pure 
parietal cells from the gastric plasma membranes and to demonstrate binding 
specifically to these cells. Soumarmon, Cheret and Lewin (1977) prepared 
fundic cell populations containing up to 70% parietai cells, and demonstrated 
binding of 3 H-labelled gastrin which was proportional to the cell concentra-
tion and temperature, and increased with time. The binding was reversed by 
ten-fold dilution of the incubation medium, and increased binding was ob-
tained with increased purification of the large cells, which were identified 
as parietal cells on electron microscopy. Thus the presence of high affinity 
binding sites for 3 H-label led gastrin on rat gastric parietal eel Is, which were 
shown to be specific by the criteria of saturability, reversibility and dis-
placement, was confirmed. 
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The sequence of events following binding of gastrin to mucosal eel Is 
prepared from guinea pig fundus was investigated by Del Mazo and McGuigan 
(1976), who demonstrated specific binding of 1251-labelled synthetic human 
gastrin to these cells. Maximum binding was demonstrated at pH 7,4 and 
at 4°C, under which condition:; 2 to 4 picograms 125 1-gastrin were bound 
by 3 x 105 gastric mucosa! cellsQ As was the case with the studies of 
Soumarmon and Lewin, the binding of labelled g::istrin to mucosa! cells pro-
duced a characteristic saturation curve with increasing concentrations of 
1251 . 
-gastnn. The 1251-gastrin was degraded following incubation with 
gastric mucosal cells, as shown by r1::duction in binding of these preparations 
· ·bod• ' b r "I r 1251 ' · h" 1 h d b to gastnn anti 1es ana y ,a1,ure or -gcsrrin w 1cn a een pre-
incubated with mucosa! cell preparations to be bound by a second prepa-
ration of fresh gastric mucosa! cells. 
Hormone degrading enzyme sysrems exist within or on the surfaces of 
cel!s containing receptors for polypeptide hormones, although these enzyme 
systems appear to be functionally independent of the hormone receptor site 
(Del Mazo and McGuis.an, 1976). The fact that the greatest degradation 
of 125 1-gastrin occurred at pH values 2 and 7,4 following incubation with 
mucosa! cells in this study suggested the presence of at least two enzyme-
degrading systems in these eel I preparations. It was shown that the mode 
of degradation did not simply invoive removal of the iodine label, since 
the 1251-gastrin following incubation with mucosa! cells did not behave 
like Na 125 1odide on paper chromatography when eluted with butanol, 
dioxane and ammonium hydroxide (Del Mazo and McGuigan, 1976). The 
precise nature of the degradation of label led gastrin by these eel Is was 
not revealed in this study. However, this demonstration of degradation 
of gastrin by fundic mucosa! cells confirms the role of the gastric fundus 
in the degradation of gastrin suggested by the in vivo studies of Evans, 
Reeder et al. (1974), as discussed 1n the previous section. 
Prior to the appearance of these three reports of binding of gastrin 
to receptors, the uptake of gastrin by a cytosol protein, rat liver ligandin, 
in vitro was demonstrated by Kirsch, Vinik, Frith, Gordon, Grant and 
Saunders (1975). Binding of both 1251-gastrin and unlabelled synthetic 
human G-17 gastrin to this basic protein was demonstrated on separate 
occasions; and the specificity of binding was confirmed by displacement 
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of the bound labelled gastrin on addition of an excess of unlabelled gastrin. 
Failure of this protein to bind No 125 1odide aione confirmed that the binding 
was not to the iodine label, and the fact that binding to the gut hormones 
glucagon and insulin was not demonstrated further indicates the specificity 
of binding. 
Ligandin, also known as Y-protein, has been purified from liver, 
kidney and intestinal homogenates of mammals and many vertebrates, where 
it constitutes approximately 4% of total supernatant protein in the case of 
liver and 2% of the tol·al supernatant protein of kidney and intestinal 
homogenates. It is a basic protein with a molecular weight of approximately 
46 000, consisting of 2 identical subunits (Fleischner, Mishkin, Reyes, 
Robbins, Levi, Gatmaitan and Arias, 1971; Litwack, Ketterer and Arias, 
1971; Fleischner and Arias, 1976). It has been localised to the paren-
chymal liver cells, the proximal renal tubular cells and the non-goblet 
mucosa! cells of the small intestine, and is known to bind certain organic 
anions including bilirubin, dyes, drugs, cholecystographic agents and 
steroids. Endogenous substances are bound non-covalently with varying 
affinities, whereas carcinogens differ from other compounds in that they 
are bound both covalently and non-covalently. Binding of different agents 
has been demonstrated both in vivo, on injection of the compounds, and 
following their addition to liver homogenates in vitro. The electrostatic 
binding of the ligand BSP to ligandin was used at each stage of the purifi-
cation to locate the ligandin peak on gel filtration (Fleischner, Mishkin 
et al., 1971; Litwack, Ketterer et al., 1971; Fleischner and Arias, 
1976). 
The levels of ligandin increase to over 200% of control values following 
administration of phenobarbitone, DDT and other compounds which induce 
the drug and steroid-metabolising enzymes of the endoplasmic reticulum. 
The increased concentrations in response to phenobarbitone administration 
result from enhanced synthesis of ligandin rather than decreased degradation, 
and the increased levels of ligandin are associated with an increase in the 
disappearance rates from plasma and increased hepatic content of bromo-
sulphthalein (BSP), indocyanine green (ICG) and bilirubin (Fle1schner, Mishkin 
et al o, 1971). This direct relationship between the hepatic concentration 
of ligandin and the net flux of bilirubin, BSP and other organic anions 
between the plasma and the liver cell suggests that ligandin is important in 
selective transfer of various organic anions from plasma into the liver 
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(Fleischner, Mishkin et al., 1971). More recent I y it has been shown that 
both liver and renal ligandin are identical with glutathione transferase B, 
confirming that ligandin is enzymic in nature (Fleischner and Arias, 1976). 
If one regards a hormone receptor as an agent which binds a hormone, 
whether it be located in the plasma membrane of the target cell or in the 
actual cytosol, then the demonstration of binding of gastrin to rat liver 
ligandin by Kirsch, Vinik et al. (1975) must be regarded as one of the 
earliest reports of binding of gastrin to a receptor. It is certainly the first 
report of evidence for gastrin entering the cytosol. The gastrin molecule 
is strongly anionic at neutral pH, due to the presence of five glutamic acid 
residues in positions (6-10) of the heptadecapeptide. This suggests the 
possibility that the binding of gastrin to rat liver ligandin in this study 
could be merely an ionic effect due to the highly charged nature of the 
gastrin molecule, in the same way that ligandin binds many other organic 
anrons. Ligandin has been shown to be an enzyme system (Fleischner and 
Arias, 1976), yet it does not appear to degrade gastrin. It may transpire 
that the liver cell is an additional target cell for gastrin, subserving a role 
yet to be clarified. 
In the pages which follow, appear details of the experimental protocols 
of studies designed to fill a part of the hiatus in knowledge of the structure-
antigenicity and physiological functions of gastrin and related peptides. 
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CHAPTER 3 
MATERIALS AND METHODS 
Section I Radioimmunoassay 
3 l(i) Raising of Antisera 
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Synthetic human heptadecapeptide gastrin G-17 I, obtained from Imperial 
Chemical Industries Ltd.(I.C.I.), was coupled toB. cincta haemocyanin with 
carbodiimide according toa modification of the method described by Goodfriend, 
Levine and Fosman (1964). Nine hundred micrograms (µg) gastrin dissolved in 
0,05M-a,1ueous ammonium hydrogen carbonate, 1 ml 0,05M-sodium phosphate 
buffer pH 7,5, 0,5 ml haemocyanin, and 40 mg 1-Ethyl-3-(3-dimethylamino-
propyl)-carbodiimide (EDAP-CDI), (Sigma), were placed in a small beaker and 
mixed gently on a magnetic stirrer for 30 minutes at room temperature. The 
mixture was then dialysed against distilled water overnight at 4°C using 6 mm 
dialysis tubing with a pore size retaining molecules greater than 12 000 (A.H. 
Thomas). The granular pearly-grey conjugate was withdrawn from the dialysis 
tubing using a syringe and mixed with an equal volume of Freund's complete 
adjuvant (Difeo) just prior to injection. Loss of gastrin through the dialysis 
tubing after conjugation was minimal as shown by me-::isureme11t of the gcstrin 
content of the dialysis fluid by radioimmunoassay. A gastrin concentration of 
172 pg/m I in a volume of l 07 4 ml gave a tota I of O, 185 pg gasrri n in the dia-
lysate, which is only 0,021% of the original dose of 900 JJ9 gostrin used for 
the conjugation. 
Three-month-old male albino rabbits were immunised with a priming dose 
of l 00 ,.ug coupled synthetic human hept::idecapeptide gastrin in an emulsion 
with Freund's adjuvant, injected painlessly at multiple dorsal subcutaneous sites. 
At the first immunisation each rabbit was also given 0,5 ml Bordetella 
pertussis (S.A.1.M.R.) (whooping cough vaccine) in the same manner to 
stimulate the immune system. Approximately 20 ml blood was collected 
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from an ear vein from each animal 30 and 60 days after the first immunisation, 
and the sera were tested for antibody titre. Subsequent injections of 50 JJg 
synthetic human gastrin I (SHG I) emulsified in Freund's complete adjuvant 
were given every six weeks, commencing 10 days after the 60-day bleed, 
and the sera collected 7-10 days after each booster injection for testing. 
Antiserum G 5 was raised using this method. 
Antiserum G 1 was obtained commercially from CEA-IRE Sorin Pharma-
ceuticals Ltd., and was raised according to the method of McGuigan {1968a) 
in which synthetic human gastrin (2-17) was coupled to bovine serum albumen, 
using EDAP-carbodiimide. G 1 antiserum was used at a final dilution of 
1 :200 000 in the assay. McGuigan's (1968a) conjugation and immunisation 
procedures are outlined in the appendix. 
Antiserum 2604-7 was donated by Dr. J. Rehfeld of Copenhagen. It 
was raised according to the method described by Rehfeld, Stadil and Rubin 
(1972), and could be used in the assay at a final dilution of 1:100 000. 
All three antisera were characterised and thei; cross-reactivity with related 
peptides was determined before use in the immunoassay. 
The terms "antibody" and "antiserum" are used interchangeably in this 
thesis. Although strictly speaking incorrect, since an antiserum may contain 
more than one population of antibodies, the fact that these antisera have 
been characterised in terms of their predominant antigenic interaction(s) 
one feels is reason enough to permit this liberty. For the purist, where the 
term "antibody" appears in the text and figures one should read "antiserum". 
3 I (ii) Iodination Procedure 
Synthetic human heptadecapeptide gastrin I (J.C. I.) was labelled with 
125 todine (Radiochemical Centre Ltd., Amersham, England) according to 
a modification of the method of Ganguli and Hunter (1971). The iodination 
was performed in a glass cone-shaped vessel to facilitate rapid mixing of 
reagents, which were blown into the vessel from glass micropipettes, with 
the exception of the radioactive iodine, which was added with a 11 hot 11 
Hamilton syringe, reserved especially for this purpose. When aiming to 
incorporate 2 000 microcuries (1JCi) 125 todine per microgram (ug) peptide, 
the reagents were added in the following volumes, in the sequence in-
dicated: 
0,2M-sodium phosphate buffer pH 7,5 
0,5 JJg SHG-17 I 
1 mCi Na 125 1 
Chloramine-T 16 µg 
Reaction volume 
Sodium metabisulphite 40 1-Jg 
Potassium iodide 2 mg 
Normal human plasma 
20 µf 
5 1JI 
55 JJI 
50 1JI 
200 ul 
20 ul 
325 ul 
(The potassium iodide was added to enable the high concentration of 
Id · od · d · 1 h 1 25 1 h · · · d co I ine to I ute out t e a toms w I ch were not incorporate 
into the hormo~e, and so reduce the damage they may cause by auto-
irradiation of the labelled hormone. The human plasma was added to 
"mop up" the free radicals generated in the iodination reaction.) 
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The iodination mixture was immediately applied to a small Sephadex 
G-10 column (0,9 x 10 cm) which had been pre-saturated with 4% human 
serum albumen, and eluted with 0,05M-sodium phosphate buffer, pH 7,5, 
at room temperature. Fractions of 1 ml volume were collected and the 
elution profile of counts per second ( c .p .s.) against fraction number was 
I ed Th . . f 1251 od. . h h p ott • e percentage I ncorporat1 on o ine into t e ormone was 
determined by charcoal adsorption of intact labelled peptide (Vinik, Deppe 
and Joubert, 1970; Binoux and Odell, 1973) using a 5 ul aliquot of the 
mother liquor before addition to the column, diluted appropriately. The 
integrity of the eluted fractions was tested by charcoal adsorption of intact 
labelled peptide (Vinik, Deppe et al., 1970; Binoux and O:lell, 1973). 
Th • I • I • . f I d f · • h 1251 · k e 1mmunoog1ca integrity o eute ract1ons int e -gastrin pea 
was determined by incubating an aliquot of the labelled hormone with an 
0 
excess of antibody for 18 hours at 4 C. For each iodination the fraction 
displaying the best immunological integrity was used in the assay. 
The purity and immunological integrity of the labelled hormone was not 
tested using high voltage paper electrophoresis as is customary for other 
hormones such as insulin (Yalow and Berson, 1960) because of the para-
doxical reversed behaviour of gastrin on celluiose paper strips, due to the 
highly charged nature of the gastrin molecule. This finding has been re-
ported by other workers as well (Yalow and Berson, 1970a). 
The ratio of 
125
1odine to cold hormone aimed at for use in the radio-
immunoassay was usu~1lly between 1 000 and 2 000 .AJCi 125 1cdine per 1vg 
protein. This term has been loosely referred to as"specific activity': 
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Alternative to this iodination procedure 1251odine-labelled synthetic 
human heptadecapeptide gastrin I was purchased from CEA- IRE Sorin and 
repurified on a Sephadex G-10 column when necessary. The integrity of 
the commercially labelled gastrin preparations was monitored by charcoal 
adsorption of intact labelled peptide in the assay. The immunological 
integrity of these preparations was assessed using antiserum G 5. Antibody 
dilution studies had shown that the maximal binding of labelled gastrin by 
this antiserum at 1 :10 dilution was 63%; therefore the immunological in-
tegrity of the tracer was assessed as a proportion of this value. 
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3 !(iii) Assay Procedure and Validation Thereof. 
All assays were performed in disposable plastic cuvettes 11 x 52 mm in 
size, obtained from LKB, Sweden, after testing a variety of materials which 
were unsuitable due to adsorption of gastrin and other small peptides to their 
surfaces. Furthermore the effects of albumen and gelatin on preventing ad-
sorption of gastrin to glass and plastic was investigated in the following way: 
four tubes were set up to test each combination of glass or plastic and albumen, 
gelatin (Haemaccel, Hoechst} or buffer. Each tube contained 1 ml 0,05M-
Barbital (Verona!) buffer, pH 8,5, plus O, l ml labelled hormone diluted in 
the same buffer. After 24 hours' incubation the tubes were counted, their 
contents decanted, and the empty tubes re-counted. The remaining counts 
were expressed as a percentage of the tota I counts. 
Sample tubes contained O, l ml serum or standards, 125 0, 1 ml I-labelled 
synthetic human gastrin G-171 (125 1-SHG-17 I), 0,1 ml antiserum, and the 
final volume was made up to 1 ml with 0,02M-Barbital (Verona!) buffer, pH 
8,4. The barbital buffer was used to dilute serum, antibody, tracer and 
standards, and the standard reference preparation used each time was synthetic 
human gastrin G-17 I obtained from CEA- IRE Sorin. Standards covered the 
range of 0,625 - 80 pg synthetic human gastrin (SHG), equivalent to 6,25 -
800 pg/ml whole serum. Buffer, standards and unknowns wern pipetted using 
a Microme:lic Automatic pipetting station (,'v\icromedic Systems, Inc.) and the 
antiserum and labelled gastrin were added with a Repette (Jencons, Heme! 
Hempstead, England} or a Hamilton Repeating Syringe. 
Assay tubes were incubated at 4°C for 18-24 hours when G l antiserum 
was used. This incubation period was found to give the most sensitive standard 
curve compared with 90 minutes at 37°( fol lowed by 30 minutes at 4°C, and 
72 hours at 4°C. Assays performed with antisera G 5 or 2604-7 were incubated 
for 72-96 hours. After incubation, 0, l ml charcoal-treated "gastrin-free 11 
serum (Wellcome) was added to all standard tubes to equalise their serum 
content with that of the unknown serum samples. 0, l ml water was added 
to the unknown tubes to correct for volume changes. To all tubes except the 
total count tubes, 0,5 ml of a constantly stirred 4% charcoal suspension in 
0 ,02M-Barbital buffer was added and the mixture agitated on a whirli-mixer. 
The tubes were al lowed to stand at 4°C for 5 minutes, then centrifuged at 
2 000 revolutions per minute (rev./min) for 15 minutes at 16°(. The super-
natant fluid was decanted by covering each polystyrene tray containing l 00 
cuvettes with surgical gauze secured by elastic bands, inverting the tray over 
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a "hot sink", and draining the tubes for 20 seconds on a bed of cotton wool 
covered with tissues. This decanting method was found to give identical results 
to those obtained when tubes were decanted and the last drop wiped manually. 
The charcoal-adsorbed rndioactivity in the precipitates and the total radio-
activity were counted in a solid-state scintillation spectrometer (Packard Systems 
Inc.) for 10 minutes or 10 000 counts. 
After correction for nonspecific adsorption of label led gastrin to the charcoal, 
the free labelled hormone was estimated as the percentage of the total counts 
per minute (c.p.m.) in the charccx::l precipitate of standard and unknowns. 
To calculate the antibody-bound labelled gastrin these values were subtracted 
from 100%. The value of '?lo binding thus obtained for the tubes containing 
zero standard, or B , was ascribed the value of 100%, and other % binding 
0 
(B) values were expressed as a fraction thereof (B/B0 x 100). Standard curves 
were constructed by plotting either % B or B/B x 100 values on semiloga-
o 
rithmic paper against the content of synthetic human gastrin or related peptides. 
Blanks without antibody were assayed on each occasion to assess non-specific 
binding of labelled gastrin by plasma proteins or other plasma factorso 
Corrections were made for all samples where the non-specific binding was 
found to be greater than 5%. The gastrin content of unknowns was determined 
by reading the corresponding value of% binding or B/B x 100 off the standard 
0 
curve o 
Mean standard curves were constructed from 16 consecutive assays us1 ng 
antiserum G 1 and 8 consecutive assays each with antisera 2604-7 and G 5. 
The lower limit of sensitivity, or the detection limit for the assay with each 
antiserum was determined as the concentration of added gastrin which depressed 
antibody binding of labelled hormone significantly {p < 0 ,05, t-test) compared 
with the binding in the absence of added hormone. 
Samples of known gastrin content estimated to fall on three different parts 
of the standard curves were assayed each time to assess inter-assay variability. 
These three samples were aliquots prepared from large batches of Hyland 
Control Serum I, and Hyland Control Serum I with synthetic human gastrin 
G-17 I added to give final concentrations of 80 pg/ml and 160 pg/ml. 
Intra-assay variation, or precision, was assessed by measuring the serum gastrin 
content of a series of samples repeatedly in the same assay. For this purpose 
serum from a patient, or a Hyland contiol serum containing a known amount 
of gastrin was used. The coefficients of variation of inter- and intra-assay 
variability were calculated as the standard deviation x 100 divided by the 
mean gastrin concentration. The index of precision was determined as the 
coefficient of variation of the ID5o value of each standard curve, where 1050 
refers to the concentration of gastrin required to displace 50% of 125 1-gastrin 
from the antibody. 
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The accuracy of the estimation, which refl eds the approximation of 
the estimation to the true concentration of the peptide being measured, 
was assessed by regression a na I ys is of observed versus expected va I ues of 
added gastri n. 
A Scatchard (1949) plot, as applied to radioimmunoassay by Berson and 
Yalow ( 1959), was constructed from the mean standard curve for each anti-
serum by converting % binding values to a bound/free ratio (B/F) and 
plotting this against the concentration of gastrin bound (B), including the 
mass of radioactive tracer added to each tubeo The mass of tracer added 
to each tube was calculated to be approximately 5 pg. The equation of 
this regression line is: 
B/F = K{x-B) 
where B = concentration of bound anrigen 
F = concentration of free antigen 
K =-slope (litres/mole) 
x = molar concentration of total antibody combining sitese 
The average affinity constants (K) (litres/mole) of the antisera were 
derived from the graphic plots o The total concentration of antibody com-
bining sites was read from the intercept on the horizontal axis, since x=B 
when B/F =0. The affinity constant and molar concentration of binding 
sites were determined for antisera G l, 2604-7 and G 5 in :-his manner. 
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3 l(iv) lmmunoreactive Studies on Gastrin Frogments a:id Related Peptides 
Using Different Antisera 
The ability of serum samples from fasted and intravenously infused 
arginine-stimulated individuals to displace 1251-labelled gastrin from G 1 
antiserum was studied to see if substitution of the gastrin standard with 
serial dilutions of serum gave parallel displacement curves to that obtained 
with synthetic human gastrin G-17 I. 
The degree of cross-reaction of various gut and gastrin-related peptides 
in the assay system using antiserum G 1 was investigated by comparing the 
effects of increasing concentrations of these peptides with those of the 
gastrin standard. The peptides studied were: porcine crystalline glucagon 
(Lilly), highly purified natural porcine secretin {Mutt), crude cholecysto-
kinin-pancreozymin (CCK-PZ) (Boots), the synthetic C-terminal octapeptide 
of CCK-PZ (Ondetti), pentagastrin (I.C.I.) and caerulein (Erspamer), the 
peptide isolated from the skin of the Australian bullfrog, Hyla caerulia. 
The immunoreactivity of the related peptides was expressed as the molar 
ratio between the inhibition dose 50 (ID5 o) for synthetic human gastrin 
G-17 I and the ID50 value for the peptide, multiplied by 100 to give a 
percent. The ID50 refers to the molar concentmtion of peptide that reduces 
the binding of labelled gastiin by antibody to 50% of its initial value. 
Using antisera G 1 and G 5 the cross-reactivity of synthetic gastrin 
peptide fragments derived from the parent heptadeccpeptide molecule, as 
compared to that of SHG-17 I, was assessed by comparing the effects of 
increasing concentrations of the fragments with those of the gastrin standard. 
The synthetic peptide fragments were prepared and kindly donated by Dr. J. 
Morley of I.C.I. The structures of the fragments used and of the related 
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peptides caerulein and the (-terminal octapeptide of CCK-PZ are dia-
grammatized in figure (3.1.1.). Comparison of the relative abilities of the 
gastrin fragments to displace labelled gastrin allowed identification of the 
antigenic sites on the gastrin molecule which are recognised by antisera G 1 
and G 5. 
Figure (3.1.2.) shows the chemical structures of gastrins G-34, G-17 
147 
and G-13 as they occur in the human, and porcine heptadecapeptide gastrin. 
Heptadecapeptide gastrin constitutes the (-terminal (18-34) sequence of big 
gastrin or G-34, and minigastrin, G-13, constitutes the (-terminal (5-17) 
sequence of the heptadecapeptide molecule. Each gastrin species may occur 
with a sulphate group on the tyrosine in position 12 of the heptadecapeptide, 
known as type II, or without a sulphate group, in the case of type I gastrins. 
Porcine heptadecapeptide gastrin differs from that of the human in that leucine 
in position 5 is replaced by methionine. 
The Centre for UI cer Research and Education (C. U. R. E .) , by courtesy of 
Dr. M.Grossman, kindly supplied preparations of natural human gastrin 17 I, 
17 II and 34 I (NHG-171, NHG-17 II, NHG-341) isolated from tumour 
extract prepared by Drs. Gregory and Tracy. These were examined with three 
antisera as outlined for the gastrin fragments, along with synthetic human 
G-171 obtained from CEA-IRE Sorin and from I.C.I. 
FRAGMENTS OF HUMAN GASTRIN I AND RELATED PEPTIDES 
Pyr Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp Phe-NHz 
l. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Pyr GI n Asp Tyr Thr 
(S031 
Asp Tyr Met 
Pentapeptide a,nide 13 - 17 
Heptapeptide amide 11 - 17 
Decapeptide amide 8 - 17 
Human Gastrin I 
Tric.ecapeptide 1- 13 
Undecapeptide 3 - 13 
Octapepti de 3 - 13 
Pentapeptice 9 - 13 
Caerulein (Oecapeptidel 
CCK-PZ Octapeptide 
Fig. (3.1.1.) The schematic structure of heptadecapeptide 
gastrin, synthetic gastrin fragments, caerulein (the frog skin 
peptide) and the (-terminal octapeptide of cholecystokinin 
pancreozymin (CCK-PZ). 
SOM£ CHU.IICALLY IOENTIF1£0 GASTRINS 
2 3 4 5 6 7 8 9 10 II ll 13 14 15 16 17 18 19 l!J Z1 21. ZJ ill 25 211 l/ zg 29 30 31 32 33 34 lal Pyr-Leu-Gly-Pro-Gln-Gly-His-Pro· Sor Leu-Val-Ala-Asp-Pro-Ser-lys-lys-GJn-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Mel-Asp-Phe-NH
2 I 
(bl 
lei 
(di 
lal Human big gaslrin IG-341 MW 3839 
lbl Human hepladecapeplide llitllel gaslrin IG-17, 16-34 ol G-341 MW 2098 
lei Human minigastrin IG-13, 22-34 ol G-34. 5-17 of G-171 MW 1647 
ldl Porcine hepladecapeplide gaslrin 
R 
l l 3 4 5 6 7 6 9 10 II 12 13 14 15 16 11 
Pyr-Glv-Pro-Trp-Leu-Glu-Glu-GJu-GJu-Glu-Ala-T yr-Gly-Trp·Met-Asp-Phe-NH z 
I 
R 
1 2 3 4 5 6 7 8 9 10 11 12 13 
leu-Glu-Glu-GJu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-?he-NH z 
I 
R 
Pyr-Gly-Pro-T rp·Met-Glu-Glu-GI u-GJ u-Ghr Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH z 
I 
R 
gaslrin I. R • H 
gastrin 11. R • sol 
Pyr • pyroglutamyl 
Fig. (3.1.2.) The chemical structures of human big gostrin, 
heptadecapeptide gastrin, mini gastrin* and porcine heptadeca-
peptide gastri n. 
*Currently it is thought that mini gastrin consists of 14 amino acids. 
3 l(v} Displacement Curves of Various Sera 
In order to establish identity of the material in serum obtained from 
patients with various disease conditions with the synthetic human heptadeca-
peptide gastrin standard, displacement curves were set up to examine the 
ability of serial dilutions of these sera to displace radioactive gastrin from 
antisera G 1, 2604-7 and G 5. Serum from patients A.K. and C.K. 
suffering from the Zollinger-Ellison syndrome, from patient M.B. with 
isolated retained antrum, and from patient M. Y. with pernicious anaemia 
were studied. 
Si nee many of the gastrin studies described in this thesis involve measure-
ment of serum gastrin levels in pigs, it was important to confirm that pig 
serum did not interfere in the assay. Displacement curves were constructed 
using serial diiutions of pig serum in place of gastrin standard and the 
resultant curve was compared with that obtained using standard gastrin. 
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3 l(vi) Measurement of Gastrin in Tissues 
Gastrin levels were measured in aqueous extracts prepared by boiling 
tissues collected from various animals at different sites along the gut, as 
described in section 3 lll(ii). The effect of different treatments during the 
extraction procedure on the recovery of gastrin was investigated using rat 
thigh muscle to which was added a known concentration of gastrin. One 
ml containing 800 pg was added to a final volume of 5 ml extract each 
time to give an expected concentration of 160 pg/ml • Gastri n measurements 
were made in the extracts after the following treatments: 
(a) gastrin added to water was measured to assess recovery from addition 
to glassware 
(b) gastrin was added to water and boiled for 20 minutes to assess the 
effect of boiling on gastrin 
(c) muscle was added to water, and after mixing the fluid was assayed 
for gastrin to see if there was any detectable gastrin in muscle 
(d) muscle with added gastrin as prepared in (c) was boiled for 20 minutes 
to see if gastrin could be recovered from boiled muscle 
(e} muscle extract was prepared by boiling muscle in water to inactivate 
any enzymes ar.d the extracted fluid was tested for gastri n content 
(f) gastrin was added to the extracted fiuid in (e) and the mixture was 
boiled again to determine whether the extract from muscle contained 
any gastrin-inactivaring enzymes 
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(g) to muscle in water, gastrin and 10% by volume of Trasylol (Aprotinin, 
100 000 KI U/10 ml) was added to test the effect of an enzyme inhibitor 
on gastrin measurement 
(h) the muscle with gastrin and Trasylol described ,n (g) was boiled and the 
extract was assayed for gastrin to assess whether inactivation of the 
enzyme inhibitor had any effect on gastri n measurement. 
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3 l(vii) In Vivo Studies in Man and the Pig 
......:...------------------= 
Serum gastrin levels were measured in 27 control subjects in the basal 
state to establish the mean fasting gastrin level and range in normal people, 
using antiserum G I. Serum gastrin measurements done routinely on a large 
number of patients were divided into categories of age (357), ethnic group 
(369) and sex (372), to see if there were any marked differences in basal 
gastrin levels between these groups. The total numbers vary slightly 
because not all the information was available for every patient. Serum 
gastrin measurements in 285 patients from this group, in which the diagnoses 
had been confirmed, were separated into groups according to the various 
disease states shown by these patients. A study was made in a group of 
patients with rheumatoid arthritis to see if there was any correlation between 
serum gastrin levels and the degree of severity of the arthritis. 
The response of normal subjects to a 30-minute intravenous infusion of 
arginine at a rate of 10 mg/kg/min, a 30 g dose of oral arginine, adjusted 
to pH 7 ,5 with sodium bicarbonate, and oral Oxo, 4 cubes in 150 ml warm 
water, was studied and the maximum increment of serum gastrin over the 
basal level was determined. In 3 patients who had been antrectomised, 
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and in 6 patients who had previously had a vagotomy and partial antrectomy, 
the serum gastrin response to a 30-minute intravenous infusion of arginine 
was investigated in the same way. 
The response of pigs to eating creep meal was tested by measuring the 
serum gastrin levels in a group of pigs at 30-minute intervals after eating 
creep meal, for up to 150 minutes. 
All the measurements of serum gastrin levels 1n the human and the pig 
described above were made using antiserum G I, which detects primarily the 
non-sulphated heptadecapeptide gastrin species. 
Section II Chromatography 
3 11 Column Procedure 
Characterisation of the nature of gastrin in various serum and human gut 
extract samples, and studies on gastrin heterogeneity were performed using 
Sephcdex column chromatography. Sephadex columns of dimensions 1,5 cm x 
100 cm and 1,5 cm x 150 cm, containing a mixture of equal volumes of 
Sephadex G-25 fine and G-50 fine were poured. Using a combination of 
two Sephadex grades gave a larger fractionation range (molecular weight 
1 000 - 30 000 for peptides and globular proteins), al lowing separation of 
gastrin species both larger and smaller than the heptadecapeptide moleculeo 
Pouring a long column, such as 1 ,5 metres, with a mixture of two grades 
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of Sephadex inevitably leads to a certain amount of uneven distribution of the 
Sephadex particles, as the G-25 beads would tend to settie faster than the 
G-50 beads, due to their larger size. To minimize the extent of this uneven 
settling the contents of the funnel attached to the top of the column were 
stirred continuously with an electric stirrer while the column was being poured. 
The packing of the column was found to be satisfactory as was evident from the 
behaviour of blue dextran and vitamin B12 on the column, which could be seen 
to move down the column in compact bands with regular fronts. 
Each column was pre-coated with 4% human serum albumen to prevent 
non-specific adsorption to the column matdx. The columns wern equilibrated 
and eluted ·with 0,05f.,\-Barbital (Verona!) buffer, pH 8,5, containing 0,01% 
sodium azide, ata constant flow rate ofbervveen 13 and 16 ml/hour, controlled 
by an LKB Varioperpex pump, at room temperature. Elution was carried out by 
downward flow and buffer passed into the column from a Mariette flask which 
was kept at a constant height. Samples were applied to the columns in 
volumes of 1-2 ml, and fractions of 1,5-2 ml were collected using an LKB 
UI trora c Fraction Collector, and assayed for gastri n content. The columns 
were washed with at least two column volumes of eluant between application 
of samples, and when the columns were not in use they were stored with 
veronal buffer containing 0,02% sodium azide to prevent growth of organisms, 
and re-equilibrated with the eluting buffer before use. 
The molecular weight markers blue dextran, albumen (Behringwerke), 
125 I-label led monocomponent porcine insulin (gift of L. Heeling, Ph.D., 
Novo Institute, Denmark), 125 1-glucagon, 1251-synthetic human gastrin I, 
· · ( bal ) d 22 N d · ' b" . vitamin B12 cyanoco amin , an a were use In varr ous com 1nat1ons 
to calibrate the columns. Internal standards of blue dextran and vitamin B12 
were run with each elution in later fractionations. The elution profile of 
gastrin species was plotted either directly as elution volume (ml) or as a 
percentage of the elution volume between blue dextran and vitamin B12 
markers, when these were used as internal standards. The concentration of 
gastrin in the eluates was expressed as the relative ability to displace 
125 1-
synthetic human gastrin G-171 from the antibody, or B/B x 100, where B 
0 
refers to% binding of 125 1-gastrin by antibody, and B denotes the value 
0 
of % binding in the absence of added standard gastrin, as detailed in 
section l(iii) of this chapter. It was not possible to determine absolute 
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levels for the concentration of the peptides obtained on fractionation because 
the standard preparation u5ed in all assays was synthetic human gastrin G-17 I. 
High gastrin-content serum from a patient wrth pernicious anaemia was 
chromatographed to investigate the heterogeneity of gastrin species found in 
this serum. The eluted fractions obtained on gel filtration of serum from 
patient K. V. were assayed with antiserum G 5. 
Standard reference preparations of natural human gastrin G-171, G-17 II, 
and pure human big gastrin, G-34 I, kindly donated by Dr. M.Grossman and 
prepared by Drs. Gregory and Tracy, were chromatographed to establish tne 
exact elution patterns of the natural gastrins in our system. Comparison of 
these elution profiles with those obtained from serum and gut extract samples 
aided the identification of the gastrin types in the various preparations. 
This chromatographic technique was applied to several other studies 
which are described in the relevant sections, and are merely outlined here: 
(a) Tissue extracts prepared by boiling biopsies of human antrum and 
duodenum in water, as described in section lll(i) of this chapter, 
were chromatographed to examine the gastrin species found in these 
extracts. 
(b) An extract prepared by boiling the skin of the frog Xenopus laevis 
in water was passed over the column to investigate the behaviour of 
the extracted material as compared to that of the gastrin standard. 
Frog serum collected from several frogs of the same species was pooled 
and 1 ml of the pooled serum was fractionated in the some way, to 
see how the gastrin-1 ike material in the skin ext re ct and serum compared 
en chromatography. 
(c) Serum samples were taken from differenr vascular sites in the pig 
following infusion of synthetic human gastrin G-171, and chromato-
graphed to see if the same gasi'rin species could be recovered. 
(d) Samples of perfusate collected during perfusion of the isolated rat liver 
in situ with synthetic human G-17 I were chromatographed. 
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Comments and Criticisms 
The method of chromatographic separation described here was suitable 
for separation of gastrin into large and small molecular weight forms on an 
analytical basis. In order to obtain total refinement of a heterogeneous 
sample on chromatography several chromatographic steps are necessary; 
refractionation of peaks of immunoreactive material on a second Sephadex 
column or on an anion exchange column would allow further purification 
on the basis of molecular weight and charge respectively. 
Although Sephadex columns permit resolution of gastrins on the basis 
of molecular weight, this is not the sole factor governing separation by 
this method. A weak ion exchange effect due to a concentrating mechanism 
within the Sephadex bead has been observed by several workers (Morris and 
Morris, 1976), which leads to non-ideal chromatographic behaviour on 
Sephadex columns. Thus for example it has been found that the aromatic 
amino acids tyrosine and tryptophan adsorb to the column matrix (Gelotte, 
1960) so that peptides and proteins containing a large proportion of these 
residues are retarded in their passage through the column, and produce an 
elution profile which deviates from that expected on the basis of molecular 
weight alone. This phenomenon is well known in the case of small peptides 
such as LRF (Luteinizing hormone releasing factor) and ADH (Antidiuretic 
hormone); and has been observed in the case of the amino-terminal (1-13) 
fragment of gastrin by Dockray and Welsh (1975). They found that this 
fragment eluted between G-34 and G-17 on Sephadex columns and suggested 
that the faster migration of the (1-13) fragmant compared with the G-17 
molecule could be due to the fact that the former contains only one aromatic 
residue whereas G-17 contains three, and is thus retarded relative to the 
tridecapeptide molecule. By coating the Sephadex columns used in this 
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study with albumen these adsorpHon effects were reduced. 
Since each sample that was chromatographed in this study was only 
fractionated once, only rough separation of the different gastrin components 
on the basis of molecular weight was obtained. However, by comparison 
of the elution profiles of unknown samples with those of pure natural gastrins 
and with the elution volumes of markers of known molecular weight, it was 
possible to identify heptadecapeptide and big gastrins on the basis of their 
chromatographic properties. 
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Section II I Extractions 
Introduction 
Since gastrin exists in the circulation in several forms, it is of interest 
to determine the tissue of origin of these various gastrins. The pyloric 
antrum is the major site of gastrin production, and gastrin originating in 
this tissue is chiefly of the heptadecapeptide species. Gastrin is also 
produced at extra-antral sites, the most important of which is the duodenum 
in the normal individual. In some instances, such as in the case of the 
Zollinger-Ellison syndrome, gastrin originates from tumour sites and grossly 
elevated levels are found in the circulation. Although these tumours, or 
gastrinomas, arise chiefly 1n the pancreas they do not involve pancreatic 
delta cells, but rather cells which resemble the antral G-cell. 
To investigate the forms of gastrin at several sites in the human stomach 
and duodenum, extracts of biopsies collected at these sites were prepared by 
boiling in water and the gastrin content of the extracted fluid was examined 
immunochemically and chromatographically. 
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The distribution of immunoreactive gastrin at various sites along the gastro-
intestinal tract was investigated in five mammalian species by preparing extracts 
of tissues collected at these sites in the same manner as for human tissue. 
This allowed the question of pancreatic gastrin to be investigated in these 
species. To examine the occurrence of immunoreactive gastrin amongst verte-
brates in general, serum samples were collected from nineteen vertebrate 
species and assayed for gastrin. A detailed study aimed at characterisation 
of a gastrin-like material found in frog serum and frog skin extracts was 
carried cut. 
Extracts were also prepared from tissues of several invertebrate species 
and tested for the presence of gastrin in an attempt to trace the origin of 
gastrin down the evolutionary tree. 
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3 lll(i) Human Tissue Extracts 
Biopsy specimens were collected by Dr. B.Novis of the Gastrointestinal 
Clinic, Groote Schuur Hospital, from the mucosa of the cardia, body and 
distal antrum of the stomach, and from the duodenal cap and second part of 
the duodenum, in 4 patients who had undergone endoscopic examinations for 
suspected but disproved peptic ulcer disease. The biopsies were taken using 
an Olympus GF type D fibrescope and standard biopsy forceps (Vinik, Grant 
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and Nevis, 1975). Gastrin extracts were prepared by boiling the tissues for 
5-10 minutes in 1 ml distilled deionized water, in test tubes covered with 
aluminium foil lids to prevent evaporation, followed by cooling and centri-
fugation of the solid matter at 3 000 rev./min for 10 minutes. The super-
natant was frozen and stored for measurement of gastrin content by radioimmuno-
assay, using antiserum G 1 • 
The tissues were lyophilised in a Virtis Freeze Drier and weighed, so 
that the gastrin content of the extracts could be expressed as gastrin per 
mg dry weight. The lyophilised tissues were then treated with 1 ml dilute 
sodium hydroxide for 1 hour to dissolve them, and homogenised in a Potter 
Elvehjem tissue homogeniser. The protein content of each homogenate was 
estimated according to the Foiin-Lowry method, which is detailed in the 
appendix. This allowed expression of the gcstrin content per mg total protein. 
The mean values of gastrir. content per mg dry weight and gastrin content per 
mg total protein for the four patients were calculated for each site biopsied. 
To characterise the gastrin extracts prepared from the antrum and second 
part of the duodenum further, the extracts of these sites taken from patient 
R .E. were chromatographed on a Sephadex G-25/G-50 fine column of 
dimensions 1,5 m x 1,5 cm, according to the chromatographic procedure 
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described in section II of this Chapter. The elution profiles were plotted and 
the distribution of the gastrin species detected in these extracts with antiserum 
G 5 was compared with that found in serum. The effect of dilution of the ex-
tracts on the binding of radioactive gastrin to antibody was examined to determine 
whether or not the curve of displacement was similar to that found with standard 
synthetic human gastrin G-17 I. 
Prior to separation of antibody-bound and free label led gastrin in assays 
containing gut extract samples and column eluates, 0, l ml charcoal-treated 
11 gastrin-free 11 serum (Wellcome) was added to the unknown tubes as well as to 
the standards to equalize the serum content throughout. 
It was critically important to ensure that the labelled hormone used in the 
radioimmunoassay was not being degraded by the tissue extracts and giving rise 
to erroneously high readings in the assay. Thus control tubes without antibody 
were run with each extract being measured, and in almost all cases the apparent 
binding to substances in the incubation medium other than antibody (non-specific 
binding) was less than 5%, indicating little non-specific adsorption of tracer to 
tissue extract, and little inactivation of the tracer during incubationo In the 
few cases where the non-specific binding was greater than 5% the appropriate 
corrections were made. This applied in the case of the vertebrate and inverte-
brate tissue extracts as wel ! • 
3 lll(ii) Tissue Extracts in Mammals and Measurements in Vertebrates 
Tissues were collected from mammalian species which included rat, rabbit, 
guinea pig, dog and pig. The animals were sacrificed by exsanguination or 
asphyxiation in nitrogen, and tissues were dissected out as soon as possible, 
within 30 minutes after death. Sites from which tissues were collected in-
cluded fundus and antrum of stomach, duodenum, jejunum, ileum, colon and 
pancreas, as indicated in figure(3.lll.1.), and a piece of muscle was taken 
from the thigh of the rat, rabbit and pig to act as controls, as one would 
expect the gastri n content of muscle to be zero. In the case of the dog and 
pig the fundic and antral mucosae were dissected free from the underlying 
muscle so that only the mucosa was used for extraction. 
The tissues were cut into small pieces, approximately 5 mm x 5 mm, and 
boiled for 20-30 minutes in a small volume of distil led deionized water, 4 to 
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6 ml, with 10% by volume of Trasylol (Aprotinin, 100 000 Kl U/10 ml) (Bayer) 
added to inactivate any proteases which may be present. As with the human 
biopsy extractions the tubes were covered with aluminium foil during boiling, 
and the supernatants obtained on centrifugation were stored frozen until assayed 
for gastrin using antisera G 1 and 2604-7. Samples containing very high levels 
of gastrin were re-assayed in several dilutions unti! they fell within the range 
of the sensitive portion of the standard curve. The tissues were lyophilised and 
weighed and then treated with a convenient volume of dilute sodium hydroxide 
for 1 hour to dissolve them, and homogenised in the same manner as the human 
tissue extracts. The gastiin content of each tissue was expressed per mg dry 
weight of tissue and per mg total protein, after correction for dilution in the 
assay and for the volumes of water and sodium hydroxide used in the extraction 
and protein estimation procedures. A table and a composite figure shOV{ing the 
1 Fundus 
2 Ant rum 
3 Duodenum 
4 Jejunum 
5 Ileum 
6 Colon 
Pancreas 
5* 6* 
Fig. (3.111.1.) Location of sampling sites along the mammalian 
gut where tissues were obtained for extraction of gastrin. 
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gastrin content of the tissues and species studied, including the human, was 
constructed. Values used for the figure were gastrin content per mg total 
protein except in the case of the rat antrum, where the gastrin content per mg 
dry weight was substituted. The gastrin extracted from these species was not 
characterised further. 
In order to study the distribution of gastrin in other vertebrate species, 
the gastrin content of serum collected from various species was measured by 
radioimmunoassay. Serum samples were received from Dr. B .Shapiro of the 
Isotope Unit, Department of Medicine, University of Cape Town, as well as 
other people mentioned in the legend to table (4 .111.2). Extracts from the 
gut were not prepared for these species, which included the rat, rabbit, 
dassie, guinea pig, fowl, frog, snake, monkey, baboon, dog, sheep, goat, 
pig, cow, springbok, stockfish, kingklip, mackerel and dogfish. The generic 
names for these animals appear in table (40111.2). The gastrin content of sera 
from these species was measured using antiserum G l, and in most cases 
2604-7 as well, and a table of the results was prepared. Figure (3 .II I .2 .) 
shows the position of the species investigated on the evolutionary tree. 
The discovery of exceptionally high"gastrini.levels in frog serum collected 
from the species Xenopus laevis prompted further investigation in this animal. 
"Gastrin"extracts were prepared by pooling tissues collected from the skin, 
stomach, intestine, brain and muscle of three animals and boiling in the same 
manne; as for the mammals studied o The frogs were sacrificed by pithing down 
the spinal cord in order to keep the brain intact. The tissues were lyophilised 
d • 1 d d th • t t I t • • d h 11 • " an we1gne an e1r o 01 pro ern content was estimate , so t. e gastrtn 
content of the tissues could be expressed per mg dry weight and per mg tota I 
protein, as described previously. No trasylol was used in the preparation of 
frog extracts. 
The nature of the gastrin-like material found in frog serum and skin 
extracts was characterised further by chromatography on a Sephadex G-25/ 
G-50 fine column, 1,5m x 1,5cm, according to the procedure described 
in section 3 II. The elution profiles thus obtained using antisera G 1 and 
2604-7 were compared with those of the gastrin standards. The effect of 
serial dilutions of frog serum and frog skin extract on the binding of 1251-
labelled gastrin to antisera G 1 and 2604-7 was examined to determine 
whether the curves of displacement were similar to that found with standard 
syn the tic human gastri n G- 17 I • 
To examine the distribution of gastrin along the gut of another vertebrate 
species, extracts of the gut of three snakes were prepared by pooling tissues 
collected from the skin, stomach, liver, intestine, brain and muscle of these 
animals and boiling as described. Tissues were lyophilised, weighed and 
estimated for protein content and the gastrin content was expressed in the 
same manner as for the mammalian extracts. The species of snake used was 
the common spotted egg eater, Dasypeltis scabra scabra. 
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Fig. (3.111.2.) Schematic representation of the evolutionary 
tree indicating the position of the toxa from which animals 
were selected for the estimation of gastrin content. 
Figure modified from Romer (1947), 11 Man and the Vertebrates 11 , 
pages 13 and 17, with permission from the University of 
Chicago Press. 
* Indicates taxa investigated. 
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3 11 l(iii) Invertebrate Tissue Extracts 
Invertebrate animals representative of four phyla were selected to investigate 
whether gastrin is present in the lower species. The sea anemone, Pseudactinia 
~-, was chosen as a representative of the Coelenterata. The Mollusca were 
represented by the mussel (Choromytilus sp .) , snail (Helix sp .) , limpet (Patella 
~o), periwinkle (Oxystele sp .) , whelk (Burnupena sp .) and chiton (Chiton sp .) • 
Crustacea were represented by the barnacle (Tetraclita sp.), and the sea urchin 
(Parechinus sp .) was selected from the phylum Echinodermata. The position of 
these species on the evolutionary tree is shown in figure (3.111.2.). 
Tissue extracts were prepared by boiling the gut, where it was possible to 
distinguish this from adjoining tissues, or alternatively the entire body contents 
except for the muscle. The tissues were chopped into small pieces and boiled 
in a minimal amount of distilled deionized water, without addition of Trasylol, 
for 20-30 minutes. The extracts were collected and stored frozen for gastrin 
radioimmunoassay with antiserum G 1 as described for human and mammalian 
tissue extracts. The gastrin content was expressed per mg dry weight of tissue 
and per mg total protein after correction for diiutions, as described previously, 
and then expressed relative to the gastrin content per mg total protein of human 
antrum, determined in section 3 lll(i), which was given the arbitrary value of 
100%0 
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Comments and Criticisms 
The extraction procedure in these studies involved boiling the biopsied 
tissues in water to extract the gastrin, and measurement of the gastrin content 
of the residual fluid after boiling and centrifugation of the solid matter. As 
shown in section 4 l(vi), approximately 77% of immunoreactive gastrin was 
recovered after boiling in water alone and 43% was recovered after boiling 
in the presence of muscle extract. Since the recovery of a known amount of 
gastrin from individual tissue extracts was not studied it must be assumed that 
the recovery probably lies somewhere betwe,en 43% and 77%. Boiling tissues 
in water is an acceptable method for extraction of gastrin; Berson and Yalow 
(1971) and Yalow and Berson (1972) described extraction of gastrin from human 
tissues obtained at post-mortem by boiling in water, followed by centrifugation 
and fractionation of the supernatant on Sephadex G-50 columns (Yalow and 
Berson, 1972). The first step in extraction and purification of hog antral 
gastrin described by Gregory and Tracy (1964) invoived boiling the antra in 
tap watero 
Control readings of gastrin measured in extracts of rat, rabbit and pig 
muscle were negligible as shown in table (4 .111.1) o The same was true in 
the case of the frog and snake extracts, although the values shown in table 
(4.111.3) are corrected for the readings obtained in muscle. 
Recoveiy of gastrin added to rat thigh muscle and treated in various ways 
was assessed in a study described in sections 3 l(vi) and 4 l(vi). 
Each gastrin estimation was made in duplicateo The gastrin content of 
human gut extracts was measured once, as was the case for the measurements 
in the invertebrate extracts. The invertebrate extracts were prepared by pooling 
two or three small animals and boiling them or their gut tissues together. In 
the case of the mammalian tissues, extracts were prepared from two batches 
of animals, measurements of gastrin content were made three times, and the 
final result is a mean of all these determinations. 
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Section IV Gastrin Kinetic Studies in the Pig 
Introduction 
Studies of the hepatic handling of gastrin under various conditions were 
performed in two groups of pigs in vivoo Group I consisted of 8 pigs in 
which basal transhepatic measurements of endogenous gastrin levels were made. 
Blood flow measurements were taken in each pig and the total gastrin mass 
entering and leaving the liver was calculated. This group acted as a base-
line for subsequent studies (Vinik, Hickman and Grant, 1978). 
Group 11 comprised 7 pigs which were given a stepwise infusion of 
synthetic human gastrin G-17 I in three increasing doses, infused for one 
hour at each dose level. This allowed investigation of the response of the 
liver to increasing doses of exogenous gastrin, and the half-life of synthetic 
human heptadecapeptide gastrin in the circulation was determined from the 
fol I off in levels from the plateau reached after three hours of infusion. 
The metabolic clearance rate and space of distribution of gastrin in the pig 
were calculated, and the daily production rate of gastrin, as an indication 
of endogenous gastrin secretion was calculated from the metabolic clearance 
rate estimations. Blood flow measurements were not made in these pigs, and 
calculations were based on the measurements made for the baseline pigs in 
Group I. 
The nature of the circulating gastrin during the second and third hour of 
infusion of synthetic human heptadecapeptide gastrin was studied chromato-
graphically to see if circulation in vivo produced changes in the type of 
gastrin which was infused (Vinik, Hickman et a I., 1978). 
Group I Pigs Basal Transhepatic Measurements of Endogenous Gastrin 
(i) Preparation of Animals 
Eight young pigs of either sex, weighing 18-22 kg, were anaesthetised 
after a 24-hour starvation period. Anaesthesia was induced with sodium 
pentothal (total dose 2-3 mg/kg} injected into an ear vein, and was main-
tained with oxygen and nitrous oxide given via an endotracheal tube. 
Under clean but not sterile conditions the animals were prepared for blood 
flow measurement by the insertion of catheters at the sites shown in figure 
(3. IV .1 .) • Catheters were inserted into the right carotid artery for pressure 
measurement and arterial sampling, and into the right internal jugular vein 
for the administration of fluids and Bromsulphthalein (BSP) or lndocyanine 
Green (ICG). A catheter was introduced into the right external jugular 
vein and was manipulated into an hepatic vein, usually the left, by intra-
abdominal palpation. Hepatic venous blood samples were drawn from this 
catheter. Two catheters were inserted into the portal vein for proximal and 
distal portal sampling. The proximal portal sampling site was in the hilum 
of the I iver 2-3 cm beyond the junction of the last tributary, and the distal 
catheter was positioned 4-6 cm into the superior mesenteric vein, against 
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the flow to ensure mixing of para-amino hippuric acid (PAH) with blood of 
intestinal and splenic origin, as this catheter was also used for the infusion of 
PAH. 
(ii) Blood Flow Measurements 
Total hepatic blood flow was measured by the clearance of BSP initially, 
and then ICG when no further supplies of BSP could be obtained. Portal 
flow was measured using PAH, according to the method described by Hickman, 
Saunders and Terblanche (1974). Blood samples were analysed for BSP 
HEPATIC VENOUS 
SAMPLE tH. V. l INFUSION OF BSP OR ICG 
!ARTERIAL SAMPLE IH.A.ljl 
: : INT. JUG. VEIN 
CAROTID ARTERY--::lf1H---EXT. JUG. VEIN 
BILE DUCT--,-::/ 
0 
~ 
-SPLENIC 
-. -Sup. Mesenteric 
Fig. (3.IV.1.) Sites of catheters fortranshepatic sampling 
and infusion of dye for blood flow measurements in the pig. 
IP. P. I I 
(Bradley, lnglefinger, Bradley and Curry, 1945), ICG (Winkler and Tygstrup, 
1960), and PAH (Bratton and Marshall, 1939; Harvey and Brothers, 1962). 
There was no interference by any dye with the measurements of the other. 
Further details of the blood flow measurement technique can be found in the 
appendix. 
(iii) Sampling Procedure 
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On completion of the operative preparation the priming dose of dye was 
given and a constant infusion of dye in saline was commenced. The priming 
dose of BSP was 300 mg and infusion was continued at the rate of 5 mg/min o 
The priming dose of ICG was 2,5 mg, followed by infusion at 0, 156 mg/min. 
Three arterial samples were taken at 10-minute intervals to ensure 
stabilization of dye levels. Thereafter, infusion continued for a further 30 
minutes and simultaneous transhepati c samples were taken from the carotid 
arterial {representative of hepatic arterial blood, HA), proximal portal (PP), 
distal portal (PD), and hepatic venous (HY) catheters at 10-minute intervals. 
At the end of the experiment the animals were sacrificed and the liver was 
weighed after draining for a standard period of 15 minutes (Hickman, Saunders 
and Terblanche, 1970). 
(iv) Gastrin Measurements 
The gastrin content of the serum samples was measured by radioimmuno-
assay as described in section I of this chapter, using antiserum G 1, which 
detects non-sulphated forms of gastri n but reacts poorly with sulphated hepta-
decapeptide gastrin. To ensure that pig serum did not interfere in the assay 
a curve of displacement of antibody-bound 1251-gastrin was prepared using 
serial dilutions of a sample containing high endogenous levels of gastrin. 
This curve was parallel with that of the synthetic human heptadecapeptide 
gastrin standard, confirming that serum gastrin measurements could be made 
in the pig without any problems. With each set of samples from a particular 
pig, control tubes in which antiserum had been omitted were included in the 
assay to monitor non-specific binding of labelled gastrin by factors in the 
serum, which would give artificially low results. Where this value exceeded 
5%, appropriate corrections were made. It was found to be unnecessary to 
substitute 11 gastrin-free 11 pig serum for the horse serum used in the separation 
procedure, since both gave similar results. 
(v) Calculations 
The rate of liver blood flow was calculated either as flow per whole 
liver or as flow per gram of liver tissueo The hepatic venous flow was 
assumed to equal the sum of the hepatic portal and hepatic arterial flow, 
or total flow e The gastrin concentration reaching the liver (AHg) was 
calculated as per equation (1): 
AH ( '/, I) = (Pf X PPg) + (HAf X HAg) •9 P9; m Tf ( 1 ) 
where Pf = absolute portal flow (ml/min) 
PPg = proximal portal gastrin concentration (pg/ml) 
HAf = hepatic arterial flow (ml/min) 
HAg = hepatic arterial gastrin concentration (pg/ml) 
Tf = total liver blood flow (ml/min). 
Total gastrin reaching the liver (TA Hg), or the afferent hepatic gastrin mass, 
was caiculated thus: 
TAHg (pg/min) = AHg x Tf (2) 
Total gastrin leaving the livei (TEHg), or the efferent hepatic gastrin mass, 
was calculated by equation (3): 
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TEHG {pg/min) = HVg x Tf (3) 
where HVg = hepatic venous gastrin concentration (pg/ml). 
The net hepatic balance of gastrin was determined as the difference between 
the afferent and efferent hepatic gastrin mass. 
Portal gastrin secretion (PGs), or portal gastrin mass, referring to the con-
tribution of gastrin by the stomach, duodenum and proximal small intestine, 
was calculated by equation (4): 
PGs (pg/min) = (PPg - PDg) x Pf (4) 
where PDg = distal portal gastrin concentration (pg/ml), and PPg and Pf 
are as defined above o 
Each measurement was the mean of three estimations made at 10-minute 
intervals. Significant differences in mean basal values were tested for by 
the paired Student's 11 t 11-test. 
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Group II Pigs : Stepwise Infusion of Exogenous Gastrin at Three Dose Levels 
(i) Preparation of Animals 
Ten pigs weighing between 29 and 32 kg were fasted for 24 hours and 
anaesthetised with sodium pentothal and nitrous oxide in the same manner as 
the pigs in group I. Catheters were inserted under clean but not sterile 
conditions at the same sites as before, viz. hepatic venous, hepatic arterial, 
and proximal and distal portal sampling sites. Blood flow measurements were 
not made in this group, and for calculations involving flow measurements the 
values determined for the pigs in group I were used. 
(ii) Experimental Procedure 
Continuous infusions of synthetic human gastrin G-17 I (I.C.I.) were 
commenced after a basal period of l hour, during which time blood samples 
were taken at 10-minute intervals. The mean of the 6 measurements made 
in this period was taken as the basal gastrin level in each pig. Synthetic 
human heptadecapeptide gastrin was infused at three increasing dose levels 
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for one hour each, via the internal jugular vein, using a Harvard Syringe 
Pump. A dose of 0,25 AJgjkg/hr was administered for the first hour, 0,5 
AJg/kg/hr for the second hour and 1 A.Jg/kg/hr for the third hour. Assuming 
that each pig weighed approximately 30 kg, the total doses made up in 14 ml 
saline each, allowing 2 ml for dead space volume, and infused at a rate of 
0,2 ml/minute, were 7,5 AJg, 15 A.Jg and 30 AJg respectively. Blood samples 
were drawn via the hepatic venous, hepatic arterial end proximal portal 
catheters at 15-minute intervals during the infusions, and at 5, l O, 20 and 
30 minutes after the infusion of the highest gastrin dose. Gastrin measure-
ments made during this decay period were used to calculate the half-life of 
synthetic human G-17 ! gastrin in the porcine circulation after a plateau level 
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had been reached. The protocol for this experiment is outlined in figure 
(3olV.2.). 
All the beakers used for making up dilutions of gastrin in this study were 
siliconised with Dow Corning Antifoam-A spray (Dow Corning Corporation, 
Midland, Michigan, U.S.A.) to minimize loss of hormone by adsorption to 
glass. The infusion solutions contained 0,25% by volume of a gelatin solution 
{Haemaccel, Hoechst}, which was added to prevent loss of gastrin through 
adsorption to syringes and tubes used for infusion. 
(iii) Gastrin Measurements 
Gastrin content of the samples was measured by radioimmunoassay with 
G 1 antiserum, which detects chiefly non-sulphated forms of gastrin. Cor-
rections were made for non-specific binding in the assay where necessary. 
(iv) Cal cu lotions 
Using the mean blood flow measurements obtained for the pigs in group I, 
the afferent and efferent hepatic mass of gastrin at each dose level was 
calculated. The blood flow values used were: hepatic venous or total flow 
580,3 ml/min, hepatic arterial flow 147,3 ml/min, and portal flow 433,0 
ml/min. Equations used in the calculations were the same as those used for 
the pigs in group I, equations (1), (2) and (3). Gastrin concentration 
values used were the mean of the three most stable readings out of four 
• 
taken during each hour of infusion. The net hepatic balance of gastrin at 
each dose level was determined as the difference between the mass of gastrin 
entering and leaving the liver, and the afferent and efferent gastrin masses 
at each dose level were compared to see if hepatic uptake of gastrin occurred 
at any dose level of infused gastrin. 
i Decay 
f col~ gastrin 
l I I I 
I 
\ 
\ 
\ 
\ Basal gastrin 
\ 
\ sampling period 
' 
' 
' ~ -Basal gastrin level 
0 30 60 120 180 240 270 
Sampling Times (minutes) 
Fig. (3.IV.2.) Outline of protocol for stepwise infusion of 
synthetic human gastrin G-17 I into group II pigs. 
(See section 3 IV in text.) 
E 
..... 
Ol 
a. 
u 
C 300 0 
u 
220 C 
·-
... 
iii 
150 0 0 
80 
0 
174 
Plateau serum gastrin levels were calculated as the mean of the closest 
three out of four serum gastrin measurements made during the last hour of 
infusion at the highest dose level, in arterial, portal and venous circulations. 
For calculation of the half-life (T !) of the infused gastrin in the circulation, 
basal or endogenous gastrin levels were subtracted from all measurements during 
and after infusion, and post-infusion gastrin values were calculated as a per-
centage of the plateau value after converting the values from picograms/ml 
to picomoles/litre. The natural log of the percent plateau gastrin concen-
tration versus time was computed to yield the elimination constant, K , from 
e 
which the T ! was calculated in the arterial, portal and venous circulations 
according to the formula: 
T ! _ 0,693 
- K 
e 
(5) 
The space (or volume} of distribution of the heptadecapeptide gastrin as a 
fraction of body weight in arterial, portal and venous circulations was cal-
culated for each pig from the equation derived by Goldstein, using the 
plateau principle (Goldstein, Aronow and Kalman, 1974): 
log V = log D - log G - log K 
e 
(6) 
where V = volume of distribution as a fraction of body weight (litresfag) 
D = dose of gastrin infused (p mol/kg-min} 
G = actual plateau blood level of gastrin above zero in arterial, 
portal or venous circulation (p mol/1 itre) 
K = elimination constant. e 
Serum gastrin levels measured as pg/ml were converted to p mot/litre by 
dividing by 2,2 assuming an approximate molecular weight for gastrin of 
2 200. The dose of gastrin infused used for these calculations was 1 .ug/kg/hr, 
or 7,575 p mol/kg-min. 
The space of distribution of gastrin in each pig was determined using the 
individual weights of each pig, and the mean ~ S .E.M. were calculated. 
The metabolic clearance rate (M .C.R.) of infused synthetic human 
heptadecapeptide gastrin in the arterial, portal and venous circulations 
was calculated using equation (7): 
M .C.R. D = G 
where M.C.R. = metabolic clearance rate (litres/kg-min) 
D = dose of gastrin infused (p mol/kg-min) 
(7) 
G = plateau gastrin concentration above basal (p mol/litre}. 
The clearance rate was calculated for each dose of gastrin infused, and 
expressed as the average of the values obtained for all three doses, and as 
the average of values obtained for the two highest dose levels. The values 
for gastrin concentrations used here were the levels above basal, in contrast 
to the absolute gastrin levels used in the calculation of the space of distri-
bution. 
The daily production of gastrin was determined using the metabolic 
clearance rate. The M.C.R. was converted to lities/day per whole animal, 
using the individual weights of each pig. The clearance rate thus obtained 
for the arterial circulation was multiplied by the mean basal serum gastrin 
level (pg/ml} to obtain the total mass of gastrin which is cleared by the 
body, and thus presumably produced by the body per day, allowing for dis-
crepancies due to recirculation. The daily production of gastrin, or the 
daily blood production rate (B.P .R.) was calculated for each pig according 
to the formula: 
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B.P.R. (ng/day) = M.C.R. (I/day) x Basal gastrin cone. (ng/1) 
and the mean and standard error were determined. 
(v) Chromatography 
Serum samples from portal and venous sites, taken via the portal and 
hepatic venous catheters in pig 500, and samples from the portal, venous 
and arterial sites in pig 521 were selected for chromatography, as very high 
serum gastrin levels were found in these pigs during the second and third 
hours of gastrin infusion. Sample volumes of 1-2 ml were chromatographed 
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on a Sephadex G-25/G-50 column of dimensions 1,5m x 1,5cm, as described 
in section II of this chapter. Internal standards of the molecular weight 
markers blue dextran and vitamin B1 2 were run with each elution and the 
column was calibrated with standard preparations of natural human gastrin 
G-17 I and G-34 I. The gastrin content of the eluted fractions was measured 
by radioimmunoassay using antiserum G 1, and the elution profile for each 
sample was plotted as for previous chromatographic procedures. 
Comparison of the elution profiles obtained here with those obtained 
using the standard preparations of natural human gastrin G-17 I and G-34 I 
gave an indication of whether the infused synthetic human heptadecapeptide 
gastrin was changed to larger or smaller forms after circulation in the pig 
for 2-3 hours. Pre- and post-hepatic samples were studied to see whether 
the gastrin type was altered by passage through the liver. 
(vi) Statistical Analysis 
Significant differences between the afferent and efferent hepatic gas tr in 
mass in the baseline pigs and following gastrin infusions were tested for by 
the paired 11 t 11-test ond the Wilcoxon Signed Rank test for non-parametric data. 
Comments and Criticisms 
An attempt was made to measure blood flow in the prgs belonging to 
group I using a cuff surrounding a b I ood vessel, connected to an electro-
magnati c flow meter. Due to technical problems {Hickman, Crosier, Smith, 
lmmelman and Terblanche, 1975) this method had to be abandoned, and 
blood flow measurements were made by infusion of dye, as described. 
The study was commenced with 8 pigs in group I, and satisfactory 
blood flow measurements were obtained with all 8 pigs. The mean flow 
rates and fractional flow rates obtained for these pigs were used in cal cu-
lotions of afferent and efferent hepatic gastrin mass for these pigs and 
group II pigs. However, gastrin measurements at one or two sites in pig 
number 15/4 gave such bizarre results that the values completely distorted 
the mean values calculated for hepatic balance of gastrin in these 8 pigs, 
and this pig was therefore excluded from the study. 
Since the weights of the pigs in groups I and II differed to such an 
extent, extrapolation of blood flow measurements made in group I pigs, 
which weighed 18-22 kg, for calculations of hepatic gastrin balance in 
group II pigs, which weighed approximataly 30 kg each, is a source of 
error which must be borne in mind when considering these results. However, 
since blood flow measurements were made relative to the weight of the pigs, 
the discrepancy should be small. 
The concentrations of gastrin used to make up the doses for infusion into 
group II pigs were measured by dilution from a stock solution of 1 mg/ml. 
It is unfortunate that the concentration was not determined spectrophoto-
metrically, using the molar extinction coefficient for gastrin of 12 261 
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(Walsh, Debes et al., 1974), as this would have given a more accurate 
representation, but this was overlooked at the time. 
178 
The infusion study was commenced on ten pigs. Due to bleeding problems 
three pigs had to be discarded before the study was completed. The 3-hour 
infusion was completed on 7 pigs, and the gastrin measurements made in these 
animals were used to ca I cu late the response of the liver to increasing doses 
of gastrin. One pig, number 447, developed bleeding problems at the end 
of the third hour of infusion, so the gastrin measurements for this pig made 
during the period of fall-off from the plateau I evel dropped to below the 
mean basal arterial level within 5 minutes after stopping the infusion. For 
this reason gastrin values in this pig during the decay period were discarded. 
All calculations involving measurements in the decay period were made for 
only 6 pigs. These calculations included Ke and T ! values, and determi-
nation of the space of distribution. Hence some results in this part of the 
study are for a total of 7 and some are for a total of 6 pigs. 
3 V(i) 
Section V Studies with Rat Liver 
Metabolism of Synthetic Human Heptadecapeptide Gastrin by the 
Isolated Perfused Rat Liver. 
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Synthetic human heptadecapeptide gastrin G-17 I was perfused cyclically 
through the isolated rat liver in situ in a plasma-free medium at physiologic 
and supraphysiologic levels, to investigate the role of the rat liver in the 
metabolism of SHG-17 I. Liver donors were Wistar rats of either sex, aged 
six weeks, weighing 85-100 grams, and al lowed water but no food for 16-18 
hours before perfusion. The rats were reared on a 20% casein diet fully 
supplemented with minerals and vitamins from the age of three weeks 
(Stead and Brock, 1972) • 
Perfusions were performed according to the recycling method of Hems, 
Ross, Berry and Krebs (1966), which involved isolating the liver from the 
rest of the animal, whilst leaving it in situ. The liver was perfused through 
the portal vein with a semi-synthetic medium under a hydrostatic pressure of 
about 20 cm of water, maintained by a reservoir of adjustable height. The 
medium I eaving the I iver through the vena cava dropped into a reservoir or 
collecting vessel, from where it was pumped to the top of a multibulb oxy-
genator, and then returned via the liver to the reservoir. The apparatus 
was housed in a perspex cabinet and was heated by a thermostatically con-
trol led fan heater. The perfusion system is diagrammatized in figure 
(3.V.(i).l). The perfusion procedure is described in detail in the appendix. 
Perfusions with gastrin were carried out by addition of synthetic human 
gastrin G-171 (!QC.IQ) to the reservoir after a 30-minute equilibration 
period. A baseline sample of 0,8 ml was collected 1 minute before the 
addition of gastrin to ascertain whether there was any endogenous gastrin 
-Fig. (3.V.(i).1.) 
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in the system which had been leeched out of the liver during this period. 
Gastrin was added in one of two doses on separate occasions to separate 
liver preparations, so that three perfusions with a supraphysiological dose 
of gastrin and three perfusions with physiological gastrin levels were per-
formed: 
(a) One hundred and sixty ng synthetic human gastrin G-17 I in 0,8 ml 
Krebs-Ringer Bicarbonate (KRB) buffer containing 0,25% crystalline human 
serum albumen (HSA) (Behringwerke) was added to give a perfusate gastrin 
concentration at equilibration, 2! minutes after addition, of approximately 
1 nM, which is supraphysiological. Samples were withdrawn from the circuit 
tubing leaving the reservoir after addition of g:1strin, centrifuged immediately 
and the supernatants were stored deep frozen at -20°C until assayed for 
gastrin using antiserum G 1, as described in section 3 l(iii). Sample volumes 
of 2,5 ml were withdrawn at 2!, 30 and 60 minutes for chromatography, 
to investigate whether gastrin was altered in molecular size by passage through 
the liver. Sample volumes of 0,6 ml were collected at 10, 20 and 45 
minutes, so that the total volume removed from the system amounted to 
9,3 ml or 15% of the total perfusate volume. No corrections were made 
for these volume losses. Samples were chromatographed on a Sephadex G-25/ 
G-50 fine column of dimensions 1,5 cm x 1,5 m as described in section 3 II, 
and the gastrin content of the eluted fractions was measured by radi oimmuno-
assay. The chromatographic profile was plotted as gcstrin concentration 
against the percent elution volume between blue dextran and vitamin B12 
as these markers were run as internal standards in the fractionation. An 
estimate of the recovery of gastrin added to the Sephadex column was made. 
(b) To follow the fate of more physiological gastrin levels approximately 
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8 ng gastrin in 0,8 ml KRB buffer containing 0,25% HSA was added to the 
system to give gastrin concentrations after equilibration of approximately 
0,05 nM. Samples were withdrawn from the circuit tubing leaving the 
reservoir at the same times and in the same volumes as for the high dose 
perfusion, viz. 0,8 ml at -1 minute, 0,6 ml at 10, 20 and 45 minutes and 
2,5 ml at 2t 30 and 60 minutes after addition of gastrin, so that the 
volume loss due to sampling was identical in both systems. The samples 
were centrifuged immediately and the supernatants stored at -20°C until 
assayed for gastrin using antiserum GI, which detects non-sulphated forms 
of gastrin but reacts poorly with sulphated heptadecapeptide gastrin. 
Gastrin levels measured at each sampling time during the perfusions 
were compared with the gastr in level at 2J minutes after addition of 
gastrin by analysis of variance. 
One control perfusion, in which the liver was omitted from the system, 
was performed at each dose level of gastrin. Perfusate samples from the 
high dose perfusion were assayed in dilutions and the values corrected 
appropriately. All standards and unknown samples were diluted in KRB 
buffer. 
In a separate series of experiments the clearance of physiological 
concentrations of rat insuiin (Lot no. R170, Novo Laboratories, Denmark) 
by the liver in the same system was investigated. The insulin was perfused 
at an equilibration concentration of approximately 1 nM, and samples of 
0,5 ml were collected from the circuit tubing leaving the reservoir at 5, 
10, 15, 20, 30, 40, 50 and 60 minutes after addition of insulin. This 
was repeated in 12 separate liver perfusion preparations. Four control 
perfusions in the absence of liver were performed. The samples were 
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centrifuged immediately after collection and the supernatant stored at -20 C 
and assayed for insulin within three weekso Insulin was measured by a 
double-antibody micro-radioimmunoassay, using the same rat insulin as was 
added to the perfusion system as standard, and 125 1-porcine insulin as tracer 
(Weinkove, Weinkove and Pimstone, 1974}. 
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3 V(ii) In Vitro Binding of Gastrin to Rat Liver Ligandin 
Ligandin is a basic protein isolated from supernates of human and rat 
liver, kidney and intestinal homogenates, which is known to bind organic 
anions, cortisol metabolites and carcinogens (Levi, Gatmaitan et al., 1969; 
Litwack, Ketterer et al., 1971; Fleischner, Mishkin et al., 1971). The 
binding of gastrin to rat liver ligandin was examined to assess the importance 
of this liver protein in relation to gastrin transport and/or inactivation. 
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A 25% homogenate of rat liver in 0,25M-sucrose/0,01 M-phosphate buffer, 
pH 7,4, was prepared as described by Kirsch, Vinik, Frith, Gordon, Grant 
and Saunders (1975). Five ml of the 100 000 xg supernate was mixed with 
l 00 mi crolitres 125 1-albumen and l 00 mi crolitres sodium bromosulphthalein 
(BSP). This mixture was chromatographed on a Sephadex G-100 column of 
dimensions l 00 cm x 2,5 cm. Elution was carried out using the same sucrose/ 
phosphate buffer in a pump-driven upward fl ow system at a flow rate of 15 ml/ 
hour. The protein concentration of the eluted fractions was estimated at 280 
nanometres (nm), using a Uni cam spectrophotometer model SP 1700, and the 
presence of BSP was monitored by reading the optical density at 580 nm. 
Radioactivity of the eluted fractions was estimated to locate the 1251-labelled 
albumen. The ligandin peak was identified by its binding with BSP and by 
immunodiffusion against rabbit anti-rat liver ligand in as described by Fleischner, 
Mishkin et al. (1971). 
Synthetic human gastrin G-171 (I.C.1.) was labelled with 1251odine 
(Radiochemical Centre Ltd., Amersham, England) to a specific activity of 
1 440 .uCi 125 todine/,,ug hormone, and purified on a small Sephadex G-10 
column of dimensions 0,9 cm x 10 cm. An aliquot containing approximately 
2 mill ion c .p .m. was mixed with 5 ml liver supernate, and chromatographed 
without delay on the Sephadex column described above. The protein 
concentration and radioactivity of the eluted fractions were monitored and 
the elution profile was plotted. 125 1-labellecl unsubstituted synthetic human 
gastrin G-17 I was also passed through the column in the absence of liver 
supernate. On another occasion Na 1251odide was mixed with 5 ml liver 
supernate and passed through the column. 
The displacement of radioactive gastrin from I igandin was achieved by 
the addition of a gross excess (100 .ug) of non-radioactive synthetic human 
gastrin G-171 to a mixture of liver supernate and 1251-gastrin before 
chromatography. In another experiment unlabelled synthetic human gastrin 
G-17 I was added to liver supernate in high concentration (15 ng) before 
chromatography, and the gastrin content of the eluted fractions was estimated 
by radioimmunoassay using antiserum G 1, which has a high affinity for 
gastrin (K=4,0 x 1010 litres/mole). 
Binding of 1251-labelled insulin and 1251-labelled glucagon to ligandin 
was investigated by mixing aliquots of each label! eel hormone with I iver 
supernate and subjecting them to the same chromatographic procedure on 
separate occasions. 
Each chromatographic procedure involving binding of 125!-gastrin, 
displacement of labelled gastrin by cold gastrin, and binding of cold 
gastrin by ligandin was repeated at least twice, and the estimations of 
recovery of radioactivity in the ligandin peak include both or all of the 
findings on these occasions. 
In the section which follows, the results of the investigations described 
will be presented. 
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CHAPTER 4 
RESULTS 
Section I Radio immunoassay 
4 l(i) Production of Antisera 
Several antisera were produced which were suitable for immunoassay. 
Antiserum G 5, obtained by this procedure, was used extensively in the 
radioimmunoassay procedures described in this thesis at a final dilution of 
1 : 35 000. Figure (4.1.1 .) shows a series of antibody binding curves 
obtained by testing the ability of another antiserum (G 9), drawn in 10 
consecutive bleeds, to bind radioactive gastrin. The dilutions shown in 
the figure refer to initial dilution of antiserum; the final dilution was 
ten times greater in each case. It can be seen that the animal became 
tolerant to the gastrin injections after approximately 6 booster injections, 
as shown by the fall off in binding of 1251-gastrin in the later bleeds. 
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4 l(ii) The Iodinated Product 
The percentage incorporation of 1251odine into the hormone was usually of 
I d f 75°' • • U "f" • • " f l 500 c• 125 iod• . /, t • tne or er o '/o, giving a spec1 1c act1v1ty o J.J , ine1 J.Jg gas rin 
when the reagents were added in the proportions described in section 3 l(ii). 
Labelled preparations used in the radioimmunoassay had"specific activities" 
ranging from 700 to l 800 J.JCi 1251odine/1Jg hormone. Greater incorporation 
of radioactive iodine was achieved when a lower"specific activity"was aimed 
for. 
The integrity of the labelled hormone as determined by charcoal adsorption 
ranged from 88% to 98%. The immunological integrity was found to vary be-
tween 74% and 95%. 
The iodination procedure described in section 3 l{ii) is not the only method 
of labelling a hormone with radioactive iodine. More delicate peptides require 
gentler treatment and in some cases the use of Chloramine- T is too harsh, so 
that one may have to resort to an iodination method utilising hydrogen peroxide 
as oxidation agent for example, as described by Mcfarlane (1956). However, 
the yield using this method is not nearly as high as that obtained with the 
Chloramine-T method, which has a yield of 80% (Aubert, 1971). Generally 
the more delicate the peptide one is trying to label, the lower the"specific 
activity"one should aim for, so that one should commence by aiming to incor-
porate approximately 200 J.JCi 1251odine/1Jg hormone. The individual doses of 
Chloromine-T and sodium metabisulphite are peculiar to the iodination of each 
hormone and often have to be determined by trial and error. 
With lube! led hormones the degree of integrity that can be obtained varies 
from hormone to hormone; for example insulin can be label led to give a prepa-
ration which is 98-99% intact, whereas gastrin does not remain as intact 
following labelling. However, it is fortunate that gastrin with an integrity of 
as low as 85% can be used successfully in the radioimmunoassay. In general, 
less intact peptides give rise to inappropriate! y elevated readings in the assay, 
and improvement of the quality of the labelled preparation may lead to a de-
crease in "apparently" measured hormone levels, as discussed by Stadil and 
Rehfeld (1973a). 
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4 l(iii) Validation of the Assay 
The results of the trial to test the adsorption of labelled gastrin to glass 
and plastic in the presence of albumen and gelatin (Haemaccel) at various 
concentrations are shown in table (4.1.1). The degree of adsorption of hormone 
to LKB cuvettes was a mere 2,2% ~ 0, 11 (S.E.M.) justifying their use in the 
assay system without additional albumen or gelatino One percent albumen was 
the most effective treatment for glass tubes, with only 4,6% ~ 0,61 (S.E.M.) 
of the labelled g:Jstrin remaining adsorbed to their surfaces. 
Figure (4.1 o2.) shows standard curves obtained for three different incubation 
times using antiserum G 1. The best curve was obtained with 24 hours' incu-
bation at 4°C, as it was the most sensitive and shONed complete displacement 
125 
of I-labelled gastrin from antibody with increasing concentrations of cold 
hormoneo 
Figures (4.1.3.), {4ol.4.) and (4.1.5.) show the mean standard curves 
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+ 95% confidence limits obtained using antisera G 1, 2604-7 and G 5. In all 
cases the standard reference preparation used was synthetic human gastrin G-17 I, 
d h 1251 h • h . G 17 I an t e tracer was -synt et1 c uman g:Jstrm - • 
Details of the gastrin radioimmunoassay with three antisera appear in table 
(4.i .2). Assays using antiserum G 5 displayed the lowest inter-assay coefficient 
of variation, which was 17,2%0 Assays involving antiserum G 1 showed the 
highest precision, with an intra-assay coefficient of variation of 4,95%0 Values 
for the index of precision ranged from 13,9% for assays utilising antiserum 
2604-7 to 28, 1 % for assays performed with antiserum G 1. The best correlation 
coefficient obtained on regression analysis of observed versus expected concen-
trations of added g:Jstrin was found for assays using antiserum G 5, with a value 
of r of O, 973 • 
The Scatchard plots derived from the mean standard curve using each anti-
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serum are shown in figure (4.1.6.). The plots are almost linear, suggesting 
homogeneity of the antibody populations. Since antisera, and not purified 
antibodies were used, the slopes of ·the graphs were expressed as the 11average 11 
affinity constants. The highest affinity antiserum was 2604-7, which showed 
the steepest slope and had an average affinity constant of 2,0 x l 011 litres/ 
mole. The affinity of antiserum G l was almost as high, with a K value of 
4,0 x 1010 litres/mole. Antiserum G 5 had the highest concentration of 
antibody binding sites (l 0,20 x l 0- l l moles/litre) and the lowest average 
affinity constant (8,3 x 109 litres/mole), which implies that it is a high 
capacity antiserum of low affinity. The concentrations of binding sites for 
-12 -12 
antisera G 1 and 2604-7 were 24,l x 10 and 10,0 x 10 moles/litreo 
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TABLE (4ol o l) 
Experiment to test the Effect of Addition of Albumen and Gelatin 
on the Adsorption of 1251-labelled Gastrin to Glass and Plastic Vessels. 
+ (Values are means - SoE.Mo n=4) 
Percentage of Total Counts remaining in Tube 
after Decanting 
Glass Tubes LKB Plastic Cuvettes 
Verona! buffer 18,4% : 1,20 2,2%: 0, 11 
Albumen 0,5% 5,8%: 0,56 l ,5% ::- 0, 15 
Albumen 1,0% 4,6% ! 0,61 1,5%: 0, 13 
Gelatin 0,25% 11,5% : 1 , 16 1,7%::- 0, 14 
Gelatin 0,5% 9,9%: 0,85 1,7%: 0, 14 
Gelatin 1,0% 10,9% : 1, 17 1,8% ~ 0, 12 
-TABLE ( 4 .1.2) 
Details of Gastrin Radioimmunoassay with Three Antisera 
Lower limit of sensitivity 
Inter-assay coefficient of 
variation 
Intra-assay coefficient of 
variation 
Index of precision 
Correlation coefficient on 
regression analysis of 
observed vs expected 
concentration of added 
gastrin 
Final dilution of antiserum 
in assay 
Average affinity constant 
derived from Scat cha rd Plot 
Concentration of 
binding sites 
Gl 
1,65 pg 
(p=0,05) 
28,9% 
(n=ll) 
4,95% 
(n=l 2) 
28, 1% 
r=0,710 
(p< 0,01) 
l :200 000 
K=4,0x101 O 
1/mol 
24, 1 xl0- 12 
mol/1 
2604-7 
0,82 pg 
(p=0,05) 
29,3% 
(n=6) 
17,7% 
(n=l 6) 
13, 9°/o 
r=0,864 
(p< 0,01) 
1: 100 000 
K=2,0x1011 
1/mol 
10 ,Ox 10- 12 
mol/1 
G5 
13,5 pg 
(p=0,05) 
l 7 ,2°/o 
(n=8) 
6,7% 
(n= 12) 
22, 1% 
r=0,973 
(p<0,01) 
1 :35 000 
9 K=8,3x10 
1/mol 
10,2xl 0- ll 
mol/1 
4 l(iv) Characteristics of Antisera and lmmunoreactivity of Gastrin Fragments 
and Gastrin-Related Peptides 
Figure (4.1 J .) shows the dose response curves obtained with dilutions of 
serum drawn from fasting and arginine-stimulated subjects, as well as those of 
various gut and gastrin-related peptides compared with synthetic human gastrin 
G-17 I, using antiserum G l. In this and the subsequent two figures the con-
centration of the peptides is expressed as femtomole equivalents, which refers 
to the amount of gastrin added to the assay in a volume of 0, l ml. The curve 
for fasted serum in dilutions was parallel to that of the SHG-17 I standard. 
The coincidence of the curves of standard synthetic G-17 I and stimulated serum 
suggests strongly that the heptadecapeptide gastrin species is produced on 
arginine stimulation. Gastrin (2-17) cross-reacted to the degree of 95% of that 
of the standard (1-17) gastrin. Porcine crystalline glucagon, highly purified 
natural porcine secretin, pentagastrin and crude CCK-PZ failed to cross-react, 
while caerulein and the (-terminal octapeptide of CCK-PZ reacted minimally. 
The ID5o values for these peptides relative to synthetic human gastrin G-17 I 
appear in table (4.1.3). 
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The cross-reaction curves obtained by testing the ability of synthetic gastrin 
fragments to reduce the binding of 125 1-labelled gastrin to antisera G 1 and G 5 
are shown in figures (4.1.8.) and (4.1.9.) and the 1050 values compared to 
that of SHG-17 I appear in table (4.1.3). Comparison of the relative ID50 
values of these peptides suggests that antiserum G l recognises chiefly the (-
terminal portion of heptadecapeptide gastrin in the region of amino acids 8 to 
17. Fragments (8-17) and (11-17) were almost equally active, whereas fragments 
which did not include the (-terminal 4 amino adds, namely (l-13), (3-13), 
(6-13) and (9-13), did not react in the system at al I. This imp I ies that anti-
serum G l requires the presence of the (-terminal tetrapeptide sequence for 
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TABLE (4.la3) 
Relative Displacement (ID50) of Antibody-Bound 
125 1-Gastrin by 
Synthetic Gastrin Fragments and Related Peptides. 
Peptide 
Caerulein (Erspamer) 
Pentagastrin (Gly- Trp-Met-Asp-Phe-NH2) 
Crude CCK-PZ 
!Q50 as a percentage of 
.!Q50 of SHG-17 I 
Gl G5 
0,033% 
0,001% 
0,001% 
Synthetic (-terminal octapeptide of CCK-PZ 0,012% 
Secretin (highly purified porcine} 0,001% 
Glucagon, crystalline porcine (Lilly) 0% 
*Synthetic gastri n peptides 
1-17 100% 100% 
1-13 0, 1% 16,9% 
3-13 0,0033% 0,0023% 
6-13 0% 0% 
9-13 0% 0% 
8-17 1,33% 1,0% 
11-17 1,29% 0,003% 
2-17 95% 
5-17 (mini-gastrin) 45,9% 0,86% 
* Synthetic gastrin peptides kindly supplied by Dr. John Morley of I .C. I a 
Pharmaceuticals, except for (1-17) which was obtained from CEA-IRE 
Sarin. 
reaction. The high degree of cross-reaction with mini-gastrin, the (5-17) 
sequence, and the almost complete cross-reaction with the (2-17) molecule as 
compared with the intact heptadecapeptide would seem to indi cote a preference 
of antiserum G 1 for the entire molecule. 
Antiserum G 5 cross-reacted to a fairly high degree (16,9% of that of the 
standard) with the sequence (1-13) and hardly at all with any other fragment. 
The very small degree of recognition for the (8-17) and (5-17) sequences seems 
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to suggest that this antiserum _reacts chiefly with the (1-5) sequence of the hepta-
decapeptide. This correlates with the lack of reaction of G 5 antiserum with 
G-34 gastrin shown in table (4.1.4), since the N-terminal pyroglutamyl residue 
of G-17 gastrin is not available for reaction with antibody in the G-34 gastrin 
sequence. 
The relative abilities of natural human gastrin G-34 I, G-17 I and G-17 II 
and of synthetic human G-17 I to displace 1251-labelled gastrin from antisera 
Gl, 2604-7 and G5 are shown in figures (4.1.10.), (4.1.11.) and (4.1.12.) 
and the corresponding ID50 values for these peptides can be found in table 
(4.1.4). The immunoreactivity of SHG-171 obtained from I.C.I. was only 46% 
and 64% of that of SHG-17 I obtained from CEA-IRE Sorin when measured using 
antisera G 1 and G 5 respectively. It may be that the preparation supplied by 
CEA-IRE Sorin is purer than that from I .C. I. As was mentioned in section 
3 l(iii) the standard reference preparation of gastrin used in al I assays for this 
thesis was obtained from CEA-IRE Sorin. 
The most surprising observation to arise from this study was the marked 
difference in immunoreoctivity of NHG-17 I and NHG-17 11 with antiserum G 1, 
to the extent that this antiserum recognised almost exclusively the non-sulphated 
type I gastrir.. In contrast antiserum 2604-7 cross-reacted strongly with both 
gastrins type I and 11, so that with these two antisera sulphated and non-sulphated 
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TABLE (4.1.4) 
Relative Displacement (ID50) of Antibody-Bound 
125 i-Gastrin by 
Various Natura I and Synthetic Human Gastrins o 
Gastrin Type 
ID50 as a percentage of m50 of SHG-17 
Gl 2604-7 GS 
SHG-17 I (CEA-IRE Sorin) 100% 100% 100% 
*NHG-34 I 14,3% 31,3% 0,72% 
*NHG-17 41,7% 61,9% 78% 
*NHG-17 II 5,2% 46,4% 61,9% 
SH G- 17 I (I. C. I • ) 46% 64% 
*Kindly supplied by Dr. M.Grossman, U.C.L.A., V.A. Hospital, 
Los Angel es. 
types of gastrin could be distinguished. NHG-34 I cross-reacted in both assay 
systems. Failure of antiserum G 5 to distinguish between sulphated and non-
sulphated gastrins is probably due to the fact that the antigenic site does not 
include the tyrosine residue in position 12 of the heptadecapeptide. 
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Another surprising finding was the complete lack of recognition of NHG-34 I 
by antiserum G 5, since earlier chromatographic data had suggested that G 5 
measured a gastrin species larger than G- 17, which had been thought to be 
G-34 gastrin (Kalk, Vinik et al., 1973). Possibly the larger gastrin species 
measured in earlier chromatographic profiles with G 5 antiserum were big gastrins 
bearing a sequence resembling the (1-13) or (1-5) sequence of the heptadeca-
peptide. The preparations of natural human gastrin 171 and II and synthetic 
human gastrin 17 I all cross-reacted to approximately the same degree with G 5 
antiserum, but at higher concentrations of gastrin standard than with antisera G 1 
and 2604-7. This movement of the displacement curve to the right with anti-
serum G 5 is an indication of the lower affinity of this antiserum. 
In view of the finding that antiserum G 1 recognised only non-sulphated 
gastrin, whereas antiserum 2604-7 recognised both sulphated and non-sulphated 
gastrins, a linear regression analysis of gastrin levels measured in the same 
samples with these two antisera was carried out. Samples used were human 
serum samples, extracts prepared by boiling biopsies collected from the gut of 
mammals, and sera collected fron, various vertebrate species, as shown in table 
(4.1.5). Regression analysis of 47 pairs of values gave a correlation coefficient 
of 0,796 (p < 0,01) wHh an equation for the straight line of y = 1 ,048x + 
104,8865. This very good coirelation suggests that the two antisera measure 
similar things. The y-intercept of 104,8865 indicates that antiserum 2604-7 
measures approximately 105 pg/ml more than does antiserum G l in the same 
sample. In the light of the cross-reacHon studies discussed, it is feasible to 
suggest that the extra peptide(s) measured by antiserum 2604-7 are the sulphated 
forms of gastrin. This material may occur consistently or inconsistently in the 
different tissue extracts and serum samoles. 
I 
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TABLE (4ol .5) 
Gastrin Levels Measured in the Same Samples with Antisera G 1 and 2604-7 
Units are pg/ml 
Human Serum Samples Mammalian Gut Extract Samples 
Gl 2604-7 Gl 2604-7 
220 510 81 172 
16 117 55 188 
13 34 59 226 
37 164 87 188 
8 35 182 717 
75 121 205 517 
49 225 792 826 
41 159 190 517 
266 195 149 340 
44 169 45 155 
114 335 86 168 
80 312 27 69 
6 30 
25 47 Vertebrate Serum Samples 
50 271 Gl 2604-7 
20 43 38 91 
140 245 95 230 
204 476 16 39 
194 256 64 67 
10 27 67 58 
17 76 87 188 
31 274 44 80 
34 55 19 44 
610 572 29 46 
191 412 51 43 
r = 0,7963 p < 0,01 
Equation for linear regression y = ] ,0480x + 104,8865 
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4 l{v) Identity of Gastrin in Biological Fluids 
Figure (4.1.13.) shows the curves of displacement of antibody-bound labelled 
gastrin obtained upon serial dilution of sera drawn from patients with hypergastrin-
aemic conditions compared with that of synthetic human gastrin G-17 I, measured 
using three antisera. Serum from Zollinger-Ellison patient A.K. gave displace-
ment curves parallel to that of the standard, using antisera G 1 and 2604-7, and 
the same result was found when serum from Zollinger-Ellison patient C.K. was 
investigated using antisera G 1 and G 5, suggesting that these sera contain 
material identical with, or similar to the gastrin standard. Displacement curves 
parallel to that of the standard were obtained on serial dilution of serum from 
patient M .B. with isolated retained antrum using antisera G 1 and 2604-7, 
providing evidence that heptadecapeptide gastri n is secreted by the portion of 
antrum remaining in this condition after incomplete gastrectomy. The elevated 
gastrin levels found in patient M. Y. with pernicious anaemia appear to be due 
to the presence of heptadecapeptide gastrin in the serum, since parallel displace-
ment curves were obtained using all three antisera. 
The curves of displacement of 1251-labelled gastrin from antisera G 1 and 
G 5 obtained by serial dilution of pig serum exhibited parallelism with that of 
standard SHG-171, as can be seen in figures (4.1.14.) and (4.1.15.). This 
confirmed that serum gastrin levels could be measured in pig serum without any 
problems. Since porcine heptodecapeptide gastrin differs from human heptadeca-
peptide gastrin only by one amino acid residue in position 5 of the heptadeca-
peptide, as shown in figure (3.1.2.), and it was found that the antigenic site 
for antiserum G 1 did not include this residue, one would not expect this anti-
serum to discriminate between porcine and human gastrin. Antiserum G 5 appears 
not to distinguish between human and porcine gastrin, which suggests that 
although the antigenic determinant for G 5 antiserum probably lies in the (1-5) 
region, substitution of the residue in position 5 does not significantly effect 
recognition of porcine gastrin by this antiserum. 
No measurements of gastrin levels could be obtained in pig bile and gastrin 
added to bi le could not be recovered in the assay. This may be due to inter-
ference by the bile salts in the assay. 
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·Fig. (4.1.13 .) The curves of displacement of antibody-
bound 125 t-S HG-17 I obtained by seria I di I uti ons of sere 
drawn from patients with Zollinger-Ellison syndrome (Z.E.), 
pernicious anaemia (P.A.) and isolated retained antrum, 
using antisera G 1, 2604-7 and G 5, compared with that 
of the synthetic human heptadecapeptide (SHG-17 I) standard. 
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4 l(vi) Recovery of Gastrin in Tissues 
The gastrin levels measured after the treatments detailed in section 
3 l(vi) are shown in table (4.106). The recovery of gastrin added to glass-
ware for the study was 93,8% and the recovery of gastrin after the other 
treatments was assessed as a percentage of this concentration, 150 pg/ml. 
Boiling led to a loss of 23,3% of immunoreactivity. No gastrin was 
detected in straight muscle extract before or after boiling, confirming that 
there were no factors in these extracts which interfered in the assay and 
produced erroneous values. The slightly higher recovery of gastrin after 
boiling muscle before addition of gastrin (48%) as opposed to direct addition 
of gastrin to muscle followed by boiling (43,3%) could indicate the presence 
of tissue enzymes which degrade gastrin, but such a small difference in 
recovery after these two treatments may be insignificant. Trasylol had no 
effect on gastrin measurement when added to muscle extract before boiling. 
Recovery of gastrin from boiled muscle with added Trasylol was 38%, which 
differs only slightly from a recovery of 43,3% for the same treatment with-
out Trasylol, suggesting that Trasylol probably had no effect on gastrin in 
muscle extracts. 
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TABLE (4.1.6) 
Recovery of Gastrin after Various Treatments, Measured with Antiserum G 1 
Each extract contained 800 pg gastrin in 1 ml made up to a final volume of 
5 ml, to give an expected concentration of 160 pg/ml. 
Gastri n measured 
(a) Gastrin in water before boiling 150 pg/ml 
(b) Gastrin in water after boiling 115 pg/ml 
(c) Muscle in water, before gastrin added undetectable 
(d) Muscle extract after gastrin added and boiled 65 pg/ml 
(e) Muscle extract after boiling before gastrin added undetectable 
(f) Muscle extract after boiling, gastrin added, boiled again 72 pg/ml 
(g) Muscle + Trasylol + gastrin before boiling 150 pg/ml 
(h) Muscle + Trasylol + gastrin after boiling 57 pg/ml 
Gastrin loss on addition to glassware 
Effect of boiling on gastrin per se 
Recovery of gastrin from boiled muscle 
Effect of inactivating muscle tissue 
enzymes by boiling before addition 
of gastrin 
Effect of Trasylol on gastrin measurement 
Effect of Trasylol on recovery of gastrin 
from boi I ed muscle 
150 
]60 X 
115 
150 X 
65 
150 X 
72 
150 X 
150 
150 X 
57 
150 X 
100 = 93,8% recovered 
100 = 76,7% recovered 
100 = 43,3% recovered 
100 = 48% recovered 
100 = 100% recovered 
100 = 38% recovered 
4 l(vii) Gastrin Levels in Serum and In Vivo Studies 
The mean basal serum gastrin level determined in 27 normal control 
subjects was 48,5 ~ 2,4 pg/ml (~ S.E.M.}, with a range from 26 to 77 
pg/ml o Figure (4 .1.16 .) shows serum gastrin levels in patients divided 
according to age, ethnic group and sex. There were no significant 
differences in the serum gastrin levels in the three different ethnic groups 
(t-test) o Serum gastrin levels in females were significantly higher than 
in males {p < 0,025, t-test). There was no obvious relationship between 
serum gastrin levels ·and advancing age, although the highest levels were 
found in the age group 51-60 years. The difference between the gastrin 
levels in this age group and in the age group 31-40 years, which were 
the lowest, was not statistically significant when tested by the t-test. 
Serum gastrin levels in various disease conditions are shown in figure 
(4.1.17 .) • The grossly elevated levels in pernicious anaemia and Zollinger-
Ellison syndrome patients are apparent, with serum gastrin concentrations 
up to ten- or a hundred-fold greater than in normal subjects in some 
instances. The~e was no significant difference between gastrin levels in 
normals and patients with hiatus hernia (H.H.}, gastric ulcer {G.U.} or 
moderate rheumatoid arthritis (R .A.). Gastrin levels in gastric carcinoma 
(gastric Ca) and duodenal ulcer (D.U.) were significantly elevated above 
the normal value (p < 0,05, t-test). 
Although the mean serum gastrin level in 11 patients with moderate 
rheumatoid arthritis was higher than that in controls and patients with mild 
rheumatoid arthritis, as shown in table (4 .I. 7), the differences were not 
significant, because one patient in this group had much higher serum gastrin 
levels than the others, producing a falsely elevated mean value. When this 
patient was excluded from the group the mean serum gastrin level in 10 
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TABLE (4.1.7) 
Serum Gastrin Levels in Rheumatoid Arthritis (pg/ml) 
X S .. E.M. n 
Moderate Rheumatoid Arthritis 112 55,4 l l 
Mi Id Rheumatoid Arthritis 81 19,5 24 
Gout 52 11,5 4 
Reiter's Syndrome 38 7,4 4 
Osteoarthritis 54 11,9 11 
patients with rheumatoid arthritis was 59 pg/ml, as indicated in figure 
(4.1.17 .) • The mean serum gastrin level in 24 patients with mild rheuma-
toid arthritis was 81 pg/ml and in the related arthritic conditions values 
were not elevated. Thus there appears to be no relation between serum 
gastrin levels and the degree of severity of rheumatoid arthritis. 
Antrectomised subjects had undetectable gastrin levels and the mean 
basal gastrin level in 6 patients who had had a truncal vagotomy and partial 
antrectomy was 26,4 _:!: 3,4 pg/ml (_:!: S.E.M.), which was significantly less 
than that in control subjects (p < 0,001), as shcmn in table (4.1.8) (Vinik, 
Kalk, Dent, Barbezat, Grant and Bank, 1975). 
Intravenous infusion of arginine into control subjects for 30 minutes 
caused a sharp early rise in serum gastrin levels to almost three times the 
basal concentration after 15 minutes. Because the peak values in some 
patients were found later than 15 minutes the mean maximum increment 
over the basal value was 389,7%. The levels returned to basal between 
45 and 60 minutes after the start of the arginine infusion, as shown in 
figure (4.1.18.) (Vinik, Kalk et al., 1975). 
There was no rise in serum gastrin concentration with orally administered 
arginine. Oral oxo produced a twofold increase in gastrin levels above the 
basal concentration in normal subjects (p < 0,05) with the peak value 
occurring at 45 minutes and a sustained plateau type of response (figure 
(4.1.18.)) (Vinik, Kalk et al., 1975). 
Intravenous arginine failed to elicit a response in antrectomised patients 
or in vagotomised and antrectomised subjects. The serum gastrin responses 
to these stimuli appear in table (4.1.8). 
19B 
lOxo Oral Arginine 
li.v. Arginine I 
- I. V. Arginine (n= 6) 
--. Oxo ( n= 6) 
•-• Oral Arginine (n=9} 
E 100 
E 
50 
30 60 
TIME lminules> 
Fig. (4.1.18.) Serum gastrin responses to intravenous arginine 
infused at a rate of 10 mg/kg/min for 30 minutes, a 30 g dose of 
oral arginine, and 4 cubes of Oxo in 150 ml warm water given 
orally. (Oxo is a commercial ox-muscle extract rich in glutamic 
acid and sulphur amino acids with a smaller proportion of hydro-
lyzed protein and yeast extract.) 
TABLE (4.1.8) 
Serum Gastrin Responses to Various Stimuli 
Basal Gastrin 
Subjects Test (pg/ml} Maximum % of Basal 
Mean 
+ 
- S.E.M. 
Controls I. V. Arginine n=6 + 48 ,3-2, 14 + 389,7-154,1 
Oral n=9 + 108 ~11 4c,d Arginine 44,3-2,8 I I 
Oral Oxo n=6 + 49,9-2,19 1 90 I 1:: 16 I t1 
Antrectomy I. V. Arginine n=3 < 1,6a ob 
Vagotomy I. V. Arginine n=6 26 42°3 4° I _ I 43,9::15,0b 
a. Basal concentration in vagotomy and antrectomy subjects is 
significantly {p<::. 0 ,001) less than that in all control groups. 
b. Significant' impairment of gastrin responses to I.V. arginine. 
c. Oral arginine causes less (p<::. 0,001) gastrin release compared 
with I.V. arginine. 
d. Oxo causes less of a rise than I. V. arginine {p< 0,05) but 
greater than oral arginine (p< 0,05). 
Figure (4.I.19.) shows the serum gastrin response of 8 pigs to eating 
creep meal. The basal serum gastrin level measured in 11 pigs was 57 : 
16 pg/ml (: S.D.) with a range of 31-118 pg/ml (Arnot, Vinik, Grant, 
Hickman, Terblanche and Louw, 1974). The postprandial serum gastrin 
measured in 8 pigs was 65 : 18 pg/ml at 30 minutes, 72 : 22 pg/ml at 
60 minutes and thereafter remained constant up to 120 minutes. Values 
quoted and shown in the figure are the mean: S.D. The 30-minute value 
did not differ significantly from the basal level, but the 60-minute and 
subsequent values were significantly increased (p < 0, 05). Basal serum 
gastrin values in pigs thus appeared to be similar to those in humans, 
although the rise in gastrin levels after eating was relatively small in pigs 
compared with that in humans, and remained elevated for a longer period o 
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Section 11 Chromatographic Characteristics of Gastrins 
4 1 l(i) Heterogeneity of Gastri n in Serum 
The chromatographic elution profile of gastrin in serum drawn from 
patient K.V., with pernicious anaemia, is shown in figure (4.11.1.). 
A small amount of a component eluting in the void volume was followed 
by two apparently paired components eluting between the albumen and 
1251 . k 
-gastri n mar ers. Another paired component eluted between the 
125 1-gastrin and Vitamin B12 markers, and this was followed by a smal I 
amount of low molecular weight material eluting in the region of the 
22 
salt volume, as indicated by the Na marker. 
200 
80 
85 i Albumen i1251-SHGI 0 0 
)( J Vit. a12 0 £D 
...... 
£D t 22Na 
Ol 90 
C 
1J 
C 
CD Patient K.V . 
... 
C 95 «, 
u ~ ... a, a.. 100 
0 50 100 150 200 
Elution Volume (ml) 
Fig. (4.11.1.) Chromatographic elution profile of immunoreactive 
gastrin measured with G 5 antiserum in serum drawn from pernicious 
anaemia patient K. V. 
I 
I 
I 
I 
I 
4 1 l(ii) Antibody Recognition of Different Gastrin Standards 
Fractionation of the natural gastrin standards was carried out using the 
molecular weight markers blue dextran and Vitamin B12 as internal standards, 
so that the elution volumes could be plotted as a percentage of the elution 
volume between these two markers. This allowed comparison of elution 
patterns obtained with natural gastrin standards with elution patterns obtained 
on chromatography of various serum samples. 
Figures (4.llo2.}, (4.11.30) and (4.11.4.) show the chromatographic 
201 
profiles obtained with the natural gastrin standards G-34 I, G-17 I and G-17 II, 
using antisera G 1, 2604-7 and G 5 respectively. The pattern obtained with 
antiserum G 1 shows that this antiserum detects the nature I G-34 I and G-17 I 
gastrin species, but fails to measure the sulphated heptadecapeptide gastri n, 
G-17 II. In contrast to this, all three species of natural gastrin tested were 
measured using antiserum 2604-7, as shown in figure (4. I I .Jo) o Antiserum G 5 
failed to detect the natural G-34 I gastrin to any noticeable extent, but 
reacted equally well with the NHG-17 I and 17 II peptides. These findings 
correlate with the poor cross-reaction of antiserum G 1 with G-17 II and of 
antiserum G 5 with G-34 I shown in section 4 l(iv)o The 125 1-gastrin marker 
coincided with the natural gastrin type I in each case, as would be expected 
since the label led preparation was prepared using synthetic human gastrin 
G-17 I. The sulphated heptadecapeptide gastrin eluted before the non-
sulphated type in each fractionation, suggesting that the presence of the 
sulphate group on Tyrosine-12 significantly alters the behaviour of the hepta-
decapeptide on Sep had ex column chromatography. 125 The fact that I-labelled 
gastrin el ures in the same position as the nature I peptide, as shown in figures 
(4.llo2.}, (4.llo3.) and (4.11.4.) suggests that the position of the labelled 
k l 25 1 t · • I · f • · · I • f h mar er -gas rrn 1n ear 1er ract1onat1ons gives a c ose representation o t e 
elution position of the natural heptadecapeptide. 
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Section 111 
4 lll(i) 
Tissue Distribution of Gastrin in Humans, Mammals and 
invertebrates, and Heterogeneity of Gastrin in Human 
Tissue Extracts 
Human Tissue Extracts 
The highest concentration of gastrin was found in the extracts prepared 
from the human antral biopsies, which had a mean gastrin content of 2 034 
202 
~ 50,76 pg/mg total protein(~ S.E.M.), or 1 420 ~ 35,45 pg/mg dry weight 
of tissue. Very high gastrin levels were also found in the duodenal cap and 
in the biopsies from the second part of the duodenum, which had gastrin con-
tents of 1 432 ~ 392,56 pg/mg total protein, and 552 ~ 78,20 (~ S.E.M.) 
pg/mg total protein respectively. These measurements were made with anti-
serum G 1, which detects almost exclusively the non-sulphated gastrin species. 
The gastrin content of all the biopsies taken from the human expressed relative 
to the total protein and per mg dry weight of tissue is shown in table (4.111.1), 
and is illustrated diagrammatically in figure (4.111.1.). 
The elution profiles following chromatography of the antral and duodenal 
extracts prepared from biopsies collected from a control subject, measured with 
antiserum G 5, are shown in figures (4.111.2.) and (4.111~3.). In both figures 
the peak preceding the albumen marker is thought to represent 11big big 11 
gastrin {Yalow and Berson, 1972) and the next peak following the albumen 
is presumed to be component I (Rehfeld, 1972; Rehfeld and Stadil, 1973a; 
Rehfeld, Stadil et al., 1974). The three paired peaks following this in both 
figures represent big gastrin (Yalow and Berson, 1970b; 1971a; Berson and 
Yalow, 1971), heptadecapeptide gastrin (Gregory, Tracy and Grossman, 1966), 
and mini-gastrin {Kalk, Vinik et al., 1973; Rehfeld, Stadil et al., 1974) 
respectively, reading in the direction of increasing elution volume (Vinik, 
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Fig. (4.111.1.) Diagrammatic representation of the gastrin 
content of tissues collected at sites along the alimentary canal 
in mammalian species, expressed as gastrin content relative 
to total protein content of the tissues; measurements made 
with antiserum G l appear on the !eft and those made with 
antiserum 2604-7 appear on the right hand side of the figure. 
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with antiserum G 5, obtained on chromatography of a boiled extract 
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Grant et al., 1975). Each peak appears to consist of two components which 
are thought to be the sulphated (type 11) and the non-sulphated (type I) 
203 
gastrin species respectively. The amount of heptadecapeptide gastrin, indicated 
as eluting between the 125 1-SHG-I and Vitamin 812 molecular weight markers, 
was much greater in the antral than in the duodenal extract, as can be seen 
from the smaller peak in this region in figure (4. 111.3 .) • This difference in 
antral and duodenal gastrin is borne out by the curves of displacement of 
125 1-labelled gastrin from antiserum G l by dilutions of the antral and duo-
denal extracts, shown in figure (4.111.4.). The antral extract gave a dis-
placement curve similar to that of the synthetic human gastrin standard G-17 I, 
whereas the duodenal extract did not, indicating that there was less hepta-
decapeptide-like material in this extract, as confirmed in the elution profile. 
125 Both extracts in dilutions produced curves of displacement of I-labelled 
gastrin from antiserum G 5 para I lei to that of the standard heptadecapeptide 
gastrin, as shown in figure (4.111.5.), due to the fact that G 5 antiserum 
measures a greater range of molecular gastrin species than does antiserum G 1. 
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4 lll(ii) Gastri n Measurements in Serum and Tissue Extracts from Vertebrates 
The gastrin content of tissues collected from the gut of the rat, rabbit, 
guinea pig, dog and pig at the sites indicated in figure (3 olll .1 o) is tabulated 
in table (4.111.1). Measurements of the gastrin content of extracts from these 
sites were made with both antisera G l and 2604-7, and in almost every in-
stance the levels measured with antiserum 2604-7 were greater than those 
measured with antiserum G l • This suggests the presence of both sulphated 
and non-sulphated gastrin in these extracts, because antiserum G 1 detects 
only non-sulphated gastrin, while antiserum 2604-7 measures both types of 
gastrin. In almost every instance the gastrin content of the tissue expressed 
per mg total protein was greater than the gastrin content per mg dry weight 
· of tissue, as would be expected. The consistency of this finding and of the 
higher gastrin levels measured with antiserum 2604-7 as opposed to measure-
ments with antiserum G l throughout the study suggests that the same material 
was being measured in the different extracts. The gastrin content of these 
tissues expressed per mg total protein, estimated by the Lowry method, is 
shown in figure (4 .II Io l .) , and quantitated diagrammatically according to the 
key shown in this figure. No readings of total protein were obtained for rat 
antral tissue, so this result was expressed as gastrin content per mg dry weight 
of tissue. 
The highest levels of gastrin were found in the antral extracts prepared 
from all the species studied with minimal amounts in the duodenum except in 
the case of the rat, where the duodenal gastrin content was 72-94% of that 
in the antrumo In the rabbit, guinea pig, dog and pig, duodenal gastrin 
comprised less than O ,5% of that in the antrum when measured with either 
antiserum. High concentrations of immunoreactive gastrin were found in the 
rat fundus, where a ratio of fundic to antral gastrin content of 40-62% was 
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found with both antisera. A considerable amount of gastrin was detected 
in the rabbit colon, 1,7-1,8% of that in the antrum, which is approximately 
a hundred times greater than the ratio of colonic to antral gastrin found in 
the other species investigated. 
Extremely high levels of gastrin were found in porcine antral mucosa, 
and higher levels of intestinal gastrin were found in the pig than in most 
of the other species examined. The canine antral mucosa was also found 
to contain large amounts of immunoreactive gastrin·. No significant levels 
of gastrin were found in pancreatic extracts of any species investigated, 
nor in the muscle extracts prepared from the rat, rabbit and pig. 
Table (4.111.2) shows the fµstrin concentrations measured in the serum 
of various mammalian and vertebrate species. In most cases the gastrin 
levels measured with antiserum 2604-7 were higher than those measured 
with antiserum G l, suggesting the presence of both gastrins type I and II 
in these sera. In three bony fish and one cartilaginous fish investigated 
(all marine in origin) no gastrin was detected in the sere using antiserum 
G l, whereas measurable levels in all four sere were found using antiserum 
2604-7. This strongly suggests that only the sulphated form of gastrin occurs 
in these species, and may be an important clue in the evolution of the 
gastrin molecule, which may have arisen for the first time in the fishes 
in the sulphated form. The serum samples from these fish were haemolysed 
when the gastrin estimations were performed, due to the manner in which 
they were collected. The fish blood was drawn from fish caught on a 
trawler and was kept on ice until the following day when it could be 
centrifuged in the laboratory. Haemolysis is known to interfere in some 
radioimmunoassay systems (Bloom, 1974) causing artificially elevated levels. 
However, since the gastrin levels in this instance were undetectable using 
Serum samples kindly donated by: 
Dr. B.Shapiro, Isotope Unit, Dept. of Medi cine, 
University .of Cape Town 
Dr. R.Millar, Dept. of Chemical Pathology, 
University of Ca?e Town 
Mr. G .Craye, De?t. of Zooiogy, 
University of Cape Town 
Mr. J. van Velden, Irvin and Johnson Trawling 
Division, Cape Town 
TABLE (4.111.2) 
Gastrin Levels in the Serum of Various Vertebrate Species 
Common Name 
Mammalia 
Baboon 
Veivet monkey 
Pig 
Cow 
Sheep 
Goat 
Springbok 
Rabbit 
Dessie 
Rat 
Guinea Pig 
Dog 
Aves 
Chicken 
Reptilia 
Snake 
Amphibia 
Clawed toad 
Ostei ch th yes 
Stockfish 
Kingklip 
Mack,:!rel 
Chondri ch th yes 
Dogfish 
Genus species 
Papio ursinus 
Cercopithecus aethiops 
Sus scrofa 
Bos taurus 
Ovis aries 
Capra hircus 
Antidorcas marsupialis 
Oryctol ugus cuniculus 
Procavia capensis 
Rattus rattus 
Cavia porcellus 
Canis fami liaris 
Gal I us gallus 
Dasypeltis scabra scabra 
Xenopus laevis 
Merlucdus capensis 
Genypterus capensis 
$comber japoni cus 
Squalus sp. 
G 1 Measurement 
{pg/ml) 
67 
64 
29 
51 
44 
19 
32 
95 
143 
38 
11 
87 
16 
25 
570-950* 
0 
0 
0 
0 
2604-7 
Measurement 
{pg/ml) 
58 
67 
46 
43 
80 
44 
230 
91 
188 
39 
61 
3 500- 10 750* 
20 
55 
51 
81 
* Range given because serum did not give a displacement curve parallel to that of 
the gastrin standard in the assay. 
antiserum G l, it is felt that the measurements made using antiserum 2604-7 
reflect genuine g::istrin levels and are not a consequence of haemolysis. 
Exceptionally high levels of"gastrin"or a gastrin-like material were 
found in the serum of the frog, Xenopus laevis, ranging from 570-950 pg/ml 
detected using antiserum G 1, and 3 500-10 750 pg/ml measured using 
2604-7 antiserum. Because the frog serum did not give a displacement 
curve parallel to that of the gastrin standard in the assay, actual"gastrin" 
levels could not be determined, hence the range of levels measured after 
correction for dilution of serum in the assay is given. 
"Gastrin"measurements made in extracts from pooled tissues collected 
from 3 frogs (Xenopus laevis) are shown in table (4.lll.3). Values were 
expressed per mg total protein and per mg dry weight of tissue, corrected 
for the readings obtained in muscle, m,easured using both antisera G 1 and 
2604-7. The highest levels of"gastrin"or a g::istrin-like material were found 
in the skin, where 3,982 and 2,653 pg/mg total protein were detected 
using antisera G l and 2604-7 respectively. The very high apparent levels 
of"gastrin"per mg total protein in the brain are thought to be a result of 
the very low protein content of brain tissue, giving rise to an erroneously 
high"gastrin"to total protein ratio. The"gastrin"levels relative to dry weight 
and total protein content of tissue measured in extracts of skin and stomach 
were greater when measured with antiserum G l than whan measured with 
antiserum 2604-7. This is in direct contrast to gastri n I eve ls measured in 
the mammalian gut extracts, where 2604-7 levels were higher than G l 
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levels in almost every case (table (4elll.1)). The 'deviation from this trend 
by frog skin and stomach extracts may point to the fact that a peptide similar 
to but not identical with gastrin was detected in these extracts. 
TABLE (4.111.3) 
Gastri n Levels in Extracts Prepared from the Frog and Snake, Expressed per 
mg Dry Weight and per mg Total Protein, Measured with Antisera G 1 and 
2604-7. All values are expressed as (pg/mg). 
Frog Snake 
Dry Total Dry Total 
Wt. Protein Wt. Protein 
Skin Gl 2,198 3,982 0 0 
2604-7 1,464 2,653 0 0 
Stomach Gl 0,348 0,608 0 0 
2604-7 0, 139 0,243 0,044 0,124 
Intestine Gl 0,075 0,097 0 0 
2604-7 0,792 1,028 0,456 1,461 
Liver Gl 0 0 
2604-7 0 0 
Brain Gl 0,397 3,310 0 0 
2604-7 0,929 7,741 0,026 0, 158 
Muscle Gl 0 0 0 0 
2604-7 0 0 0 0 
Gastrin measurements made in extracts of snake gut prepared by pooling 
tissues collected from three snakes of the genus Dasypeltis sea bra scabra, 
the common spotted egg eater, appear in table (4.111.3). Values were 
corrected for readings found in muscle. The only site where a significant 
amount of gastrin was detected in the snake, apart from the serum, was in 
on extract of intestine, and this was only detected with 2604-7 antiserum, 
suggesting the presence of a sma II amount of sulphated type gastrin. 
The elution profiles of frog serum and frog skin extract measured with 
antisero G 1 and 2604-7 ore shown in figures (4.111.6.) and (4.111.7.). 
Both profiles show a large brood peak which eluted in a molecular weight 
region smaller than that of the natural human gastrin G-171 marker, while 
the serum contained an additional large molecular weight component eluting 
in the void volume. The elution profiles obtained with the two antisera 
gave a very similar pattern in each case, and antiserum 2604-7 detected 
more material than did antiserum G 1, suggesting the presence of sulphated 
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and non-sulphated material.. A component was detected in the serum with 
antiserum 2604-7 which was not measured with antiserum G 1, ct approximately 
20% elution volume. This could be component I, or a component I-like 
peptide, as this was detected with Rehfeld 1s antiserum. He has described 
this component (Rehfeld, 1972; Rehfeld and Stadii, 1973a; Rehfeld, Stadil 
and Vikelspe, 1974) which elutes later than 11 big big 11 gastrin but before big 
gastrin. The large brood peaks representing most of the eluted material in 
both serum and skin extract could be caerulein (Anastasi, Erspamer et al., 
1967) or a related peptide of molecular weight smaller than heptadecapeptide 
gastrin. This suggestion is upheld by the demonstration of caerulein in skin 
extracts of Xenopus laevis and another species of frog by Anastasi ,B ertoccini, 
Cei, De Caro, Erspamer, lmpicciatore and Roseghini (1970). 
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Fig. (4.111.6.) Elution profile of immunoreactive material obtained on 
chromatography of frog serum, measured with antisera G 1 and 2604-7. 
Details of chromatographic procedure used for this and subsequent figure 
appear in section 3.11. in the text. 
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Fig. (4.111.7.) Elution profile of immunoreactive material obtained 
on chromatography of a boiled extract prepared from frog skin, measured 
with antisera G 1 and 2604-7. 
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The displacement curves obtained on serial dilution of frog serum and 
frog skin extract using both antisera, appear in figure (4elll.8.). Frog serum 
caused almost parallel displacement of radioactive gastrin from both antisera 
2604-7 and G 1, but although the curve of displacement in the first instance 
was almost para I lel to that of the standard, in the latter it deviated con-
siderably. Coupling these findings with the elution profile suggests that frog 
serum contains large amounts of sulphated material bearing a heptadecapeptide 
gastrin-like sequence, occurring in a large and a small molecular weight form. 
Frog skin extract appeared to cause para! lei displacement of 1251-label led 
gastrin from both antisera, and at approximately ten-fold greater dilutions 
than the serum. This does not necessarily mean that there is more "gastrin" 
in the frog skin compared with the serum, because the "gastrin" content of 
the serum and the skin was not quantitated. Antiserum 2604-7 reacted more 
strongly with the skin extract material, shifting the curve to the left, but the 
curve had the same shape as that of the standard. This greater sensitivity 
may explain why 2604-7 detected more high molecular weight material than 
did G 1 in the chromatographic profile. Frog skin extract appeared to con-
tain only one component of gastrin-like material eluting in a region with 
molecular weight comparable to that of caerulein, occurring in both sulphated 
end non-sulphated forms. 
Fig. (4.111.8.) The curves of displacement of antibody-
bound 125 1-SHG-17 I obtained by serial dilutions of frog 
serum and skin extract using antisera G l and 2604-7, 
compared with that of the synthetic human heptadeca-
peptide (SHG-17 I) standard. 
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4 I ll(iii) Gastrin Measurements in Lower Species 
Gastrin levels detected in extracts from the animals representative of 
the phyla Coelenterata, Mollusca, Crustacea and Echinodermata were 
tabulated as gastrin content per mg dry weight of tissue and per mg total 
protein, and appear in table (4 .111.4). Gastrin levels per mg total protein 
were expressed as a percentage of the gastrin content per mg total protein 
of human antrum, which was 2 034 pg/mg protein. The levels obtained 
ranged from 0,007% in the sea urchin up to 0,03% in the limpet gut, and 
the control measurements in muscle ranged from 0,001 % in limpet muscle 
to 0,01% in whelk muscle. Since the background gastrin measurement in 
whelk muscle was greater than some of the values measured in the animals 
or gut tissues themselves, the gastrin content of these tissues is probably 
negligibleo There was no obvious trend of higher gastrin content in tissues 
of invertebrates higher up the evolutionary scale. 
209 
TA
BL
E 
(4
.11
1.4
) 
G
as
tr
in
 L
ev
el
s 
in
 I
nv
er
te
br
at
e 
G
ut
 E
xt
ra
ct
s 
M
ea
su
re
d 
w
ith
 G
 1
 A
nt
is
er
um
 
G
as
tr
in
 C
on
e.
 
G
as
tr
in
 C
on
te
nt
 
G
as
tri
 n 
C
on
te
nt
 
G
as
tr
i n
 
C
on
te
nt
 
in
 E
xt
ra
ct
 
pe
r 
m
g 
dr
y 
w
t.
 
pe
r 
m
g 
to
ta
l 
pe
r 
m
g 
pr
ot
ei
n 
Ph
yl
um
 
A
ni
m
al
 
pr
ot
ei
n 
re
la
tiv
e 
to
 
(p
g/
ml
) 
(p
g/m
g)
 
{p
g/m
g) 
hu
m
an
 a
n
tr
um
 
C
oe
le
nt
er
at
a 
Se
a 
A
ne
m
on
e 
Ps
eu
da
ct
in
ia
 s
p.
 
11 
0,
05
0 
0,
09
7 
0,
00
48
%
 
M
ol
lu
sc
a 
M
us
se
l 
Ch
or
om
yt
i I
 us
 
sp
. 
16
 
0,
10
2 
0,
 16
 7
 
0,
00
82
%
 
Sn
ai
l 
H
el
ix
 s
p.
 
31
 
0,
08
8 
0,
34
8 
0,
01
71
%
 
Li
m
pe
t 
Pa
te
lla
 s
p.
 
50
 
0,
37
0 
0,
68
7 
0,
03
38
%
 
Pe
ri
w
in
kl
e 
O
xy
st
el
e 
s
p.
 
40
 
0,
26
0 
0,
55
 9
 
0,
02
75
%
 
VV
he
~k
 
B
ur
nu
pe
na
 s
p.
 
42
 
0,
38
1 
0,
57
9 
0,
02
84
%
 
Ch
i t
on
 
C
hi
to
n 
sp
. 
36
 
0,
13
7 
0,
26
3 
0,
01
29
%
 
C
ru
st
ac
ea
 
B
ar
na
cl
e 
Te
tr
ac
lit
a 
sp
. 
15
 
0,
04
2 
0,
58
0 
0,
02
85
%
 
E c
hi
 no
d e
rm
a 
ta
 
Se
a 
U
rc
hi
n 
Pa
 r
ec
hi
 nu
s 
sp
. 
13
 
0,
07
5 
0,
 14
4 
0,
00
71
%
 
Co
nt
ro
l 
Li
m
pe
t 
m
u
sc
le
 
2 
0,
01
6 
0,
03
0 
0,
00
15
%
 
M
ea
su
re
m
en
ts
 
Pe
ri
w
in
kl
e 
m
u
sc
le
 
5 
0,
08
3 
0,
09
6 
0,
00
47
%
 
W
he
lk
 m
u
sc
le
 
12
 
0,
16
3 
0,
22
6 
0,
01
11
%
 
Ea
ch
 g
as
tri
n 
le
ve
l 
is 
th
e 
a
v
e
ra
ge
 o
f 
2 
e
st
im
at
io
ns
. 
G
as
tr
in
 c
o
n
te
nt
 o
f 
hu
m
an
 a
n
tr
um
 =
 
2 
03
4 
pg
/m
g 
pr
ot
ei
n.
 
210 
Section IV Gastrin Kinetics in the Pig 
Blood flow measurements obtained in the 8 pigs in group I are shown 
in table (4.IV.1). The mean~ S 0 E.M. values for blood flow were: portal 
432 ~ 35,6 ml/min, hepatic arterial 147,3 ~ 34,4 ml/min and total flow 
580,3 ~ 24,0 ml/min. Since each of these values is the mean of 8 separate 
estimations, the sum of the mean portal and arterial blooo flow measurements 
is not exactiy the same as the mean total flow rate estimation. Values for 
fractional flow per gram liver weight also appear in table (4.IV.1), from 
which it is apparent that total blood flow was not dependent upon liver mass. 
Table (4. IV .2) shows individual gastrin measurements made at various sampling 
sites in 7 pigs belonging to group I. Values for the sites A5, PD, PP and 
HV are a mean of three estimations made at 10-minute intervals. Arterial 
serum gastrin levels were remarkably constant throughout the study, with 
mean values for the different sampling times ranging from 71,0 to 78,6 pg/ml. 
Gastrin levels at the proximal portal site were significantly higher than those 
at the distal portal site {p<0,001); hepatic venous gastrin levels were similar 
to proximal portal levels, whereas arterial gastrin concentrations were signifi-
cantly lower (p<0,001). 
The afferent and efferent hepatic mass and the net hepatic balance of 
endogenous gastrin, determined as the difference between these parameters 
for each pig, appear in table (4.,IV.3a). Five pigs showed a positive balance 
and two pigs had a negative hepatic balance of gastrin, as shown in figure 
{4. IV .1 .) , although the difference between the mass of gastrin entering and 
leaving the liver in the group of 7 pigs was not significant ( 11t 11-test). Table 
(4. IV .3b) shO"Ns the afferent and efferent hepatic gastrin mass corrected for 
the individual weights of the liver in each pig, which did not change these 
results. 
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Fig. (4.IV.1.) Measurement of endogenous gastrin mass 
(concentration (pg/ml) x blood flow (ml/min)) entering and 
leaving the liver. A positive balance indicates net hepatic 
uptake of gastrin. Numbers refer to pig numbers which be-
long to group I. (See section 3.IV. in text.) 
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The portal contribution of gastrin was determined as the difference in 
gastrin levels measured at the proximal and distal portal sampling sites and 
converted to portal gastrin mass using the measurement of portal flow. The 
mean portal contribution of gastrin in 7 pigs was 33,9: 7,6 pg/ml or 
13 154: 2 289 pg/min(: S.E.M.), as shown in table (4.IV.4). The 
mean daily secretion rate of gastrin from the portal site was 18,9 AJg, 
with a range from 6 ,69 to 30, 98 AJg/day. 
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Table (4.IV.5) shows the actual gastrin levels and the levels above basal 
measured in each of the group II pigs during the three-hour stepwise infusion 
of synthetic human heptadecapeptide gastrin I. The mean basal arterial levels 
of serum gostrin in these 7 pigs ranged from 19 to 81 pg/ml. The total mass 
of gastrin entering and leaving the liver, and the net hepatic balance of 
gastrin during each hour of infusion for each pig is shown in table (4.IV.6). 
These results are shown diagrammatically in figure (4. IV .2.). Using the 
paired 11 t 11-test no significant difference was found between the afferent and 
efferent gastrin mass at any dose level, a fact which is borne out by the 
linear relationship between afferent and efferent hepatic gastrin mass at each 
dose level, with the slope of the line approximating 1, as shown in figure 
(4.IV.3.). Significant differences were found between the afferent gastrin 
mass at the first and second, and second and third dose levels of gastrin, 
and the same for the efferent gastrin masses at each dose level, using the 
paired "t"-test. The p values for these tests are shown in table (4.IV.7) 
and in the legend to figure (4.IV.2.). 
Table {4.IV.8) shows the gastrin levels measured in the arterial, portal 
and venous circulations in each of 6 pigs during the 30-minute decay period 
after stopping the gastrin infusion. The elimination constants and half-life 
values calculated for each pig in the arterial, portal and venous circulation 
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TABLE (4.IV.4) 
Portal Gastrin Contribution in Group I Pigs 
Animal PP - PD Porta I Gastri n Mass 
(pg/ml) (pg/min) 
14/4 48 17 280 
16/4 26 12 194 
18/4 14 4 648 
20/4 44 21 516 
21/4 19 9 937 
23/4 68 18 224 
25/4 18 8 280 
X 33,9 13 154 
S .E.M. 7,6 2 289 
The difference between PP and PD gastrin concentration is signifi cxmt, 
p < 0,005. 
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TABLE (4.IV.7). 
Mean Gastrin Mass Entering and Leaving Liver in Pigs in the Basal 
State (Group I) and Pigs Given Gastrin Infusion (Group II)* 
Basal 
0 ,25 A.Jg/kg/min 
0,5 A.Jg/kg/min 
1 ,0 A.Jg/kg/min 
(a} VS (b}, {c} 
(c} VS (e) 
(e} VS {g} 
X 
S.E.M. 
n 
X 
S.E.M. 
n 
X 
S .E.M. 
n 
X 
S .E.M. 
n 
VS (d}, (e} 
all p<0,01 
Gastri n Mass 
Entering Liver 
49 069 (a) 
4 092 
7 
45 667 (c) 
5 630 
7 
85 405 (e) 
5 662 
7 
185 223 (g} 
28 878 
7 
VS (f), {g) VS 
{d} VS (f) (paired 11 t 11-test} 
( f) vs (h) 
* Units are picograms/minute. 
(h) 
Gastrin Mass 
Leaving Liver 
55 298 (b) 
7 911 
7 
42 693 {d} 
5 008 
7 
78 672 (f) 
6 702 
7 
156 598 (h) 
23 895 
7 
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over 10 minutes and over 30 minutes appear in table (4 .IV .9). Half-life 
values for heptadecapeptide gastrin calculated during the first 10 minutes 
cf the decay period in the arterial, portal and venous circulations respec-
tively were 3, 19; 4,23; and 4,32 minutes. Half-life values calculated 
over the first 30 minutes of the decay period v1ere 6,51; 7,98; and 7,39 
minutes for the arterial, portal and venous circulations respectively. The 
longer half-life calculated over 30 minutes was due to recirculation of 
gastrin, as shown by the marked levelling of the decay graph after 10 
minutes. This is exemplified by the graph of decay of infused gastrin in 
the arterial circulation constructed using the mean gastrin concentrations in 
6 pigs, shown in figure (4.IV .4.). The longer half-life found in the portal 
and venous circulations may be due to the endogenous gastrin produced at 
the portal site. 
The mean + SoE.M. space of distribution of heptadecapeptide gastrin I 
in the arterial circulation was 6,401 ~ 2,095 litres, in the portal circulation 
it was 13,677 ~ 1,976 litres, and in the venous circulation it was 16,614 + 
4,958 litres. The individual values in 6 pigs appear in table (4olV .10). 
The space of distribution of 6,401 I itres in the arterial circulation amounts 
to 21,6% of the total body weight. 
The metabolic clearance rate (MoC.R.) of infused heptadecapeptide 
gastrin was calculated at each dose level, and expressed as the average of 
all three infusion doses, as well as the average of the two highest infusion 
doseso The mean~ S.E.M. for the metabolic clearance rate in the arterial, 
portal and venous circulations, calculated as the average of 3 doses was 
212 
2,014 ~ 0,233; 3,232 + 0,440; and 3,170 + 0,470 litres/minute respectively. 
- -
Expressed relative to body weight these values were 67,8 ml/kg/min, 108,8 
ml/kg/min and 106,7 ml/kg/min respectively. The corresponding values 
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Fig. (4.IV.4.) The disappearance of gastrin from the arterial 
circulation during the 30-minute period after stopping the gastrin 
infusion; the graph is drawn from the mean values obtained in 
6 pigs. 
TABLE (4.IV.9) 
Elimination Constants (K ) and Half Life Values (T!) of Heetadecaeeptide 
e 
Gastrin in Arterial, Porta! end Venous Circulations of 6 Pigs, calculated 
during the first 10 minutes and during the first 30 minutes of the decal 
pericd. 
Arterial Circulaiion 
Cver 10 minutes Over 30 minutes 
Pig Ke T ! (mins ,) Ke T ! (mins.) 
452 0,2275 3,05 0,0834 8,31 
466 0,1213 5 ,71 0,0607 11,42 
500 0,2063 3,36 0,1282 5,41 
501 0,3870 1,79 0, 1472 4,71 
494 0,2226 3, 11 0, 1796 3,86 
521 0,3262 2, 12 0, 1298 5,34 
X 0,2485 3, 19 0,1215 6,51 
S .E.M. 0,0384 0,563 0,0176 1,1574 
n 6 6 6 6 
Portal Circulation 
452 0, 1902 3,64 0,0629 11 ,01 
466 0, 1309 5,29 0,0621 11, 17 
500 0, 1417 4,89 0,0993 6,98 
501 0,1861 3,72 0,1132 6, 12 
494 0, 1643 4,22 0, 1943 3,57 
521 0, 1908 3,63 o,ono 9,00 
X 0, 1674 4,23 0, 1015 7,98 
S.E.M. 0,0107 0,2903 0,0203 1,215 
n 6 6 6 6 
Venous Circulation 
452 0,2127 3,26 0,1693 4,09 
466 0,0787 8,81 0,0486 14,26 
500 
501 O, 1907 3,63 0,1008 6,88 
494 0,2130 3,25 O, 1572 4,41 
521 0,2597 2,67 0,0951 7,29 
X 0, 1910 4,32 0, 1142 7,39 
S.E.M. 0,0302 1,132 0,0221 1,834 
n 5 5 5 5 
TABLE (4.IV.10) 
Space of Distribution of Heptadecapeptide Gastrin in Arterial, Portal and 
Venous Circulations of 6 Pigs, calculated during the first 10 minutes of 
Decay Period. Units are I itres o 
Pig Weight (kg) 
452 30 
466 31 
500 32 
501 28 
494 29 
521 28 
X 29,7 
S.Eotv\. 0,7 
n 6 
Space of Distribution, V (I itres) 
Arterial 
l 0,464 
14,722 
3,146 
1,994 
5,597 
2,484 
6,401 
2,095 
6 
Portal 
21,543 
17,078 
8,326 
13, 199 
11,098 
10,819 
13,677 
1,976 
6 
Venous 
22,383 
33,344 
11,651 
7,743 
7,949 
16,614 
4,958 
5 
cal cu lated as the average of the two highest doses were l ,685 :!:_ 0 ,280; 
2,663 ::t 0,364; and 2,777 ::t 0,401 litres/minute respectively. The individual 
values of M.C.R. for 7 pigs are shown in table (4.IV.11). 
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Table (4.JV.12) shows the daily production of gastrin in the arterial cir-
culation for each pig as calculated from the metabolic clearance rate. The 
mean daily production of gastrin in 7 pigs was found to be between 113,9 + 
40,3 and 125,9 ::t 32,0 (::!:. S.E.M.) micrograms/day. Since only approximately 
20 J.Jg gastrin was produced at the portal site per day in the case of the pigs 
in group I it would appear that gastrin is produced at an additional site or 
sites in the body to account for a daily blood production rate of gastrin of 
approximately 120 A.Jg. 
The chromatographic elution profiles of arterial, portal and venous samples 
collected at various times during infusion of gastrin into pigs 500 and 521 are 
shown in figures (4.IV.5.), (4.IV.6.) and (4.IV.7.). In the portal and 
venous samples from both pigs 500 and 521 it appeared that smaller gastrin 
species as well as the heptadecapeptide form were present, whereas the elution 
profile of the arterial sample collected from pig 521 150 minutes after commence-
ment of the gastrin infusion suggested the presence of an additional higher 
molecular weight gastrin species, eluting in the region of the G-34 marker. 
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Section V Studies with Rat Liver 
4 V(i) Metabolism of Synthetic Human Heptadecapeptide Gastrin by the 
Isolated Perfused Rat Liver. 
The flow rate during the perfusion was usually of the order of 10 ml/min 
with a range of between 8 and 12 ml/min in different perfusions. Liver 
weight varied between 3 and 3,5 grams, giving a flow rate of approximately 
3 ml/min/g. Bile production during the perfusion ranged from 200 to 400 
µf/hr. The residual volume in the system at the end of the perfusion was 
approximately 53 ml. 
Although the high dose of gastrin added to the perfusion system was 
diluted to give 200 ng/ml, the actual gastrin concentrations detected in 
the assay after correction for dilution ranged from 85 to 236 ng/ml, giving 
a mean recovery of gastrin added to the system of 73,9% with a range of 
42,5 to 118%. In the case of the low dose perfusion recovery of added 
gastrin ranged from 32 to 67,4%, with a mean of 49 ,7%. 
Irrespective of the dose of gastrin added to the perfusion system the 
immunoreactive gastrin levels showed no statistically significant change for 
up to 60 minutes, as determined by analysis of variance. As can be seen 
in figure (4. V .(i) .1.) insulin disappeared rapidly from the perfusate, in sharp 
contrast to gastrin, indicating the role of the liver in clearing insulin from 
the blood. In the control perfusions without the liver the levels of both 
hormones did not change significantly. The fluctuation of gastrin levels 
observed during the high dose perfusions both in the presence and absence 
of liver may be due to some gastrin becoming adsorbed to surfaces in the 
perfusion apparatus and then dislodged by the mechanica I action of the per-
fusion. The actual gastrin concentrations recorded in these experiments are 
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shown in tables (4.V.(i).l) and (4.V.(i).2). There was no detectable gastrin 
in the samples taken 1 minute before addition of gastrin to the system. 
The chromatographic elution profiles measured with antiserum G 1 obtained 
with samples collected at 2!, 30 and 60 minutes after addition of the high 
dose of gastrin appear in figure (4. V .(i) .2 .) o For the duration of the 
experiment gastrin remained as a single well-defined peak which corresponds 
with the elution volume of natural human heptadecapeptide gastrin type I. 
It is quite evident that no conversion to larger or smaller gastrin species 
occurred. The identical chromatographic profile was obtained when the 
procedure was repeated with samples collected during another perfusion. 
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The recovery on the column of gastrin added was 75,8% for the 2! minute 
sample, 61,S°/o for the 30 minute sample and 44,2% for the 60 minute sample. 
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4 V(ii) In Vitro Binding of Gastrin to Rat Liver Ligandin 
Figure (4.V.(ii).1.) shows the elution profile of rat liver supernate, BSP, 
125 
and I-albumen. The O. D •280 nm profile shows three major protein peaks 
in the liver supernate, the middle one being known as the Y-peak. The 
Y-peak contains liver ligandin and its identity was confirmed by the binding 
of BSP to this fraction, as shown by the coincidence of the two peaks in the 
elution profile. lmmunodiffusion studies against rabbit anti-rat liver ligandin 
confirmed the presence of ligandin in this peak (Fleischner, Mishkin et al., 
1971). 
Figure (4.V.(ii).2.) shows the elution profile obtained when 125 1-gastrin 
was added to the liver supernate and chromatographed. Approximately 80% 
of the radioactively-labelled gastrin was eluted in the peak containing 
ligandin (Kirsch, Vinik et al., 1975). This peak is clearly distinct from 
that obtained on chromatography of labelled gastrin alone, which eluted at 
approximately 3 times the void volume, and from 125 1-gastrin bound non-
specifically to larger proteins, as shown by the small peaks preceding the 
main gastrin peak. The elution profile obtained when Na 125 todide was 
eluted with liver supernate showed some binding of radioactivity to the 
proteins in the large early peak, but none eluted in the region of the 
ligandin peak, confirming that it was actually the g:istrin and not the 
125 1odine label that was bound by the ligandin. 
Addition of excess unlabelled gastrin to liver supernate treated with 
1251-gastrin caused displacement of approximately half the labelled hormone 
from the ligandin peak, giving a recovery in this peak of less than 40% of 
the radioactivity applied. Measurement of gastrin content in the eluted 
fractions obtained on chromatography of liver supernate mixed with 15 ng 
cold gastrin produced a gastrin peak coinciding with the ligandin peak, 
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as shown in fig. (4.V.(ii).3.) (Kirsch, Vinik et ala, 1975). The fact that 
it was possible to measure gastrin bound to I igandin by radioimmunoassay 
suggests that gastrin was bound to ligandin at a site other than the antigenic 
site on the heptadecapeptide molecule which is recognised by antiserum G 1. 
Since the antigenic determinant for antiserum G 1 lies in the (8-17) region 
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of the heptadecapeptide molecule (Section 4 l(iv)), it is probable that ligand in 
binds to the N-terminal (1-8) region of heptadecapeptide gastrin. 
Figure ( 4o V o(ii) .4.) shows the chromatographic profiles obtained when 
1 25 1 • 1 • d 1 25 1 I dd d 1 • t d d -insu in an -g ucagon were a e to 1ver superna e an posse 
through the column at separate times. There was no evidence of binding of 
either of these hormones to ligandin. The small early peaks probably repre-
sent non-specific attachment of these labelled hormones to the larger proteins. 
In summary, these studies show that rat liver ligandin binds radioactively 
labelled and non-labelled gastrin in vitro, the binding is to the gastrin itself 
and not to the 125 todine label, bound radioactive gastrin may be displaced 
by an excess of cold gastrin, and gastrin bound to rat I iver ligandin may be 
measured by radioimmunoassay. This binding is specific for gastrin and was 
not observed with the other hormones tested in the same way, viz. insulin 
and glucagon. 
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CHAPTER 5 
DISCUSSION 
Rodi oimmunoossay 
There are several aspects of the radioimmunoossay which need to be 
discussed. These include the antisera, the iodinated hormone, validation 
of the assay and measurement of gastrin in biological fluids, which will 
be discussed in the sequence mentioned. 
The Antisera 
There does not appear to be one uniform immunization procedure that 
is suitable for all antigens and all species in which antibody production is 
attempted. Heptadecapeptide gastrin, being of small molecular size, is not 
very antigenic and must of necessity be linked to a larger carrier molecule, 
such as the haemocyanin used in this study, prior to injection. The coupled 
antigen was injected in an emulsion with Freund's complete adjuvant on 
each occasion via the subcutaneous route. Subcutaneous injections result 
in the formation of an emulsion depot at the site of injection with slow 
release of the antigen over a prolonged period, providing prolonged anti-
genic stimulation. Although it hos been suggested that the subcutaneous 
route of injection should not be used for emulsions with Freund's complete 
adjuvant due to abscess formation (:Heir, 1973), it was our experience that 
with careful treatment of the animals this regime led to the production of 
good antisera. 
Raising antisero by immunizing laboratory animals is really a hit-and-
miss affair and it is purely a matter of chance if an antiserum of sufficient 
titre and affinity for use in an immunoassay is obtained. It is necessary to 
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immunize several animals at a time in the hope that at least one wil I 
produce a suitable antiserum. This is upheld by the fact that Rehfeld, 
Stadil et al o (i972) obtained antibodies to gcstrin in 23 animals out of 
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a total of I 13 immunized, and only three of these antisera had sufficiently 
high affinity to be used for measurement of circulating gastrin concentrations. 
The antiserum obtained with each bleed from the same animal may vary 
in titre, affinity and capacity, which means that each bleed should be 
treated individually and characterised with regard to these parameters. 
The titre of an antiserum is a quantitative indication of the amount of 
antigen it can bind; it is determined as the final dilution of antiserum 
which binds 50% of the maximum of a constant dose of radioactive tracer 
hormone. The affinity refers to the avidity with which the antibody binds 
the antigen and is shown by the slope of the antibody-dilution curve or 
the curve of displacement of 125 1-labelled gastrin produced by increasing 
doses of unlabelled gastrin. The capacity of the antiserum is described by 
the concentration of binding sites, expressed in moles per litre, and is de-
noted by the percent binding of labelled hormone at a given dilution of 
antiserum o Given the optimum concentrations of labelled hormone and 
antiserum, the theoretical maximum binding obtainable would be 100%; 
however, such a situation is never realised due to steric factors relating 
to the three-dimensional conformational arrangement of the antibody and 
antigen, and to subtle changes induced in the antigen by the label ling 
process. The maximum binding obtained in the case of antiserum G 5 at 
1: 10 dilution was 63% and in the case of the third bleed of antiserum G 9 
this value was 66% at 1 :10 dilution. 
The variation in titre, affinity and capacity between different bleeds 
was demonstrated in the case of antiserum G 9 in figure (4.1.1.). The 
increase in titre, capacity and affinity from the first to the second bleed 
is apparent. The fall-off in binding of 1251-labelled gastrin, accompanied 
by a decrease in titre and affinity in the sixth and subsequent bleeds showed 
that the animal had become tolerant to the gastrin injections and was of no 
further use for antibody production. 
The average affinity constants of antisera G 1, 2604-7 and G 5 were 
determined using the corresponding Scotchard plots as described in sections 
3 !(iii) and 4 !(iii). As shown in table (4.1.2), antiserum 2604-7 had the 
highest value of K, the affinity constant, of 2,0 x 1011 litres/mole, 
followed by antiserum G 1, with a K value of 4,0 x 1010 litres/mole. 
The affinity constant of antiserum 2604-7 in our assay system was close to 
the values for this parameter determined by Rehfeld, Stadil et al. (1972) 
in the case of the third, fourth and fifth bleeds from this rabbit, which 
11 11 • ranged between 1,79 x 10 and 6,67 x 10 litres/mole. Both antisera 
2604-7 and G 1 were of sufficient affinity to enable measurement of basal 
levels of circulating gastrin as low as 8,2 and 16,5 pg/ml respectively. 
Berson and Yalow (1959) obtained affinity constants for their antisera 
in the serum of insulin-treated human diabetic subjects in the range of 
8 10 1/mol, which were used for detecting nanogram quantities of insulin 
in plasma. In the case of gastrin, the circulating levels are 1 000 fold 
lower; hence an antiserum with approximately a thousand times greater 
affinity than the insulin-binding antibodies of Berson and Yalow (1959) is 
required for sensitive measurement of basal values. Antisera 2604-7 and 
G 1 complied with these requirements. 
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Antiserum G 5 was found to be of low affinity, confirming that it was 
not entirely suitable for measurement of actual circulating gastrin levels. 
Hormone measurements with low affinity antisera such as G 5 lead to spuriously 
elevated values, a phenomenon which was encountered with the much higher 
serum gastrin values determined using antiserum G 5 in comparison with the 
values obtained using antisera Gland 2604-7. As shown in table (4.1.2), 
antiserum G 5 produces a much less sensitive radioimmunoossay than do the other 
two antisera and in fact it was the antiserum with the lowest titre as well. 
In view of these differences, antiserum G 5 was not used for measurement of 
gastrin concentrations in serum but was reserved for specificity studies investi-
gating its cross-reaction with gastrin peptide fragments and related peptides. 
The three antisera used in these studies, G l, 2604-7 and G 5, were 
characterised with regard to their specificity for gastrin by extensive cross-
reaction studies of these antisera with various peptides. lmmunoreactivity 
studies using peptide fragments corresponding to portions of the heptadeca-
peptide gastrin molecule led to localisation of the antigenic site recognised 
by antiserum G l as lying in the (8-17) region, although a marked preference 
for the entire molecule was noted, whereas antiserum G 5 was specific for 
the (l-5) sequence of the heptadecapeptide. 
Characterisation of antiserum G l with regard to its cross-reaction with 
other gut and gastrin-related peptides revealed minimal recognition of caerulein 
and the synthetic octapeptide of CCK-PZ, although at concentrations several 
orders of magnitude higher than the range of the assay. Failure of this anti-
serum to react with pentagastrin or CCK-PZ, coupled with the demonstration 
by Rehfeld, Stadil et al. (1972) that antiserum 2604 cross-reacted minimally 
with CCK-PZ and not at all with pentagastrin, meant that both antisera G 1 
and 2604-7 could be used for measurement of immunoreactive gastrin in 
serum with the knowledge that any interference due to these related pep-
tides was excluded. The cross-reaction of antiserum G 5 with these 
related peptides was not tested, which is an additional reason why this 
antiserum was not suitable for serum gastrin measurementso 
Studies comparing the immunoreactivity of the natural gastrin prepara-
tions with that of synthetic human heptadecapeptide gastrin I revealed that 
w ith all three antisera synthetic human G-17 I was more reactive than 
natura I human G-17 Io This may have been due to the fact that the 
natural preparations were not quite as pure as the synthetic oneso The 
same study revealed the specificity of G 1 antiserum for the non-sulphated 
heptadecapeptide gastrin species and the failure of this antiserum to recog-
nise the sulphated heptadecapeptide, in contrast to the recognition of both 
sulphated and non-s.ulphated gastrin species by antiserum 2604-7. These 
cross-reaction studies were confirmed by the chromatographic studies using 
Sephadex G-25/G-50. The elution profiles obtained on gel filtration of 
NHG-34 I, NHG-17 I and NHG-17 II using antiserum 2604-7 revealed 
three peaks, one corresponding to each peptide chromatographed, whereas 
the profile measured with antiserum G 1 comprised only two peaks since the 
NHG- 17 11 peak was not detected. 
An antiserum capable of distinguishing between the presence or absence 
of a sulphate group on the tyrosine residue of gastrin has been described 
previously. Hansky, Soveny et alo (1973) found that serum gastrin levels 
measured with their antiserum which was specific for both gastrins type I 
and II were significantly higher than levels measured using their antiserum 
that recognised only non-5ufphated gastrin. Walsh, Trout et al. (1974) have 
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also described an antiserum, i 292, which distinguishes between sulphated 
and non-sulphated G-17. 
The fact that an antiserum such as G 1 can discriminate between the 
presence or absence of a sulphate group on the tyrosine ring of a peptide 
gives some indication of how sensitive and specific the recognition of the 
antigenic site by an antibody must be. According to McGuigan (1968a) 
and McGuigan and Herbst (1975), the antibody-combining site on a peptide 
probably consists of a portion of the peptide backbone comprising approxi-
mately six amino acid residues. The localisation of the antibody-combining 
site of G 5 antibody to the N-terminal (1-5) sequence of the heptadeca-
peptide complies with this suggestion. The antigenic region recognised by 
antiserum G 1 was found to lie between residues 8 and 17; since it recog-
nises the tyrosine in position 12 it follows that the antigenic site comprises 
a sequence which includes this residue. 
Returning to the studies of cross-reaction of the natura I gastrin peptides 
in the assay system, it was found that NHG-34 I was not recognised as 
strongly as NHG-171 by either antisera G 1 or 2604-7, as shown in figures 
(4.1.lOo) and (4ol.1L) and table (4.1.4). It appeared then that antiserum 
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G l was specific for non-sulphated heptadecapeptide gastrin and it recognised 
non-sulphated big gastrin to a lesser degree. Antiserum 2604-7 reacted with 
both sulphated and non-sulphated heptadecapeptide gastrin and almost as 
strongly with non-sulphated big gastrin. This agrees with the report by 
Stadil and Rehfeld (1973a) that antiserum 2604 does not distinguish between 
the different serum gastrin components or between the different components 
and synthetic human gastrin. 
With regard to antiserum G 5, a similar correlation of cross-reaction 
studies with the chromatographic data was found. The immunoreactivity 
studies showed failure of this antiserum to recognise NHG-34 I (figure 
(4.lo12.) end table (4ol.4)) and this was borne out by the elution profile 
obtained with this antiserum fol lowing chromatography of the three natural 
gastrin peptides (figure (4.11.4.) ). Only two major peaks of immune-
reactivity were found, corresponding to the elution positions of natural 
G- 17 I o nd G- 17 11. 
Comparison of the specificity of our ontisera with those in the 
literature suggests similarities between antiserum G 5 and antiserum 1295 
described by Dockray (1975) and Walsh, Trout et al. (1974). Both appear 
to recognise the amino-terminal portion of heptadecapeptide gastrin, do not 
distinguish between sulphated and non-sulphated G-17, and do not detect 
the natural G-34 peptide. 
Likewise, there is a similarity between the specificities of antiserum 
G 1 and antiserum L 6 described by Dockray and Taylor (1976), although 
not as striking as in the above instance. Both G 1 and L 6 are specific 
for heptadecapeptide gastrin, although G 1 recognises only non-sulphated 
G-17 whereas L 6 recognises both G-17 I and II. Although antiserum G 1 
recognises G-17 I to a greater extent than G-34 I, it does show cross-
reaction with big gastrin, whereas L6 is absolutely specific for G-17. 
Knowledge of the specificity of antisera permits manipulations such as 
subtraction of measurements of G-17, obtained using antiserum L 6, from 
"total II gastrin, estimated with antiserum 1296, to give an indirect esti mo-
tion of big gastrin levels {Dockray and Taylor, 1976) o Such estimations 
are the closest approximation to true measurement of the different gastrin 
forms that one can hope to achieve, short of chromatographic separation 
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of the gastrin components on a Sep had ex column prior to measurement with 
antisera of known specificity. However, specific assays for these fragments 
are required for absolute quantitation of these fragments. 
The two basic requirements for the establishment of a sensitive radio-
immunoassay, capable of measuring basal circulating levels of a hormone 
are, firstly, an antiserum of high affinity, as has been mentioned, and, 
secondly, a labelled hormone preparation of high "specific activity". 
The Iodinated Hormone 
A tracer of high "specific activity" provides sufficient discharges per 
second to be detectable on a scintillation spectrometer with sufficient 
accuracy so that the content of hormone is lower than the levels one 
desires to measure in the assay, since the rodioimmunoassay is basically 
competitive.. This condition was satisfied in the assays performed for this 
study, in which case a discharge rate of 10 000 to 20 000 disintegrations 
per minute gave a count rate of 5 000 to 10 000 c .p .m. for 5 pi cograms 
of gastrin, assuming a 54% efficiency of counting. It was ideal to count 
10 000 counts for each sample since this incurs a 1 % error cf counting. 
Being a relatively stable molecule, it was not difficult to iodinate 
gastrin to a fairly high 11specifi c activity", so that preparations with 
"specific activities" ranging from 700 to 1 800 JJCi 125 todine per }Jg 
hormone were routinely prepared.. The preparations with higher "specific 
activities" suffered from the disadvantage of being less intact, as deter-
mined by charcoal adsorption of intact labelled peptide. This "specific 
activity" was considerably higher than that used in radioimmunoassays 
described by other groups, as outlined in table (2.111.1). 
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Labelled preparations of high specific activity consist of a mixture of 
mono-iodinated and di-iodinated gastrins, from which it is possible to purify 
mono-iodinated 1251-gastrin using AE-cellulose anion exchange chromato-
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graphy as described by Dockray, Walsh and Grossman (1976). This separation 
of mono- and di-iodinated gastrins was not perfonned routinely fer the 
f h h f "od" d 1251 . purposes o t is study. T e "specific activity 11 o mono-1 mate -gastn n 
is between 900 and l 000 µCijµg according to the reports of Walsh (1974) 
and Ganguli and Hunter (1971), which suggests that preparations in this 
study with a 11specific activity 11 of l 500 µCi/µg consisted of approximately 
equal amounts of mono- and di-iodinated gastrin, since there is only one 
tyrosine residue in the heptadecapeptide gastrin molecule. 
Four methods are generally available for testing the biochemical integrity 
of peptide hormones following label ling with radioactive iodineo These 
include: (i) chromatoelectrophoresis, (ii) trichloroacetic acid precipitation 
of the labelled peptide hormone, (iii) adsorption of the tracer with charcoal, 
and (iv) immunoprecipitation. For the purposes of this study methods (iii) 
and (iv) were found to be adequate for assessment of the biochemical and 
immunological integrity respectively, as described in section 3 l(ii). The 
technique of chromatoelectrophoresis on paper strips was found to be un-
suitable for separation of intact and broken-down labelled gastrin, due to 
the paradoxical reversed behaviour of gastrin on paper strips. This pheno-
menon was also noted by Yalow and Berson (1970a) and is attributed to the 
highly acidic nature of the gastrin molecule. 
A recurrent problem concerning preparations of iodinated hormones is 
whether the label led product possesses biological activity, since this may 
be abolished during the iodination process in some instances. Although the 
biological activity of the labelled gastrin preparations used in this study 
• • d h d • r b" d" f 125• • "•h was not investigate , t e emonstrat1on or 111 1ng o ,-gastnn, w:r 
a "specific activity" of 1 440 µCi/JJg, to the liver cytosol protein, ligan-
din (sections 3 V(ii) and 4 V(ii)) (Kirsch, Vinik et al., 1975) provides 
indirect evidence for the bio!cgical integrity of this iabelled preparation. 
The difficulty in preparing a biologically active preparation of 125 1-
heptadecapeptide gastrin of high specific activity stems from the fact that 
during the iodination procedure with chloramine-T the methionine residue 
in position 15 becomes oxidized to the sulphoxide. Since methionine 15 
is situated in the biologically active (-terminal tetrapeptide amide sequence 
(Tracy and Gregory, 1964), any change in this residue is likely to destroy 
the biological activity of the molecule. To circumvent this problem, pre-
parations of 15-leucine gastrin have been synthesised (Wunsch) and used for 
· od · · · h 1 251 od • d · b d b D k W I h I ( 1976) 1 1nat1on wit ine, as ·escn e y oc ray, a s et a • • 
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Dockray, Walsh et al. (1976) compared the biological and immuno-
chemical potency of mono- and di-iodinated natural human heptadecapeptide 
gastrin I and synthetic human 15-leucine gastrin which were purified by 
Sephadex G-10 chromatography, followed by gradient elution on AE cellulose. 
The 1251-15-leucine G-17 I preparations were shown to be 50% more potent 
than the 125 1-G-17 I preparations in stimulation of acid secretion in dogs 
with gastric fistulae, although the immunochemi cal potency of the former 
was only 40% of that of G-17 I. However, there are several objections 
to this study, the most important being the dose of labelled gastrin which 
was used to produce the observed acid secretion e The dose was far in excess 
of the physiological range, and the measurements were made by bioassay, 
which has a sensitivity of approximately 15 ng (Smith, Lawrence et al., 
1970). This is a million-fold greater than the dose of pentagastrin in the 
range of 5 femtograrns/ml which has been shown to stimulate a biological 
response in the parietal eel I, using the cytochemical bioassay (Loveridge, 
Bloom et al., 1974). 
Preparations of 125 1-gastrin have been used to demonstrate binding to 
receptors, as an indication of biological activity, in a couple of instances, 
such as in the study of Del Mazo and McGuigan (1976). Such studies of 
necessity involve label led preparations with extremely high 11specific activi-
ties", because a very smal I proportion of the total radioactivity is bound. 
As mentioned earlier, we have observed a decrease in integrity of the 
tracer with increased 11specific activity". 
Another group has resorted to the use of tritiated gastrin of high 
"specific activity" to demonstrate gastrin binding to receptors (Lewin, 
Soumarmon et al., 1976; Soumarmon, Cheret et al., 1977). No studies 
have yet been reported in which the binding of 1251-15-leucine gastrin to 
receptors was studied; such an investigation may prove extremely useful 
in the field of gastrin-receptor interaction studies. 
It is thus evident that the problem of obtaining labelled gastrin prepa-
rations of high "specific activity" which are biologically intact is not yet 
entirely resolved. 
Having discussed the antiserum and tracer used in the radioimmunoassay, 
the question of validation of the assay will now be dealt with. 
Validation of the Assay 
With two high affinity antisera and a high "specific activity" tracer, 
the assay sensitivity obtained using antisera G 1 and 2604-7 was 16,5 
pg/ml and 8 ,2 pg/ml respectively. This compares favourably with other 
reported gastrin radioimmunoossays. The lowest detectable gastrin 
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concentration which differed significantly from zero was of the order of 
5 pg/ml in many cases (Hansky and Cain, 1969; Yalow and Berson, 
1970a; Schrumpf and Sand, 1972; Feurle, Ketterer et al., 1972), while 
Stadil and Rehfeld (1971) obtained an assay sensitivity of 2 pg/ml. 
By including internal standards in every a:;say the week-to-week assay 
variation could be monitored. The inter-assay coefficient of variation was 
high for assays involving all three antisera, ranging from 17,2% to 29,3%. 
Since this parameter is high in all cases it is likely that the variation is 
due to a factor common to assays involving all three antisera; variations 
in the quality of the commercially prepared 125 1-gastrin used in these 
assays is the probable explanation. 
The intra-assay coefficient of variation, an indication of the precision 
of the assay, was high only in the case of assays involving antiserum 
2604-7, in which case a value of 17 ,7% was obtained. Such variation 
could be attributed to pipetting errors or possibly the nature of the assay 
diluent buffer, but since these were common to assays involving all three 
antisera and yet the variation occurred in only one instance, this points 
to the fact that the variation may involve the antiserum. Perhaps the · 
incubation period of 72-96 hours used for assays involving this antiserum 
was not long enough for the antibody-antigen reaction to reach equilibrium, 
in which case conditions in the assay would be unstable and could account 
for variation between samples in the same assay. However it was noted 
that Stadil and Rehfeld (1973a) used an incubation period of 48 hours with 
0 
antiserum 2604 at 5 C. Since this group did not specify the bleed of this 
antiserum used in this study it may be that these differences can be attri-
buted to differences between bleeds from the same animal. Alternatively 
it may be that we have not optimized the 2604-7 assay. 
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The variation in the standard curve produced by different incubation 
times and temperatures was illustrated in the case of antiserum G 1 as 
shown in figure (4.1.2.). Such variations may occur on a smaller scale 
during the separation of free and bound labelled hormone in an assay in-
volving several hundred tubes, due to the time lag between addition of 
the separating reagent to tubes early and later in the assay o Assay tubes 
situated near the end of an assay may stand for 30 to 45 minutes at room 
temperature before addition of charcoal suspension, for example, during 
which time the antibody-antigen equilibrium may well be disturbed. With 
this in mind it is good practice to include a standard curve every 200 
tubes in large assays and to read the results for the different tubes from 
the corresponding curves, to reduce intra-assay variation due to this 
phenomenon. 
The index of precision, determined as the coefficient of variation of 
the 1050 value of each standard curve, gives an indication of how the 
mid-point of the standard curve varies from week to week. It is interesting 
that assays involving antiserum 2604-7 varied least from week to week, 
with an index of precision of 13,9%, although the highest within assay 
variation was encountered in assays involving this antiserum. 
The best correlation between observed and expected values was found 
for assays involving antiserum G 5 with a value for r, the correlation co-
efficient, of 0,973. This good correlation was due to the fact that the 
standard curve obtained with G 5 antiserum is sensitive at high levels of 
added gastrin standard, under which conditions greater stability is obtained. 
This is borne out by the poorer correlation between observed and expected 
values found in the case of antisera G 1 and 2604-7, which measure lower 
concentrations of gastrin. 
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In keeping with reports in the literature of variations in immunochemical 
potency befween different batches of synthetic human gastrin obtained from 
I.C.I. (Yalow and Berson, 1970a; Stadil and Rehfeld, 1972), such variations 
were noted in studies in this iaboratory as wel Io in addition, it was shown 
that the i.Cal. preparation of SHG (1-17) was approximately half as potent 
imrnunochemically as the preparation obtained from CEA- !RE Sorin (Table 
(4. l .4)). In view of the variations in potency of I oC. I. preparations of 
SHG-17 I, this peptide was only used in the immunoreactivity studies 
specified o For the purposes of all regular assays the CEA-IRE Sorin prepa-
ration of SHG-17 I was used. 
The establishment of this radioimmunoassay system enabled measurement 
of gastrin concentrations in several types of biological fluid, as discussed 
below. 
Measurement of Gastrin in Biological Fluids 
Measurements of gastrin concentrations were made by radioimmunoassay 
in various biological fluids during the course of this study. These included 
human and porcine serum cs well as serum from other vertebrate species, 
aqueous extracts of gut tissues of various species, fractions eluted from 
Sephadex columns in 0,05 M - veronal buffer, and the perfusion medium 
with which the isolated rat liver was perfused in situ. An unsuccessful 
attempt was made to measure gastrin in pig bile which probably failed due 
to interference by bile salts in the assay. 
No difference was found between measurements made in human plasma 
or serum, and in practically all cases serum was used. It was imperative 
to rule out any interference in the assay by factors in the sample; which 
may give rise to erroneous readings, as discussed by Berson and Yalow (1959) 
in the case of insulin radioimmunoassay. . In some instances enzymes present 
in plasma er serum may degrade the labelled or unlabelled hormone; gluca-
gon is susceptible to such degradation, so in these cases the protease inhibi-
tor, Trasylol, is included in the incubation mixture. This was not necessary 
in the gastrin assay. In all assays, control tubes in which antiserum was 
omitted, were included with serum samples from each patient or samples of 
the other biological fluids mentioned, to monitor non-specific binding of the 
tracer by factors in the sample and to allow correction for any damage to 
the labelled hormone on incubation. 
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Prior to separation of free and antibody-bound labelled gastrin by char-
coal adsorption, the serum content of the standard curve was equalized with 
that of the rest of the serum samples in the assay by addition of an equivalent 
quantity of serum which had previously been treated with charcoal to remove 
all peptide hormones - such serum is referred to as "gastrin-free". In the 
same manner the serum content of samples containing column eluates, gut 
tissue extracts and perfusion medium was equalized with that of normal serum 
before commencing the separation procedure. 
The preparation of serial dilutions of a serum sample or other unknown 
sample and comparison of the shape of the displacement curve produced by 
such dilutions with that obtained with the purified standard hormone prepa-
ration is the best method available for ascertaining how closely the hormone 
in the unknown sample resembles the standard a Parallel ism of the two curves 
suggests that the material in the biological sample resembles the standard 
preparation, since they behave immunochemically identically. By coupling 
such observations on the immunological behaviour of a sample with the 
elution profile of the same sample obtained on Sephadex chromatography, 
which gives an indication of molecular size, a good indication of the 
species of gastrin present in the sample is obtained. This procedure was 
used many times in this study, such as in the characterisation of the gastrin 
present in hypergastrinaemic serum and human tissue extracts, and of the 
material found in frog serum and skin extracts. 
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Although ~he procedure described above gives a good indication of the 
nature of the material in the unknown sample, only extraction of the material 
in sufficient quantity from serum or biological fluid for purification and 
determination of the amino acid sequence will provide the ultimate demon-
stration of identity of the material with the standard hormone preparation. 
Turning to the recovery of gastrin in tissue extracts, it was shown that 
straight boiling of gastri n in water alone led to 77% recovery of added 
gastrin, whereas the recovery of gastri n following boiling in the presence of 
control tissue in the form of rat thigh muscle was 43%, as shown in table 
(4.1.6). Since the recovery of a known amount of gastrin added to individual 
tissues before boi Ii ng was not assessed, one had to assume that the recovery 
of extracted gastrin from the different tissue extracts was similar, so that 
comparison of the gastri n content of various tissues from different sped es 
could be made. Tissues such as pancreas contain proteolytic enzymes which 
would inactivate any hormone present in the tissue; consequently the tissues 
were boiled as soon as possible after removal from the animal in the hope of 
inactivating these enzymes. As was shown in section 4 l{vi), the addition of 
Trasylol (protease inhibitor) had no effect on the recovery of gastrin added to 
boiled muscle extracts, justifying its omission in the preparation of most tissue 
extracts. 
In the next section, actual serum gastrin measurements in control subjects 
and patients with various disease conditions are discussed. 
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Serum Gastrin Measurements in Health and Disease 
The mean fasting serum gastrin level in control subjects of 48 1 5 pg/ml 
ts close to the values found by Schrumpf and Sand (1972), Feurle, Ketterer 
et al. (1972) and Walsh (1974) and agrees with the general finding of normal 
levels below 100 pg/ml. 
In contrast to the findings of McGuigan and Trudeau (1970a) no direct 
relationship between increasing age and fasting serum gastrin levels was noted 
in this study. However, the population of patients investigated in this study 
included both normal subjects and patients suffering from various complaints, 
whereas the group investigated by McGuigan and Trudeau (1970a) comprised 
only normal subjects, which may account in part for the discrepancy. 
Neither Ganguli and Hunter (1972) nor Stadil and Rehfeld (1973a) could 
confirm the findings of McGuigan and Trudeau (1970a). 
Significantly higher serum gastrin levels in females than in males were 
noted in this study, in contrast to the reports of Ganguli and Hunter (1972) 
and Stadil and Rehfeld (1973a). This discrepancy may be due to differences 
in specificity of the antisera used, as discussed below. The fact that serum 
gastrin levels in three ethnic groups were not significantly different in this 
laboratory suggests that serum gastri n is probably not related to the qua I ity 
of dietary intake. 
The rise in serum gastrin levels in control subjects after oral ingestion 
of Oxo with a maximum 45 minutes after eating agrees with the findings of 
peak postprandial gastrin levels between 30 and 60 minutes after eating 
reported by Ganguli (1970) and Korman, Soveny et al. (1971). The peak 
gastrin levels reported by these two groups were approximately five times 
basal, whereas the peak response to Oxo found here was only twice basal 
(Vinik, Kalk et al., 1975). Since Oxo consists of hydrolyzed prntein one 
may expect a slightly different response to that found with ordinary food. 
HON ever, Forrester and Ganguli (1970) demonstrated postprandial gastrin 
levels of four to five times basal following oral administration of Oxo. 
The reason for the lower postprandial gastrin levels in this study may wel I 
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lie with the specificity of antiserum G 1 used for these measurements. Since 
this antiserum measures only non-sulphated gastrins, chiefly of the heptadeca-
peptide or smaller size, any sulphated gastrins released in this situation would 
not have been detected by this antiserum. 
The elevated serum gastrin levels found in patients with duodenal ulcer 
and the normal levels in gastric ulcer are at variance with most of the 
reports in the literature, in which the opposite situation was found, as 
outlined in section 2 111. The only group whose findings agree with ours 
is that of Byrnes, Young et al. (1970), but their normal levels are so high 
(400 pg/ml), probably due to a poor qua I ity tracer or low affinity antiserum 
used in the assay, that these values do not form a good basis for comparison. 
The reason for the differences between our findings and those in the literature 
may be due to the specificity of G 1 antiserum, as previously mentioned. 
In support of this suggestion is the report of differences in serum gastrin levels 
measured in normal subjects and ulcer patients with two antisera showing 
different specificities for sulphated and non-sulphated gastrins by Hansky, 
Soveny et al. (1973). 
We have no idea whether sulphated and non-sulphated gastrins are secreted 
in the same proportions under normal and pathologic conditions; the results of 
this study underline the importance of determining the specificity of the anti-
serum used for serum gastrin measurements under various conditions. Although 
it is known that the presence of a sulphated tyrosine residue on the CCK-PZ 
molecule is essential for biological activity, whereas biologically active 
gcstrin occurs naturally in both sulphated non-sulphated forms, the signifi-
cance of sulphation of the tyrosine residue in type II g:istrins is poorly 
understood at present. 
Extremely elevated serum gastrin levels were found in patients with 
Zollinger-El I ison syndrome and pernicious anaemia, although the pattern 
of these levels differed from that found by other groups in that the levels 
in cases of pernicious anaemia were sometimes ten fold greater than those 
in Zollinger-Ellison syndrome. Serum gastrin levels measured in patients 
with Zollinger-Ellison syndrome in this study were only of the order of 
300 pg/ml, whereas levels reported in the literature ranged from 1 ng/ml 
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to 94 ng/ml (Schrumpf and Sand, 1972; Ya I ow and Berson, 1970a; Ganguli 
and Hunter, 1972). 
Again the failure of antiserum G 1, used for these estimations, to 
measure sulphated gastrins may account for this discrepancy. Many circu-
lating gastrin fragments in this syndrome may not be detected by antiserum 
G 1, which could account for the fact that only 4 cases of Zollinger-Ellison 
syndrome were detected in this hospital over a period of 3 years. This 
incidence is much lower than that generally found, and it is felt that had 
antiserum 2604-7 been used for these estimations a completely different 
picture may have emerged. 
Serum gastrin estimations rn patients with pernicious anaemia gave a 
mean value of approximately 3 000 pg/ml; this is in line with the values 
reported by other groups, which fel I between 300 and 9 000 pg/ml, the 
range quoted by Yalow and Berson (1970a). This may indicate a difference 
between the forms of gastrin circulating in pernicious anaemia and Zollinger-
El Ii son syndrome, since a much greater proportion of non-sulphated heptadeca-
peptide gcstrin was detected using antiserum G l in the former condition. 
The finding that antrectomised patients had undetectable gastrin levels 
when measured with antiserum G 1 suggested that the gastrin secreted by 
the human antrum is chiefly the non-sulphated heptadecapeptide species 
and that the antrum appears to be the primary source of non-sulphated 
heptadecapeptide gastrin in the human. The former suggestion is borne out 
by the immunological identity of the material in the serum of a patient with 
isolated retained antrum with the G-17 I standard, as shown by the parallel 
displacement curves obtained in figure (4.I.13.). 
The marked stimulation of gastrin release by intravenous arginine and 
the relatively poor response to oral arginine 111 normal subjects (Vinik, Kalk 
et al., 1975) suggests that a high concentration of arginine in the blood 
can stimulate gastrin releaseo The way in which arginine produces this 
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effect has not been definitely established. Arginine may act as a general 
non-specific stimulant of hormone release, since it has been shown to 
stimulate the release of gl ucagon (Ohneda, Parada, Eisentrout and Unger, 
1968), growth hormone (Merimee, Lillicrap and Rabinowitz, 1965), and 
insulin (Fajans, Floyd, Knopf and Conn, 1967). Alternatively, the release 
of gastrin may be brought about by electrolyte changes in the G-cell. It 
has been shown that intravenous arginine produced a significant rise in red 
blood cell potassium in subjects who secreted insulin in response to arginine, 
suggesting that a similar event may occur in pancreatic beta cells (Vinik and 
Jessop, 1974). Perhaps a similar event occurs in the G-cell in response to 
arginine. 
The behaviour of serum from a patient whose gastrin levels had been 
stimulated by administration of intravenous arginine on dilution in the assay 
was identical with that of the standard G-17 I; as shown in figure (4.1.7.), 
suggesting that intravenous arginine stimulated the release of heptadeca-
peptide gastrin I from the antrum o 
Failure of antrectomised or vagotomised and partially antrectomised 
patients to respond to intravenous arginine, as measured with antiserum 
G 1, again supports the suggestion that heptadecapeptide gastrin is chiefly 
antral in origin. In addition, these findings suggest that the effect of 
arginine in stimulating antral gastrin release is mediated by the vagus. 
An account of the findings reiating to the heterogeneity of gastrin in 
human serum fol lows in the next section. 
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Gastr!n Heterogeneitt in Human Serum 
The relative proportions of the various molecular gastrin species in serum 
may vary in normal subjects and patients with different hypergcstrinaemic 
conditions. Even in the same individual, the total circulating gastrin con-
tent does not comprise the same proportions of the different gastrin types at 
all times; differences in turnover rates of the gastrin subtypes in !·he circu-
lation, and the release of different components follCM'ing stimuli such as 
ingestion of food, are factors affecting the relative distribution of gastrin 
cornponents in the circulation. Hence the characterisation of gastrin sub-
types in serum under various conditions reflects the situation at the time of 
collection of the blood sample. 
Gastrin heterogeneity in human serum was studied using serum collected 
from a patient with pernicious anaemia in the basal state. This sample was 
chromatographed in the early stages of the study, before the preparations of 
natural human gastrins donated by Dr. M. Grossman had been received. The 
elution profiles in this instance and in the case of the human gut tissue ex-
tracts were plotted as actual elution volume in millilitres against 8/80 x 100, 
as defined in section 3 l(iii), an indication of the relative peptide content 
of the eluted fractions. The molecular weight markers used were albumen and 
1251-SHG-17 I. 
In later chromatographic procedures the abscissa was plotted as a percen-
tage of the elution volume between blue dextran and Vitamin 812 , which 
were chromatographed with each sample to provide standardization of elution 
profiles performed on different occasions. Vitamin 812 is a small molecule 
with a molecular weight of 1 355 and is bright red in colour. It was more 
convenient to use this substance, which eluted in a volume almost as large 
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as the salt volume of the column, as shown in figure (4.11.1.), in preference 
to 22 Na as an index of total volume, since the position of Vitamin B12 1n 
the eluted fractions could be determined by visual inspection as opposed to 
counting the radioactivity in the eluted samples. Likewise, the elution 
position of blue dextran was determined visually. Comparison of elution 
profiles plotted in this manner with the profiles of the natural human gastrins 
G-34 I, G-17 I and G-17 11 chromatographed on the same Sephadex column 
allowed identification of the gastrin components found in the samples under 
investigation. Although such comparisons could not be made in the case of 
earlier chromatographic profiles, the fact that the position of the 1251-SHG-
17 I marker in the elution profiles in figures (4.11.2.), (4.11.3.) and (4.11.4.) 
corresponded exactly with that of the NHG-17 I peptide suggests that the 
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t-gastrin marker used in earlier fractionations was a reliable indicator of 
elution volume of heptadecapeptide gastrin type I. 
As was mentioned in section 3 II, the chromatographic profiles in this 
study were obtained after one fractionation on a Sephadex column, which 
did not provide complete resolution of the different gastrin components. 
However, the separation was good enough to permit identification of the 
various gastrin types in chromatographic profiles which were compared with 
the natural gastrin standards. 
Bearing these factors in mind, complete identification of the immune-
reactive gastrin peaks in figure (4.11. l .) was not possible; their probable 
identities had to be inferred from their elution positions relative to the 
albumen, 1251-SHG-17 I, Vitamin B 12 and 22 Na markers. The elution 
profile in this figure was obtained on chromatography of fasting serum from 
a patient with pernicious anaemia, follONed by estimation of the gastrin 
content of the eluted fractions using antiserum G 5. The paired peaks 
are thought to represent sulphated and non-sulphated gastrins, since this 
antiserum recognised both these forms (section 4 l(iv)). A smal I amount 
of minigastrin appeared to be present, as well as some material eiuting in 
the region of the void volume. 
Calibration of the Sephadex column with the natural gastrin standards 
showed that the sulphated type 11 heptadecapeptide gcstrin eluted before 
the non-sulphated species, and the degree of separation between the two 
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was greater than would be expected on the basis of molecular weight alone. 
This may be due to a weak ion exchange effect between the charged sulphate 
group and the column matrix, as discussed in section 3 II. The emergence 
of sulphated G-17 before non-sulphated G-17 on Sep had ex gel filtration has 
also been reported by Rehfeld, Stadil et al. (1974) and Dockray and Walsh 
(1975). 
Although the primary structures of big, heptadecapeptide and minigastrin 
have been determined, component I and 11 big big 11 gastrin have not yet been 
chemically characterised. It has been established that tryptic digestion of 
component I liberates heptadecapeptide gastrin, and material apparently 
corresponding to serum component I has been identified and partially purified 
from extracts of porcine antra I mucosa and gastrinoma tissue (Gregory, 1976). 
It thus appears that component I is a real entity. 
The existence of 11big big 11 gastrin is more doubtful rn the light of the 
demonstrations by Rehfeld, Stadil et al. (1975) and Dockray (1975) that 
11 big big 11 gastrin detected in serum may actually be due to association of 
smaller gastrin molecules with large serum proteins, producing a large com-
plex which elutes in the void volume on Sephadex columns and behaves 
immunologically like gastrin. This is further substantiated by the detailed 
study of Rehfeld, Schwartz and Stc:dil (1977), demonstrating the presence 
of macromolecuiar gastrin species in two out of four gastrinoma extracts, 
but not in normal serum or antral, duodenal or jejuna! tissue extracts. 
The phenomenon of non-specific binding of smaller gastrins to piasma 
proteins may have produced the first peak of gastrin immunoreactivity in 
the elution profile shown in figure (4.11.1.), which had originally been 
thought to represent "big big 11 gastrin. This controversy wi 11 only be 
resolved if and when "big big" gastrin is isolated and characterised entirely. 
Malagelada (1977) has proposed that a large form of gastrin, which is 
biologically inactive, occurs in the circulation of some patients from his 
findings of very elevated serum gastrin levels in 5 patients who, on the 
basis of their serum gastrin levels, would be classified as Zollinger-Ellison 
cases, although they did not present with the clinical features of the 
Zollinger-Ellison syndrome. These high serum gastrin measurements were 
obtained with only one antiserum, whereas measurements using another anti-
serum with a different region specificity for gastrin revealed normal levels. 
In addition, none of these patients responded with increased serum gastrin 
levels to infusions of calcium or secretin as normally happens in the case 
of patients with Zollinger-Ellison syndrome. On Sephadex G-50 chromato-
graphy this large gastrin component eluted as a single peak between the 
void volume and the position of G-34. Incubation with trypsin converted 
this component to a fragment with the elution profile of G-34 and in one 
case to a fragment which eluted in the region of G-17. It thus appears 
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that this large species of gastrin described by Malagelada may be an inactive 
precursor form which contains gastrin fragments resembling G-17 and G-34 
within its structure. It may or may not be a separate entity to 11 big big" 
gastrin and component I. This accidental finding may provide a clue to 
the possible role of these big gastrins as precursors of the biologically active 
g:1strins, similar to proinsulin and insulin. 
It is thus apparent that the relationship between the different gastrin 
components in serum 1s far from wel i understood, as is the case for the 
relationship between serum and tissue gastrin components. Isolation and 
purification of different gastrin types from normal antral mucosa and tumour 
tissues has allowed chemical characterisation of these components. Only 
when the various gastrin components can be isolated from serum in sufficient 
amounts for determination of their primary structure can the identity of 
gastrins in serum and tissues be confirmed and their interrelationships better 
understood. 
In the next section the heterogeneity cf gastrins in tissue will be 
considered. 
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Gastrin Heterogeneity and Distribution in Human Tissues 
Chromatographic profiles obtained on fractionation of aqueous extracts 
prepared from biopsies of human antral and duodenal mucosa differed, in 
that a higher proportion of the heptadecapeptide component was found in 
the antral extract. The peak eluting in the void volume on chromato-
graphy of both these extracts (flgures(4.lll.2.) and (4.1!1.3.))was tentatively 
referred to as 11 big big" gastrin. This agreed with the report of Rehfeld, 
Stadil et al. (1974), who identified a heterogeneous 11 big big" gastrin 
component in extracts of antral mucosa and gastrinoma tissue. However, 
the recent demonstration by Rehfeld, Schwartz et al. (1977) that a macro-
molecular gastrin species was present in gastrinoma tissue only and not in 
normal tissue extracts emphasises the fact that this aspect requires further 
clarification. 
The immunoreactive gastrin in these extracts was resolved into peaks 
which eluted in a biphasic manner, as shown in figures (4.111.2.) and 
(4 .111.3 .) • This reflects detection of both sulphated and non-sulphated 
gastrins by antiserum G 5. As was shown in sections 4 l(iv) and 4 ll(ii), 
this antiserum recognises both gastri n types. 
Confirmation of the difference between antral and duodenal gastrins 
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was further demonstrated by their differences in immunoreactivity when 
measured with antisera G 1 and G 5. Both extracts produced para I lei 
displacement curves when assayed with antiserum G 5, although measurement 
with antiserum G 1 revealed differences in immunoreactivity between the two 
extracts. The curve of displacement of 1251-labelled gastrin from antiserum 
G 1 obtained with the duodenal extract was not parallel with that of the 
G-17 I standard, indicating non-identity of duodena! gastrin and pure 
heptadecapeptide gastrin type Io 
The higher proportion of immunoreactive heptadecapeptide gastrin in 
antral as opposed to duodenal extracts (Vinik, Grant et al., 1975) is in 
agreement with the findings of Berson and Yalow (1971) and was confirmed 
by Rehfeld, Stadil et al. (1975), Malmstrpm, Stadil et al. (1976) and 
Creutzfeldt, Arnold et al. (1976)0 The findings of Lai (1964b) and Elwin 
and Uvri!s (1966) that the biological activity of antral gastrin was greater 
than that of duodenal gastrin is in keeping with the demonstration that 
heptadecapeptide gastrin, which predominates at this site, is the most 
biologically potent form of gastrin (Walsh, Debas et al., 1974; Debas, 
Walsh et a I • , 197 4). 
The demonstration that the elevated serum gastrin levels produced in 
response to intravenous arginine infusion are due chiefly to an increase in 
the heptadecapeptide and smaller gastrin components (Kalk, Vinik et al., 
1973), and that antrectomy abolished the response to arginine (Vinik, Kalk 
et al., 1975) provides additional evidence that the antrum is the primary 
source of heptadecape:ptide gastrin. These findings suggest that the duo-
denum is a relatively unimportant source of heptadecapeptide gastrin re-
leased in response to arginine, but does not exclude the duodenum as a 
source of 11 gastrins 11 when other untested provocative substances are used. 
The negligible levels of gastrin found in extracts of the cardia and 
body of the human stomach is in keeping with the findings of Malmstrpm, 
Stadil et al. (1976). The gastrin content of the body of the stomach was 
11 3% of that in the antrum, which agrees closely with the value of 0,5-
1 % found by Malmstrpm, Stadil et al. (1976). 
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The actual tissue content of gastrin measured in human antral extract 
was 1,42 µg/g dry weight, or 2,034 µg/g total protein, as shown in table 
(4.111.1). These values are far lower than those found by Berson and YalO'vV 
(1971), Rehfeld, Stadil et al. (1975) and Creutzfeldt, Arnold et al. (1976), 
who found 30 J-19/9, 28,38 ,ug/g and 15,9 µ9/9 frozen tissue respectively 
in human antral mucosa. Gastrin measurements in the proximal duodenum 
agreed more closely, since Rehfeld, Stadil et al. (1975) detected 3,96 µg/g 
and Creutzfeldt, Arnold et al. (1976) found 1,8 µg/g, in comparison with 
the values of 0,97 pg/g dry weight or 1,432 pg/g protein in the duodenal 
cap found in this study. 
246 
The duodenal gastrin content was 68-70% of that in the antrum in the 
duodenal cap, with a lower proportion, 27%, in the biopsy taken from the 
second part of the duodenum. These measurements reflect chiefly the non-
sulphated gastrin content since the estimations were made with antiserum G l. 
This high ratio of duodenal to antral gastrin content per unit weight of tissue 
contrasts with the findings of Malmstr,¢'m, Stadil et al. (1976) who showed 
the proximal duodena! gastrin content to be 10% of that of the antrum, and 
that in the distal duodenum to be 1-2% of that in the antral mucosa. 
Creutzfeldt, Arnold et al. (1976) also found approximately 10% of the antral 
immunoreactive gastrin content in the proximal duodenal mucosa of control 
subjects. The biological gastrin activity in the duodenum was likewise found 
to be 10% of that in the antrum by Elwin and Uvn8s (1966), although the 
corresponding value found by Em8s, Borg and Fyr8 (1971) was approximately 
33%. 
In looking for a reason for the differences between absolute values of 
tissue gastrin content and the relative proportions of antral and duodenal 
immunoreactive gastri n content between this study and those of Malmstr.¢'m, 
Stadil et al. (1976) and Creutzfeldt, Arnold et al. (1976), several 
possibilities arise. The gradient of immunoreactive gastrin activity along 
the duodenum found in this study and that of Malmstrpm, Stadil et al. 
(1976) may help to explain the discrepancies, since the exact site of 
samp Ii ng may be different. 
An alternative explanation derives from the fact that the estimations 
of gastrin content in this study were made relative to dry weight or total 
protein content of the tissue, whereas other groups expressed the gastri n 
content relative to the frozen weight of the tissue, although, if anything, 
one would expect the gastrin content per unit frozen tissue to be lower 
than that expressed per unit dry weight of tissue. In this study the gastrin 
content relative to the dry weight of tissue was always less than that 
expressed relative to the total protein (table (4. 111.1)), as would be 
expected, and the relative gastrin content at different sites agreed very 
closely when expressed either way, indicating consistency in the results 
expressed in either manner. 
No estimations of total antral or duodenal gastrin content were made 
in this study. The total mass of extractable immunoreactive gastrin in the 
human duodenum was 97% of that of the ant rum according to Nilsson, 
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Yalow et al. (1973) and the total extractable biologically active gastrin in 
the human duodenum was actually greater than that in the antrum as 
determined by Lai (1964b). This only applies in the case of the human, 
suggesting that duodenal gastrin in man may differ from that in other species. 
Although no estimations of total duodenal gastri n content were made for the 
purposes of this thesis, the relative duodenal gastrin content in man was 
found to be far higher than that in the rabbit, guinea pig, dog or pig, 
aithough the duodenal gastrin levels in the rat were similar to the value 
found for the human. 
Hence differences in extraction techniques could have resulted in 
marked differences in yield. The relatively lower yields of tissue gastrin 
content found here may be due to the fact that the tissues were not homo-
genised after boiling, in which case some of the gastrin may have remained 
in the tissue, although it was thought that cutting the tissue into small 
pieces before boiling in the case of the animal tissues (the human tissue 
biopsies were very small to start with) would have been sufficient to 
I iberate the gastri n present. As shown in section 4 l(vi), the recovery 
of gastrin added to control muscle tissue treated in this manner was 43%. 
Even allowing for recovery of less than half of the gastrin in the tissues, 
the estimated gastrin content of the antrum was less than that observed 
by other authors. 
Another factor contributing to the apparently lower yield found in 
this study compared with that found by other workers may be the fact 
that the tissues were not frozen as soon as they were removed from the 
animal, but were merely boiled within 30 minutes of this procedure. Both 
Berson and Yalow (1971) and Malmstrpm and Stadil (1975) showed that the 
yield of gastrin from tissues which were quick frozen fol lowing excision 
from the animal was higher than that in tissues which were left for up to 
an hour before extraction by boiling in water. Since the tissues in this 
study stood for up to 30 mi nut es at room temperature prior to extraction, 
this possibility is real. As the tissues were all boiled the same time after 
collection it was assumed that the relative yields for the different sites 
were the same. Unfortunateiy, the data of Berson and Yalow (1971) and 
Malmstr.¢'m and Stadil (1975) do not allow an absolute comparison of the 
yield from tissues fast frozen and then extracted with tissues treated by 
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extraction a lone, nor do I have the data to verify or exclude this possibility. 
The lower number of tissue extracts investigated here (4) compared with 
8 normal subjects studied by Malmstrpm, Stadil et al. (1976) and 21 subjects 
investigated by Creutzfeldt, Arnold et al. (1976) may a !so account in part 
for the discrepancy. 
Another reason for the difference in the relative gastrin content of 
human antrum and duodenum between this study and that found by other 
workers could i ie in the difference in specificities of antisera used in these 
studies. Measurements with antiserum G 1 reflect chiefly non-sulphated 
gastrin, and differences in the components of gastrin found at these two 
sites may well produce different values when measured with antisera of 
differing specificities. Malmstrpm, Stadil et al. (1976) made their esti-
mations using antiserum 2604-7, which recognises both sulphated and non-
sulphated gastrin components I, II and Ill, whereas Creutzfeldt, Arnold 
et al. (1976) used an antiserum that reacted with human G-34 with only 
one third of its affinity for equimolar amounts of G-17, although it did 
react with both sulphated and non-sulphated forms of gastrin. The anti-
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serum used by Berson and Yalow (1971) and Nilsson, Yalow et al. (1973) 
detects a large gastrin component in serum (Yalow and Berson, 1972) which 
has not been detected by other workers. In addition, the antiserum employed 
by this group appears to cross-react with CCK-PZ or a CCK-PZ peptide to 
a certain extent (Straus, Yalow and Gainer, 1975), suggesting that the high 
values of tissue gastrin content reported by this group may not in fact 
represent only true gastrin. 
It would seem therefore that, allowing for differences in extraction 
techniques and assay variables, the actual gastrin content of various tissues 
would probably be lower than those of earlier estimates. This is not 
unusual in the immunoassay sphere, where with the advent of purer, better 
defined standards and improved labelling of the peptide, circulating and 
tissue levels have fallen. 
The question of extra-gastric gastrin poses problems in the treatment of 
ulcer disease, since surgical antrectomy does not remove the only source of 
gastrin, and from the reports of Nilsson, Yalow et al. (1973), Lai (1964b), 
Stern and Walsh (1973) and Korman, Soveny and Hansky (1972b) it appears 
that in the human the duodenum is an important source of gastrin. The term 
"extra-gastric gastrin" also includes the "big big" gastrin found in extracts 
of human jejunum by Yalow and Berson (1972). Why this form of gastrin 
should be produced at a site so distant from the antrum is at present un-
explained. 
Reports of gastrin release in gastrectomised subjects from different groups 
should be viewed with caution, since the techniques of Bil lroth I and 
Billroth II gastrectomy may produce different results. Thus in the case of 
a Billroth II gastrectomy, which involves antrectomy and gastrojejunal ana-
stomosis, failure to remove the entire antrum may result in the condition 
of isolated retained antrum, in which gastrin is secreted continuously from 
the antral remnant which has been removed from the influence of acid 
inhibition of gastrin secretion. 
Total gastrectomy is the current surgical treatment of choice in cases 
of Zollinger-Ellison syndromea Removal of the target organ of gastrin is 
more effective than removal of a gastrinoma, since these tumours are often 
so small that they are difficult to find, and since more than 90% of gastri-
nomas are malignant and have metastasised by the time of operation 
(Creutzfeldt, 1977). Thus the chances of complete removal of the gastrin 
secreting tumour at operation are very small. 
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The aspect of pancreatic gastrin was not investigated in the human, 
although negligible amounts of gastrin were detected in pancreatic extracts 
prepared from the rat, rabbit, guinea pig, dog or pig when measured with 
both antisera G 1 and 2604-7. The pancreatic gastrin detected by other 
groups in the human was below l O ng/g tissue (Nilsson, Yalow et al., 
1973; Rehfeld and Iversen, 1973; Gepts, 1973) except in the study 
reported by Greider and McGuigan (1971), who reported a value of 75 ng 
gastrin per gram human pancreas. However, although the human neonatal 
pancreas does contain gastrin, the data on the adult human pancreas are 
controversial. Pancreatic G-cells do occur in other species, but in man 
there has been no conclusive evidence for the presence of G-cells in the 
pancreas. In contrast, pancreatic gastrin has been localized by immuno-
histochemi ca I techniques in the pancreatic D-cell in man (Erlandsen, Hegre 
et al., 1976), and it seems possible that pancreatic gastrin may differ from 
antral and duodenal gastrin, since at both the latter sites gastrin is secreted 
by the G-cell (McGuigan, 1968b; McGuigan and Greider, 1971; Pearse 
and Bussolati, 1972; Polak, Stagg and Pearse, 1972; Creutzfeldt, Creutz-
feldt et al., 1974). 
The demonstration of somatostatin and gastrin in the same pancreatic 
D-cell by Erlandsen, Hegre et al. (1976) is not the first instance of the 
concept of two hormones which are secreted by the same cell. This has 
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also been shown in the case of two cells in the pituitary (Erlandsen, Hegre 
et al., 1976), one of which has been shown to produce melanocyte-
stimulating hormone and adrenocorticotrophic hormone, while the other 
appears to produce both follicle-stimulating hormone and luteinizing hormone. 
Further studies are needed to substantiate and clarify these findings. 
As was mentioned previously, measurement of the different gastrin 
components in the circulation at any given t:me represents an estimation 
of the balance between secretion into and removal of the various gastrin 
components from the circulation. The rate of removal from the circulation 
of the different gastrin components differs for each component and the 
half-lives of pure human big, heptadecapeptide and mini-gastrins in the 
canine circulation are respectively 9-15,8 minutes, 3-5 minutes and 
1 ,8 minutes (Straus and Yalow, 1974; Walsh, Debas et al., 1974; Debos, 
Wa !sh et al., 1974). On the other hand I ittle is known about the rate of 
secretion of these forms of gastri n. Whether the hypothetical biosynthetic 
sequence BBG -+ component I -+ big gastrin _.,. heptadecapeptide 
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gastrin -;.. minigastrin will prov,a to be a reality, whether all these forms 
originate in the same cell type and tissue, and why so many different gastrin 
types are present in the circulation are al I questions that need to be 
answered. It is known that oral ingestion of food (Stadil, Rehfeld et al., 
1975) and intravenous administration of arginine (Kalk, Vinik et al., 1973) 
produce an increase in the levels of heptadecapeptide and smaller gastrins 
liberated by the antrum, but whether this release follows tryptic cleavage 
from big gastrin or a larger precursor form in the antral G-cell is not known. 
It follows that the conditions under which the different components are 
detected, such as whether the individual was in the fasting or postprandial 
state when the blood was collected, are important in determining the 
relative proportions of the different components, and careful attention to 
these parameters may help in finally understanding the relationship between 
the different gastrin types. The biological potency of the various gastrin 
forms also varies, so that G-17 is roughly five times more potent than G-34 
when the plateau level is measured endogenously after an infusion (Walsh, 
Debas et al., 1974). Since the generai concept of a precursor-hormone 
relationship involves a large precursor form which has low or no biological 
activity, as discussed in section 2 VII, the lower biological potency of 
G-34 relative to G-17, coupled with the fact that G-17 is liberated from 
G-34 by tryptic cleavage in vitro (Yalow and Berson, 1971a; Rehfeld, 
1972) suggests that G-34 may wel I be a precursor of G- 17. The demon-
stration of a macromolecular form of gastrin in serum which was devoid of 
biological activity (Malagelada, 1977), provides evidence for the existence 
of a large biologically inactive gastrin which may be a precursor. 
The cleavage of G-17 from larger gastrin forms in vivo must still be 
demonstrated; it may occur via enzymes with trypsin-like specificity such 
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as the enzymes responsible for the conversion of proinsulin to insulin (Steiner, 
Kemmler et al., 1974). If the hypothetical biosynthetic sequence progressing 
from the larger to the smaller gastrin forms can be demonstrated it will be of 
importance to determine whether all the conversion steps take place in the 
cell of origin and, if so, what the relation between the antral and duodenal 
G-cell is. Conversion of the larger to the smaller hormonal form has been 
demonstrated to take place by enzymatic cleavage in the cell of origin in 
the case of insulin (Steiner, Kemmler et al., 1974) and in vitro in the case 
of ACTH (Yalow, 1974a), glucagon (Rigopoulou, Valverde et al., 1970) and 
several other peptide hormones. A significant contribution to the gastrin 
story will arise when an antiserum to the amino-terminal heptadecapeptide 
fragment of G-34 can be raised, which will be useful for measuring circula-
ting levels of this gastrin fragment. In addition it will be interesting to 
determine whether this fragment possesses biological activity, and how its 
potency compares with that of the other forms of gastrin. 
The distribution of immunoreactive gaslTin along the gastrointestinal 
tract of five mammalian species was studied by preparation of aqueous 
extracts of gut tissue in the same manner as for the human tissues. This 
is discussed in the next section o 
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Gastrin 1n Tissues of Mammals and Lower Species and 
Phylogenetic Considerations 
The cntral gastrin content in the pig was 10 to 30 times greater than 
that found in the human, in keeping with the finding of 11 times more 
antral gastrin in the pig compared with the human reported by Nilsson, 
Yalow et al. (1973), but at variance with the findings of /V,a!mstr,6n and 
Stadil (1975). The actual tissue gastrin content of 15,5 .ug/g and 25,9 
,ug/g dry weight of tissue measured with antisera G 1 and 2604-7 is close 
to the porcine antral gastrin content of 22 ~g/g found by Nilsson, Yalow 
et al. (1973). In the dog the antral gastrin content measured with anti-
serum G l was 4 to 11 times greater than in the human, while in the other 
species the antral gastrin content was similar to that of the human. The 
ratio of duodenal to antral gastrin of less than 1:200 found in this study 
in the case of the rabbit, guinea pig, dog and pig agrees closely with the 
corresponding ratio found in the dog, cat and pig by Nilsson, Yalow et al. 
(1973). This is in direct contrast to the much higher ratio of duodenal to 
antral gastrin found in the human, as discussed previously. 
The high gastrin content of the fundic and duodenal mucosa of the rat 
1s surprising and has not been described in the literature reviewed. The 
duodenal gastri n content relative to that of the antrum approximated that 
found in the human, while the high levels in the fundus are difficult to 
explain. The low antral gastrin content in the rat found in this study 1s 
in agreement with the findings of Thompson, Reeder et al. (1973) who re-
ported a much !ower antral gastrin content in the rat compared with other 
species. 
The relatively high gastrin content found in rabbit colonic mucosa 1s 
also surprising. Perhaps further investigations would show this to be a type 
of macromolecular gastrin, as was found in the case of human gastrin ex-
tracted from tissues situated distally in the gastrointestinal tract (Yalow and 
Berson, 1972). The significance of this observation may relate to the fact 
that the rabbit is herbivorous, and it may be that the distribution of 9astrin 
in the rabbit gut differs from that in carnivorous mammals. 
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Although gastrin was detected in the pancreas in a number of species, 
the quantities were of an extremely low order and cast some doubt on the 
validity of the observations. By the very nature of the measurement, radio-
immunoassay is subject to a host of variables which could yield spurious 
results at low detection limits, which could be erroneously interpreted as 
11 true gastrin 11 • The absence of G-cells in the pancreas of most species 
including adult man would support this notion. Nilsson, Yalow et al. (1973) 
failed to detect gastrin in the pancreas of the cat, dog or pig, whereas 
Thompson, Reeder et al. (1973) reported high concentrations (2 020 and 
2 800 ng/g) in the rat and cat pancreas, as well as in the frog. HONever, 
these values may in fact be a printing error, since in the same paper these 
authors quote values in the units 11 pg/g 11 as opposed to the units "ng/g 11 
shown in their table. If in fact the true values are 2 020 and 2 800 pg/g, 
then this brings the pancreatic gastri n content of the rat and the cat, found 
by Thompson, Reeder et al. (1973), in line with the very low content of 
gastrin in mammalian pancreatic tissue extracts found in this study, as shown 
in table (4.111.1), in which instance the units are"pg/mg" tissue. 
The demonstration of immunoreactive gastrin in the serum of the dozen 
mammals tested, coupled with the higher levels detected by antiserum 2604-7 
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compared with antiserum G l, indicates the presence of both sulphated and 
non-sulphated gastrin in these species. !n the chicken, demonstration of 
immunoreactive gostrin in the serum 1s in keeping with the findings of immune-
reactive gastrin in extracts of the gizzard-duodenal junction of the chicken 
by Larsson, Sundler et al. (1974), the demonstration of biologically active 
gastrin in extracts of chicken gut by Clowo-Okorun and Amure (1973), and 
the immunoh istochemi ca I demonstration of gastri n cells in the chicken gut by 
Polak, Pearse et al. (1974). 
Both sulphated and non-sulphated gastrin were found in the serum of the 
reptile, Dasypeltis scabra scabra, and extracts of various gut tissues showed 
that the highest tissue gastrin content was in the intestine, in which case 
only sulphated gastrin was detected. Extracts of the stomach of this species 
contained approximately one tenth the amount of sulphated gastrin found in 
the intestine. The only other report of reptilian gastrin comes from Olowo-
Okorun (1975b) who demonstrated the presence of antral gastrin by bioassay 
of an extract prepared from the python, Python molurus. 
In three species of teleost and one elasmobranch, only sulphated gastrin 
was found in the serum. In a conclusive and well-controlled study, Hansen 
(1975) demonstrated the presence of biologically active gastrin in the antrum 
of an elasmobranch or cartilaginous fish, Rhinobatus productus, confirming 
the presence of this hormone in the lowest form of vertebrate investigated 
in this study. 
If one disregards the amphibia, the logical sequence of the evolution of 
gastrin in the species investigated in this study suggests that in the vertebrates 
gastrin first arose only in the sulphated form, as was found in the fishes 
investigated. In the reptile both species of gastrin were detected in the 
serum, whereas extracts of the gut of the snake investigated contained only 
sulphated gastrin, since antiserum G 1 failed to detect any immunoreactive 
material in these extracts. In all the species situated higher on the evolu-
tionary tree which were investigated, both sulphated and non-sulphated 
gastrin were detected in the serum. Thus it is tempting to speculate that 
gastrin was present in the fishes in the sulphated form, and only in later 
evolutionary development did the non-sulphated species of gastrin appear. 
This would imply that the sulphated molecule was the more stable, and 
resisted evolutionary change. 
The failure to detect immunoreactive gastrin in the invertebrate species 
studied using antiserum G l, which measures primarily non-sulphated hepta-
decapeptide gastrin, could be explained 1n the light of this hypothesis. 
Since the invertebrate extracts were not measured with antiserum 2604-7 
as wel I, it was not established whether sulphated gastrin was present in 
these species, which included representatives of the phyla Coelenterata, 
Mollusca, Crustacea and Echinodermata. However, it is felt that these 
results would have been negative. 
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The finding of a negligible amount of non-sulphated gastrin in extracts 
of the snail, Helix~- which amounted to only 0,0171% of that of the 
human antrum is upheld by the failure of Fritsch, Van Noorden et al. (1976) 
to demonstrate gastrin-containing cells in the intestine of another molluscan 
species, Mytilus edulis, using the technique of immunofluorescence. 
The findings in this study are difficult to reconcile with those of Straus, 
Yalow et al. (1975), who measured gastrin levels in the blood of two species 
of mollusc, one being the land snail, Otala lactea, which were comparable 
to the levels found in the human circulation. The immunoreactive g::istrin 
content of the intestinal tissues investigated by Straus, Yalow et al. (1975) 
was roughly one hundred fold greater than the gastrin content of the total 
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body tissues extracted in the case of Helix~· in this study. In ac!dition, 
Straus, Yalow et al. (1975) demonstrated molecular heterogeneity of their 
molluscan gastrin using Sephadex G-50 chromatography. However, certain 
objections can be raised against this study. Firstly, the antiserum used by 
Straus, Yalow et cl. (1975) was raised to crude porcine gastr:n, which 
means that it may not be entirely specific for gastrin only but may measure 
additional peptides such as CCK-PZ. Secondly, the exact position of the 
smaller gastrin species in the eiution profile on Sephadex G-50 was a con-
siderable distance from the 1251-porcine heptadecapeptide gastrin I marker, 
suggesting that this molecular species may in fact represent a small CCK-PZ 
peptide and not G-17 gastrin. However, this is a criticism which could be 
levelled at some of the elution profiles in this study as well, and is a 
reminder that the technique of Sephadex gel filtration only permits inference 
of the nature of the molecular species fractionated from its molecular size, 
but does not provide information on the precise chemical nature of the 
molecule. 
No ol·her studies concerning gastri n in invertebrates have been reported. 
Gastrin-containing cells were demonstrated by immunofluorescence in the 
II intestinal epithelium of the hagfish, Myxine glutinosa, (Qtberg, Van Noorden 
et al., 1976) confirming the presence of this hormone in the cyclostomes. 
The cyclostomata are the only living representatives of the class Agnatha 
(Romer, 1971), the earliest class in the subphylum Vertebrata, having arisen 
rn the Ordovician period, some 480 million years ago. 
Coupling the findings of gastrin distribution in this investigation, which 
failed to demonstrate gastrin in invertebrate tissues, with the immunohisto-
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chemical demonstration of gostrin-containing cells in the cyclostomata (Ostberg, 
Van Noorden et al., 1976) makes it tempting to suggest that gastrin arose 
for the first time in the lowest class of vertebrates, the Agnatha. One 
could postulate that the sulphated gastrin species arose at this time and 
persisted until some time in the Carboniferous Period, 300 million years 
ago, when the reptiles emerged, end non-sulphated gastrin appeared for 
the first time. This 1s postulated on the basis of the finding of non-
sulphated gastrin for the first time in the species of reptile examined in 
this study. 
The evolutionary origins of the pancreatic peptide hormones, insulin 
and g! ucagon, have been fairly well established. lmmunoreactive insulin 
has been demonstrated in the intestines of molluscs, echinoderms, crusta-
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ceans, tunicates and many vertebrates (Wilson and Falkmer, 1965; Davidson, 
Falkmer et al., 1971). Glucagon immunoreactivity has been convincingly 
demonstrated in higher vertebrates and there is evidence, although less 
concrete, for the presence of immunoreactive glucagon in the mollusca and 
the crustacea (Assen, Tchobroutsky et al., 1969). 
Makhlouf (1974) has suggested that secretin and insulin were present in 
invertebrate species and that glucagon and sastrin arose for the first time in 
the gnathostomes, coincidentally with the development of jaws and a stomach. 
Biological activity suggesting the presence of the structurally related hormone, 
CCK-PZ, as well as secretin, was found in the intestine of the lowest form 
of agnathan vertebrates, two species of the order cyclostomata, by Barrington 
and Dockray (1970). Makhlouf (1974) proposed that CCK-PZ and secretin 
are the molecular ancestors of gastrin and glucagon respectively. 
Thus the demonstration of gastrin-containing cells in the gut of an 
II 
agnathan vertebrate by Ostberg, Van Noorden et al. (1976) dates the 
appearance of gastrin earlier than suggested by Makhlouf (1974). The 
theory of origin of the gut peptide hormones proposed by Makhlouf (1974) 
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1s, however, a very attradive one, and it would be unwise to discount it 
on the basis of one report, especially a report based on immunohistochemical 
observations, which may be subject to sources of error based on cross-reaction 
between related hormones. It is probably fair to assume that gastrin appeared 
for the first time either just before or coincident with the appearance of the 
gnathostomes. It will be difficult to obtain much information on this aspect 
because most of the agnathan species are extinct 1 but confirmation of the 
presence of gastrin in the lwo living species of cyclostome by other workers 
will be useful. In addition, it would be of value to determine whether 
immunoreactive gastrin is present in extracts cf the tunicate, Cione~., 
which belongs to the subphylum Urochordata, a division of the phylum 
Chordata. This is an accessible species which arose in evolution after the 
invertebrates, but before the subphylum Vertebrata, and would thus form an 
additional link in such investigations. 
The arrangement of hormone producing cells in these early species differs 
from that of present day mammals, in which the endocrine cells have become 
grouped into more discrete areas and in some instances into hormone pro-
ducing glands. The gastrin-containing cells in the hagfish, described by 
II 
Ostberg, Van Noorden et al. (1976) were found scattered amongst the 
intestinal epithelial cells, as was the case for cells containing pentagastrin, 
caerulein and glucagon. The insulin-containing beta cells in this species 
were four.d in islet tissue parenchyma located around the bile duct and 
II 
intestine (Ostberg, Van Noorden et al., 1976). The gastrin-containing 
cells in the hagfish differed from those of mammals in that the APUD 
characteristics could not be demonstrated in these cells. However, the 
cytochemical architecture of the gastrin-containing cell in the hagfish 
was of the "open type", extending from the basal membrane to the lumena/ 
surface of the gut, a primitive arrangement which has been retained in the 
momma lion antral G-cell to:lay. 
The functions subserved by these hormones found in primitive vertebrate 
species aimost certainly differ from their functions in mammals to a certain 
extent, because the digestive systems of these animals are not as complex as 
those of higher mammals. For example, Barrington and Dockray (1970) 
suggested that the substances with secretin and CCK-PZ activity found in 
the river and marine lamprey may act locally as tissue hormones, released 
for instance by secretagogues in f·he food. Steiner, Kemmler et al. (i974) 
suggested that many peptide hormones evolved from more primitive enzymes 
such as secreted hydrolases, and Adelson (1971) also proposed that many of 
the secreted proteins of vertebrates originated among the digestive enzymes 
of the gut of pre-vertebrate species. 
The current concept that many gut peptide hormones may also have a 
neurotransmitter or regulatory function, as has been suggested in the case of 
somatostatin (Polak, Pearse et al., 1975), is upheld by the recent findings 
of gut-related peptides in the brain and neural tissue of several species. 
A brain gastrin peptide (BGP) has been described in the cerebral cortex and 
other parts of the brain of the human, dog, pigeon, frog and trout by 
Vanderhaegen, Signeau et al. (1975). Thus there is evidence for this 
peptide, which is immunologically similar to but not identical with gastrin 
(2-17), in species dating back to the fishes. CCK-PZ-like peptides have 
been described in the brain of the rat, pig and dog (Dockray, 1976). 
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Straus, ,\i\uller et al. (1977) confirmed these findings by describing a peptide 
resembling the (-terminal octapeptide of CCK-PZ in the rat cerebral cortex, 
and two CCK-PZ-like peptides were found in extracts of pig cerebral cortex 
by Muller, Strous et al. (1977). Vasoactive intestinal polypeptide (VIP) 
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has been demonstrated in brain and intestinal tissue of the human and the 
pig by Said and Rosenberg (1976) and Bryant, Bloom et al. (1976). Further 
studies on the distribution of these "neurotransmitter" peptides in lower verte-
brate species and possibly invertebrates should help clarify the physiological 
significance and interrelationships of these neural and gut related peptides. 
Since much of the foregoing discussion on the evolutionary origin of the 
gastrin molecule embraces the aspect of the presence or absence of a sulphate 
group on the tyrosine residue situated six positions from the (-terminus, the 
significance of sulphation in the related hormones, CCK-PZ and caerulein 
should be mentioned. Both sulphated and non-sulphated forms of heptadeca-
peptide gastrin are biologically active {Gregory and Tracy, 1964), and both 
sulphated and non-sulphated versions of the larger and smaller gastrin peptides 
have been described, although the relative proportions of sulphated to non-
sulphated gastri ns differ in man and hog ( Gregory and Tracy, 1975). In the 
case of CCK-PZ and caerulein, both have the identical (-terminal octapeptide 
sequence except for one residue, and both possess a sulphated tyrosine residue 
in the seventh position from the (-terminus {Ondetti, Plusec et al., 1970; 
Anastasi, Erspamer et al., 1967). Unlike gastrin, the presence of this sulphate 
group is essential for biological activity in the case of caerulein (Johnson, 
Stening and Grossman, 1970) and CCK-PZ {Erspamer, 1973). The overlap 
in actions produced by pharmacologic doses of the three peptides caerulein, 
CCK-PZ and gastrin II 1s a result of the structural similarities between the 
molecules and the fact that they al I contain the identical pentapeptide 
sequence. 
Since it has been suggested that CCK-PZ is the molecular ancestor of 
gastrin (Makhlouf, 1974), and CCK-PZ is only active in the sulphated form, 
the observations in this study that gastrin arose for the first time in the 
sulphated form, and is present in higher species in both sulphated and non-
sulphated forms suggest that in more recent times the gastrin molecule lost 
the prerequisite of a sulphated tyrosine for biological activity. This is con-
firmed by the finding of biologically active gastrin in both sulphated and 
non-sulphated forms today (Gregory and Tracy, 1964; 1975). 
These studies demonstrated that the gastrin-like material found in the 
serum and skin extracts of the frog, Xenopus laevis, differed considerably 
from heptadecapeptide gastrin. The material found may well be caerulein, 
since the majority of immunoreactive material obtained on Sephadex G-25/ 
G-50 chromatography was of a molecular weight smaller than the G-17 I 
marker, and caerulein is composed of 10 amino acids (Erspamer, 1973). 
This suggestion seems likely in view of the demonstration by Anastasi, 
Bertaccini et al. (1970) of the presence of caerulein in extracts of the skin 
of the same species of frog. Measurement of this gastrin-like material in 
tissue extracts of Xenopus laevis here showed higher concentrations in the 
skin than at any other site, except in the brain tissue extract. However, 
this high ratio is thought to be artefactual due to the low protein content 
of brain tissue, resulting in a spuriously elevated "gastrin" to total protein 
ratio in this instance. The readings obtained with antiserum G l in the 
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skin and stomach extracts of this species were greater than those found using 
antiserum 2604-7. This is the only instance where readings with 2604-7 
antiserum were not greater than those obtained with G l antiserum, and 
again points to the fact that material different from pure heptadecapeptide 
gastrin is present in these tissues. 
Fractionation of the serum of Xenopus laevis produced one peak eluting 
in the void volume and a brocd poorly-defined peak in the molecular weight 
region which may correspond to caerulein. This pattern differed from that 
found on G-50 Sephadex chromatography cf serum from the frog Rana cates-
beiana by Gibson, Mihas et al. (1976) in which case two well-defined 
peaks, one in the void volume and one coincident with the natural G-34 
marker, were obtained. Rana and Xenoous, although both anuran amphibia, 
may differ considerably in their way of life; whereas Rana can survive on 
land for long periods of time, Xenopus is more dependent on an aquatic 
habitat for survival. It would thus appear logical to find a molecular hetero-
geneity of gastrin in Rana which resembles that in man more closely than did 
that found in Xenopus. Unfortunate I y, the report of Gibson, Mi has et al. 
(1976) does not allow comparison of the nature of immuncreactive gastrin in 
Rana skin extracts with that of Xenopus described in this study. 
It is obvious that the 11 gastrin 11 immunoreactivity found in the serum and 
skin extracts of Xenopus laevis does not fall in with the proposed hypothesis 
on the evolutionary origin of gastrin based on measurements of gastrin in 
other vertebrate species described in this study. One needs to ask what the 
significance of this gastrin-like peptide in this species is, and whether in 
fact it was actually caerulein that was being measured. A reason for the 
presence of high concentrations of this material in the skin of Xenopus must 
be found. 
The true story, when it emerges, may turn out to be far more complex 
than imagined. According to Erspamer (1973) seven new polypeptides have 
been identified in and ;:iurified from amphibian skin. These include physa-
laemin, phyllokinin, phyllomedusin, caerulein, phyllocaerulein, alytesin and 
bombesin. All these polypeptides have been synthesised subsequent to their 
purification (Erspamer, 1973) and many contain sequences common to 
mammalian neural and endocrine peptides (Pearse, 1976). Recently the 
presence of the mammalian tripeptide, thyrotropin-releasing hormone in 
the skin of the frog Rana pipiens has been demonstrated (Jackson and 
Reichlin, 1977). This peptide occurred in the frog skin in concentrations 
double that found in the hypothalamus of this species, and it was shown to 
be biologically active. These findings also point to the fact that frog skin 
may be a huge endocrine organ (Jackson and Reichlin, 1977). 
A logical explanation for these findings has been proposed by Pearse 
(1976). He points out that anuran cutaneous glands arise from specialised 
ectoderm which originates in the embryonic region adjacent to the neural 
plate and neural crest. It is thus easy to see that these glands have a 
common origin with cells producing the brain and intestinal peptides. · 
Pearse (1976) has suggested that the cutaneous glands and skin peptides of 
the frog evolved in parallel with the nervous system in response to the 
hostile external environment. 
Several possible roles of the gastrin-like peptide found in the skin 
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extracts and serum of Xenopus laevis in this study may be suggested. Since 
this amphibian species is mainly aquatic in nature, this peptide may perhaps 
subserve a function connected with regulation of passage of water and electro-
lytes through the skin, as has been suggested by Erspamer (1973). Along the 
same lines, one could suggest that this material plays a role regarding 
external secretion of the skin, as a pheromone or even as a sexual attractant. 
It may even transpire that this peptide is important as a growth factor, 
influencing the development of young tadpoles. This suggestion is substan-
tiated by the demonstration that gastrin possesses a trophic action in mammals; 
for example, it has been shOVvn to affect the tissues of the gastrointestina I 
tract in the rat by increasing the synthesi:; and total tissue content of DNA 
(Johnson, 1977). 
The following section deals with studies investigating aspects of the 
porcine and rat I iver in relation to heptadecapeptide gastri n, as well as 
measurement of kinetic parameters of infused synthetic human heptadeca-
peptide gastrin I in the porcine circulation. 
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The Role of the Liver in Relation to Circulating Gastrin and Kinetics of 
G-17 I Gastrin in the Porcine Circulation 
The half-life value of 3,19 minutes for synthetic human G-17 gastrin 
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in the porcine circulation found in this study using samples drawn at the 
carotid arterial site is in gooo agreement with the values found in the dog 
following infusion of natural or synthetic gastrin preparations (Reeder, 
Jackson et al., 1972; Thompson,Reeder et al., 1973; Schrumpf and Semb, 
1973; Walsh, Debas et al., 1974; Strunz, Walsh et al., 1978) as shown 
in table (2.IX.1). The half-life of heptadecapeptide gastrin in the circu-
lation is rapid in comparison with the clearance rate of pancreatic peptide 
hormones from the circulation. The half-life time of insulin in the circu-
lotion has been shown to lie between 13,8 and 50 minutes, as determined 
by infusion of 131 l-labelled insulin into man, stimulation of endogenous 
insulin levels by glucose infusion, and perfusion of the isolated rat liver 
(Berson, Yalow et al., 1956; Berson and Yalow, 1966; Rubenstein, 
Pottenger, Mako, Getz and Steiner, 1972). The removal of proinsulin 
from the circulation was ten to fifteen times slower than that of insuiin 
(Rubenstein, Pottenger et al., 1972). The half-life time for clearance of 
endogenous glucagon in the pig was 42-55 minutes, and 2-4 and 36-57 
minutes for the first and second disappearance phases of exogenous glucagon 
from the porcine circulation (Van Hoorn, Vinik and Van Hoorn-Hickman, 
1978). Pancreatic polypeptide (P.P .) had an average half-life time of 34 
minutes in the circulation, comprising first end second disappearance com-
ponents of 6,8 and 60 minutes respectively (Sive, Lund, Van Tonder and 
Vinik, 1977; Sive, 1978). 
269 
In contrast to the pancreatic peptide hormones, the gut peptide hormones 
appear to be more rapidly removed from the circulation. Recent reports have 
shown a half-life time of 4,06 minutes for removal of exogenous secretin from 
the circulation in man (Kolts and McGuigan, 1977); 3, l minutes for the 
clearance of exogenous porcine VIP from the canine circulation (Strunz, 
Walsh, Bloom, Thompson and Grossman, 1977); and half-life values of 
4,36 minutes following infusion of exogenous synthetic 13-norleucine motilin 
in man, and 4,56 minutes for the clearance of endogenous motilin from the 
human circulation (Mitznegg, Bloom, Domschke, Domschke, Wuensch and 
Demi ing, 1977). 
Since the half-life of gastrin in the circulation is very short, a study 
was designed to investigate whether the liver was responsible for metabolism 
and clearance of gastrin from the circuiation. This was deemed possible in 
the light of reports of hepatic inactivation of the peptide hormones insulin 
(Samols and Ryder, 1961; Kaden, Harding et al., 1973), glucagon (Kenny, 
1956) and secretin (Skillman, Silen et al., 1962). In addition, it seemed 
likely that the liver may affect circulating gastrin because all gastrin pro-
duced by the gut passes through the liver before it reaches its primary site 
of action, the parietal cells of the gastric fundus. 
The study showed that the pig Ii ver had no effect on circulating levels 
of immunoreactive endogenous gastrin or on elevated levels simulating post-
prandial levels and greater, produced by infusion of synthetic human hepta-
decapeptide gastrin I (Vinik, Hickman et a I., 1978). Following stepwise 
infusions an increased mass of gastrin was presented to the liver, which 
did not differ significantly from the corresponding increased gastrin mass 
leaving the liver at each stage of the infusion. These findings confirm the 
reports that the I iver did not remove immunoreactive G- 17 from the 
circulation (McGuigo.n, Joffe et al., 1970; Reeder, Brandt et al., 1972; 
Dencker, H8kanson et al., 1973), and the demonstration that the liver did 
not reduce the biological activity of gastrin by Gillespie and Grossman 
(1962). In contrast, the findings do net support the report by Thompson, 
Reeder et al. (1969) i·har the liver inactivates 46% of supraphysiologica! 
levels of G-17 g::istrin presented to it, but this assay was too insensitive 
to measure basal levels of circulating gastrin. 
It wcs further evident that even if one considered variations in hepatic 
arterial, portal and venous blood flow and liver mass, quantitatively the 
liver had no effect on gastrin transit. 
In keeping with these findings that the liver did not remove immune-
reactive G- i7 from the circulation is the observation by Le Reith, Vinik 
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et al. (1975) that immunoreactive gastrin levels were not elevated in patients 
with chronic liver disease. In other words, an alternative site(s) for the 
removal of gastrin must exist. The finding of elevated gastrin levels in 
renal disease reported by Dent, Hirsch et al. (1972), Korman, Laver et al. 
(1972), Le Reith, Vinik et al. (1975), Sullivan, Tustanoff et al. (1976) 
and many others suggests that the kidney may be important in this respect. 
Although this study showed that G-17 gastrin was not removed by the 
pig liver (Vinik, Hickman et al., 1978) or the rat liver (Sacks, Vinik et 
al., 1978) these measurements were of immunoreactive gastrin, and no 
estimations of biological gastrin activity were made. Both these studies 
involved measurements made with G 1 antiserum, which has been shown to 
react equally well with human and porcine G-17 and to recognise the 
(8-17) sequence of non-sulphated heptadecapeptide gastrin, as described in 
section 4 l(iv). Since this antigenic region includes the (-terminal penta-
peptide amide sequence of gastrin, which is responsible for its biological 
activity (Tracy and Gregory, 1964), it is likely that measurements with this 
antiserum reflect biological activity as well cs immunoreactivity. This is 
substantiated by the demonstration that antiserum G 1 failed to cross-react 
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with heptadecapeptide gastrin fragments which did not include the C-terminal 
4 amino acids, such as the (6-13} and (9-13) sequences, as shewn in section 
4 l(iv). Thus if cleavage of the biologically active portion from the rest of 
the molecule had occurred it is unlikely that any remaining inactive fragments 
would have been detected with antiserum G 1. However, such a situation 
was described by Lewin, Hunziker et al. (1971), who showed biological 
inactivation of gastrin by the liver with no apparent effect on immunoreactive 
measurements of gastrin in the same study. 
It may mean that antiserum G 1 continues to detect the carboxyl-
terminal portion of gastrin despite alterations which would reduce biological 
potency. Hence changes in the molecular form during hepatic transit could 
account for qualitative rather than quantitative effects. 
No changes in the molecular form of gastrin for up to 60 minutes of 
perfusion of the isolated rat liver in situ with synthetic human G-17 I were 
detected using Sephadex G-25/G-50 chromatography, as shown in figure 
(4.V.(i).2.). In the case of the pig liver, chromatography of serum samples 
collected during the second and third hours of stepwise infusion of synthetic 
human G-17 I into the pig suggested changes in the molecular size of gastrin 
in the porcine circulation. Samples drawn from the venous and portal sites 
in two pigs revealed broadening of the peaks in the chromatographic profile 
with a suggestion of the presence of gastrin species smaller than the hepta-
decapeptide (figures (4.IV.5.) and (4.IV.7.)). Chromatography of a serum 
sample drawn from the arterial site in one pig suggested the presence of a 
larger form of gastrin in addition to the heptadecapeptide, as shown in 
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figure (4.IV.6.). 
The discrepancy in the chromatographic profiles of gastrin obtained in 
the rat and pig transhepatic studies may be due to differences in the hepatic 
handling of G-17 gastrin by these two species. Alternatively the differences 
could be explained by the longer time of circulation of the exogenous gastrin 
in the pig cs opposed to the rat, or by the fact that the study on the pig 
was performed in vivo, whereas that on the rat was performed in situ, so 
that the former study reflects measurements of immunoreactive gastrin in 
blood, whereas the latter involved measurements in perfusion medium. It 
may be that the smaller peptides detected in the venous and portal samples 
of the pig are artefacts or breakdown products produced as a result of pro-
longed circulation in vivo. It is difficult to explain the appearance of a 
larger gastrin form in the arterial circulation after prolonged circulation, 
as this does not correlate with the hypothetical biosynthetic sequence of 
gastrin leading from larger to smaller forms as discussed in section 2 Vl(iii). 
Neither is this sequence supported by the observation in vivo that 
infusion of pure human G-34 into a human subject produced a clear cut 
peak of G-34 on gel chromatography, with no evidence of conversion to 
G-17 or other smaller gastrin species (Walsh, 1975b). However, infusion 
of supraphysiological doses of a hormone does not necessarily reflect the 
normal physiological situation, and it may well be that in the physiological 
situation such conversion from larger to smal !er forms does occur. In the 
same study Walsh (1975b) showed that pure human G-17 I eluted as a 
single well-defined peak on gel chromatography following infusion of this 
material into a human. Walsh (1975b) did not specify how long after 
commencement of the infusion the samples were collected for chromate-
graphy. Possibly they were collected earlier than the samples used for 
chromatography in this study, and had our samples been collected earlier 
during the gastrin infusion a similar clean peak of G-17 gastrin might have 
been obtained. 
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The failure of the rat liver to alter the molecular form of gastrin during 
~ situ perfusion, as revec!ecl by Sephadex chromatography, found in this 
study is in agreement with the demonstration of Dencker, H8kanson et al. 
(1973) of no difference in the immunoreactive gastrin components in human 
serum drawn from portal and peripheral sites. 
It thus appears from these studies and those reported by Gillespie and 
Grossman (1962); McGuigan, Jaffe et al. (1970); Reeder, Brandt et al. 
(1972) and Dencker, H8kanson et cl. (1973) that the liver does not inac-
tivate heptadecapeptide gastri n. That the liver appears to i na cti vote gastri n 
peptides shorter than the heptadecapeptide has been conclusively demonstrated 
by Temperley, Stagg and Wyllie (1971), Stagg, Temperley et al. (1971) 
and Debas and Grossman, 1974) in studies in the dog and rat. 
The data on ligandin binding of gastrin add to the conflict of whether 
or not the liver inactivates gastrin. If the data on altered molecular size 
after hepatic transit in the pig can be confirmed, it may be that g::istrin is 
bound to ligandin in which form it circulates. This may represent inacti-
vation, since ostensibly the active site(s) could be masked by binding to 
the protein. Further studies are needed to establish that this postulate is 
indeed true. Alternatively, the binding could represent merely an artefactual 
situation created by the experimental protocol. Indeed, the studies with 
isolated rot I iver tend to support the latter suggestion. Because of the 
possibility of species differences it would be premature to draw any firm 
conclusions. 
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The sites of inactivation of heptadecapeptide gastrin include the gastric 
fundus (Evans, Reeder et al., 1974), small bowel (Becker, Reeder et al., 
1973) and kidney, as suggested by the studies of Dent, Hirsch et al. (1972), 
Korman, Laver et al. (1972), Clendinnen, Reeder et al. (1973), Suliivan, 
Tustanoff et al. (l 976) and others, as outlined in section 2 IX(i). The renal 
clearance of gastrin of 80 ml/minute amounts to a small fraction of the total 
clearance of gastrin of approximately 2 litres/minute determined in this study. 
Thus it appears that although elevated gastrin levels have been reported in 
many instances of renal disease (Dent, Hirsch et al., 1972; Korman, Laver 
et al., 1972; Clendinnen, Reeder et al., 1973; Le Roith, Vinik et al., 
1975; Sullivan, Tustanoff et al., 1976), the actual contribution of the 
kidneys to removal of gastri n from the circulation may not be as large as 
is sometimes thought. The major site of inactivation of gastrin has not been 
definitely established, but it is likely that the gastric fundus may play a 
large role, and the possibility that gastrin is inactivated locally at the site 
of its target organ, the parietal eel I, is real. This suggestion is borne out 
by the report of binding and inactivation of 125 1-labelled gastrin by isolated 
gastric mucosa! cells by Del Mazo and McGuigan (1976) and the localisation 
of gastrin receptors on isolated rat parietal cells by Soumarmon, Cheret et al. 
(1977). 
The metabolic clearance rate of 2,014 litres/minute or 67,8 ml/kg/min 
found in this study using samples collected from the arterial site is in good 
agreement with the value of 83 ml/kg/min found in the dog following infusion 
of NHG-171 by Debes, Walsh et al. (1974) and the value of 70 ml/kg/min 
following infusion of SHG into the dog by Schrumpf and Semb (1973). The 
high M.C.R. coupled with the short half-life of 3,19 min for SHG-171 1n 
the pig found in this study agrees well with the corresponding va !ues of 
70 ml/kg/min and 3,7 min found by Schrumpf and Semb (1973), 3,2 min 
for T! found by Walsh, Debas et al. (1974) and 83 ml/kg/min found by 
Debas, Walsh et al. (1974) following infusion of synthetic and natural G-17 
gastrins into dogs. This suggests that human G-17 gastrin is cleared from 
the porcine and canine circulations in a similar manner, and that the 
clearance of heterologous gastrin in this study was more rapid than the 
clearance of homologous gastrin. This was illustrated by the findings of 
longer half-life values and lower metabolic clearance rates of human gastrin 
follo,,,ing infusion into human subjects by Ganguli, Elder et al. (1970) 
(T! = 5,5 - 10,5 min), Schrumpf, Semb et al. (1973) (T! = 7,5 min and 
12,8 min in first and second disappearance phases, M .C.R. = 9, 1 ml/kg/ 
min) and Wa !sh, Maxwel I et al. (1975) (T! = 5 min, M.C. R. = 16 ,5 ml/ 
min). 
The higher metabolic clearance rate found in the portal circulation 
(3,232 I/min) as opposed to the value found in the arterial circulation 
(2,014 I/min) may be due to extraction of gastrin from the circulation by 
the gastric fund us. If this were the only reason for the differences found 
at this site, it would be expected that the T! value would be shorter in 
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the portal than in the arterial circulation. In fact the opposite was found, 
with T! values of 3,19; 4,23 and 4,32 minutes determined in the arterial, 
portal and venous circulations respectively during the first ten minutes after 
cessation of the gastrin infusion (table (4.IV.9)). This deviation from the 
expected findings could be due to the production of gastrin at one or more 
sites in the gut, which would result in a longer disappearance time of gastrin 
measured at the portal site. Thus measurements in the portal circulation 
represent a balance between secretion of gastrin into the circulation and 
extraction of gastrin by the gastric fundus. 
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The fact that the M.C.R. found in the hepatic venous circulation 
(3,170 I/min) was similar to that measured in the portal suggests that passage 
through the liver had no effect on this parameter, in keeping with the 
findings in this study that the liver had no effect on gastrin concentrations 
in the circulation, even at supraphysiologic doses of exogenous gastrin. 
As shown in table (4.IV.11), when the M.C.R. was determined using 
the two highest dose levels of infused gastrin the values obtained at the 
arterial, portal and venous sites were lower than the mean M.C.R. values 
calculated using the mean of values obtained at all three dose levels of 
gastrin in each case. This discrepancy, found by expressing the findings 
in the same study in two different ways, emphasises how variation between 
values for the same parameter can occur based merely on the manner in 
which the results of the calculations are expressed. Naturally, further 
differences arise between studies in which the infusion is given in a step-
wise manner as opposed to a constant dose over a prolonged period of time, 
and in instances where studies are commenced by administration of a loading 
dose before the infusion. Further variation in values for these parameters 
may be due to sampling of blood at different sites, as illustrated by the 
differences in M.CoR. values found using samples drawn from the arterial, 
portal and hepatic venous circulations in the pig. 
Similar variation was found in the values of V, the space of distribution 
of human G-17 gastrin, determined from samples drawn at these sites in the 
pig. As shown in table (4.IV.10), the space of distribution of G-17 deter-
mined using arterial samples was 6,401 litres or 0,216 I/kg, which amounts 
to 21,6% of body weight, or roughly equal to the extracellular fluid volume. 
However, the same parameter determined using portal and venous samples was 
more than double this value in both cases, giving spaces of distribution of 
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46% and 56% of body weight respectively. This distortion in the estimations 
of volume of distribution of infused gastrin may be due to the endogenous 
gastrin secreted into the portal circulation, which correspondingly affected 
estimations in hepatic venous blood. The space of distribution of 21,6% of 
body weight determined using the arterial samples is in good agreement with 
the value of 0,24 I/kg for the space of distribution of NHG-17 I in the dog, 
found by Walsh, Debas et al. (1974), and is close to the values of 19,2% 
and 28 ,5% of body weight for the distribution of SHG-17 I in the dog 
reported by McGuigan, Isaza et al. (1971). The finding thct SHG-17 I 
distributed itself in a volume roughly equivalent to the extracellular fluid 
volume in this study in the pig is not supported by the reports of spaces of 
distribution of infused gastrin equal to plasmcJ volume in the dog (Strunz, 
Walsh et al., 1978), or twice plasma volume in the human (Walsh, Maxwell 
et al., 1975), or twice plasma volume following pulse injection in the dog, 
as reported by Straus and Yalow (1974). 
This great variation in values determined for these various parameters 
between different groups almost certainly reflects differences in experimental 
design and te~hnique, as already discussed, as well as differences in sites of 
sampling in the experimental animals. As has been shown in this study, the 
values of T!, M.C.R. and Vall varied according to the sampling site. Very 
few of the studies reviewed in section 2 IX(iii) actually specified where the 
samples were collected and in those that did, the sampling site involved a 
peripheral vein (McGuigan, Isaza et al., 1971; Straus and Yalow, 1974; 
Le Reith, Vinik et al., 1975). It seems reasonable to assume that when 
the sampling site is not specified it was in fact a peripheral venous site. 
Considering the various possibilities as regards experimental determination of 
these different paramel·ers, it is hardly surprising that such great variation 
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between the work of different g;oups occurs. Most of the studies on gastrin 
kinetics have been reported in the human or the dog. it would appear that, 
bearing in mind the discrepancies due to experimental technique, the kinetics 
of S HG-17 I in the pig are similar to those found by other workers in the 
dog under similar conditions. 
As shown in table (4.IV.12), the daily production of gastrin in the pig 
was approximately 120 µg/day as determined usrng the M.C.R. estimations 
made at the arterial site. The portal gastrin production was estimated to be 
approximately 19 µg/day as determined in a separate group of pigs. Bearing 
in mind that these two estimations were made in two separate groups of pigs 
and that these figures were arrived at by different calculations in the two 
instances, the discrepancy between the two estimations is still remarkable. 
One cannot escape the obvious conclusion that there is an alternate site or 
sites of gastrin production, in the pig at least. In looking for possible can-
didates for sites of extra-gastric gastrin secretion, the recent reports of the 
presence of gastrin-like peptides in the brain by Vanderhaegen, Signeau et 
al. (1975), Dockray (1976), Muller, Straus et al. (1977) and Straus, Muller 
et aL (1977) as discussed in section 2 Vl(i) suggest the possibility that brain 
and neural tissue may be far more important sites of gastrin production than 
previously believed. The validity of these observations and suggestions would 
be substantiated by further work in this exciting field. 
CHAPTER 6 
SUM/v\ARY AND CONCLUSIONS 
In this chapter a summary of the most important findings of the studies 
for this thesis is presented. This is followed by suggestions for lines of 
future research arising from the findings documented in this thesis. 
A sensitive gastrin rcdioimmunoassay, capable of detecting basal levels 
of circulating gastrin as low as 8 ,2 pg/ml was established and the assay 
criteria of validity and reliability were fulfilled. Three antisera used in 
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the radioimmunoassay system were characterised with respect to their affinities 
for gastrin and their degree of cross-reaction with synthetic gastrin fragments, 
various natural and synthetic gastrin peptides and related gut peptides. The 
identity of gastrin in normal and hypergastrinaemic serum with the synthetic 
human heptadecapeptide standard was confirmed by dilution curves in the 
assay, and the recovery of gastrin extracted from tissues by boiling in water 
combined with various treatments was determined. The behaviour of pig 
serum on dilution in the assay was identical with that of the gastrin sl'andard, 
confirming that porcine serum gastrin could be measured with this assay 
system. 
Using the radioimmunoassay system incorporating antiserum G 1, a normal 
range of basal circulating gastrin levels in the human was determined. Serum 
gastrin measurements in a large group of patients showed no correlation be-
tween age or ethnic group and circulating gastrin levels, although signifi-
cantly higher levels of gastrin were found in females than in males. Elevated 
serum gastrin levels were recorded in disease conditions such as Zollinger-
Ellison syndrome, pernicious anaemia, duodenal ulcer and gastric carcinoma. 
In normal subjects elevated IEavels of serum gastrin were produced by 
administration of oral Oxo and intravenous arginine. 
The heterogeneity of gastrin in serum from a hypergastrinaemic patient 
wos investigated using Sephcdex G-25/G-50 gel chromatography. The 
chromatographic profile revealed at least four and possibly five components 
of gastrin, in agreement with the findings of other workers in this field. 
The elution profiles of natura I human big and heptadecapeptide gastrins in 
the chromatographic system were established. 
The gastrin content of extracts prepared from human antral and duodenal 
tissue biopsies was measured and characterised immunochemi cal ly end the 
heterogeneity of the gastrin in these extracts was studied. The tissues were 
found to contain the same gastrin components as did serum, with a greater 
proportion of the heptadecapeptide species in the antral as opposed to the 
duodenal extracts. 
Measurement of the gastri n content of tissue extracts prepared from 
biopsies collected at various sites in the gastrointestinal tract of five 
mammalian species showed that the highest levels of gastrin occurred in 
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the antral extracts. Unlike the human, the duodenal gastrin content of 
these species was small relative to that of the antrum. Other sites where 
gastrin levels were found to be higher than expected included the rat fundus 
and the rabbit colon. 
Measurement of serum gastrin concentrations in nineteen vertebrate 
species with two antisera of known specificity revealed the presence of 
both sulphated and non-sulphated gcstrin types in all animals investigafed, 
with the exception of three species of bony fish and one cartilaginous fish, 
in which cases only sulphated gastrin was detected in the serum. This 
suggested the possibility that sulphated gastrin arose before non-sulphated 
gastrin in evolution. 
Inordinately high levels of a peptide displaying gastrin-1,ke immuno-
reactivity were measured in the serum and skin extract of the frog Xencpus 
laevis. An attempt to characterise this material by investigating its be-
haviour on dilution in the essay and on Sephadex gel filtration suggested 
the possibility that this material is similar to the decapeptide, caerulein, 
which has been isolated from the skin of the Australian bullfrog, Hyla 
caeru! ia, by Anastasi, Erspamer et a I. ( 1967). The nature of the gastri n-
1 ike material in frog skin and frog serum was different, as shown by the 
different elution profiles obtained on Sephadex chromatography of the two 
samples. 
Measurements of the content of immunoreactive "gastrin" in various 
tissue extracts prepared from the frog, Xenopus laevis, with two antisera 
of known specificity suggested that ihe immunoreactive material differed 
from gastrin, since higher levels were measured with antiserum G 1 than 
with antiserum 2604-7, in contrast to the situation found in plasma and 
tissues from higher species. 
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No remarkably high levels of gastrin-like immunoreactivity were recorded 
in the tissue extracts prepared from the snake, Dasypeltis scabra scabra. 
These findings, coupled with the "normal" levels of serum gastrin in the 
snake, were very different from the findings in the frog, Xenopus laevis. 
Suggestions relating to the significonce of these observations were discussed. 
No immunore:active gastrin was detected rn any tissue extracts prepared 
from invertebrates, represenl"i ng four different invertebrate phyla. The 
absence of gastrin at this stage in evolutionary development, coupled with 
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the findings of only sulphated gastrin in the fishes and both sulphated and 
non-sulphated gastrin in higher vertebrate species, suggested that the gastrin 
molecule arose in evolution at approximately the same time as the appearance 
of the gnathostomes. The evolutionary development of related gut hormones 
was discussed. 
Transhepatic measurements of circulating gastrin in the pig revealed 
that the liver had no effect on basal endogenous or elevated levels of 
exogenous gastrin produced by prolonged infusion of synthetic human hepta-
decapeptide gastri n. 
The daily production rate of gastrin at the portal site rn the pig was 
estimated to be approximately 20 micrograms. 
The half-life for the disappearance of infused SHG-17 I from the porcine 
circulation was 3, 19 minutes, as determined using samples drawn from the 
hepatic arterial circulation. 
Longer half-life values of 4,23 and 4,32 minutes, calculated using 
hepatic portal and hepatic venous samples are thought to be due to endo-
genous gastrin production into the portal circulation. 
The metabolic clearance rate of the infused gastrin was 2,014 litres/ 
minute or 67 ,8 ml/kg/min, when estimated using hepatic arterial samples. 
The corresponding values determined using samples obtained at the portal 
and venous sites were higher, reflecting the longer half-life values at these 
sites. 
The space of distribu!-ion of infused gastrin in the pig calculated from 
the arterial samples was 6,401 litres or 21,6% of body weight, which 
corresponds with the extracellular fluid volume. 
The total daily production of gastrin in the pig, calculated from the 
metabolic clearance rate, was of the order of 120 micrograms. Since the 
calculated portal production of gastrin was only 20 J.Jg/day, an alternative 
site or sites of gcstrin production is suggested. The possibility that neural 
tissue is a source of gastrin production appears feasible from these obser-
vat ions. 
283 
Sephadex G-25/G-50 chromatography of serum samples collected during 
the infusion suggested the appearance of a gastrin species larger than the 
heptadecapeptide at the arterial site during the 3rd hour of infusion of 
SHG-171, whereas at the portal and venous sites the presence of a smaller 
gastrin species in addition to the heptadecapeptide was detected after two 
hours of infusion. The significance of these observations is poorly understood. 
Perfusion of the isolated rat liver in situ with a plasma-free medium 
containing synthetic human heptadecapeptide gastrin showed that the rat 
liver did not change the levels of circulating gastrin either at physiologic 
or supraphysiologic dose levels. This is in agreement with the findings that 
the pig liver had no effect on basal or stimulated levels of circulating gastrin. 
Gel filtration of samples of perfusate collected at different times during 
the perfusion of the isolated rat liver revealed no change in the chromato-
graphic profile of the heptadecapeptide gastrin during the 60 minutes of 
perfusion. This is at variance with the appearance of smaller and larger 
gastrin species in the porcine circulation fol lowing prolonged infusion of 
SHG-171 in vivo. The additional peaks found in the porcine circulation 
may in part be due to artefacts produced by prolonged circulation in vivo. 
The binding of 125 1-labelled and unlabelled SHG-171 to the rat liver 
cytosol protein, ligandin, in vitro was demonstrated. This binding was 
specific for g.:strin and was not foLmd with the gut hormones insulin er 
glucagon. Bound 1251-gastrin could be displaced by addition of excess 
unlabelled gastrin and it was shown that the binding involved the gastrin 
molecule itself and not the 125 1odine label. 
This phenomenon of binding of gastrin by a rat liver protein does not 
correlate with the finding that the pig liver did not take up gastrin at 
high delivery rates. Whether the binding of gastrin to rat liver ligandin 
is the result of a non-specific ionic attraction due to the highly anionic 
nature of the gastrin molecule, or whether it represents a role of the 
liver in relation to gastrin which is not yet understood, remains to be 
explained. 
As is the case with most research, when one sets out to answer one 
question several more avenues open up during the investigation. This was 
experienced many times during the studies described here, so that many of 
the newly-posed questions remain unanswered. The following is an outline 
of possible lines of future research which stem from the findings reported in 
this thesis. 
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The successful production of an antiserum directed towards the N-terminal 
(l-17) portion of the big gastrin molecule, followed by measurement of the 
circulating levels of this gastrin fragment in normal subjects under basal and 
post-prandial conditions, and in hypergastrinaemic conditions would be in-
valuable for investigation of the possible biosynthetic precursor relationship 
of the G-34 and G-17 molecules. Measurement of gastrin at duodenal and 
antral sites in vivo and of gastrin secretion by in vitro oriented sheets of 
antral or duodenal mucosa with such an antiserum would bring us a long way 
towards understanding the significance of the different gastrin components at 
these hvo sites. 
Characterisation of the high levels of gastrin found in the rat fundus and 
rabbit colon by gel chromatography and dilution in the assay, using antisera 
of known specificity would help clarify the significance of these findings. 
The gastrin content of neural tissue should be systematically investigated 
by preparing extracts of various parts of the brain and perhaps large nerves, 
such as the vagus, from different species. Such a study would possibly 
substantiate the sprinkling of reports of the presence of gastrin or gastrin-
like peptides in brain and neural tissue which have appeared recently. In 
additicn,such an investigation would confirm or refute the suggestion that 
gastrin production by neural tissue may in part account for the difference 
in daily production of gastrin found in the whole body of the pig as opposed 
to the production at the portal site. Should such studies not be rewarding, 
alternative sites for gastrin production, in the pig at least, could be inves-
tigated. 
In order to verify the hypothesis put forward in this study concerning 
the evolutionary origin of the gastrin molecule, a study of the occurrence 
of gastrin measured with antisera of known specificity in other species 
situated on the evolutionary tree at the point where the vertebrates arose 
would be invaluable. Such an investigation wou!d, however, be limited by 
the number of species from this era which are living today. Collection of 
serum samples from a large number of teleosts and chondrichthyes for 
measurement with antisera specific for both sulphated and non-sulphated 
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types of gastrin would help verify the findings reported here. 
The immunoreactive gastrin-like material found in the serum and skin 
extracts of the frog, Xenopus !aevis, could be extracted in large amounts 
and purified, followed by testing of the immunological and biological 
activity of the pure peptide. Determination of the amino acid sequence 
of such a purified peptide would confirm whether it was in fact identical 
with caerulein. 
The significance of the gastrin-like material found in frog skin may 
relate to the stimulation of growth of tadpoles or possibly act as an ionic 
regulator or sexual attractant, and could be investigated. It may be that 
"gastrin" is a pheromone in the frog. 
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If sufficient amounts of the purified natural and synthetic gastrin pe-ptides 
were available, the response of the pig liver to infusion of increasing doses 
of these preparations could be investigated. The kinetics of these prepara-
tions in the porcine circulation could be studied in the same way as the 
kinetics of SHG-17 I in the pig were follO'Hed. Gel filtration of serum 
samples collected during the infusion would reveal any changes in the molecular 
forms in vivo, possibly throwing some light on the interconversion of the 
different gastrin components in vivo. 
Repetition of the study of the transhepatic response to basal and stimulated 
levels of circulating gastrin accompanied by measurements of both immuno-
reactive gastrin and measurements of gastri n bioactivity using a bioassay would 
confirm the assumption that the liver had no effect on the biological activity 
of gastrin. 
Further studies on the binding of gastrin to rat liver ligandin in vitro, 
such as displacement of bound 
1251-labelled gastrin with increasing concen-
trations of unlabelled gastrin, as in a radioimmunoassay system, would help 
to characterise the nature of the binding observed in these studies and 
possibly throw sorne light on its biological significance. 
These are some of the many unanswered questions raised by the studies 
in this thesis. Gastrin attracted me as a simple, well-defined peptide which 
would be easy to study. The ever increasing complexities as the studies 
progressed were exasperating at times, but some of the observations may 
prove useful as a basis for further study for such diverse disciplines as gastro-
enterology, endocrinology, neurology, dermatology and genetics. If I have 
succeeded in this small respect, I will feel vindicated for the sufferings and 
forbearance of my husband, supervisor and colleagues. 
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CHAPTER 7 
APPENDIX 
7 (i) Outline of McGuigan's Conjugation and Immunisation Procedures 
(McGuigan J.E., Gastroenterology 54 (6) : 1005-1111 (1968)) 
Conjugation Procedure 
Six mi Iii grams of SHG 2-17 were dissolved in 0,4 ml N, N-dimethyl 
formamide, to which was added 0,6 ml 0,05M-potassium phosphate, pH 7,4. 
Twelve milligrams bovine serum albumen in 0,4 ml 0,05M-potassium phosphate, 
pH 7,4, and 50 mg EDAP-carbodiimide in 0,2 ml 0,05M-potassium phosphate, 
pH 7 ,4, were added. The reaction mixture was gently stirred for 20 hours at 
20°C, and then dialysed for 48 hours against 2 litres of 0, 15M-NaCI -0, lM-
o 
potassium phosphate, pH 7,4, at 4 C. 
Immunisation 
The conjugate was emulsified with an equal volume of 4: l mineral oil -
Arlacel A. Eight hundred µI, containing 2 mg gastrin, was injected into the 
foot pads of New Zealand white rabbits, so that an equal volume was given 
via each foot pad. Immunisation was repeated 2 months and 5 months after 
the first injection. Fourteen days after each injection 30-45 ml blood was 
collected from each rabbit by cardiac puncture e Sera were individually 
precipitated by dropwise addition of saturated ammonium sulphate to a final 
concentration of 40% to isolate the gamma-globulin fraction. 
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7 (ii) Folin-Lowry Protein Determination 
(Work T .S. and Work E. Laboratory Techniques in Biochemistry and 
Molecular Biology. Vol. 1 : 366 (1970). North Holland, Amsterdam, 
London.) 
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The principle of the method is that a copper-tartrate complex is allowed to 
react with the protein in alkaiine solution. The protein-copper complex can 
reduce phosphomolybdate to form a blue substance with a broad absorption peak 
around 750 nm. The procedure described here is a modification of the original 
method described by Lowry, Rosebrough, Farr et al. in 1951, and detailed in 
Work and Work (1970). 
Reagents 
Reagent A 2% anhydrous Na 2co3 in 0, 1 N-NaOH 
Reagent B 0,5% CuS04 .5H20 in 1% Na Tartrate 
Reagent C 1 ml reagent B mixed with 50 ml reagent A, made up fresh daily. 
Reagent D Commercially available Folin-Ciocalteu reagent (Analar), 1,8 N, 
diluted 1:1 with water. 
Protein standards were prepared using Highland Control Serum I. One hundred JJI 
of the stock solution containing 6g/100 ml was diluted to 6 ml with distilled 
deionized water to give a solution containing 1 mg/ml, or 100 ,ug/100 ,ul. 
A series of six standards ranging from 100 ,ug/100 ,ul down to 10 ,ug/100 µI 
was prepared by dilution of this solution with 0, 1 N-NaOH. Unknowns were 
diluted to fall within the range of these standards. The degree of dilution for 
the unknowns was determined by trial and error. 
To 100 µI of standard or unknown, 100 µI of 0,1 N-NaOH was added. 
The blank tubes contained 200 pl 0, 1 N-NaOH. Two ml reagent C were 
added to each tube, which were then shaken and allowed to stand for 10 
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minutes at room temperature. Two hundred µi of reagent D, the diluted Fol in 
reagent, was added and the tubes were mixed rapidly o After leaving the tubes 
to stand for at !east 30 minutes to allow the blue end product to stabilize, the 
solutions were read spectrophotometrically at 750 nm. If the protein concen-
trations were too high, the solutions were read at 500 nm, where the absorbency 
is lower. The standard curve was constructed and the unknowns were read off 
and corrected for dilution. 
7 (iii) Details of Operative Preparation of Pigs and Blood Flow Measurement 
Technique 
Anaesthesia was maintained with oxygen and nitrous oxide given via a 
Magill-type circuit. The animals were ai lowed to breathe spontaneously to 
avoid possible interference by intermittent positive pressure ventilation with 
portal flow (Rabinovici, 1968). 
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The catheter introduced via the right external jugular vein was manipulated 
into the left hepatic vein by intra-abdominal palpation, and could almost always 
be felt within the liver substance when small pigs were usedo The position of 
the catheter was confirmed by a bloodless patch in the liver upon rapid infusion 
of saline. The cather was then withdrawn 1-2 cm to prevent wedging. 
The portal catheters were inserted via a small tributary draining the pancreas 
in order not to disturb portal circulation. No pancreatic oedema or infarction 
was noted. 
Total operating time was between 60 and 90 minutes in all cases. Al I 
animals were given 20 m Eq. sodium bicarbonate to counteract the mild meta-
bolic acidosis (base deficit 5-7 m Eq/1) which occurred after pentothal induction, 
and heparin 2 mg/kg to prevent clotting in the catheters. 
The priming dose of BSP was 300 mg and infusion was continued at the rate 
of 5 mg/min. The priming dose of ICG was 2,5 mg fol lowed by infusion at 
0, 156 mg/min. Portal flow was measured with PAH using a priming dose of 
12,5 mg and subsequent infusion at 72 mg/min. 
Individual flow values for each experiment were a mean of the three samples 
taken during the second 30-minute period, and for each group a mean of these 
individual values was taken. 
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7 {iv) Technique of Perfusion of the lsoiated Rat Liver in Situ 
(Hems, R., Rossr B.D., Berry, M.N., Krebs, H.A., 
Biochem. J. 101 : 284-292 (1966)) 
For each perfusion 62 ml of medium were used, which consisted of: 
(i) Krebs-Ringer Bicarbonate buffer (KRB)*; (ii) 4-5 week old donor human 
erythrocytes, thrice washed with 2-3 volumes KRB, with a hcematocrit of 8% 
and a haemoglobin concentration of 2,7 g/100 ml; (iii) 4,5 mM D+ glucose, 
and (iv) 2,5% (w/v) bovine serum albumen, fraction V (Miles Laboratories, 
Cape Town). The final pH of the medium was 7,38 - 7,50. 
Rats were lightly anaesthetised with diethyl ether end the bile duct 
ccnnulcted. During portal and inferior vena caval cannulation the liver 
was perfused with plasmclyte B (35-38°C) containing in millimoles/litre, 
+ + 2+ Na 130, K 4, Mg 1,5, er 109, and HC03- 28. The usual time 
from portal venous ligation to establishment of perfusate flow was 3! - 4 
minutes. The first 2 or 3 ml effluent were discarded. The perfusion pressure 
was adjusted to 15-20 cm water to provide flow rates of 3,0 - 5,0 ml/min/ 
g wet weight of liver, which would satisfy maximal oxygen requirements 
without liver swelling or surface exudation. Flow rates, monitored by 
timing 10 ml vena ca val effluent every ! hour, were uniform 30 minutes 
after the start and for a further 90 minutes of perfusion. Adjustments were 
made to maintain flow rates where necessary. Liver temperature was 
monitored by a telethermometer probe placed befween adjacent lobes, 
and was maintained at 37-38°C. Under the conditions of the perfusion 
the metabolic integrity of the liver, assessed in separate preliminary 
experiments, was confirmed by satisfactory maximal rates of lactate gluconeo-
genesis from 30-120 minutes, time O minutes being taken as the start of the 
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perfusion. The values, 0,85 ::= 0,05 µrno!es glucose/min/g liver, (mean 2: S.E.Mo, 
n=9) accord closely with those reported by Hems et al. (1966) and Exton and 
Perk (1967). Bile production ranged from 100-160 µljg wet liver bet-.veen 30 
and 120 minutes perfusion. 
* The KRB buffer was made up as follows: 
0,9% N:JCI 100 parts by volume 
1, 15% KCI 4 parts by volume 
1,22% CaCl2 3 parts by volume 
2, 11% KHl04 part by volume 
3,82% MgSO 4 .7H20 1 part by volume 
1,3% NaHC03 21 parts by volume 
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